

5 **TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA**
 CHIMERIC ANTIGEN RECEPTOR

 This application claims priority to PCT Application No. PCT/CN2014/090501, filed
November 6, 2014, and PCT Application No. PCT/CN2014/082586, filed July 21, 2014. The
10 entire contents of these applications are incorporated herein by reference.

SEQUENCE LISTING

 The instant application contains a Sequence Listing which has been submitted
electronically in ASCII format and is hereby incorporated by reference in its entirety. Said
15 ASCII copy, created on July 15, 2015, is named N2067-7045WO3_SL.txt and is 771,026 bytes
in size.

FIELD OF THE INVENTION

 The present invention relates generally to the use of immune effector cells (e.g., T cells,
20 NK cells) engineered to express a Chimeric Antigen Receptor (CAR) to treat a disease
associated with expression of the B-cell maturation antigen protein (BCMA).

BACKGROUND OF THE INVENTION

 B-cell maturation antigen (BCMA) is a tumor necrosis family receptor (TNFR) member
25 expressed cells of the B-cell lineage. BCMA expression is the highest on terminally
differentiated B cells. BCMA is involved in mediating the survival of plasma cells for
maintaining long-term humoral immunity. The expression of BCMA has been recently linked to
a number of cancers, autoimmune disorders, and infectious diseases. Cancers with increased
expression of BCMA include some hematological cancers, such as multiple myeloma,
30 Hodgkin's and non-Hodgkin's lymphoma, various leukemias, and glioblastoma.

SUMMARY OF THE INVENTION

 In a first aspect, the invention features an isolated nucleic acid molecule encoding a
chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody
fragment which includes a human anti-BCMA binding domain or a humanized anti-BCMA

- 5 binding domain, a transmembrane domain, and an intracellular signaling domain (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain). In one embodiment, the CAR comprises an antibody or antibody fragment which includes a human anti-BCMA binding domain described herein or a humanized anti-BCMA binding domain, described herein, a transmembrane domain described herein, and an
- 10 intracellular signaling domain described herein (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain).

In one embodiment, the encoded BCMA binding domain (e.g., human or humanized anti-BCMA binding domain) comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC

15 CDR2), and light chain complementary determining region 3 (LC CDR3) of a human or humanized anti-BCMA binding domain described herein, and/or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of an anti-BCMA binding domain described herein, e.g., a human or humanized anti-

20 BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the encoded human anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 1) and/or a heavy chain variable region described herein (e.g., in Table 1). In one embodiment, the encoded humanized anti-BCMA binding domain comprises a light chain variable region provided in SEQ ID NO:

25 271 or 273 and/or a heavy chain variable region provided in SEQ ID NO: 271 or 273. In one embodiment, the encoded human anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Table 1. In one embodiment, the encoded humanized anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of SEQ ID NO: 271 or 273. In an embodiment, the human or

30 humanized anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99%

35 identity with an amino acid sequence of Table 1 or SEQ ID NO: 271 or 273; and/or a heavy

5 chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99% identity to an amino acid sequence of Table 1. In one embodiment, the encoded

10 human anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID

15 NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149, or a sequence with 95-99% identity thereof. In one embodiment, the encoded humanized anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO:

20 271 or SEQ ID NO: 273, or a sequence with 95-99% identity thereof. In one embodiment, the encoded human or humanized anti-BCMA binding domain includes a (Gly4-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4 (SEQ ID NO:26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain

25 variable region-linker-light chain variable region.

In other embodiments, the encoded BCMA binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In embodiments, the BCMA binding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments, the BCMA binding domain comprises

30 a LC CDR1, a LC CDR2, and a LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16.

In some embodiments, the encoded BCMA binding domain comprises one, two or all of LC CDR1, LC CDR2, and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, and one, two or all of HC CDR1, HC CDR2, and HC CDR3

35 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16.

5 In one embodiment, the encoded anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 16) and/or a heavy chain variable region described herein (e.g., in Table 16). In one embodiment, the encoded humanized anti-BCMA binding domain comprises a light chain variable region provided in SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, and/or a heavy chain variable region provided
10 in SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258. In one embodiment, the encoded anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Table 16. In an embodiment, the human or humanized anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g.,
15 substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, or a sequence with 95-99% identity thereof; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g.,
20 substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, or a sequence with 95-99% identity thereof. In one embodiment, the encoded anti-BCMA binding domain includes a (Gly4-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably
25 3 or 4 (SEQ ID NO:26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

In one embodiment, the encoded human anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO:
30 265, and SEQ ID NO: 266, or a sequence with 95-99% identity thereof.

In one embodiment, the encoded CAR includes a transmembrane domain that comprises a transmembrane domain of a protein, e.g., described herein, e.g., selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and
35 CD154. In one embodiment, the encoded transmembrane domain comprises the sequence of

5 SEQ ID NO: 6. In one embodiment, the encoded transmembrane domain comprises an amino acid sequence comprising at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:6, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:6. In one embodiment, the nucleic acid sequence encoding the transmembrane domain comprises the sequence of SEQ ID NO: 17, or a sequence
10 with 95-99% identity thereof.

In one embodiment, the encoded anti-BCMA binding domain is connected to the transmembrane domain by a hinge region, e.g., a hinge region described herein. In one embodiment, the encoded hinge region comprises SEQ ID NO:2, or a sequence with 95-99% identity thereof. In one embodiment, the nucleic acid sequence encoding the hinge region
15 comprises the sequence of SEQ ID NO: 13, or a sequence with 95-99% identity thereof.

In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain, e.g., a costimulatory domain described herein. In embodiments, the intracellular signaling domain comprises a costimulatory domain. In embodiments, the intracellular signaling domain comprises a primary signaling domain. In
20 embodiments, the intracellular signaling domain comprises one or more (e.g., one or more, two or more, or three or more) of a costimulatory domain and a primary signaling domain.

In one embodiment, the encoded costimulatory domain is a functional signaling domain obtained from a protein, e.g., described herein, e.g., selected from the group consisting of MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine
25 receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R
30 alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108),
35 SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT,

- 5 GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.. In embodiments, the encoded costimulatory domain comprises 4-1BB, CD27, CD28, or ICOS.

In one embodiment, the encoded costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO:7. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but
10 not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:7, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:7. In one embodiment, the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO:18, or a sequence with 95-99% identity thereof. In another embodiment, the encoded costimulatory domain of CD28 comprises the amino acid sequence
15 of SEQ ID NO:1104. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1104, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1104. In one embodiment, the nucleic acid sequence encoding the costimulatory domain of CD28 comprises the nucleotide sequence of
20 SEQ ID NO:1105 or a sequence with 95-99% identity thereof. In another embodiment, the encoded costimulatory domain of CD27 comprises the amino acid sequence of SEQ ID NO:8. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:8, or a sequence with 95-99% identity to an amino acid
25 sequence of SEQ ID NO:8. In one embodiment, the nucleic acid sequence encoding the costimulatory domain of CD27 comprises the nucleotide sequence of SEQ ID NO:19, or a sequence with 95-99% identity thereof. In another embodiment, the encoded costimulatory domain of ICOS comprises the amino acid sequence of SEQ ID NO:1106. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two
30 or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1106, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1106. In one embodiment, the nucleic acid sequence encoding the costimulatory domain of ICOS comprises the nucleotide sequence of SEQ ID NO:1107 or a sequence with 95-99% identity thereof.

5 In embodiments, the encoded primary signaling domain comprises a functional signaling domain of CD3 zeta. In embodiments, the functional signaling domain of CD3 zeta comprises the amino acid sequence of SEQ ID NO: 9 (mutant CD3zeta) or SEQ ID NO: 10 (wild type human CD3zeta), or a sequence with 95-99% identity thereof.

10 In one embodiment, the encoded intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta. In one embodiment, the encoded intracellular signaling domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 7 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5
15 modifications of an amino acid sequence of SEQ ID NO:7 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:7 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the encoded intracellular signaling domain comprises the sequence of SEQ ID NO:7 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences
20 comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of 4-1BB comprises the nucleotide sequence of SEQ ID NO:18, or a sequence with 95-99% identity thereof, and/or the CD3 zeta nucleotide sequence of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereof.

25 In one embodiment, the encoded intracellular signaling domain comprises a functional signaling domain of CD27 and/or a functional signaling domain of CD3 zeta. In one embodiment, the encoded intracellular signaling domain of CD27 comprises the amino acid sequence of SEQ ID NO: 8 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid
30 sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:8 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:8 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the encoded intracellular signaling domain comprises the sequence of SEQ
35 ID NO:8 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences

5 comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of CD27 comprises the nucleotide sequence of SEQ ID NO:19, or a sequence with 95-99% identity thereof, and/or the CD3 zeta nucleotide sequence of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereof.

10 In one embodiment, the encoded intracellular signaling domain comprises a functional signaling domain of CD28 and/or a functional signaling domain of CD3 zeta. In one embodiment, the encoded intracellular signaling domain of CD28 comprises the amino acid sequence of SEQ ID NO: 1104 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino
15 acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1104 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1104 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID
20 NO:10. In one embodiment, the encoded intracellular signaling domain comprises the sequence of SEQ ID NO:1104 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of CD28 comprises the nucleotide sequence of SEQ ID
25 NO:1105, or a sequence with 95-99% identity thereof, and/or the CD3 zeta nucleotide sequence of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereof.

In one embodiment, the encoded intracellular signaling domain comprises a functional signaling domain of ICOS and/or a functional signaling domain of CD3 zeta. In one embodiment, the encoded intracellular signaling domain of ICOS comprises the amino acid sequence of SEQ ID NO: 1106 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or
30 SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1106 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1106 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID
35 NO:10. In one embodiment, the encoded intracellular signaling domain comprises the

5 sequence of SEQ ID NO:1106 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the nucleic acid sequence encoding the intracellular signaling domain of ICOS comprises the nucleotide sequence of SEQ ID NO:1107, or a sequence with 95-99% identity thereof, and/or the CD3 zeta nucleotide sequence
10 of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereof.

In another aspect, the invention pertains to an isolated nucleic acid molecule encoding a CAR construct comprising a leader sequence, e.g., a leader sequence described herein, e.g., the amino acid sequence of SEQ ID NO: 1; an anti-BCMA binding domain described herein, e.g.,
15 human anti-BCMA binding domain comprising a LC CDR1, a LC CDR2, a LC CDR3, a HC CDR1, a HC CDR2 and a HC CDR3 described herein (e.g., a human anti-BCMA binding domain described in Table 1 or 16), or a sequence with 95-99% identify thereof; a hinge region described herein, e.g., the amino acid sequence of SEQ ID NO:2; a transmembrane domain described herein, e.g., having a sequence of SEQ ID NO: 6; and an intracellular signaling
20 domain, e.g., an intracellular signaling domain described herein. In one embodiment, the encoded intracellular signaling domain comprises a costimulatory domain, e.g., a costimulatory domain described herein (e.g., a 4-1BB costimulatory domain having the amino acid sequence of SEQ ID NO:7 or a CD27 costimulatory domain having the amino acid sequence of SEQ ID NO:8), and/or a primary signaling domain, e.g., a primary signaling domain described herein,
25 (e.g., a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:9 or SEQ ID NO:10). In one embodiment, the isolated nucleic acid molecule encoding the CAR construct includes a leader sequence encoded by the nucleic acid sequence of SEQ ID NO:1, or a sequence with 95-99% identity thereto.

30 In another aspect, the invention pertains to an isolated nucleic acid molecule encoding a CAR construct comprising a leader sequence, e.g., a leader sequence described herein, e.g., the amino acid sequence of SEQ ID NO: 1; an anti-BCMA binding domain described herein (e.g., humanized anti-BCMA binding domain comprising a LC CDR1, a LC CDR2, a LC CDR3, a HC CDR1, a HC CDR2 and/or a HC CDR3 described herein, e.g., a humanized anti-BCMA

5 binding domain described herein (e.g., a humanized anti-BCMA binding domain comprising a sequence selected from a group consisting of SEQ ID NO: 271 or SEQ ID NO: 273), or a sequence with 95-99% identity thereof); a hinge region described herein, e.g., the amino acid sequence of SEQ ID NO:2; a transmembrane domain described herein, e.g., having a sequence of SEQ ID NO: 6, and an intracellular signaling domain, e.g., an intracellular signaling domain
 10 described herein. In one embodiment, the encoded intracellular signaling domain comprises a costimulatory domain, e.g., a costimulatory domain described herein (e.g., a 4-1BB costimulatory domain having a sequence of SEQ ID NO:7), and/or a primary signaling domain, e.g., a primary signaling domain described herein (e.g., a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:9 or SEQ ID NO:10). In one embodiment, the isolated nucleic acid
 15 molecule encoding the CAR construct includes a leader sequence encoded by the nucleic acid sequence of SEQ ID NO:1, or a sequence with 95-99% identity thereto.

In one embodiment, the isolated nucleic acid molecule encoding the CAR construct includes a human anti-BCMA binding domain sequence encoded by the nucleic acid sequence of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ
 20 ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165,
 25 SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, or SEQ ID NO: 170, or a sequence with 95-99% identity thereto. In one embodiment, the isolated nucleic acid molecule encoding the CAR construct includes a humanized anti-BCMA binding domain sequence encoded by the nucleic acid sequence of SEQ ID NO: 272, SEQ ID NO: 274, or a sequence with 95-99% identity thereto.

30 In one embodiment, the isolated nucleic acid molecule comprises (e.g., consists of) a nucleic acid encoding a CAR amino acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID
 35 NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID

5 NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID
 NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID
 NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 233, or an amino acid
 sequence having 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to or having one, two or
 three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30,
 10 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid
 sequence of an amino acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101,
 SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106,
 SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111,
 SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215,
 15 SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220,
 SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225,
 SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230,
 SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 233.

In one embodiment, the isolated nucleic acid molecule comprises (e.g., consists of) a
 20 nucleic acid sequence of SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO:
 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO:
 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO:
 127, SEQ ID NO: 128, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO:
 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO:
 25 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO:
 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO:
 252, SEQ ID NO: 253, or SEQ ID NO: 254, or a nucleic acid sequence having 85%, 90%, 95%,
 96%, 97%, 98% or 99% identity to or having one, two or three modifications (e.g.,
 substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications
 30 (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a nucleic acid
 sequence of SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID
 NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID
 NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID
 NO: 128, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID
 35 NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID

5 NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, or SEQ ID NO: 254.

In one aspect, the invention pertains to an isolated nucleic acid molecule encoding an anti-BCMA binding domain, wherein the anti-BCMA binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and/or light chain complementary determining region 3 (LC CDR3) of an anti-BCMA binding domain described herein, and one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and/or heavy chain complementary determining region 3 (HC CDR3) of an anti-BCMA binding domain described herein, e.g., a human anti-BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the encoded anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in SEQ ID NO: 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 259, 260, 261, or 262) and/or a heavy chain variable region described herein (e.g., in SEQ ID NO: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 255, 256, 257, or 258). In one embodiment, the encoded anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of in SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, or SEQ ID NO: 266, or a sequence with 95-99% identity thereof. In an embodiment, the anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative

5 substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in SEQ ID NO: 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 259, 260, 261, or 262 or a sequence with 95-99% identity with an amino acid sequence of SEQ ID NO:

10 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 259, 260, 261, or 262; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid

15 sequence of a heavy chain variable region provided in SEQ ID NO: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 255, 256, 257, or 258 or a sequence with 95-99% identity to an amino acid sequence in SEQ ID NO: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 81, 82, 83, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189,

20 190, 191, 255, 256, 257, or 258. In one embodiment, the anti-BCMA binding domain comprises a sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ

25 ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, or SEQ ID NO: 266, or a sequence with 95-99% identity thereof. In one

30 embodiment, the encoded anti-BCMA binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, is attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, via a linker, e.g., a linker described herein. In one embodiment, the encoded anti-BCMA binding domain includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6,

35 preferably 4 (SEQ ID NO: 26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-

5 heavy chain variable region or heavy chain variable region-linker-light chain variable region. In one embodiment, the isolated nucleic acid sequence encoding the human anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, and SEQ ID NO: 170, or a sequence with 95-99%
15 identity thereof.

In other embodiments, the encoded BCMA binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In embodiments, the BCMA binding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments, the BCMA binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16.
20

In some embodiments, the encoded BCMA binding domain comprises one, two or all of LC CDR1, LC CDR2, and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, and one, two or all of HC CDR1, HC CDR2, and HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16.
25

In an embodiment, the anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence comprising (or consisting of) a light chain variable region of SEQ ID NO: 271 or 273; and amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in SEQ ID NO: 271 or 273, or a sequence with 95-99% identify thereof; and/or a heavy chain variable region comprising an amino acid sequence comprising (or consisting of) a heavy chain variable region of SEQ ID NO: 271 or 273; and amino acid sequence having at least one, two or three modifications (e.g.,
30
35

5 substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in SEQ ID NO: 271 or 273, or a sequence with 95-99% identity thereof. In one embodiment, the encoded humanized anti-BCMA binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, e.g.,
10 provided in SEQ ID NO: 271 or 273, is attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., provided in SEQ ID NO: 271 or 273, via a linker, e.g., a linker described herein. In one embodiment, the encoded anti-BCMA binding domain includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 4 (SEQ ID NO: 26).

In another aspect, the invention pertains to an isolated polypeptide molecule, e.g.,
15 isolated chimeric antigen receptor (CAR) molecule, encoded by the nucleic acid molecule. In one embodiment, the isolated polypeptide molecule comprises a sequence selected from the group consisting of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112,
20 SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, and SEQ ID NO: 233, or a sequence with 95-99% identity thereof.

25 In another aspect, the invention pertains to an isolated chimeric antigen receptor (CAR) molecule (e.g., polypeptide) comprising an anti-BCMA binding domain (e.g., a human or humanized antibody or antibody fragment that specifically binds to BCMA), a transmembrane domain, and an intracellular signaling domain (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain). In one embodiment,
30 the CAR comprises an antibody or antibody fragment which includes an anti-BCMA binding domain described herein (e.g., a human antibody or antibody fragment that specifically binds to BCMA as described herein), a transmembrane domain described herein, and an intracellular signaling domain described herein (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain described herein).

5 In one embodiment, the anti-BCMA binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of an anti-BCMA binding domain described herein, and one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of an anti-BCMA binding domain described herein, e.g., a human or humanized anti-BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 1 or SEQ ID NO: 271 or 273) and/or a heavy chain variable region described herein (e.g., in Table 1 or SEQ ID NO: 271 or 273). In one embodiment, the anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence listed in Table 1, SEQ ID NO: 271 or 273. In an embodiment, the anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99% identity with an amino acid sequence provided in Table 1 or SEQ ID NO: 271 or 273; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99% identity to an amino acid sequence provided in Table 1 or SEQ ID NO: 271 or 273. In one embodiment, the anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO:

5 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, or SEQ ID NO: 266; or an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) to any of the aforesaid sequences; or a sequence with 95-99% identify to any of the aforesaid sequences. In one embodiment, the anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 271 or SEQ ID NO: 273, or a sequence with 95-99% identify thereof. In one embodiment, the anti-BCMA binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273, is attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273, via a linker, e.g., a linker described herein. In one embodiment, the anti-BCMA binding domain includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 4 (SEQ ID NO: 26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

In other embodiments, the BCMA binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In embodiments, the BCMA binding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments, the BCMA binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16.

In some embodiments, the BCMA binding domain comprises one, two or all of LC CDR1, LC CDR2, and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, and one, two or all of HC CDR1, HC CDR2, and HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16.

In one embodiment, the isolated CAR molecule comprises a transmembrane domain of a protein, e.g., described herein, e.g., selected from the group consisting of the the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16,

5 CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain comprises a sequence of SEQ ID NO: 6. In one embodiment, the transmembrane domain comprises an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 20, 10 or 5 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of
 10 SEQ ID NO: 6, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO: 6.

In one embodiment, the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region, e.g., a hinge region described herein. In one embodiment, the encoded hinge region comprises SEQ ID NO:2, or a sequence with 95-99% identity thereof.

15 In one embodiment, the isolated CAR molecule further comprises a sequence encoding a costimulatory domain, e.g., a costimulatory domain described herein. In embodiments, the intracellular signaling domain of the isolated CAR molecule comprises a costimulatory domain. In embodiments, the intracellular signaling domain of the isolated CAR molecule comprises a primary signaling domain. In embodiments, the intracellular signaling
 20 domain of the isolated CAR molecule comprises a costimulatory domain and a primary signaling domain.

In one embodiment, the costimulatory domain comprises a functional signaling domain of a protein selected from the group consisting of MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic
 25 activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1,
 30 CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150,

- 5 IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

In one embodiment, the costimulatory domain comprises a sequence of SEQ ID NO:7. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but
10 not more than 20, 10 or 5 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of SEQ ID NO:7, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:7. In another embodiment, the costimulatory domain of CD28 comprises the amino acid sequence of SEQ ID NO:1104. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two or three
15 modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1104, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1104. In another embodiment, the costimulatory domain of CD27 comprises the amino acid sequence of SEQ ID NO:8. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or
20 5 modifications of an amino acid sequence of SEQ ID NO:8, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:8. In another embodiment, the costimulatory domain of ICOS comprises the amino acid sequence of SEQ ID NO:1106. In one embodiment, the costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid
25 sequence of SEQ ID NO:1106, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1106.

In embodiments, the primary signaling domain comprises a signaling domain or CD3 zeta. In embodiments, the functional signaling domain of CD3 zeta comprises SEQ ID NO: 9 (mutant CD3 zeta) or SEQ ID NO: 10 (wild type human CD3 zeta), or a sequence with 95-99%
30 identity thereof.

In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO: 7 and/or the sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain
35 comprises an amino acid sequence having at least one, two or three modifications (e.g.,

5 substitutions, e.g., conservative substitutions) but not more than 20, 10 or 5 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of SEQ ID NO: 7 and/or the sequence of SEQ ID NO:9 or SEQ ID NO:10., or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO: 7 and/or the sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ
10 ID NO: 7 and/or the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

In one embodiment, the intracellular signaling domain comprises a functional signaling domain of CD27 and/or a functional signaling domain of CD3 zeta. In one
15 embodiment, the intracellular signaling domain of CD27 comprises the amino acid sequence of SEQ ID NO: 8 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:8 and/or an amino acid sequence of SEQ ID NO:9 or
20 SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:8 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO:8 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

25 In one embodiment, the intracellular signaling domain comprises a functional signaling domain of CD28 and/or a functional signaling domain of CD3 zeta. In one embodiment, the encoded intracellular signaling domain of CD28 comprises the amino acid sequence of SEQ ID NO: 1104 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having
30 at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO: 1104 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO: 379 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO: 1104 and the sequence

5 of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

In one embodiment, the intracellular signaling domain comprises a functional signaling domain of ICOS and/or a functional signaling domain of CD3 zeta. In one embodiment, the intracellular signaling domain of ICOS comprises the amino acid sequence of SEQ ID NO: 1106 and/or the CD3 zeta amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the intracellular signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:1106 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1106 and/or an amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10. In one embodiment, the encoded intracellular signaling domain comprises the sequence of SEQ ID NO:1106 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

20 In one embodiment, the isolated CAR molecule further comprises a leader sequence, e.g., a leader sequence described herein. In one embodiment, the leader sequence comprises an amino acid sequence of SEQ ID NO: 1, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:1

In another aspect, the invention pertains to an isolated CAR molecule comprising a leader sequence, e.g., a leader sequence described herein, e.g., a leader sequence of SEQ ID NO: 1, or having 95-99% identity thereof, an anti-BCMA binding domain described herein, e.g., an anti-BCMA binding domain comprising a LC CDR1, a LC CDR2, a LC CDR3, a HC CDR1, a HC CDR2 and a HC CDR3 described herein, e.g., an anti-BCMA binding domain described in Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273, or a sequence with 95-99% identify thereof, a hinge region, e.g., a hinge region described herein, e.g., a hinge region of SEQ ID NO:2, or having 95-99% identity thereof, a transmembrane domain, e.g., a transmembrane domain described herein, e.g., a transmembrane domain having a sequence of SEQ ID NO: 6 or a sequence having 95-99% identity thereof, an intracellular signaling domain, e.g., an intracellular signaling domain described herein (e.g., an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain). In one embodiment,

5 the intracellular signaling domain comprises a costimulatory domain, e.g., a costimulatory domain described herein, e.g., a 4-1BB costimulatory domain having a sequence of SEQ ID NO:7, or having 95-99% identity thereof, and/or a primary signaling domain, e.g., a primary signaling domain described herein, e.g., a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:9 or SEQ ID NO:10, or having 95-99% identity thereof. In one embodiment, the
 10 intracellular signaling domain comprises a costimulatory domain, e.g., a costimulatory domain described herein, e.g., a 4-1BB costimulatory domain having a sequence of SEQ ID NO:7, and/or a primary signaling domain, e.g., a primary signaling domain described herein, e.g., a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:9 or SEQ ID NO:10.

In one embodiment, the isolated CAR molecule comprises (e.g., consists of) an amino
 15 acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID
 20 NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 233, or an amino acid sequence having at least one, two, three, four, five, 10, 15, 20 or 30 modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 60, 50 or 40 modifications (e.g., substitutions, e.g., conservative substitutions) of an
 25 amino acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO:
 30 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 233, or an amino acid sequence having 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to an amino acid sequence of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID
 35 NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID

5 NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 233.

10 In other embodiments, the anti-BCMA binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In embodiments, the BCMA binding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments, the BCMA binding domain comprises a LC CDR1, a LC CDR2, and a LC CDR3 of any BCMA light chain binding domain amino
15 acid sequences listed in Table 1 or 16.

In some embodiments, the anti-BCMA binding domain comprises one, two or all of LC CDR1, LC CDR2, and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, and one, two or all of HC CDR1, HC CDR2, and HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16.

20

In one aspect, the invention pertains to a BCMA binding domain comprising one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a BCMA binding domain described herein, and/or one or more (e.g., all
25 three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a BCMA binding domain described herein, e.g., a BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs.

30 In other embodiments, the BCMA binding domain comprises a HC CDR1, a HC CDR2, and a HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In embodiments, the BCMA binding domain further comprises a LC CDR1, a LC CDR2, and a LC CDR3. In embodiments, the BCMA binding domain comprises

- 5 a LC CDR1, a LC CDR2, and a LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16.

In some embodiments, the BCMA binding domain comprises one, two or all of LC CDR1, LC CDR2, and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, and one, two or all of HC CDR1, HC CDR2, and HC CDR3
10 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16.

In one embodiment, the BCMA binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of an BCMA binding domain described herein, and one or more (e.g., all three) heavy
15 chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of an BCMA binding domain described herein, e.g., a human or humanized anti-BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the BCMA binding domain comprises a light chain
20 variable region described herein (e.g., in Table 1 or SEQ ID NO: 271 or 273) and/or a heavy chain variable region described herein (e.g., in Table 1 or SEQ ID NO: 271 or 273). In one embodiment, the BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence listed in Table 1, SEQ ID NO: 271 or 273. In an embodiment, the BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an
25 amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99% identity with an amino acid sequence provided in Table 1 or SEQ ID NO: 271 or 273; and/or a heavy chain
30 variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 1 or SEQ ID NO: 271 or 273, or a sequence with 95-99% identity to an amino acid sequence provided in Table 1 or SEQ ID NO: 271 or
35 273. In one embodiment, the BCMA binding domain comprises a sequence selected from a

5 group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, or SEQ ID NO: 266; or an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) to any of the aforesaid sequences; or a sequence with 95-99% identify to any of the aforesaid sequences. In one embodiment, the BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 271 or SEQ ID NO: 273, or a sequence with 95-99% identify thereof. In one embodiment, the anti-BCMA binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273, is attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., in Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273, via a linker, e.g., a linker described herein. In one embodiment, the BCMA binding domain includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 4 (SEQ ID NO: 26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

In another aspect, the invention pertains to a vector comprising a nucleic acid molecule described herein, e.g., a nucleic acid molecule encoding a CAR described herein. In one embodiment, the vector is selected from the group consisting of a DNA, a RNA, a plasmid, a lentivirus vector, adenoviral vector, or a retrovirus vector.

In one embodiment, the vector is a lentivirus vector. In one embodiment, the vector further comprises a promoter. In one embodiment, the promoter is an EF-1 promoter. In one embodiment, the EF-1 promoter comprises a sequence of SEQ ID NO: 11. In another

5 embodiment, the promoter is a PGK promoter, e.g., a truncated PGK promoter as described herein.

In one embodiment, the vector is an in vitro transcribed vector, e.g., a vector that transcribes RNA of a nucleic acid molecule described herein. In one embodiment, the nucleic acid sequence in the vector further comprises a poly(A) tail, e.g., a poly A tail described herein, 10 e.g., comprising about 150 adenosine bases (SEQ ID NO: 382). In one embodiment, the nucleic acid sequence in the vector further comprises a 3'UTR, e.g., a 3' UTR described herein, e.g., comprising at least one repeat of a 3'UTR derived from human beta-globulin. In one embodiment, the nucleic acid sequence in the vector further comprises promoter, e.g., a T2A promoter.

15 In another aspect, the invention pertains to a cell comprising a vector described herein. In one embodiment, the cell is a cell described herein, e.g., an immune effector cell, e.g., a human T cell or a human NK cell, e.g., a human T cell described herein or a human NK cell described herein. In one embodiment, the human T cell is a CD8+ T cell.

In another embodiment, the CAR-expressing cell described herein can further express 20 another agent, e.g., an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or 25 CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta. In embodiments, the agent is an agent that inhibits PD1. In embodiments, the agent is an agent that inhibits PD-L1. In one embodiment, the agent which inhibits an inhibitory molecule can be an agent described herein, such as, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the 30 cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, PD-L2, LAG3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), CTLA4, VISTA, CD160, BTLA, LAIR1, TIM3, 2B4, TGFR beta, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, 35 adenosine, and TIGIT, or a fragment of any of these (e.g., at least a portion of the extracellular

5 domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1), and a second
10 polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and/or a CD3 zeta signaling domain described herein).

In another aspect, the invention pertains to a method of making a cell comprising transducing a cell described herein, e.g., an immune effector cell described herein, e.g., a T cell or NK cell described herein, with a vector of comprising a nucleic acid encoding a CAR, e.g., a
15 CAR described herein.

The present invention also provides a method of generating a population of RNA-engineered cells, e.g., cells described herein, e.g., immune effector cells, e.g., T cells or NK cells, transiently expressing exogenous RNA. The method comprises introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises a nucleic acid
20 encoding a CAR molecule described herein.

In another aspect, the invention pertains to a method of providing an anti-tumor immunity in a mammal comprising administering to the mammal an effective amount of a cell expressing a CAR molecule, e.g., a cell expressing a CAR molecule described herein. In one embodiment, the cell is an autologous immune effector cell, e.g., T cell or an autologous NK
25 cell. In one embodiment, the cell is an immune effector cell, e.g., allogeneic T cell or an allogeneic NK cell. In one embodiment, the mammal is a human, e.g., a patient with a hematologic cancer.

In another aspect, the invention pertains to a method of treating a mammal having a disease associated with expression of BCMA (e.g., a proliferative disease, a precancerous
30 condition, and a noncancer related indication associated with the expression of BCMA) comprising administering to the mammal an effective amount of the cells expressing a CAR molecule, e.g., a CAR molecule described herein. In one embodiment, the mammal is a human, e.g., a patient with a hematologic cancer.

5 In one embodiment, the disease is a disease described herein. In one embodiment, the disease associated with BCMA expression is selected from a hematologic cancer such as acute leukemias including but not limited to acute myeloid leukemia (AML); myelodysplastic syndrome; myeloproliferative neoplasms; chronic myeloid leukemia (CML); Blastic plasmacytoid dendritic cell neoplasm; and to disease associated with BCMA expression
10 including, but not limited to atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing BCMA; and combinations thereof. In one embodiment, the disease associated with BCMA expression is a hematologic cancer selected from the group consisting of one or more acute leukemias including but not limited to B-cell acute lymphoid leukemia ("BALL"), T-cell acute lymphoid leukemia ("TALL"), acute
15 lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic cancers or hematologic conditions including, but not limited to B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular
20 lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and "preleukemia" which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood
25 cells, and to disease associated with BCMA expression include, but not limited to atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing BCMA; and combinations thereof.

In embodiments, a disease associated with expression of BCMA includes a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent
30 myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome).

5 In embodiments, a disease associated with expression of BCMA includes a cancer, e.g., a cancer described herein, e.g., a prostate cancer (e.g., castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), pancreatic cancer, or lung cancer.

In one embodiment of the therapeutic methods, the cell expressing a CAR molecule described herein (e.g., a BCMA CAR molecule) is administered in combination with a cell
10 comprising a CD19 CAR molecule. In one embodiment, the cell expressing the BCMA CAR molecule is administered before, subsequent to, or simultaneously with administration of the cell expressing the CD19 CAR. In one embodiment, the cell expressing the BCMA CAR molecule and the cell expressing the CD19 CAR molecule are part of a single composition, and in other embodiments the cell expressing the BCMA CAR molecule and the cell expressing the
15 CD19 CAR molecule are part of separate compositions. In one embodiment, the cell expressing a CAR molecule described herein (e.g., a BCMA CAR molecule) also express a CD19 CAR molecule. In one embodiment, the disease associated with BCMA is multiple myeloma, e.g., CD19-negative multiple myeloma. In one embodiment, the disease associated with expression of BCMA is multiple myeloma e.g., a multiple myeloma that is CD19-
20 negative, e.g., having a vast majority (e.g., 99.95%) of the neoplastic plasma cells with a CD19-negative phenotype, e.g., as detected by both flow cytometry and RT-PCR.

In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that increases the efficacy of a cell expressing a CAR molecule, e.g., an agent described herein.

25 In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with a low, immune enhancing dose of an mTOR inhibitor. While not wishing to be bound by theory, it is believed that treatment with a low, immune enhancing, dose (e.g., a dose that is insufficient to completely suppress the immune system but sufficient to improve immune function) is accompanied by a decrease in
30 PD-1 positive immune effector cells, e.g., T cells or NK cells, or an increase in PD-1 negative cells. PD-1 positive immune effector cells, e.g., T cells or NK cells, but not PD-1 negative immune effector cells (e.g., T cells or NK cells), can be exhausted by engagement with cells which express a PD-1 ligand, e.g., PD-L1 or PD-L2.

In an embodiment this approach can be used to optimize the performance of CAR cells
35 described herein in the subject. While not wishing to be bound by theory, it is believed that, in

5 an embodiment, the performance of endogenous, non-modified immune effector cells, e.g., T cells or NK cells, is improved. While not wishing to be bound by theory, it is believed that, in an embodiment, the performance of a BCMA CAR expressing cell is improved. In other embodiments, cells, e.g., immune effector cells (e.g., T cells or NK cells), which have, or will be engineered to express a CAR, can be treated ex vivo by contact with an amount of an mTOR
10 inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells or NK cells, or increases the ratio of PD1 negative immune effector cells, e.g., T cells or NK cells / PD1 positive immune effector cells, e.g., T cells or NK cells.

In an embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalytic inhibitor, is initiated prior to
15 administration of an CAR expressing cell described herein, e.g., immune effector cells (e.g., T cells or NK cells). In an embodiment, the CAR cells are administered after a sufficient time, or sufficient dosing, of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells or NK cells, or the ratio of PD1 negative immune effector cells, e.g., T cells or NK cells/ PD1 positive immune effector cells, e.g., T cells or NK cells, has been, at least
20 transiently, increased.

In an embodiment, the cell, e.g., immune effector cell (e.g., T cell or NK cell), to be engineered to express a CAR, is harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells or NK cells, or the ratio of PD1 negative immune effector
25 cells, e.g., T cells or NK cells/ PD1 positive immune effector cells, e.g., T cells or NK cells, in the subject or harvested from the subject has been, at least transiently, increased.

In an embodiment, the invention provides an mTOR inhibitor for use in the treatment of a subject, wherein said mTOR inhibitor enhances an immune response of said subject, and wherein said subject has received, is receiving or is about to receive an immune effector cell
30 that expresses a BCMA CAR as described herein. In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that ameliorates one or more side effect associated with administration of a cell expressing a CAR molecule, e.g., an agent described herein.

5 In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that treats the disease associated with BCMA, e.g., an agent described herein.

In certain embodiments, the disease associated with BCMA is a proliferative disease such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a
10 myelodysplastic syndrome or a preleukemia, or is a non-cancer related indication associated with expression of BCMA.

In certain embodiments, the disease associated with BCMA is a hematologic cancer selected from the group consisting of one or more acute leukemias including but not limited to acute myeloid leukemia (AML); myelodysplastic syndrome; myeloproliferative neoplasms;
15 chronic myeloid leukemia (CML); Blastic plasmacytoid dendritic cell neoplasm; multiple myeloma; and to disease associated with BMCA expression including, but not limited to atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing BCMA; and combinations thereof. In one embodiment, the disease associated with BCMA is multiple myeloma. In embodiments, a disease associated with
20 expression of BCMA includes a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome
25 (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome). In embodiments, a disease associated with expression of BCMA includes a cancer, e.g., a cancer described herein, e.g., a prostate cancer (e.g., castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), pancreatic cancer, or lung cancer.

In embodiments, a BCMA CAR-expressing cell, e.g., a BCMA CAR-expressing cell
30 described herein, is used to treat a subject having multiple myeloma. In embodiments, a BCMA CAR-expressing cell, e.g., BCMA CAR-expressing cell described herein, is used to treat a subject having a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g.,
35 plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma,

5 and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome). In
embodiments, a BCMA CAR-expressing cell, e.g., BCMA CAR-expressing cell described
herein, is used to treat a subject having a cancer, e.g., a cancer described herein, e.g., a prostate
cancer (e.g., castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate
10 cancer), pancreatic cancer, or lung cancer.

In embodiments, a BCMA CAR-expressing cell, e.g., a BCMA CAR-expressing cell
described herein, is administered to the subject according to a dosing regimen comprising a
total dose of cells administered to the subject by dose fractionation, e.g., one, two, three or
more separate administration of a partial dose. In embodiments, a first percentage of the total
15 dose is administered on a first day of treatment, a second percentage of the total dose is
administered on a subsequent (e.g., second, third, fourth, fifth, sixth, or seventh or later) day of
treatment, and optionally, a third percentage (e.g., the remaining percentage) of the total dose is
administered on a yet subsequent (e.g., third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or
later) day of treatment. For example, 10% of the total dose of cells is delivered on the first day,
20 30% of the total dose of cells is delivered on the second day, and the remaining 60% of the total
dose of cells is delivered on the third day of treatment. For example, a total cell dose includes
1 to 5×10^7 or 1 to 5×10^8 BCMA-CART cells.

In embodiments, a lympho-depleting therapy (e.g., Cytosan, e.g., at 1.5 g/m^2) is
administered to the subject before CAR-expressing cell administration. In embodiments, no
25 lympho-depleting therapy (e.g., cytoxan) is administered to the subject before CAR-expressing
cell administration.

In embodiments, no lympho-depleting chemotherapy is administered, and a total
BCMA-CART cell dose of 1 to 5×10^7 is administered (e.g., by infusion) with 10% of the cell
dose on day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment. In
30 another embodiment, no lympho-depleting chemotherapy is administered, and a total BCMA-
CART cell dose of 1 to 5×10^8 is administered (e.g., by infusion) with 10% of the cell dose on
day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment. In
embodiments, , a lympho-depleting chemotherapy (cytoxan at 1.5 g/m^2) is administered three
days before BCMA-CART cell administration, and then a total BCMA-CART cell dose of 1 to
35 5×10^7 is administered (e.g., by infusion) with 10% of the cell dose on day 1 of treatment, 30%

5 on day 2 of treatment, and 60% on day 3 of treatment. In embodiments, a lympho-depleting chemotherapy (cytoxan at 1.5 g/m^2) is administered three days before BCMA-CART cell administration, and then a total BCMA-CART cell dose of 1 to 5×10^8 is administered (e.g., by infusion) with 10% of the cell dose on day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment.

10 In another aspect, the invention pertains to a method of conditioning a subject prior to cell transplantation comprising administering to the subject an effective amount of the cell of comprising a CAR molecule described herein. In one embodiment, the cell transplantation is a stem cell transplantation. The stem cell transplantation is a hematopoietic stem cell
15 stransplantation or a bone marrow transplantation. In one embodiment, the cell transplantation is allogeneic or autologous.

In one embodiment, the conditioning a subject prior to cell transplantation comprises reducing the number of BCMA-expressing cells in a subject. The BCMA-expressing cells in the subject are BCMA-expressing normal cells or BCMA-expressing cancer cells, and in some
20 cases, the condition in the subject will reduce both BCMA-expressing normal and cancer cells prior to a cell transplantation.

In another aspect, the invention pertains to the isolated nucleic acid molecule encoding a CAR of the invention, the isolated polypeptide molecule of a CAR of the invention, the vector comprising a CAR of the invention, and the cell comprising a CAR of the invention for
25 use as a medicament, e.g., as described herein.

In another aspect, the invention pertains to a the isolated nucleic acid molecule encoding a CAR of the invention, the isolated polypeptide molecule of a CAR of the invention, the vector comprising a CAR of the invention, and the cell comprising a CAR of the invention for use in the treatment of a disease expressing BCMA, e.g., a disease expressing BCMA as
30 described herein.

Additional features and embodiments of the aforesaid compositions and methods include one or more of the following:

In certain embodiments, the BCMA CAR molecule (e.g., a BCMA CAR nucleic acid or a BCMA CAR polypeptide as described herein), or the BCMA binding domain as described

5 herein, includes one, two or three CDRs from the heavy chain variable region (e.g., HC CDR1, HC CDR2 and/or HC CDR3), provided in Table 20; and/or one, two or three CDRs from the light chain variable region (e.g., LC CDR1, LC CDR2 and/or LC CDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365,
 10 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, C13F12.1, provided in Table 21; or a sequence
 15 substantially identical (e.g., 95-99% identical, or up to 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

In certain embodiments, the BCMA CAR molecule (e.g., a BCMA CAR nucleic acid or a BCMA CAR polypeptide as described herein), or the anti-BCMA antigen binding domain as described herein, includes one, two or three CDRs from the heavy chain variable region (e.g.,
 20 HC CDR1, HC CDR2 and/or HC CDR3), provided in Table 22; and/or one, two or three CDRs from the light chain variable region (e.g., LC CDR1, LC CDR2 and/or LC CDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1,
 25 BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, C13F12.1, provided in Table 23; or a sequence substantially identical (e.g., 95-99% identical, or up to 5, 4, 3, 2, or 1 amino acid changes, e.g.,
 30 substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 24; and/or one, two or three CDRs from the light chain variable region (e.g., LC CDR1, LC CDR2 and/or LC CDR3) of BCMA-1, BCMA-2, BCMA-3,
 35 BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366,

149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, C13F12.1, provided in Table 25; or a sequence substantially identical (e.g., 95-99% identical, or up to 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes

(i) a LC CDR1, LC CDR2 and LC CDR3 of any BCMA light chain binding domain amino acid sequences listed in Table 1 or 16, in SEQ ID NO: 271 or 273, or in the LC CDRs in Table 21, , 23 or 25; and/or.

(ii) a HC CDR1, HC CDR2 and HC CDR3 of any BCMA heavy chain binding domain amino acid sequences listed in Table 1 or 16, in SEQ ID NO: 271 or 273, or in the HC CDRs in Table 20, 22, or 24.

In certain embodiments, the BCMA molecule (e.g., a BCMA CAR nucleic acid or a BCMA CAR polypeptide as described herein), or the anti-BCMA antigen binding domain as described herein, includes:

(1) three light chain (LC) CDRs chosen from one of the following:

(i) a LC CDR1 of SEQ ID NO: 504, LC CDR2 of SEQ ID NO: 544 and LC CDR3 of SEQ ID NO: 584 of BCMA-4 CAR (139103);

(ii) a LC CDR1 of SEQ ID NO: 514, LC CDR2 of SEQ ID NO: 554 and LC CDR3 of SEQ ID NO: 594 of BCMA-10 CAR (139109);

(iii) a LC CDR1 of SEQ ID NO: 516, LC CDR2 of SEQ ID NO: 556 and LC CDR3 of SEQ ID NO: 596 of BCMA-13 CAR (139112); or

(iv) a LC CDR1 of SEQ ID NO: 518, LC CDR2 of SEQ ID NO: 558 and LC CDR3 of SEQ ID NO: 598 of BCMA-15 CAR (139114); and/or

(2) three heavy chain (HC) CDRs chosen from one of the following:

(i) a HC CDR1 of SEQ ID NO: 384, HC CDR2 of SEQ ID NO: 424 and HC CDR3 of SEQ ID NO: 464 of BCMA-4 CAR (139103);

- 5 (ii) a HC CDR1 of SEQ ID NO: 394, HC CDR2 of SEQ ID NO: 434 and HC CDR3 of SEQ ID NO: 474 of BCMA-10 CAR (139109);
- (iii) a HC CDR1 of SEQ ID NO: 396, HC CDR2 of SEQ ID NO: 436 and HC CDR3 of SEQ ID NO: 476 of BCMA-13 CAR (139112); or
- (iv) a HC CDR1 of SEQ ID NO: 398, HC CDR2 of SEQ ID NO: 438 and HC CDR3 of
- 10 SEQ ID NO: 478 of BCMA-15 (139114).

In certain embodiments, the BCMA CAR molecule (e.g., a BCMA CAR nucleic acid or a BCMA CAR polypeptide as described herein), or the anti-BCMA antigen binding domain as described herein, includes:

- 15 (1) three light chain (LC) CDRs chosen from one of the following:
- (i) a LC CDR1 of SEQ ID NO: 744, LC CDR2 of SEQ ID NO: 784 and LC CDR3 of SEQ ID NO: 824 of BCMA-4 CAR (139103);
- (ii) a LC CDR1 of SEQ ID NO: 754, LC CDR2 of SEQ ID NO: 794 and LC CDR3 of SEQ ID NO: 834 of BCMA-10 CAR (139109);
- 20 (iii) a LC CDR1 of SEQ ID NO: 756, LC CDR2 of SEQ ID NO: 796 and LC CDR3 of SEQ ID NO: 836 of BCMA-13 CAR (139112); or
- (iv) a LC CDR1 of SEQ ID NO: 758, LC CDR2 of SEQ ID NO: 798 and LC CDR3 of SEQ ID NO: 838 of BCMA-15 CAR (139114); and/or
- (2) three heavy chain (HC) CDRs chosen from one of the following:
- 25 (i) a HC CDR1 of SEQ ID NO: 624, HC CDR2 of SEQ ID NO: 664 and HC CDR3 of SEQ ID NO: 704 of BCMA-4 CAR (139103);
- (ii) a HC CDR1 of SEQ ID NO: 634, HC CDR2 of SEQ ID NO: 674 and HC CDR3 of SEQ ID NO: 714 of BCMA-10 CAR (139109);
- (iii) a HC CDR1 of SEQ ID NO: 636, HC CDR2 of SEQ ID NO: 676 and HC CDR3 of
- 30 SEQ ID NO: 716 of BCMA-13 CAR (139112); or
- (iv) a HC CDR1 of SEQ ID NO: 638, HC CDR2 of SEQ ID NO: 678 and HC CDR3 of SEQ ID NO: 718 of BCMA-15 CAR (139114).

In certain embodiments, the BCMA CAR molecule (e.g., a BCMA CAR nucleic acid or

35 a BCMA CAR polypeptide as described herein), or the anti-BCMA antigen binding domain as described herein, includes:

- 5 (1) three light chain (LC) CDRs chosen from one of the following:
- (i) a LC CDR1 of SEQ ID NO: 984 LC CDR2 of SEQ ID NO: 1024 and LC CDR3 of SEQ ID NO: 1064 of BCMA-4 CAR (139103);
 - (ii) a LC CDR1 of SEQ ID NO: 994, LC CDR2 of SEQ ID NO: 1034 and LC CDR3 of SEQ ID NO: 1074 of BCMA-10 CAR (139109);
 - 10 (iii) a LC CDR1 of SEQ ID NO: 996, LC CDR2 of SEQ ID NO: 1036 and LC CDR3 of SEQ ID NO: 1076 of BCMA-13 CAR (139112); or
 - (iv) a LC CDR1 of SEQ ID NO: 998, LC CDR2 of SEQ ID NO: 1038 and LC CDR3 of SEQ ID NO: 1078 of BCMA-15 CAR (139114); and/or
- (2) three heavy chain (HC) CDRs chosen from one of the following:
- 15 (i) a HC CDR1 of SEQ ID NO: 864, HC CDR2 of SEQ ID NO: 904 and HC CDR3 of SEQ ID NO: 944 of BCMA-4 CAR (139103);
 - (ii) a HC CDR1 of SEQ ID NO: 874, HC CDR2 of SEQ ID NO: 914 and HC CDR3 of SEQ ID NO: 954 of BCMA-10 CAR (139109);
 - (iii) a HC CDR1 of SEQ ID NO: 876, HC CDR2 of SEQ ID NO: 916 and HC CDR3 of SEQ ID NO: 956 of BCMA-13 CAR (139112);
 - 20 (iv) a HC CDR1 of SEQ ID NO: 878, HC CDR2 of SEQ ID NO: 918 and HC CDR3 of SEQ ID NO: 958 of BCMA-15 CAR (139114).

In certain embodiments, the BCMA CAR molecule (e.g., a BCMA CAR nucleic acid or a BCMA CAR polypeptide as described herein), or the anti-BCMA antigen binding domain as described herein, includes the humanized scFv amino acid sequence of SEQ ID NO: 271 or 273 or a nucleotide sequence encoding scFv (SEQ ID NO: 272 or 274), or an antigen binding domain thereof (e.g., a VH, VL or one or more CDRs thereof).

30

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned

35

5 herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Headings, sub-headings or numbered or lettered elements, e.g., (a), (b), (i) etc, are presented merely for ease of reading. The use of headings or numbered or lettered elements in this document does not require the steps or elements be performed in alphabetical order or that the steps or elements are
10 necessarily discrete from one another. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1, comprising Figures 1A and 1B, is two graphical representations of BCMA
15 expression in myeloma samples as determined by quantitative PCR. BCMA expression was determined in different myeloma cell lines (Fig. 1A). BCMA expression was compared between normal plasma cells and myeloma patient samples (Fig. 1B)

Figure 2, comprising Figures 2A, 2B, 2C, 2D, and 2E, is a series of graphical
20 representations of BCMA expression in multiple myeloma cell lines and primary samples by flow cytometry. BCMA was detected on the surface of cell lines U266 (Fig. 2A), H929 (Fig. 2B), and 8226 (Fig. 2C). BCMA was also homogenously expressed on the majority of clonal plasma cells in 9 out of 10 multiple myeloma patients analyzed (Figs. 2D and 2E).

Figure 3, comprising Figures 3A and 3B, is a series of graphical representations
25 demonstrating the lack of BCMA expression in normal peripheral blood cells and after CD3/CD28 expansion (Fig. 3A) and on normal bone marrow cells (Fig. 3B).

Figure 4, comprising Figures 4A, 4B, 4C, 4D, 4E, and 4F, is a series of pictures and a
graph showing BCMA expression in normal tissues. Tissues that stained positive for BCMA
expression in immunohistochemical analysis were lymph node (Fig. 4A) and tonsil (Fig. 4B).
Representative tissues that did not stain for BCMA expression (BCMA negative) included lung
30 (Fig. 4C), pancreas (Fig. 4D), and thyroid (Fig. 4E). RNA in situ hybridization analysis in different tissues was also performed (Fig. 4F).

Figure 5 is a schematic representation of the four CAR constructs containing humanized murine anti-BCMA scFvs, designated pBCMA1, pBCMA2, pBCMA3, and pBCMA4.

5 Figure 6 is a series of flow cytometry plots showing the transduction efficiency and expression of the BMCA-CAR constructs on T cells. SS1-BBz represents anti-mesothelin CAR, which serves as a negative control.

 Figure 7, comprising Figure 7A and Figure 7B, is two graphs demonstrating the antigen-specific cytokine production of BCMA-CARTs, as measured by ELISA assays. IL2
10 (Fig. 7A) and interferon-gamma (IFNg) (Fig. 7B) production was assessed.

 Figure 8, comprising Figure 8A, Figure 8B, Figure 8C, and Figure 8D, is a series of graphs demonstrating the cytotoxic activity BCMA-CARTs on the indicated myeloma cell lines: K562-expressing BCMA (Fig. 8A); 8226 (Fig. 8B); NCI H929 (Fig. 8C); and OPM2 (Fig. 8D).

 Figure 9, comprising Figure 9A and Figure 9B, is a graph and a series of pictures
15 showing the anti-tumor activity of the BCMA-CARTs in a preclinical multiple myeloma animal model. Figure 9A shows the quantification of mean bioluminescence representing disease burden in the whole animal (represented by photons /second). Figure 9B shows pictures of the bioluminescence detected in the treated mice at 5, 15, and 20 days after treatment.

20 Figure 10, comprising Figures 10A and 10B, is a series of schematic representations of tool BCMA CAR constructs containing humanized murine anti-BCMA scFvs.

 Figure 11 is a series of graphs demonstrating target-specific activation of tool BCMA CAR constructs transduced in a reporter cell line by luciferase reporter assay.

 Figure 12 is a flow cytometry plot showing the distribution of CD4+ and CD8+
25 populations of T cells after CD3/CD28 expansion prior to transduction with tool BCMA CAR constructs.

 Figure 13 is a series of plots showing CART transduction efficiency by detection of the BCMA-Fc antigen 10 days after transduction by flow cytometry analysis and corresponding histograms.

30 Figure 14 is a series of histogram plots showing proliferation of the tool BCMA CART cells by CFSE staining after stimulation with the indicated target cells (e.g., K562, K562 expressing BCMA, KMS11-luc, MM1-S-luc, NCI-H929, KMs26, RPMI 8226, and CD3/CD28 beads).

5 Figure 15, comprising Figures 15A and 15B, are two graphs showing the proliferation of the tool BCMA CART cells by cell count (as measured by flow cytometry) for CART-expressing cells (Fig. 15A) and the total number of cells (Fig. 15B), after stimulation with the indicated target cells.

10 Figure 16 is a graph showing the tool BCMA CART killing in response to BCMA-expressing target cells KMS11-luciferase cells (left) and MM1-S-luciferase cells (right) by luciferase assay.

 Figure 17 is a series of graphs showing tool BCMA CART killing in response to BCMA-expressing target cells by CFSE cell killing assay.

15 Figure 18 is a series of graphs demonstrating target-specific activation of BCMA CARs containing human anti-BCMA scFvs transduced in a reporter cell line by luciferase reporter assay.

 Figure 19 is a flow cytometry plot showing the distribution of CD4+ and CD8+ T cell populations after CD3/CD28 expansion, and before CAR transduction.

20 Figure 20 is a series of flow cytometry plots and corresponding histogram plots showing the transduction efficiency by assessing CAR expression on the transduced T cells.

 Figure 21 is a series of histogram plots showing the cell proliferation of BCMA CART cells in response to stimulation with the indicated target cells (K562, K562 expressing BCMA, RPMI 8226, KM11-luc, and NCI-H929), as measured by CFSE staining.

25 Figure 22, comprising Figure 22A, Figure 22B, and Figure 22C, is a series of graphs that demonstrate BCMA CART cell proliferation in response to stimulation with the indicated target cells (K562, K562 expressing BCMA, RPMI 8226, KMS11-luc, and NCI-H929), as measured by flow cytometry analysis. Proliferation of the CART cells was independently analyzed for each T cell populations expressing CD3 (Fig. 22A), CD4 (Fig. 22B), and CD8 (Fig. 22C).

30 Figure 23, comprising Figures 23A, 23B, and 23C, is a series of graphs showing BCMA CART killing in response to BCMA-expressing KMS11-luciferase target cells, by luciferase assay. Killing capacity (percent of target cells killed) of each BCMA CAR construct is compared to BCMA-3NP and BCMA-4NP in each graph in Figure 23A. In Figure 23B, select

- 5 BCMA CAR constructs were compared to each other. In Figure 23C, the effector:target ratio was normalized to the CAR-expressing cells. X-axis represents the percent of target cells killed; Y-axis represents effector:target (E:T) ratio.

Figure 24 is a graph showing that treatment with BCMA CARTs results in control of disease progression in the KMS-11-luc human multiple myeloma xenograft in NSG mice.

- 10 Mean bioluminescence (+/- SEM) of the tumor cells shows the disease burden in the whole animal, as represented in the graph as photons/second (p/s) of the ROI (region of interest, e.g., the whole mouse). Significance calculated by ANOVA versus the vehicle; * denotes $P < 0.01$.

Figure 25, comprising Figures 25A and 25B, is two graphs demonstrating anti-tumor activity of BCMA CAR T cells in the KMS-11 human multiple myeloma model in two independent experiments. Mean bioluminescence (+/- SEM) of the tumor cells shows the disease burden in the whole animal, represented in the graph as photons/second (p/s) (or total flux or BLI) of the whole mouse. Significance calculated by ANOVA versus the vehicle on day 28; * denotes $P < 0.01$ in Figure 25A. In Figure 25B, BCMA-4NP* denotes the BCMA-4NP results from the first experiment (results shown in Figure 25A).

- 20 Figure 26, comprising Figures 26A, 26B, 26C, and 26D, is graphs showing the proliferation of BCMA-CART cells by quantification of BCMA-CART cell number in the peripheral blood of KMS-11-luc tumor-bearing mice. Peripheral blood T cells were analyzed on days 1, 3, 7, 10, 14 and weekly thereafter following CAR T cell treatment. From the first tumor experiment (results shown in Figure 25A), the CD4+ CART population was assessed in Figure 26A and the CD8+ CART population was assessed in Figure 26B. From the second tumor experiment (results shown in Figure 25B), the CD4+ CART population was assessed in Figure 26C and the CD8+ CART population was assessed in Figure 26D.

- 30 Figure 27, comprising Figures 27A, 27B, 27C, and 27D, is graphs showing the expansion of BCMA CAR-expressing T cells in the bone marrow and spleen at the end of the first tumor experiment (results shown in Figure 25A). The average number of CD4+ BCMA CAR-expressing T cells in the bone marrow (Fig. 27A) and the spleen (Fig. 27B) was calculated. The average number of CD4+8+ BCMA CAR-expressing T cells in the bone marrow (Fig. 27C) and the spleen (Fig. 27D) was calculated. J6MO sample represents CAR T cells expressing the BCMA-4NP CAR construct.

5 Figure 28, comprising Figures 28A and 28B, is graphs showing the lentiviral titer for select BCMA CAR constructs in two independent lentiviral experiments. In the first test run, two different DNA preps of the BCMA CAR constructs were tested (A and B) (Fig. 28A). In the second test run, three different DNA preps of the BCMA CAR constructs were tested (A, B, and C) (Fig. 28B).

10 Figure 29 is a graph showing the competition assay between BCMA-4NP and select BCMA CAR constructs, BCMA-4 (B4), BCMA-10 (B10), BCMA-13 (B13) and BCMA-15 (B15).

 Figure 30, comprising Figures 30A, 30B, 30C, 30D, and 30E, is graphs showing the results of affinity assays for select BCMA constructs: BCMA-10 (Fig. 30A); BCMA-13 (Fig. 15 30B), BCMA-15 (Fig. 30C), BCMA-4 (Fig. 30D), and BCMA-4NP (Fig. 30E).

 Figure 31 is a graph showing the selective binding of select BCMA CAR-expressing T cells for recombinant BCMA. Recombinant forms of BCMA and closely related family members BAFFR and TACI comprising the proteins fused to Fc domains were incubated with T cells expressing BCMA-4, BCMA-10, BCMA-13, and BCMA-15. The percentage of cells 20 that bound to the recombinant proteins (% positive cells) was detected.

 Figure 32, comprising Figures 32A, 32B, 32C, 32D, 32E, and 32F, is a series of images depicting the immunohistochemical staining of BCMA in brain tissue. BCMA-staining in climbing fibers of the cerebellum of cynomolgus macaque (Fig. 32A). BCMA-staining in the neuronal cell bodies in the inferior olivary nucleus of cynomolgus macaque (Fig. 32B). 25 BCMA-staining (Fig. 32C) and Ig staining (control) (Fig. 32E) in cynomolgus macaque medulla oblongata. BCMA-staining (Fig. 32D) and Ig staining (control) (Fig. 32F) in human medulla oblongata.

 Figure 33, comprising Figures 33A, 33B, 33C, 33D, and 33E, is a series of images and a graph that depicts RNA analysis of BCMA expression in brain tissue. BCMA, DAPB, and 30 PPIB RNA in situ hybridization of non-human primate cerebellum (Fig. 33A). BCMA, DAPB, and PPIB RNA in situ hybridization of non-human primate medulla oblongata (Fig. 33B). Quantitative PCR analysis of BCMA in cerebellum, medulla oblongata, stomach, and kidney in human (Fig. 33C). Quantitative PCR analysis of BCMA in white matter, grey matter, medulla

- 5 oblongata, stomach, and kidney in cynomolgus macaque (Fig. 33D). RNAseq analysis of normal tissue in human (Fig. 33E); the box indicates BCMA-expression in cerebellum.

Figure 34 is a schematic diagram showing the timeline of the study to assess the safety and feasibility of BCMA CART cell therapy in relapsed and/or refractory myeloma.

- 10 Figures 35A and 35B are graphs showing the concentration of cytokines secreted by BCMA-10 CARTs when co-cultured with target cells. Figure 35A is a graph showing the concentration of interleukin-2 (IL-2) and interferon-gamma (IFN γ) secreted by BCMA-10 CARTs. Figure 35B is a graph showing the concentration of tumor necrosis factor-alpha (TNF- α) secreted by BCMA-10 CARTs.

- 15 Figures 36A and 36B are graphs/plots showing the growth curve and efficiency of huBCMA-BBz lentiviral transduction of T cells. Figure 36A is a graph showing the number of T cell transduced with huBCMA-BBz vector on several days after expansion. Figure 36B is a panel of flow cytometry plots showing the expression on day 6 of ex vivo expansion of BCMA on CART-BCMA cells (T cells transduced with huBCMA-BBz vector) compared to non-transduced NTD cells.

- 20 Figure 37 is a panel of flow cytometry histograms showing the BCMA surface expression on various cell lines, including K562- BCMA cells and multiple myeloma cell lines NCI H929, U266, RPMI 8226, OPM2 and MM1S. For all plots, the orange solid peak represents isotype control and the blue solid peak staining with BCMA antibody.

- 25 Figures 38A and 38B are graphs showing the concentration of cytokines produced by CART-BCMA cells in response to myeloma cell lines. Figure 38A shows the concentration of IL-2 produced, and Figure 38B shows the concentration of IFN- γ produced. Values represent cytokine concentration in pg/mL.

- 30 Figures 39A, 39B, and 39C are graphs showing the antigen-specific killing of BCMA⁺ multiple myeloma cell lines by CART-BCMA cells. Figure 39A shows the antigen-specific killing of K562-BCMA cells, Figure 39B shows the antigen specific killing of RPMI 8226 cells, and Figure 39C shows the antigen specific killing of MM1S cells.

Figures 40A, 40B, and 40C are graphs showing that CART-BCMA cells displayed effective anti-myeloma activity *in vivo*. Figure 40A is a graph showing total radiance in non-transduced mice, and Figure 40B is a graph showing total radiance in CART-BCMA mice.

5 Figure 40C is a graph showing percent survival of NTD or CART-BCMA mice after T cell injection. Dorsal photon emission from RPMI 8226 CBG+ tumors are shown with individual animals depicted in grey and median total radiance shown in red. n=10 for each group. Time is shown in weeks following T cell injection.

10 Figure 41A-41D show the various configurations on a single vector, e.g., where the U6 regulated shRNA is upstream or downstream of the EF1 alpha regulated CAR encoding elements. In the exemplary constructs depicted in Fig. 41A and 41B, the transcription occurs through the U6 and EF1 alpha promoters in the same direction. In the exemplary constructs depicted in Fig. 41C and 41D, the transcription occurs through the U6 and EF1 alpha promoters in different directions. In Figure 41E, the shRNA (and corresponding U6 promoter) is on a first
15 vector, and the CAR (and corresponding EF1 alpha promoter) is on a second vector.

Figure 42 depicts the structures of two exemplary RCAR configurations. The antigen binding members comprise an antigen binding domain, a transmembrane domain, and a switch domain. The intracellular binding members comprise a switch domain, a co-stimulatory signaling domain and a primary signaling domain. The two configurations demonstrate that the
20 first and second switch domains described herein can be in different orientations with respect to the antigen binding member and the intracellular binding member. Other RCAR configurations are further described herein.

Figure 43 shows that the proliferation of CAR-expressing, transduced T cells is enhanced by low doses of RAD001 in a cell culture system. CARTs were co-cultured with
25 Nalm-6 cells in the presence of different concentrations of RAD001. The number of CAR-positive CD3-positive T cells (black) and total T cells (gray) was assessed after 4 days of co-culture.

Figure 44 depicts tumor growth measurements of NALM6-luc cells with daily RAD001 dosing at 0.3, 1, 3, and 10 mg/kg (mpk) or vehicle dosing. Circles denote the vehicle; squares
30 denote the 10 mg/kg dose of RAD001; triangles denote the 3 mg/kg dose of RAD001, inverted triangles denote the 1 mg/kg dose of RAD001; and diamonds denote the 0.3 mg/kg dose of RAD001.

Figures 45A and 45B show pharmacokinetic curves showing the amount of RAD001 in the blood of NSG mice with NALM6 tumors. FIG. 45A shows day 0 PK following the first

5 dose of RAD001. FIG. 45B shows Day 14 PK following the final RAD001 dose. Diamonds denote the 10 mg/kg dose of RAD001; squares denote the 1 mg/kg dose of RAD001; triangles denote the 3 mg/kg dose of RAD001; and x's denote the 10 mg/kg dose of RAD001.

Figures 46A and 46B show *in vivo* proliferation of humanized CD19 CART cells with and without RAD001 dosing. Low doses of RAD001 (0.003 mg/kg) daily lead to an
10 enhancement in CAR T cell proliferation, above the normal level of huCAR19 proliferation. Figures 46A shows CD4⁺ CAR T cells; FIG. 46B shows CD8⁺ CAR T cells. Circles denote PBS; squares denote huCTL019; triangles denote huCTL019 with 3 mg/kg RAD001; inverted triangles denote huCTL019 with 0.3 mg/kg RAD001; diamonds denote huCTL019 with 0.03 mg/kg RAD001; and circles denote huCTL019 with 0.003 mg/kg RAD001.

15 FIG. 47 depicts CD19 expression in a patient's tumor cells. CD138⁺ CD45^{dim} tumor cells were stained for CD19 (x-axis) and CD38 (y-axis). Approximately 1-2% of the tumor cells expressed the CD19 antigen.

DETAILED DESCRIPTION

20 Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.

The term "a" and "an" refers to one or to more than one (i.e., to at least one) of the
25 grammatical object of the article. By way of example, "an element" means one element or more than one element.

The term "about" when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of $\pm 20\%$ or in some instances $\pm 10\%$, or
30 in some instances $\pm 5\%$, or in some instances $\pm 1\%$, or in some instances $\pm 0.1\%$ from the specified value, as such variations are appropriate to perform the disclosed methods.

The term "Chimeric Antigen Receptor" or alternatively a "CAR" refers to a recombinant polypeptide construct comprising at least an extracellular antigen binding domain,

5 a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from a stimulatory molecule as defined below. In some embodiments, the domains in the CAR polypeptide construct are in the same polypeptide chain, e.g., comprise a chimeric fusion protein. In some embodiments, the domains in the CAR polypeptide construct are not
10 contiguous with each other, e.g., are in different polypeptide chains, e.g., as provided in an RCAR as described herein.

In one aspect, the stimulatory molecule of the CAR is the zeta chain associated with the T cell receptor complex. In one aspect, the cytoplasmic signaling domain comprises a primary signaling domain (e.g., a primary signaling domain of CD3-zeta). In one aspect, the
15 cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule as defined below. In one aspect, the costimulatory molecule is chosen from 4-1BB (i.e., CD137), CD27, ICOS, and/or CD28. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising
20 a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising a functional signaling domain derived from a co-stimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein
25 comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular signaling domain comprising two functional signaling domains derived from one or more co-stimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen recognition domain, a transmembrane domain and an intracellular
30 signaling domain comprising at least two functional signaling domains derived from one or more co-stimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule. In one aspect the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein. In one aspect, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen recognition domain, wherein the leader sequence
35 is optionally cleaved from the antigen recognition domain (e.g., aa scFv) during cellular processing and localization of the CAR to the cellular membrane.

5 A CAR that comprises an antigen binding domain (e.g., a scFv, a single domain antibody, or TCR (e.g., a TCR alpha binding domain or TCR beta binding domain)) that targets a specific tumor marker X, wherein X can be a tumor marker as described herein, is also referred to as XCAR. For example, a CAR that comprises an antigen binding domain that targets BCMA is referred to as BCMACAR. The CAR can be expressed in any cell, e.g., an
10 immune effector cell as described herein (e.g., a T cell or an NK cell).

 The term “signaling domain” refers to the functional portion of a protein which acts by transmitting information within the cell to regulate cellular activity via defined signaling pathways by generating second messengers or functioning as effectors by responding to such messengers.

15 As used herein, the term “BCMA” refers to B-cell maturation antigen. BCMA (also known as TNFRSF17, BCM or CD269) is a member of the tumor necrosis receptor (TNFR) family and is predominantly expressed on terminally differentiated B cells, e.g., memory B cells, and plasma cells. Its ligand is called B-cell activator of the TNF family (BAFF) and a proliferation inducing ligand (APRIL). BCMA is involved in mediating the survival of plasma
20 cells for maintaining long-term humoral immunity. The gene for BCMA is encoded on chromosome 16 producing a primary mRNA transcript of 994 nucleotides in length (NCBI accession NM_001192.2) that encodes a protein of 184 amino acids (NP_001183.2). A second antisense transcript derived from the BCMA locus has been described, which may play a role in regulating BCMA expression. (Laabi Y. et al., *Nucleic Acids Res.*, 1994, 22:1147-1154).
25 Additional transcript variants have been described with unknown significance (Smirnova AS et al. *Mol Immunol.*, 2008, 45(4):1179-1183. A second isoform, also known as TV4, has been identified (Uniprot identifier Q02223-2). As used herein, “BCMA” includes proteins comprising mutations, e.g., point mutations, fragments, insertions, deletions and splice variants of full length wild-type BCMA.

30 The term “antibody,” as used herein, refers to a protein, or polypeptide sequence derived from an immunoglobulin molecule, which specifically binds with an antigen. Antibodies can be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins, and may be derived from natural sources or from recombinant sources. Antibodies can be tetramers of immunoglobulin molecules.

5 The term “antibody fragment” refers to at least one portion of an intact antibody, or recombinant variants thereof, and refers to the antigen binding domain, e.g., an antigenic determining variable region of an intact antibody, that is sufficient to confer recognition and specific binding of the antibody fragment to a target, such as an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')₂, and Fv fragments, scFv antibody
10 fragments, linear antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains, and multi-specific molecules formed from antibody fragments, such as a bivalent fragment comprising two or more, e.g., two, Fab fragments linked by a disulfide bridge at the hinge region, or two or more, e.g., two isolated CDR or other epitope binding fragments of an antibody linked. An antibody fragment can also be incorporated into single
15 domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antibody fragments can also be grafted into scaffolds based on polypeptides such as a fibronectin type III (Fn3) (see U.S. Patent No.: 6,703,199, which describes fibronectin polypeptide minibodies).

20 The term “scFv” refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker, and capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody
25 from which it is derived. Unless specified, as used herein an scFv may have the VL and VH variable regions in either order, e.g., with respect to the N-terminal and C-terminal ends of the polypeptide, the scFv may comprise VL-linker-VH or may comprise VH-linker-VL.

 The terms “complementarity determining region” or “CDR,” as used herein, refer to the sequences of amino acids within antibody variable regions which confer antigen specificity and
30 binding affinity. For example, in general, there are three CDRs in each heavy chain variable region (e.g., HCDR1, HCDR2, and HCDR3) and three CDRs in each light chain variable region (LCDR1, LCDR2, and LCDR3). The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed.
35 Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme), or a

5 combination thereof. Under the Kabat numbering scheme, in some embodiments, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3). Under the Chothia numbering scheme, in some embodiments, the
10 CDR amino acids in the VH are numbered 26-32 (HCDR1), 52-56 (HCDR2), and 95-102 (HCDR3); and the CDR amino acid residues in the VL are numbered 26-32 (LCDR1), 50-52 (LCDR2), and 91-96 (LCDR3). In a combined Kabat and Chothia numbering scheme, in some embodiments, the CDRs correspond to the amino acid residues that are part of a Kabat CDR, a Chothia CDR, or both. For instance, in some
15 embodiments, the CDRs correspond to amino acid residues 26-35 (HCDR1), 50-65 (HCDR2), and 95-102 (HCDR3) in a VH, e.g., a mammalian VH, e.g., a human VH; and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2), and 89-97 (LCDR3) in a VL, e.g., a mammalian VL, e.g., a human VL.

The portion of the CAR composition of the invention comprising an antibody or
20 antibody fragment thereof may exist in a variety of forms, for example, where the antigen binding domain is expressed as part of a polypeptide chain including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv), or e.g., a humanized antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold
25 Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen binding domain of a CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment that comprises a scFv.

As used herein, the term "binding domain" or "antibody molecule" (also referred to
30 herein as "anti-target (e.g., BCMA) binding domain") refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. The term "binding domain" or "antibody molecule" encompasses antibodies and antibody fragments. In an embodiment, an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein
35 a first immunoglobulin variable domain sequence of the plurality has binding specificity for a

5 first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second
10 immunoglobulin variable domain sequence that has binding specificity for a second epitope. The term “antibody heavy chain,” refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and which normally determines the class to which the antibody belongs.

The term “antibody light chain,” refers to the smaller of the two types of polypeptide
15 chains present in antibody molecules in their naturally occurring conformations. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.

The term “recombinant antibody” refers to an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage or yeast expression system. The term should also be construed to mean an antibody which has
20 been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequence technology which is available and well known in the art.

The term “antigen” or “Ag” refers to a molecule that provokes an immune response.
25 This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide
30 sequence encoding a protein that elicits an immune response therefore encodes an “antigen” as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations
35 to encode polypeptides that elicit the desired immune response. Moreover, a skilled artisan will

5 understand that an antigen need not be encoded by a “gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample, or might be macromolecule besides a polypeptide. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a fluid with other biological components.

The term “anti-tumor effect” refers to a biological effect which can be manifested by
10 various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastases, an increase in life expectancy, decrease in tumor cell proliferation, decrease in tumor cell survival, or amelioration of various physiological symptoms associated with the cancerous condition. An “anti-tumor effect” can also be manifested by the ability of the peptides, polynucleotides, cells and antibodies of the
15 invention in prevention of the occurrence of tumor in the first place.

The term “anti-cancer effect” refers to a biological effect which can be manifested by various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of cancer cells, a decrease in the number of metastases, an increase in life expectancy, decrease in cancer cell proliferation, decrease in cancer cell survival, or amelioration of various
20 physiological symptoms associated with the cancerous condition. An “anti-cancer effect” can also be manifested by the ability of the peptides, polynucleotides, cells and antibodies in prevention of the occurrence of cancer in the first place. The term “anti-tumor effect” refers to a biological effect which can be manifested by various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell
25 proliferation, or a decrease in tumor cell survival. The term “autologous” refers to any material derived from the same individual to whom it is later to be re-introduced into the individual.

The term “allogeneic” refers to any material derived from a different animal of the same species as the individual to whom the material is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some
30 aspects, allogeneic material from individuals of the same species may be sufficiently unlike genetically to interact antigenically

The term “xenogeneic” refers to a graft derived from an animal of a different species.

The term “apheresis” as used herein refers to the art-recognized extracorporeal process by which the blood of a donor or patient is removed from the donor or patient and

5 passed through an apparatus that separates out selected particular constituent(s) and returns the remainder to the circulation of the donor or patient, e.g., by retransfusion. Thus, in the context of “an apheresis sample” refers to a sample obtained using apheresis.

The term “combination” refers to either a fixed combination in one dosage unit form, or a combined administration where a compound of the present invention and a combination
10 partner (e.g. another drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect. The single components may be packaged in a kit or separately. One or both of the components (e.g., powders or liquids) may be reconstituted or diluted to a desired
15 dose prior to administration. The terms “co-administration” or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term “pharmaceutical combination” as used herein
20 means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, e.g. a compound of the present invention and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, e.g. a
25 compound of the present invention and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.

30 The term “cancer” refers to a disease characterized by the rapid and uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers are described herein and include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain
35 cancer, lymphoma, leukemia, lung cancer and the like. Preferred cancers treated by the

5 methods described herein include multiple myeloma, Hodgkin's lymphoma or non-Hodgkin's lymphoma.

The terms "tumor" and "cancer" are used interchangeably herein, e.g., both terms encompass solid and liquid, e.g., diffuse or circulating, tumors. As used herein, the term "cancer" or "tumor" includes premalignant, as well as malignant cancers and
10 tumors.

"Derived from" as that term is used herein, indicates a relationship between a first and a second molecule. It generally refers to structural similarity between the first molecule and a second molecule and does not connote or include a process or source limitation on a first molecule that is derived from a second molecule. For example, in
15 the case of an intracellular signaling domain that is derived from a CD3zeta molecule, the intracellular signaling domain retains sufficient CD3zeta structure such that it has the required function, namely, the ability to generate a signal under the appropriate conditions. It does not connote or include a limitation to a particular process of producing the intracellular signaling domain, e.g., it does not mean that, to provide the
20 intracellular signaling domain, one must start with a CD3zeta sequence and delete unwanted sequence, or impose mutations, to arrive at the intracellular signaling domain.

The phrase "disease associated with expression of BCMA" includes, but is not limited to, a disease associated with a cell which expresses BCMA (e.g., wild-type or mutant BCMA) or condition associated with a cell which expresses BCMA (e.g., wild-type or mutant BCMA)
25 including, e.g., proliferative diseases such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication associated with a cell which expresses BCMA (e.g., wild-type or mutant BCMA). For the avoidance of doubt, a disease associated with expression of BCMA may include a condition associated with a cell which does not presently express BCMA, e.g.,
30 because BCMA expression has been downregulated, e.g., due to treatment with a molecule targeting BCMA, e.g., a BCMA inhibitor described herein, but which at one time expressed BCMA. In one aspect, a cancer associated with expression of BCMA (e.g., wild-type or mutant BCMA) is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a cancer associated with expression of BCMA (e.g., wild-type
35 or mutant BCMA) is a malignancy of differentiated plasma B cells. In one aspect, a cancer associated with expression of BCMA (e.g., wild-type or mutant BCMA) includes cancers and

5 malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute Lymphoid Leukemia (“BALL”), T-cell acute Lymphoid Leukemia (“TALL”), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL). Additional cancers or hematologic conditions associated with expression of BCMA (e.g., wild-
 10 type or mutant BCMA) comprise, but are not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic
 15 syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. In some embodiments, the cancer is multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or glioblastoma. In embodiments, a disease associated
 20 with expression of BCMA includes a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome
 25 (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome). Further diseases associated with expression of BCMA (e.g., wild-type or mutant BCMA) expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of BCMA (e.g., wild-type or mutant BCMA), e.g., a cancer described herein, e.g., a prostate cancer (e.g.,
 30 castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), pancreatic cancer, or lung cancer.

Non-cancer related conditions that are associated with BCMA (e.g., wild-type or mutant BCMA) include viral infections; e.g., HIV, fungal infections, e.g., *C. neoformans*; autoimmune disease; e.g. rheumatoid arthritis, system lupus erythematosus (SLE or lupus), pemphigus
 35 vulgaris, and Sjogren's syndrome; inflammatory bowel disease, ulcerative colitis; transplant-

5 related allospecific immunity disorders related to mucosal immunity; and unwanted immune responses towards biologics (e.g., Factor VIII) where humoral immunity is important. In embodiments, a non-cancer related indication associated with expression of BCMA includes but is not limited to, e.g., autoimmune disease, (e.g., lupus), inflammatory disorders (allergy and asthma) and transplantation. In some
10 embodiments, the tumor antigen-expressing cell expresses, or at any time expressed, mRNA encoding the tumor antigen. In an embodiment, the tumor antigen -expressing cell produces the tumor antigen protein (e.g., wild-type or mutant), and the tumor antigen protein may be present at normal levels or reduced levels. In an embodiment, the tumor antigen -expressing cell produced detectable levels of a tumor antigen protein
15 at one point, and subsequently produced substantially no detectable tumor antigen protein.

The term “conservative sequence modifications” refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino
20 acid substitutions, additions and deletions. Modifications can be introduced into an antibody or antibody fragment of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
25 These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine,
30 phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within a CAR of the invention can be replaced with other amino acid residues from the same side chain family and the altered CAR can be tested using the functional assays described herein.

The term “stimulation,” refers to a primary response induced by binding of a stimulatory molecule (e.g., a TCR/CD3 complex) with its cognate ligand thereby mediating a
35 signal transduction event, such as, but not limited to, signal transduction via the TCR/CD3

5 complex. Stimulation can mediate altered expression of certain molecules, such as downregulation of TGF- β , and/or reorganization of cytoskeletal structures, and the like.

The term “stimulatory molecule,” refers to a molecule expressed by a T cell that provides the primary cytoplasmic signaling sequence(s) that regulate primary activation of the TCR complex in a stimulatory way for at least some aspect of the T cell signaling pathway. In some embodiments, the ITAM-containing domain within the CAR recapitulates the signaling of the primary TCR independently of endogenous TCR complexes. In one aspect, the primary signal is initiated by, for instance, binding of a TCR/CD3 complex with an MHC molecule loaded with peptide, and which leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A primary cytoplasmic signaling sequence (also referred to as a “primary signaling domain”) that acts in a stimulatory manner may contain a signaling motif which is known as immunoreceptor tyrosine-based activation motif or ITAM. Examples of an ITAM containing primary cytoplasmic signaling sequence that is of particular use in the invention includes, but is not limited to, those derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as “ICOS”), Fc ϵ RI and CD66d, DAP10 and DAP12. In a specific CAR of the invention, the intracellular signaling domain in any one or more CARS of the invention comprises an intracellular signaling sequence, e.g., a primary signaling sequence of CD3-zeta. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence provided as SEQ ID NO:9, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence as provided in SEQ ID NO:10, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. The term “antigen presenting cell” or “APC” refers to an immune system cell such as an accessory cell (e.g., a B-cell, a dendritic cell, and the like) that displays a foreign antigen complexed with major histocompatibility complexes (MHC's) on its surface. T-cells may recognize these complexes using their T-cell receptors (TCRs). APCs process antigens and present them to T-cells.

An “intracellular signaling domain,” as the term is used herein, refers to an intracellular portion of a molecule. In embodiments, the intracellular signal domain transduces the effector function signal and directs the cell to perform a specialized function. While the entire

5 intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector
10 function signal.

The intracellular signaling domain generates a signal that promotes an immune effector function of the CAR containing cell, e.g., a CART cell. Examples of immune effector function, e.g., in a CART cell, include cytolytic activity and helper activity, including the secretion of cytokines.

15 In an embodiment, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from the molecules responsible for primary stimulation, or antigen dependent stimulation. In an embodiment, the intracellular signaling domain can comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those
20 derived from molecules responsible for costimulatory signals, or antigen independent stimulation. For example, in the case of a CART, a primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, and a costimulatory intracellular signaling domain can comprise cytoplasmic sequence from co-receptor or costimulatory molecule.

25 A primary intracellular signaling domain can comprise a signaling motif which is known as an immunoreceptor tyrosine-based activation motif or ITAM. Examples of ITAM containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, CD66d, DAP10 and DAP12.

30 The term "zeta" or alternatively "zeta chain", "CD3-zeta" or "TCR-zeta" is defined as the protein provided as GenBan Acc. No. BAG36664.1, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, and a "zeta stimulatory domain" or alternatively a "CD3-zeta stimulatory domain" or a "TCR-zeta stimulatory domain" is defined as the amino acid residues from the cytoplasmic domain of the zeta chain that are
35 sufficient to functionally transmit an initial signal necessary for T cell activation. In one aspect

5 the cytoplasmic domain of zeta comprises residues 52 through 164 of GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, that are functional orthologs thereof. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the sequence provided as SEQ ID NO:9. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the
10 sequence provided as SEQ ID NO:10.

The term “costimulatory molecule” refers to the cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are required for an efficient immune
15 response. Costimulatory molecules include, but are not limited to an MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFR,
20 LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4
25 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

A costimulatory intracellular signaling domain refers to the intracellular portion of a
30 costimulatory molecule.

The intracellular signaling domain can comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment thereof.

The term “4-1BB” refers to a member of the TNFR superfamily with an amino acid
35 sequence provided as GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-

5 human species, e.g., mouse, rodent, monkey, ape and the like; and a “4-1BB costimulatory domain” is defined as amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In one aspect, the “4-1BB costimulatory domain” is the sequence provided as SEQ ID NO:7 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the
10 like.

“Immune effector cell,” as that term is used herein, refers to a cell that is involved in an immune response, e.g., in the promotion of an immune effector response. Examples of immune effector cells include T cells, e.g., alpha/beta T cells and gamma/delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast
15 cells, and myeloid-derived phagocytes.

“Immune effector function or immune effector response,” as that term is used herein, refers to function or response, e.g., of an immune effector cell, that enhances or promotes an immune attack of a target cell. E.g., an immune effector function or response refers a property of a T or NK cell that promotes killing or the inhibition of
20 growth or proliferation, of a target cell. In the case of a T cell, primary stimulation and co-stimulation are examples of immune effector function or response.

The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines.

25 The term “encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene, cDNA, or RNA, encodes a protein if
30 transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.

5 Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or a RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).

10 The term “effective amount” or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result.

The term “endogenous” refers to any material from or produced inside an organism, cell, tissue or system.

15 The term “exogenous” refers to any material introduced from or produced outside an organism, cell, tissue or system.

The term “expression” refers to the transcription and/or translation of a particular nucleotide sequence driven by a promoter.

The term “transfer vector” refers to a composition of matter which comprises an
20 isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “transfer vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to further include non-plasmid and non-viral
25 compounds which facilitate transfer of nucleic acid into cells, such as, for example, a polylysine compound, liposome, and the like. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, and the like.

The term “expression vector” refers to a vector comprising a recombinant
30 polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids,

5 plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

The term “lentivirus” refers to a genus of the Retroviridae family. Lentiviruses are unique among the retroviruses in being able to infect non-dividing cells; they can deliver a significant amount of genetic information into the DNA of the host cell, so they are one of the
10 most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of lentiviruses.

The term “lentiviral vector” refers to a vector derived from at least a portion of a lentivirus genome, including especially a self-inactivating lentiviral vector as provided in Milone et al., Mol. Ther. 17(8): 1453–1464 (2009). Other examples of lentivirus vectors that
15 may be used in the clinic, include but are not limited to, e.g., the LENTIVECTOR® gene delivery technology from Oxford BioMedica, the LENTIMAX™ vector system from Lentigen and the like. Nonclinical types of lentiviral vectors are also available and would be known to one skilled in the art.

The term “homologous” or “identity” refers to the subunit sequence identity between
20 two polymeric molecules, e.g., between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position. The homology between two sequences is a direct function of the
25 number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous.

“Humanized” forms of non-human (e.g., murine) antibodies are chimeric
30 immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementary-determining region (CDR) of the recipient are replaced

- 5 by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized antibody/antibody fragment can comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
- 10 These modifications can further refine and optimize antibody or antibody fragment performance. In general, the humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a significant portion of the FR regions are those of a human immunoglobulin sequence.
- 15 The humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., *Nature*, 321: 522-525, 1986; Reichmann et al., *Nature*, 332: 323-329, 1988; Presta, *Curr. Op. Struct. Biol.*, 2: 593-596, 1992.

“Fully human” refers to an immunoglobulin, such as an antibody or antibody fragment, where the whole molecule is of human origin or consists of an amino acid sequence identical to a human form of the antibody or immunoglobulin.

The term “isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.” An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytosine, “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.

30 The term “operably linked” or “transcriptional control” refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding

5 sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, e.g., where necessary to join two protein coding regions, are in the same reading frame.

The term “parenteral” administration of an immunogenic composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), or intrasternal injection,
10 intratumoral, or infusion techniques.

The term “nucleic acid” or “polynucleotide” refers to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are
15 metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions, e.g., conservative substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions, e.g., conservative substitutions may be achieved
20 by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka et al., *J. Biol. Chem.* 260:2605-2608 (1985); and Rossolini et al., *Mol. Cell. Probes* 8:91-98 (1994)).

The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer
25 to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein’s or peptide’s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are
30 referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. A polypeptide includes a
35 natural peptide, a recombinant peptide, or a combination thereof.

5 The term “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.

 The term “promoter/regulatory sequence” refers to a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence.
10 In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner.

 The term “constitutive” promoter refers to a nucleotide sequence which, when operably
15 linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.

 The term “inducible” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the
20 promoter is present in the cell.

 The term “tissue-specific” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

25 The terms “cancer associated antigen” or “tumor antigen” interchangeably refers to a molecule (typically a protein, carbohydrate or lipid) that is expressed on the surface of a cancer cell, either entirely or as a fragment (e.g., MHC/peptide), and which is useful for the preferential targeting of a pharmacological agent to the cancer cell. In some embodiments, a tumor antigen is a marker expressed by both normal cells and cancer cells, e.g., a lineage
30 marker, e.g., CD19 on B cells. In some embodiments, a tumor antigen is a cell surface molecule that is overexpressed in a cancer cell in comparison to a normal cell, for instance, 1-fold over expression, 2-fold overexpression, 3-fold overexpression or more in comparison to a normal cell. In some embodiments, a tumor antigen is a cell surface molecule that is inappropriately synthesized in the cancer cell, for instance, a molecule that contains deletions,

5 additions or mutations in comparison to the molecule expressed on a normal cell. In some embodiments, a tumor antigen will be expressed exclusively on the cell surface of a cancer cell, entirely or as a fragment (e.g., MHC/peptide), and not synthesized or expressed on the surface of a normal cell. In some embodiments, the CARs of the present invention includes CARs comprising an antigen binding domain (e.g., antibody
 10 or antibody fragment) that binds to a MHC presented peptide. Normally, peptides derived from endogenous proteins fill the pockets of Major histocompatibility complex (MHC) class I molecules, and are recognized by T cell receptors (TCRs) on CD8 + T lymphocytes. The MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and/or tumor-specific peptide/MHC complexes represent
 15 a unique class of cell surface targets for immunotherapy. TCR-like antibodies targeting peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608 ;
 20 Dao et al., Sci Transl Med 2013 5(176):176ra33 ; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibody can be identified from screening a library, such as a human scFv phage displayed library.

The term “tumor-supporting antigen” or “cancer-supporting antigen” interchangeably refer to a molecule (typically a protein, carbohydrate or lipid) that is
 25 expressed on the surface of a cell that is, itself, not cancerous, but supports the cancer cells, e.g., by promoting their growth or survival e.g., resistance to immune cells. Exemplary cells of this type include stromal cells and myeloid-derived suppressor cells (MDSCs). The tumor-supporting antigen itself need not play a role in supporting the tumor cells so long as the antigen is present on a cell that supports cancer cells.

30 The term “flexible polypeptide linker” or “linker” as used in the context of a scFv refers to a peptide linker that consists of amino acids such as glycine and/or serine residues used alone or in combination, to link variable heavy and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly/Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)_n (SEQ ID NO: 38), where n is a positive integer equal to or
 35 greater than 1. For example, n=1, n=2, n=3, n=4, n=5 and n=6, n=7, n=8, n=9 and n=10 In one embodiment, the flexible polypeptide linkers include, but are not limited to, (Gly₄Ser)₄ (SEQ

5 ID NO:27) or (Gly₄Ser)₃ (SEQ ID NO:28). In another embodiment, the linkers include multiple repeats of (Gly₂Ser), (GlySer) or (Gly₃Ser) (SEQ ID NO:29). Also included within the scope of the invention are linkers described in WO2012/138475, incorporated herein by reference).

As used herein, a 5' cap (also termed an RNA cap, an RNA 7-methylguanosine cap or an RNA m⁷G cap) is a modified guanine nucleotide that has been added to the “front” or 5' end
10 of a eukaryotic messenger RNA shortly after the start of transcription. The 5' cap consists of a terminal group which is linked to the first transcribed nucleotide. Its presence is critical for recognition by the ribosome and protection from RNases. Cap addition is coupled to transcription, and occurs co-transcriptionally, such that each influences the other. Shortly after the start of transcription, the 5' end of the mRNA being synthesized is bound by a cap-
15 synthesizing complex associated with RNA polymerase. This enzymatic complex catalyzes the chemical reactions that are required for mRNA capping. Synthesis proceeds as a multi-step biochemical reaction. The capping moiety can be modified to modulate functionality of mRNA such as its stability or efficiency of translation.

As used herein, “in vitro transcribed RNA” refers to RNA, preferably mRNA, that has
20 been synthesized in vitro. Generally, the in vitro transcribed RNA is generated from an in vitro transcription vector. The in vitro transcription vector comprises a template that is used to generate the in vitro transcribed RNA.

As used herein, a “poly(A)” is a series of adenosines attached by polyadenylation to the mRNA. In the preferred embodiment of a construct for transient expression, the polyA is
25 between 50 and 5000 (SEQ ID NO: 30), preferably greater than 64, more preferably greater than 100, most preferably greater than 300 or 400. poly(A) sequences can be modified chemically or enzymatically to modulate mRNA functionality such as localization, stability or efficiency of translation.

As used herein, “polyadenylation” refers to the covalent linkage of a polyadenylyl
30 moiety, or its modified variant, to a messenger RNA molecule. In eukaryotic organisms, most messenger RNA (mRNA) molecules are polyadenylated at the 3' end. The 3' poly(A) tail is a long sequence of adenine nucleotides (often several hundred) added to the pre-mRNA through the action of an enzyme, polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is added onto transcripts that contain a specific sequence, the polyadenylation signal. The poly(A)

5 tail and the protein bound to it aid in protecting mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, export of the mRNA from the nucleus, and translation. Polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but additionally can also occur later in the cytoplasm. After transcription has been terminated, the mRNA chain is cleaved through the action of an endonuclease
10 complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA has been cleaved, adenosine residues are added to the free 3' end at the cleavage site.

As used herein, “transient” refers to expression of a non-integrated transgene for a period of hours, days or weeks, wherein the period of time of expression is less than the period
15 of time for expression of the gene if integrated into the genome or contained within a stable plasmid replicon in the host cell.

As used herein, the terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of a proliferative disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a
20 proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a CAR of the invention). In specific embodiments, the terms “treat”, “treatment” and “treating” refer to the amelioration of at least one measurable physical parameter of a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient. In other embodiments the terms “treat”, “treatment” and “treating” -refer to the
25 inhibition of the progression of a proliferative disorder, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the terms “treat”, “treatment” and “treating” refer to the reduction or stabilization of tumor size or cancerous cell count.

The term “signal transduction pathway” refers to the biochemical relationship between
30 a variety of signal transduction molecules that play a role in the transmission of a signal from one portion of a cell to another portion of a cell. The phrase “cell surface receptor” includes molecules and complexes of molecules capable of receiving a signal and transmitting signal across the membrane of a cell.

5 The term “subject” is intended to include living organisms in which an immune response can be elicited (e.g., mammals, human).

 The term, a “substantially purified” cell refers to a cell that is essentially free of other cell types. A substantially purified cell also refers to a cell which has been separated from other cell types with which it is normally associated in its naturally occurring state. In some
10 instances, a population of substantially purified cells refers to a homogenous population of cells. In other instances, this term refers simply to cell that have been separated from the cells with which they are naturally associated in their natural state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro.

 The term “therapeutic” as used herein means a treatment. A therapeutic effect is
15 obtained by reduction, suppression, remission, or eradication of a disease state.

 The term “prophylaxis” as used herein means the prevention of or protective treatment for a disease or disease state.

 In the context of the present invention, “tumor antigen” or “hyperproliferative disorder antigen” or “antigen associated with a hyperproliferative disorder” refers to antigens that are
20 common to specific hyperproliferative disorders. In certain aspects, the hyperproliferative disorder antigens of the present invention are derived from, cancers including but not limited to primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, leukemias, uterine cancer, cervical cancer, bladder cancer, kidney cancer and adenocarcinomas such as breast cancer, prostate cancer (e.g.,
25 castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), ovarian cancer, pancreatic cancer, and the like, or a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom’s macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma,
30 extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome).

 The term “transfected” or “transformed” or “transduced” refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or

5 “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

The term “specifically binds,” refers to an antibody, or a ligand, which recognizes and binds with a cognate binding partner (e.g., a stimulatory and/or costimulatory molecule present
10 on a T cell) protein present in a sample, but which antibody or ligand does not substantially recognize or bind other molecules in the sample.

“Regulatable chimeric antigen receptor (RCAR),” as used herein, refers to a set of polypeptides, typically two in the simplest embodiments, which when in an immune effector cell, provides the cell with specificity for a target cell, typically a cancer cell,
15 and with intracellular signal generation. In some embodiments, an RCAR comprises at least an extracellular antigen binding domain, a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from a stimulatory molecule and/or costimulatory molecule as defined herein in the context of a CAR
20 molecule. In some embodiments, the set of polypeptides in the RCAR are not contiguous with each other, e.g., are in different polypeptide chains. In some embodiments, the RCAR includes a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signaling domain. In some embodiments, the
25 RCAR is expressed in a cell (e.g., an immune effector cell) as described herein, e.g., an RCAR-expressing cell (also referred to herein as “RCARX cell”). In an embodiment the RCARX cell is a T cell, and is referred to as a RCART cell. In an embodiment the RCARX cell is an NK cell, and is referred to as a RCARN cell. The RCAR can provide the RCAR-expressing cell with specificity for a target cell, typically a cancer cell, and
30 with regulatable intracellular signal generation or proliferation, which can optimize an immune effector property of the RCAR-expressing cell. In embodiments, an RCAR cell relies at least in part, on an antigen binding domain to provide specificity to a target cell that comprises the antigen bound by the antigen binding domain.

5 “Membrane anchor” or “membrane tethering domain”, as that term is used herein, refers to a polypeptide or moiety, e.g., a myristoyl group, sufficient to anchor an extracellular or intracellular domain to the plasma membrane.

 “Switch domain,” as that term is used herein, e.g., when referring to an RCAR, refers to an entity, typically a polypeptide-based entity, that, in the presence of a dimerization molecule, associates with another switch domain. The association results in a functional coupling of a first entity linked to, e.g., fused to, a first switch domain, and a second entity linked to, e.g., fused to, a second switch domain. A first and second switch domain are collectively referred to as a dimerization switch. In embodiments, the first and second switch domains are the same as one another, e.g., they are polypeptides having the same primary amino acid sequence, and are referred to collectively as a homodimerization switch. In embodiments, the first and second switch domains are different from one another, e.g., they are polypeptides having different primary amino acid sequences, and are referred to collectively as a heterodimerization switch. In embodiments, the switch is intracellular. In embodiments, the switch is extracellular. In embodiments, the switch domain is a polypeptide-based entity, e.g., FKBP or FRB-based, and the dimerization molecule is small molecule, e.g., a rapalogue. In embodiments, the switch domain is a polypeptide-based entity, e.g., an scFv that binds a myc peptide, and the dimerization molecule is a polypeptide, a fragment thereof, or a multimer of a polypeptide, e.g., a myc ligand or multimers of a myc ligand that bind to one or more myc scFvs. In embodiments, the switch domain is a polypeptide-based entity, e.g., myc receptor, and the dimerization molecule is an antibody or fragments thereof, e.g., myc antibody.

 “Dimerization molecule,” as that term is used herein, e.g., when referring to an RCAR, refers to a molecule that promotes the association of a first switch domain with a second switch domain. In embodiments, the dimerization molecule does not naturally occur in the subject, or does not occur in concentrations that would result in significant dimerization. In embodiments, the dimerization molecule is a small molecule, e.g., rapamycin or a rapalogue, e.g., RAD001.

 The term “bioequivalent” refers to an amount of an agent other than the reference compound (e.g., RAD001), required to produce an effect equivalent to the effect produced by the reference dose or reference amount of the reference compound (e.g., RAD001). In an embodiment the effect is the level of mTOR inhibition, e.g., as measured by P70 S6 kinase inhibition, e.g., as evaluated in an *in vivo* or *in vitro* assay, e.g., as measured by an assay described herein, e.g., the Boulay assay, or measurement of phosphorylated S6 levels by

5 western blot. In an embodiment, the effect is alteration of the ratio of PD-1 positive/PD-1 negative T cells, as measured by cell sorting. In an embodiment a bioequivalent amount or dose of an mTOR inhibitor is the amount or dose that achieves the same level of P70 S6 kinase inhibition as does the reference dose or reference amount of a reference compound. In an embodiment, a bioequivalent amount or dose of an mTOR inhibitor is the amount or dose that
10 achieves the same level of alteration in the ratio of PD-1 positive/PD-1 negative T cells as does the reference dose or reference amount of a reference compound.

The term “low, immune enhancing, dose” when used in conjunction with an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 or rapamycin, or a catalytic mTOR inhibitor, refers to a dose of mTOR inhibitor that partially, but not fully, inhibits mTOR
15 activity, e.g., as measured by the inhibition of P70 S6 kinase activity. Methods for evaluating mTOR activity, e.g., by inhibition of P70 S6 kinase, are discussed herein. The dose is insufficient to result in complete immune suppression but is sufficient to enhance the immune response. In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in a decrease in the number of PD-1 positive immune effector cells, e.g., T cells or NK cells, and/or
20 an increase in the number of PD-1 negative immune effector cells, e.g., T cells or NK cells, or an increase in the ratio of PD-1 negative immune effector cells (e.g., T cells or NK cells) /PD-1 positive immune effector cells (e.g., T cells or NK cells).

In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in an increase in the number of naive T cells. In an embodiment, the low, immune enhancing, dose
25 of mTOR inhibitor results in one or more of the following:

an increase in the expression of one or more of the following markers: CD62L^{high}, CD127^{high}, CD27⁺, and BCL2, e.g., on memory T cells, e.g., memory T cell precursors;

a decrease in the expression of KLRG1, e.g., on memory T cells, e.g., memory T cell precursors; and

30 an increase in the number of memory T cell precursors, e.g., cells with any one or combination of the following characteristics: increased CD62L^{high}, increased CD127^{high}, increased CD27⁺, decreased KLRG1, and increased BCL2;

wherein any of the changes described above occurs, e.g., at least transiently, e.g., as compared to a non-treated subject.

5 “Refractory” as used herein refers to a disease, e.g., cancer, that does not respond to a treatment. In embodiments, a refractory cancer can be resistant to a treatment before or at the beginning of the treatment. In other embodiments, the refractory cancer can become resistant during a treatment. A refractory cancer is also called a resistant cancer.

 “Relapsed” or a “relapse” as used herein refers to the reappearance of a disease
10 (e.g., cancer) or the signs and symptoms of a disease such as cancer after a period of improvement or responsiveness, e.g., after prior treatment of a therapy, e.g., cancer therapy. For example, the period of responsiveness may involve the level of cancer cells falling below a certain threshold, e.g., below 20%, 1%, 10%, 5%, 4%, 3%, 2%, or 1%. The reappearance may involve the level of cancer cells rising above a certain threshold, e.g., above 20%, 1%, 10%,
15 5%, 4%, 3%, 2%, or 1%.

 Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically
20 disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity, includes something
25 with 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This applies regardless of the breadth of the range.

Description

 Provided herein are compositions of matter and methods of use for the treatment of a
30 disease such as cancer using cells expressing BCMA chimeric antigen receptors (CAR), e.g., CART-BCMA.

 In one aspect, the invention provides a number of chimeric antigen receptors (CAR) comprising an antibody or antibody fragment engineered for enhanced binding to a BCMA protein. In one aspect, the invention provides a cell (e.g., an immune effector cell, e.g., T cell
35 or NK cell) engineered to express a CAR, wherein the CAR T cell (“CART”) or CAR NK cell

5 exhibits an antitumor property. In one aspect a cell is transformed with the CAR and the CAR is expressed on the cell surface. In some embodiments, the cell (e.g., an immune effector cell, e.g., T cell or NK cell) is transduced with a viral vector encoding a CAR. In some
embodiments, the viral vector is a retroviral vector. In some embodiments, the viral vector is a lentiviral vector. In some such embodiments, the cell may stably express the CAR. In another
10 embodiment, the cell (e.g., an immune effector cell, e.g., T cell or NK cell) is transfected with a nucleic acid, e.g., mRNA, cDNA, DNA, encoding a CAR. In some such embodiments, the cell may transiently express the CAR.

In one aspect, the anti-BCMA antigen binding portion of the CAR is a scFv antibody fragment. In one aspect such antibody fragments are functional in that they retain the
15 equivalent binding affinity, e.g., they bind the same antigen with comparable efficacy, as the IgG antibody from which it is derived. In other embodiments, the antibody fragment has a lower binding affinity, e.g., it binds the same antigen with a lower binding affinity than the antibody from which it is derived, but is functional in that it provides a biological response described herein. In one embodiment, the CAR molecule comprises an antibody fragment that
20 has a binding affinity K_D of 10^{-4} M to 10^{-8} M, e.g., 10^{-5} M to 10^{-7} M, e.g., 10^{-6} M or 10^{-7} M, for the target antigen. In one embodiment, the antibody fragment has a binding affinity that is at least five-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold or 1,000-fold less than a reference antibody, e.g., an antibody described herein.

In one aspect such antibody fragments are functional in that they provide a biological
25 response that can include, but is not limited to, activation of an immune response, inhibition of signal-transduction origination from its target antigen, inhibition of kinase activity, and the like, as will be understood by a skilled artisan. In one aspect, the anti-BCMA antigen binding domain of the CAR is a scFv antibody fragment that is humanized compared to the murine sequence of the scFv from which it is derived. In one embodiment, the anti-BCMA antigen
30 binding domain is a human anti-BCMA antigen binding domain. In one embodiment, the anti-BCMA antigen binding domain is a humanized anti-BCMA antigen binding domain.

In some aspects, the antibodies of the invention are incorporated into a chimeric antigen receptor (CAR). In one aspect, the CAR comprises a BCMA binding domain comprising a sequence of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO:
35 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ

5 ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID
 NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID
 NO:134, SEQ ID NO: 135, SEQ ID NO:136, SEQ ID NO: 137, SEQ ID NO:138, SEQ ID NO:
 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO:
 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO:
 10 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, or SEQ ID NO: 266. In one
 aspect, the scFv domains are human. In another aspect, the scFv domains are humanized
 variants of the scFv domain of the antibodies or antibody fragments described in PCT
 Publication No. WO 2012/163805, US Patent No. 7,083,785, EP Patent No. 1975231B1, or
 PCT Publication No. WO 13/154760 (the contents of each are hereby incorporated by reference
 15 in their entireties), which disclose antibodies or scFv fragments of murine origin that
 specifically binds to human BCMA. Humanization of these mouse antibodies and/or scFvs
 may be desired for the clinical setting, where the mouse-specific residues may induce a human-
 anti-mouse antigen (HAMA) response in patients who receive CART-BCMA treatment, e.g.,
 treatment with immune effector cells, e.g., T cells or NK cells, transduced with the anti-BCMA
 20 CAR construct.

In one aspect, the anti-BCMA binding domain, e.g., human or humanized scFv, portion
 of a CAR of the invention is encoded by a transgene whose sequence has been codon optimized
 for expression in a mammalian cell. In one aspect, entire CAR construct of the invention is
 encoded by a transgene whose entire sequence has been codon optimized for expression in a
 25 mammalian cell. Codon optimization refers to the discovery that the frequency of occurrence
 of synonymous codons (i.e., codons that code for the same amino acid) in coding DNA is
 biased in different species. Such codon degeneracy allows an identical polypeptide to be
 encoded by a variety of nucleotide sequences. A variety of codon optimization methods is
 known in the art, and include, e.g., methods disclosed in at least US Patent Numbers 5,786,464
 30 and 6,114,148.

In one aspect, the human anti-BCMA binding domain comprises the scFv portion
 provided in SEQ ID NO: 39. In one aspect, the human anti-BCMA CAR comprises the scFv
 portion provided in SEQ ID NO: 40. In one aspect, the human anti-BCMA binding domain
 comprises the scFv portion provided in SEQ ID NO: 41. In one aspect, the human anti-BCMA
 35 binding domain comprises the scFv portion provided in SEQ ID NO: 42. In one aspect, the

5 human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 43. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 44. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 45. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 46. In one aspect, the human anti-BCMA
10 binding domain comprises the scFv portion provided in SEQ ID NO: 47. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 48. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 49. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 50. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 51. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 52. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 53. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 129. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 130. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 131. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 132. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 133. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID
25 NO: 134. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 135. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 136. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 137. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 138. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 139. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 140. In one aspect, the human anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 141. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 142. In one aspect, the human anti-BCMA
30 CAR comprises the scFv portion provided in SEQ ID NO: 143. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 144. In one aspect, the

5 human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 145. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 146. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 147. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 148. In one aspect, the human anti-BCMA CAR comprises the scFv portion
 10 provided in SEQ ID NO: 149. In one aspect, the humanized anti-BCMA binding domain comprises the scFv portion provided in SEQ ID NO: 255. In one aspect, the humanized anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 257.

In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 263. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided
 15 in SEQ ID NO: 264. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 265. In one aspect, the human anti-BCMA CAR comprises the scFv portion provided in SEQ ID NO: 266.

In one aspect, the CARs of the invention combine an antigen binding domain of a specific antibody with an intracellular signaling molecule. For example, in some aspects, the
 20 intracellular signaling molecule includes, but is not limited to, CD3-zeta chain, 4-1BB and CD28 signaling modules and combinations thereof. In one aspect, the antigen binding domain binds to BCMA. In one aspect, the BCMA CAR comprises a CAR selected from the sequence provided in one or more of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO:
 25 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO:
 30 231, SEQ ID NO: 232, and SEQ ID NO: 233. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO: 99. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO: 100. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO: 101. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO: 102. In one aspect, the BCMA CAR comprises the sequence
 35 provided in SEQ ID NO: 103. In one aspect, the BCMA CAR comprises the sequence

5 provided in SEQ ID NO:104. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:105. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:106. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:107. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:108. In one aspect, the BCMA CAR comprises the sequence
10 provided in SEQ ID NO:109. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:110. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:111. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:112. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:213. In one aspect, the BCMA CAR comprises the sequence provided
15 in SEQ ID NO:214. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:215. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:216. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:217. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:218. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:219. In one aspect,
20 the BCMA CAR comprises the sequence provided in SEQ ID NO:220. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:221. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:222. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:223. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:224. In one aspect, the BCMA CAR
25 comprises the sequence provided in SEQ ID NO:225. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:226. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:227. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:228. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:229. In one aspect, the BCMA CAR
30 comprises the sequence provided in SEQ ID NO:230. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:231. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:232. In one aspect, the BCMA CAR comprises the sequence provided in SEQ ID NO:233.

5 Furthermore, the present invention provides BCMA CAR compositions and their use in medicaments or methods for treating, among other diseases, cancer or any malignancy or autoimmune diseases involving cells or tissues which express BCMA

In one aspect, the CAR of the invention can be used to eradicate BCMA-expressing normal cells, thereby applicable for use as a cellular conditioning therapy prior to cell
10 transplantation. In one aspect, the BCMA-expressing normal cell is a BCMA-expressing normal stem cell and the cell transplantation is a stem cell transplantation.

In one aspect, the invention provides a cell (e.g., T cell or NK cell) engineered to express a chimeric antigen receptor (CAR), wherein the CAR T cell ("CART") or the CAR NK cell exhibits an antitumor property. A preferred antigen is BCMA. In one aspect, the antigen
15 binding domain of the CAR comprises a human anti-BCMA antibody fragment or a partially humanized anti-BCMA antibody fragment. In one aspect, the antigen binding domain of the CAR comprises human anti-BCMA antibody fragment or a partially humanized anti-BCMA antibody fragment comprising an scFv. Accordingly, the invention provides a BCMA-CAR that comprises a humanized anti-BCMA binding domain and is engineered into a cell, e.g., a T
20 cell or NK cell, and methods of their use for adoptive therapy.

In one aspect, the BCMA-CAR comprises at least one intracellular domain selected from the group of a CD137 (4-1BB) signaling domain, a CD28 signaling domain, a CD3zeta signal domain, and any combination thereof. In one aspect, the BCMA-CAR comprises at least one intracellular signaling domain is from one or more co-stimulatory molecule(s) other
25 than a CD137 (4-1BB) or CD28.

Chimeric Antigen Receptor (CAR)

The present invention provides a CAR (e.g., a CAR polypeptide) that comprises an anti-BCMA binding domain (e.g., human or humanized BCMA binding domain as described
30 herein), a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any anti-BMCA heavy chain binding domain amino acid sequences listed in Table 1 or 16. The anti-BCMA binding domain of the

5 CAR can further comprise a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any anti-BMCA heavy chain binding domain amino acid sequences listed in Table 1 or 16.

The present invention also provides nucleic acid molecules encoding the CAR as
 10 described herein, e.g., encoding a CAR that comprises an anti-BCMA binding domain (e.g., human or humanized BCMA binding domain as described herein), a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC
 15 CDR3) of any anti-BMCA heavy chain binding domain amino acid sequences listed in Table 1 or 16. In one embodiment, the encoded anti-BCMA binding domain of the CAR can further comprise a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any anti-BMCA heavy chain binding domain amino acid
 20 sequences listed in Table 1 or 16.

In specific aspects, a CAR construct of the invention comprises a scFv domain selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO:
 25 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, and SEQ ID NO:
 30 266, wherein the scFv may be preceded by an optional leader sequence such as provided in SEQ ID NO: 1, and followed by an optional hinge sequence such as provided in SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5, a transmembrane region such as provided in SEQ ID NO:6, an intracellular signalling domain that includes SEQ ID NO:7 or SEQ ID NO:8 and a CD3 zeta sequence that includes SEQ ID NO:9 or SEQ ID NO:10, wherein the
 35 domains are contiguous with and in the same reading frame to form a single fusion protein.

5 Also included in the invention is a nucleotide sequence that encodes the polypeptide of each of the scFv fragments selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ
 10 ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, and SEQ ID NO: 266.

15 Also included in the invention is a nucleotide sequence that encodes the polypeptide of each of the scFv fragments selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, and SEQ ID NO: 266, and each of the domains of SEQ ID NOS: 1,2,
 20 and 6-9, plus the encoded BCMA CAR fusion protein of the invention.

In one aspect, an exemplary BCMA CAR constructs comprise an optional leader sequence, an extracellular antigen binding domain, a hinge, a transmembrane domain, and an intracellular stimulatory domain. In one aspect an exemplary BCMA CAR construct comprises an optional leader sequence, an extracellular antigen binding domain, a hinge, a
 30 transmembrane domain, an intracellular costimulatory domain and an intracellular stimulatory domain. Specific BCMA CAR constructs containing human scFv domains of the invention are provided as SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO:
 35

5 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149. Full-length CAR sequences are also provided herein as SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45,
 10 SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149 as shown in Table 1.

An exemplary leader sequence is provided as SEQ ID NO: 1. An exemplary hinge/spacer sequence is provided as SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5. An exemplary transmembrane domain sequence is provided as SEQ ID NO:6. An exemplary sequence of the intracellular signaling domain of the 4-1BB protein is provided as
 20 SEQ ID NO: 7. An exemplary sequence of the intracellular signaling domain of CD27 is provided as SEQ ID NO:8. An exemplary CD3zeta domain sequence is provided as SEQ ID NO: 9 or SEQ ID NO:10.

In one aspect, the present invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule
 25 comprises the nucleic acid sequence encoding an anti-BCMA binding domain, e.g., described herein, that is contiguous with and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain. In one aspect, the anti-BCMA binding domain is selected from one or more of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ
 30 ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, and SEQ ID NO: 170. In one aspect, the anti-BCMA binding domain comprises SEQ ID
 35

- 5 NO: 54. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 55. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 56. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 57. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 58. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 59. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 60. In
- 10 one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 61. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 62. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 63. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 64. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 65. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 66. In one aspect, the anti-
- 15 BCMA binding domain comprises SEQ ID NO: 67. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 68. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 150. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 151. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 152. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 153. In one aspect, the anti-BCMA
- 20 binding domain comprises SEQ ID NO: 154. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 155. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 156. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 157. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 158. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 159. In one aspect, the anti-BCMA binding
- 25 domain comprises SEQ ID NO: 160. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 161. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 162. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 163. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 164. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 165. In one aspect, the anti-BCMA binding domain
- 30 comprises SEQ ID NO: 166. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 167. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 168. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 169. In one aspect, the anti-BCMA binding domain comprises SEQ ID NO: 170.

5 In one aspect, the present invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding an anti- BCMA binding domain selected from one or more of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ
10 ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, and SEQ ID
15 NO: 170, e.g., wherein the sequence is contiguous with and in the same reading frame as the nucleic acid sequence encoding an intracellular signaling domain. An exemplary intracellular signaling domain that can be used in the CAR includes, but is not limited to, one or more intracellular signaling domains of, e.g., CD3-zeta, CD28, 4-1BB, and the like. In some instances, the CAR can comprise any combination of CD3-zeta, CD28, 4-1BB, and the like. In
20 one aspect the nucleic acid sequence of a CAR construct of the invention is selected from one or more of SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237, SEQ ID
25 NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253, or SEQ ID NO: 254. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 114. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO:
30 115. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 116. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 117. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 118. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 119. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 120. In one aspect the nucleic acid sequence of a CAR
35 construct is SEQ ID NO: 121. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 122. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO:

5 123. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 124. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 125. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 126. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 127. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 128. In one aspect the nucleic acid sequence of a CAR
10 construct is SEQ ID NO: 234. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 235. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 236. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 237. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 238. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 239. In one aspect the nucleic acid
15 sequence of a CAR construct is SEQ ID NO: 240. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 241. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 242. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 243. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 244. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 245. In one
20 aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 246. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 247. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 248. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 249. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 250. In one aspect the nucleic acid sequence of a CAR construct is
25 SEQ ID NO: 251. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 252. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 253. In one aspect the nucleic acid sequence of a CAR construct is SEQ ID NO: 254.

The nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells
30 expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the nucleic acid of interest can be produced synthetically, rather than cloned.

The present invention includes retroviral and lentiviral vector constructs expressing a CAR that can be directly transduced into a cell.

5 The present invention also includes an RNA construct that can be directly transfected into a cell. A method for generating mRNA for use in transfection involves in vitro transcription (IVT) of a template with specially designed primers, followed by polyA addition, to produce a construct containing 3' and 5' untranslated sequence ("UTR"), a 5' cap and/or Internal Ribosome Entry Site (IRES), the nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO:35). RNA so produced can efficiently transfect different kinds of cells. In one embodiment, the template includes sequences for the CAR. In an embodiment, an RNA CAR vector is transduced into a cell, e.g., T cell or NK cell, by electroporation.

15 **Antigen binding domain**

 The CARs of the present invention comprise a target-specific binding domain. The choice of moiety depends upon the type and number of ligands that define the surface of a target cell. For example, the antigen binding domain may be chosen to recognize an antigen that acts as a cell surface marker on target cells associated with a particular disease state.

20 In one aspect, the CAR-mediated T-cell response can be directed to an antigen of interest by way of engineering an antigen binding domain that specifically binds a desired antigen into the CAR.

 In one aspect, the CAR of the present invention comprises a binding domain that specifically binds BCMA. In one aspect, the CAR of the present invention comprises an antigen binding domain that specifically binds human BCMA.

25 The antigen binding domain can be any protein that binds to the antigen including but not limited to a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof, including but not limited to a single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived nanobody, and to an alternative scaffold known in the art to function as antigen binding domain, such as a recombinant fibronectin domain, and the like. In some instances, it is beneficial for the antigen binding domain to be derived from the same species in which the CAR will ultimately be used in. For example, for use in humans, it may be beneficial for the antigen binding domain of the CAR to

- 5 comprise human or humanized residues for the antigen binding domain of an antibody or antibody fragment.

Thus, in one aspect, the antigen binding domain comprises a human or a humanized antibody or an antibody fragment. In one embodiment, the human anti-BCMA binding domain comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of a human anti-BCMA binding domain described herein, and/or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a human anti-BCMA binding domain described herein, e.g., a human anti-BCMA binding domain comprising one or more, e.g., all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the human anti-BCMA binding domain comprises one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a human anti-BCMA binding domain described herein, e.g., the human anti-BCMA binding domain has two variable heavy chain regions, each comprising a HC CDR1, a HC CDR2 and a HC CDR3 described herein. In one embodiment, the human anti-BCMA binding domain comprises a human light chain variable region described herein (e.g., in Table 1) and/or a human heavy chain variable region described herein (e.g., in Table 1). In one embodiment, the human anti-BCMA binding domain comprises a human heavy chain variable region described herein (e.g., in Table 1), e.g., at least two human heavy chain variable regions described herein (e.g., in Table 1). In one embodiment, the anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Table 1. In an embodiment, the anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 1, or a sequence with 95-99% identity with an amino acid sequence of Table 11; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not

5 more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 1, or a sequence with 95-99% identity to an amino acid sequence of Table 1.

In one embodiment, the human anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID
 10 NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO:
 15 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149, or a sequence with 95-99% identify thereof. In one embodiment, the nucleic acid sequence encoding the human anti-BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ
 20 ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168,
 25 SEQ ID NO: 169, and SEQ ID NO: 170, or a sequence with 95-99% identify thereof. In one embodiment, the human anti-BCMA binding domain is a scFv, and a light chain variable region comprising an amino acid sequence described herein, e.g., in Table 1, is attached to a heavy chain variable region comprising an amino acid sequence described herein, e.g., in Table 1, via a linker, e.g., a linker described herein. In one embodiment, the human anti-BCMA
 30 binding domain includes a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4 (SEQ ID NO:26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region. In one aspect, the antigen binding domain portion comprises one or more sequence selected from SEQ ID
 35 NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44,

5 SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 10 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, and SEQ ID NO: 149. In one aspect the CAR is selected from one or more sequence selected from SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, and SEQ ID NO: 233.

In one embodiment, the anti- BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 16) and/or a heavy chain variable region described herein (e.g., in Table 16). In one embodiment, the encoded humanized anti-BCMA binding domain comprises a light chain variable region provided in SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, and/or a heavy chain variable region provided in SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258. In one 20 embodiment, the encoded anti- BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Table 16. In an embodiment, the human or humanized anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications 25 (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262, or a sequence with 95-99% identity thereof; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications 30 (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain 35

5 variable region provided in SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ ID NO: 258, or a sequence with 95-99% identity thereof. In one embodiment, the encoded anti-BCMA binding domain includes a (Gly4-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4 (SEQ ID NO:26). The light chain variable region and heavy chain variable region of a scFv can be, e.g., in any of the following orientations: light chain variable region-linker-heavy
10 chain variable region or heavy chain variable region-linker-light chain variable region.

In one embodiment, the human anti- BCMA binding domain comprises a sequence selected from a group consisting of SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, and SEQ ID NO: 266, or a sequence with 95-99% identity thereof.

In some aspects, a non-human antibody is humanized, where specific sequences or
15 regions of the antibody are modified to increase similarity to an antibody naturally produced in a human or fragment thereof. In one aspect, the antigen binding domain is humanized.

A humanized antibody can be produced using a variety of techniques known in the art, including but not limited to, CDR-grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and
20 5,585,089, each of which is incorporated herein in its entirety by reference), veneering or resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973, each of which is incorporated herein by its entirety by reference), chain shuffling (see, e.g., U.S. Pat. No. 5,565,332, which is
25 incorporated herein in its entirety by reference), and techniques disclosed in, e.g., U.S. Patent Application Publication No. US2005/0042664, U.S. Patent Application Publication No. US2005/0048617, U.S. Pat. No. 6,407,213, U.S. Pat. No. 5,766,886, International Publication No. WO 9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem.,
30 272(16):10678-84 (1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu J S, Gene, 150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994), each of which is incorporated herein in its entirety by reference. Often, framework residues in the framework regions will be substituted with the corresponding residue from the
35 CDR donor antibody to alter, for example improve, antigen binding. These framework

5 substitutions, e.g., conservative substitutions are identified by methods well-known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, *Nature*, 332:323, which are incorporated herein by reference in their
10 entirety.)

A humanized antibody or antibody fragment has one or more amino acid residues remaining in it from a source which is nonhuman. These nonhuman amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. As provided herein, humanized antibodies or antibody fragments comprise one or
15 more CDRs from nonhuman immunoglobulin molecules and framework regions wherein the amino acid residues comprising the framework are derived completely or mostly from human germline. Multiple techniques for humanization of antibodies or antibody fragments are well-known in the art and can essentially be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327
20 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody, i.e., CDR-grafting (EP 239,400; PCT Publication No. WO 91/09967; and U.S. Pat. Nos. 4,816,567; 6,331,415; 5,225,539; 5,530,101; 5,585,089; 6,548,640, the contents of which are incorporated herein by reference herein in their entirety). In such humanized antibodies and antibody fragments,
25 substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species. Humanized antibodies are often human antibodies in which some CDR residues and possibly some framework (FR) residues are substituted by residues from analogous sites in rodent antibodies. Humanization of antibodies and antibody fragments can also be achieved by veneering or resurfacing (EP 592,106; EP
30 519,596; Padlan, 1991, *Molecular Immunology*, 28(4/5):489-498; Studnicka et al., *Protein Engineering*, 7(6):805-814 (1994); and Roguska et al., *PNAS*, 91:969-973 (1994)) or chain shuffling (U.S. Pat. No. 5,565,332), the contents of which are incorporated herein by reference herein in their entirety.

The choice of human variable domains, both light and heavy, to be used in making the
35 humanized antibodies is to reduce antigenicity. According to the so-called "best-fit" method,

5 the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987), the contents of which are incorporated herein by reference herein in their entirety). Another method uses a
10 particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (see, e.g., Nicholson et al. Mol. Immun. 34 (16-17): 1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference herein in their
15 entirety). In some embodiments, the framework region, e.g., all four framework regions, of the heavy chain variable region are derived from a VH4_4-59 germline sequence. In one embodiment, the framework region can comprise, one, two, three, four or five modifications, e.g., substitutions, e.g., conservative substitutions, e.g., from the amino acid at the corresponding murine sequence. In one embodiment, the framework region, e.g., all four
20 framework regions of the light chain variable region are derived from a VK3_1.25 germline sequence. In one embodiment, the framework region can comprise, one, two, three, four or five modifications, e.g., substitutions, e.g., conservative substitutions, e.g., from the amino acid at the corresponding murine sequence.

In some aspects, the portion of a CAR composition of the invention that comprises an
25 antibody fragment is humanized with retention of high affinity for the target antigen and other favorable biological properties. According to one aspect of the invention, humanized antibodies and antibody fragments are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and
30 are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, e.g., the analysis of residues that influence the ability of the candidate immunoglobulin to bind the target antigen.
35 In this way, FR residues can be selected and combined from the recipient and import sequences

5 so that the desired antibody or antibody fragment characteristic, such as increased affinity for the target antigen, is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

A humanized antibody or antibody fragment may retain a similar antigenic specificity as the original antibody, e.g., in the present invention, the ability to bind human BCMA In
10 some embodiments, a humanized antibody or antibody fragment may have improved affinity and/or specificity of binding to human BCMA.

In one embodiment, the humanized anti-BCMA binding domain of the CAR, comprises one or more (e.g., all three) light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary
15 determining region 3 (LC CDR3) of a humanized anti-BCMA binding domain described herein, and/or one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a humanized anti-BCMA binding domain described herein, e.g., a humanized anti-BCMA binding domain comprising one or more, e.g.,
20 all three, LC CDRs and one or more, e.g., all three, HC CDRs. In one embodiment, the humanized anti-BCMA binding domain comprises one or more (e.g., all three) heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of a humanized anti-BCMA binding domain described herein, e.g., the humanized anti-BCMA
25 binding domain has two variable heavy chain regions, each comprising a HC CDR1, a HC CDR2 and a HC CDR3 described herein. In one embodiment, the humanized anti-BCMA binding domain comprises a humanized light chain variable region described herein (e.g., SEQ ID NO:255 or 257) and/or a human heavy chain variable region described herein (e.g., SEQ ID NO:255 or 257).

30 In one aspect, the anti-BCMA binding domain is characterized by particular functional features or properties of an antibody or antibody fragment. For example, in one aspect, the portion of a CAR composition of the invention that comprises an antigen binding domain specifically binds human BCMA

5 In one aspect, the antigen binding domain has the same or a similar binding specificity to human BCMA as mouse BCMA. In one aspect, the invention relates to an antigen binding domain comprising an antibody or antibody fragment, wherein the antibody binding domain specifically binds to a BCMA protein or fragment thereof, wherein the antibody or antibody fragment comprises a variable light chain and/or a variable heavy chain that includes an amino acid sequence of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, or SEQ ID NO: 149. In one aspect, the antigen binding domain comprises an amino acid sequence of an scFv selected from SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, or SEQ ID NO: 149. In certain aspects, the scFv is contiguous with and in the same reading frame as a leader sequence. In one aspect the leader sequence is the polypeptide sequence provided as SEQ ID NO:1.

In one aspect, the anti-BCMA binding domain is a fragment, e.g., a single chain variable fragment (scFv). In one aspect, the anti-BCMA binding domain is a Fv, a Fab, a (Fab')₂, or a bi-functional (e.g. bi-specific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one aspect, the antibodies and fragments thereof of the invention binds a BCMA protein with wild-type or enhanced affinity.

In some instances, scFvs can be prepared according to method known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking VH and VL regions

5 together using flexible polypeptide linkers. The scFv molecules comprise a linker (e.g., a Ser-Gly linker) with an optimized length and/or amino acid composition. The linker length can greatly affect how the variable regions of a scFv fold and interact. In fact, if a short polypeptide linker is employed (e.g., between 5-10 amino acids) intrachain folding is prevented. Interchain folding is also required to bring the two variable regions together to form a functional epitope
 10 binding site. For examples of linker orientation and size see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCT publication Nos. WO2006/020258 and WO2007/024715, is incorporated herein by reference.

An scFv can comprise a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
 15 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid residues between its VL and VH regions. The linker sequence may comprise any naturally occurring amino acid. In some embodiments, the linker sequence comprises amino acids glycine and serine. In another embodiment, the linker sequence comprises sets of glycine and serine repeats such as (Gly₄Ser)_n, where n is a positive integer equal to or greater than 1 (SEQ ID NO:25). In one
 20 embodiment, the linker can be (Gly₄Ser)₄ (SEQ ID NO:27) or (Gly₄Ser)₃ (SEQ ID NO:28). Variation in the linker length may retain or enhance activity, giving rise to superior efficacy in activity studies.

Exemplary Human BCMA CAR Constructs and Antigen Binding Domains

Exemplary BCMA CAR constructs disclose herein comprise an scFv (e.g., a scFv as
 25 disclosed in Tables 1 or 16, optionally preceded with an optional leader sequence (e.g., SEQ ID NO:1 and SEQ ID NO:12 for exemplary leader amino acid and nucleotide sequences, respectively). The sequences of the scFv fragments (SEQ ID NOs: 39-53, 129-149, or 263-266, not including the optional leader sequence) are provided herein in Tables 1 or 16. The BCMA CAR construct can further include an optional hinge domain, e.g., a CD8 hinge domain
 30 (e.g., including the amino acid sequence of SEQ ID NO: 2 or encoded by a nucleic acid sequence of SEQ ID NO:13); a transmembrane domain, e.g., a CD8 transmembrane domain (e.g., including the amino acid sequence of SEQ ID NO: 6 or encoded by the nucleotide sequence of SEQ ID NO: 17); an intracellular domain, e.g., a 4-1BB intracellular domain (e.g., including the amino acid sequence of SEQ ID NO: 7 or encoded by the nucleotide sequence of
 35 SEQ ID NO: 18; and a functional signaling domain, e.g., a CD3 zeta domain (e.g., including

5 amino acid sequence of SEQ ID NO: 9 or 10, or encoded by the nucleotide sequence of SEQ ID NO: 20 or 21). In certain embodiments, the domains are contiguous with and in the same reading frame to form a single fusion protein. In other embodiments, the domain are in separate polypeptides, e.g., as in an RCAR molecule as described herein.

In certain embodiments, the full length BCMA CAR molecule includes the amino acid
 10 sequence of, or is encoded by the nucleotide sequence of, BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4,
 15 BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 1 or 16, or a sequence substantially (e.g., 95-99%) identical thereto.

In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes the scFv amino acid sequence of BCMA-1, BCMA-2, BCMA-3, BCMA-4,
 20 BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-
 25 C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 1 or 16 (with or without the leader sequence), or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding
 30 domain, includes the heavy chain variable region and/or the light chain variable region of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-
 35 C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-

5 C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 1 or 16, or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

10 In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 20; and/or one, two or three CDRs from the light chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 15 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 21; or a sequence substantially identical 20 (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 22; and/or one, two or three CDRs from the light 25 chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB- 30 C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 23; or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences.

35 In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1,

- 5 HCDR2 and/or HCDR3), provided in Table 24; and/or one, two or three CDRs from the light chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1,
- 10 BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 25; or a sequence substantially identical (e.g., 95-99% identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions
- 15 (e.g., conservative substitutions)) to any of the aforesaid sequences.

The sequences of human CDR sequences of the scFv domains are shown in Tables 20, 22, and 24 for the heavy chain variable domains and in Tables 21, 23, and 25 for the light chain variable domains. "ID" stands for the respective SEQ ID NO for each CDR.

- 20 Table 20: Heavy Chain Variable Domain CDRs according to the Kabat numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD)

Candidate	HCDR1	ID	HCDR2	ID	HCDR3	ID
139109	NHGMS	394	GIVYSGSTYYAASV KG	434	HGGESDV	474
139103	NYAMS	384	GISRSGENTYYADS VKG	424	SPAHHYGGMDV	464
139105	DYAMH	385	GISWNSGSIGYADSV KG	425	HSFLAY	465
139111	NHGMS	386	GIVYSGSTYYAASV KG	426	HGGESDV	466
139100	NFGIN	387	WINPKNNNTNYAQ KFQG	427	GPYYYQSYMDV	467
139101	SDAMT	388	VISGSGGTYYADS VKG	428	LDSSGYYYARGPRY	468
139102	NYGIT	389	WISAYNGNTNYAQ KFQG	429	GPYYYMDV	469
139104	NHGMS	390	GIVYSGSTYYAASV KG	430	HGGESDV	470
139106	NHGMS	391	GIVYSGSTYYAASV KG	431	HGGESDV	471
139107	NHGMS	392	GIVYSGSTYYAASV KG	432	HGGESDV	472
139108	DYYMS	393	YISSSGSTIYYADSV KG	433	ESGDGMDV	473

139110	DYYMS	395	YISSSGNTIYYADSV KG	435	STMVREDY	475
139112	NHGMS	396	GIVYSGSTYYAASV KG	436	HGGESDV	476
139113	NHGMS	397	GIVYSGSTYYAASV KG	437	HGGESDV	477
139114	NHGMS	398	GIVYSGSTYYAASV KG	438	HGGESDV	478
149362	SSYYYWG	399	SIYYSGSAYYNPSLK S	439	HWQEWPAFDI	479
149363	TSGMCVS	400	RIDWDEDKFYSTSL KT	440	SGAGGTSATAFDI	480
149364	SYSMN	401	SISSSSYIYYADSVK G	441	TIAAVYAFDI	481
149365	DYYMS	402	YISSSGSTIYYADSV KG	442	DLRGAFDI	482
149366	SHYIH	403	MINPSGGVTAYSQT LQG	443	EGSGSGWYFDF	483
149367	SGGYYS	404	YIYYSGSTYYNPSLK S	444	AGIAARLRGAFDI	484
149368	SYAIS	405	GIPIFGTANYAQKF QG	445	RGGYQLLRWDVGLL RSAFDI	485
149369	SNSAAWN	406	RTYYRSKWYSFYAI SLKS	446	SSPEGLFLYWFDP	486
BCMA_EBB- C1978-A4	SYAMS	407	AISGSGGSTYYADS VKG	447	VEGSGSLDY	487
BCMA_EBB- C1978-G1	RYPMS	408	GISDSGVSTYYADS AKG	448	RAGSEASDI	488
BCMA_EBB- C1979-C1	SYAMS	409	AISGSGGSTYYADS VKG	449	ATYKRELRYYYGM DV	489
BCMA_EBB- C1978-C7	SYAMS	410	AISGSGGSTYYADS VKG	450	ATYKRELRYYYGM DV	490
BCMA_EBB- C1978-D10	DYAMH	411	GISWNSGSIGYADSV KG	451	VGKAVPDV	491
BCMA_EBB- C1979-C12	DYAMH	412	SINWKGNLAYGDS VKG	452	HQGVAYNYAMDV	492
BCMA_EBB- C1980-G4	SYAMS	413	AISGSGGSTYYADS VKG	453	VVRDGMDDV	493
BCMA_EBB- C1980-D2	SYAMS	414	AISGSGGSTYYADS VKG	454	IPQTGTFDY	494
BCMA_EBB- C1978-A10	SYAMS	415	AISGSGGSTYYADS VKG	455	ANYKRELRYYYGM DV	495
BCMA_EBB- C1978-D4	SYAMS	416	AISGSGGSTYYADS VKG	456	ALVGATGAFDI	496
BCMA_EBB- C1980-A2	SYAMS	417	AISGSGGSTYYADS VKG	457	WFGEGFDP	497
BCMA_EBB- C1981-C3	SYAMS	418	AISGSGGSTYYADS VKG	458	VGYDSSGYRDYYG MDV	498
BCMA_EBB- C1978-G4	SYAMS	419	AISGSGGSTYYADS VKG	459	MGWSSGYLGAFDI	499
A7D12.2	NFGMN	420	WINTYTGESYFADD FKG	460	GEIYYGYDGGFAY	500
C11D5.3	DYSIN	421	WINTETREPAYAYD FRG	461	DYSYAMDY	501
C12A3.2	HYSMN	422	RINTESGVPIYADDF	462	DYLYSLDF	502

			KG			
C13F12.1	HYSMN	423	RINTETGEPLYADDF KG	463	DYLYSCDY	503

5

Table 21: Light Chain Variable Domain CDRs according to the Kabat numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD)

Candidate	LCDR1	ID	LCDR2	ID	LCDR3	ID
139109	RASQSISSYLN	514	AASSLQS	554	QQSYSTPYT	594
139103	RASQSISSFLA	504	GASRRAT	544	QQYHSSPSWT	584
139105	RSSQSLHLSNGYNYLD	505	LGSNRAS	545	MQALQTPYT	585
139111	KSSQSLLRNDGKTPLY	506	EVSNRFS	546	MQNIQFPS	586
139100	RSSQSLHLSNGYNYLN	507	LGSKRAS	547	MQALQTPYT	587
139101	RASQSISSYLN	508	GASTLAS	548	QQSYKRAS	588
139102	RSSQSLLYSNGYNYVD	509	LGSNRAS	549	MQGRQFPYS	589
139104	RASQSVSSNLA	510	GASTRAS	550	QQYGSSLT	590
139106	RASQSVSSKLA	511	GASIRAT	551	QQYGSSSWT	591
139107	RASQSVGSTNLA	512	DASNRAT	552	QQYGSSPPWT	592
139108	RASQSISSYLN	513	AASSLQS	553	QQSYTLA	593
139110	KSSSLVHNSGKTYLN	515	EVSNRDS	555	MQGTHWPGT	595
139112	QASEDINKFLN	516	DASTLQT	556	QQYESLPLT	596
139113	RASQSVGSNLA	517	GASTRAT	557	QQYNDWLPVT	597
139114	RASQSIGSSSLA	518	GASSRAS	558	QQYAGSPFFT	598
149362	KASQDIDDAMN	519	SATSPVP	559	LQHDNFPLT	599
149363	RASQDIYNNLA	520	AANKSQS	560	QHYYRFPYS	600
149364	RSSQSLHLSNGYNYLD	521	LGSNRAS	561	MQALQTPYT	601
149365	GGNNIGTKSVH	522	DDSVRPS	562	QVWDSDEHV V	602
149366	SGDGLSKKYVS	523	RDKERPS	563	QAWDDTTVV	603
149367	RASQGIRNWLA	524	AASNLQS	564	QKYNSAPFT	604
149368	GGNNIGSKSVH	525	GKNNRPS	565	SSRDSSGDHLR V	605
149369	QGDSLGNYYAT	526	GTNNRPS	566	NSRDSSGHLL	606
BCMA_EBB- C1978-A4	RASQSVSSAYLA	527	GASTRAT	567	QHYGSSFNSS LFT	607
BCMA_EBB- C1978-G1	RASQSVSNSLA	528	DASSRAT	568	QQFGTSSGLT	608
BCMA_EBB- C1979-C1	RASQSVSSSFLA	529	GASSRAT	569	QQYHSSPSWT	609
BCMA_EBB- C1978-C7	RASQSVSTTFLA	530	GSSNRAT	570	QQYHSSPSWT	610
BCMA_EBB- C1978-D10	RASQSISSYLN	531	AASSLQS	571	QQSYSTPYS	611
BCMA_EBB- C1979-C12	RATQSIGSSFLA	532	GASQRAT	572	QHYESSPSWT	612

BCMA_EBB-C1980-G4	RASQSVSSSYLA	533	GASSRAT	573	QQYGSPPRFT	613
BCMA_EBB-C1980-D2	RASQSVSSSYLA	534	GASSRAT	574	QHYGSSPSWT	614
BCMA_EBB-C1978-A10	RASQRVASNYLA	535	GASSRAT	575	QHYDSSPSWT	615
BCMA_EBB-C1978-D4	RASQSLSSNFLA	536	GASNWAT	576	QYYGTSPMYT	616
BCMA_EBB-C1980-A2	RSSQSLLSNGYNYLD	537	LGSNRAS	577	MQALQTPLT	617
BCMA_EBB-C1981-C3	RASQSVSSSYLA	538	GTSSRAT	578	QHYGNSPPKFT	618
BCMA_EBB-C1978-G4	RASQSVASSFLA	539	GASGRAT	579	QHYGGSPRLT	619
A7D12.2	RASQDVNTAVS	540	SASYRYT	580	QQHYSTPWT	620
C11D5.3	RASESVSIGAHLIH	541	LASNLET	581	LQSRIFPRT	621
C12A3.2	RASESVTILGSHLIY	542	LASNVQT	582	LQSRITPRT	622
C13F12.1	RASESVTILGSHLIY	543	LASNVQT	583	LQSRITPRT	623

5

Table 22: Heavy Chain Variable Domain CDRs according to the Chothia numbering scheme (Al-Lazikani et al., (1997) JMB 273,927-948)

Candidate	HCDR1	ID	HCDR2	ID	HCDR3	ID
139109	GFALSNH	634	VYSGS	674	HGGESDV	714
139103	GFTFSNY	624	SRSGEN	664	SPAHHYYGGMDV	704
139105	GFTFDDY	625	SWNSGS	665	HSFLAY	705
139111	GFALSNH	626	VYSGS	666	HGGESDV	706
139100	GYIFDNF	627	NPKNNN	667	GPYYYQSYMVDV	707
139101	GFTFSSD	628	SGSGGT	668	LDSSGYYYARGPRY	708
139102	GYTFSNY	629	SAYNGN	669	GPYYYMDV	709
139104	GFALSNH	630	VYSGS	670	HGGESDV	710
139106	GFALSNH	631	VYSGS	671	HGGESDV	711
139107	GFALSNH	632	VYSGS	672	HGGESDV	712
139108	GFTFSDY	633	SSSGST	673	ESGDGMDV	713
139110	GFTFSDY	635	SSSGNT	675	STMVREDY	715
139112	GFALSNH	636	VYSGS	676	HGGESDV	716
139113	GFALSNH	637	VYSGS	677	HGGESDV	717
139114	GFALSNH	638	VYSGS	678	HGGESDV	718
149362	GGSISSYY	639	YYSGS	679	HWQEWPAFDI	719
149363	GFSLRITSGM	640	DWDED	680	SGAGGTSATAFDI	720
149364	GFTFSSY	641	SSSSSY	681	TIAAVYAFDI	721
149365	GFTFSDY	642	SSSGST	682	DLRGAFDI	722
149366	GYTVTSH	643	NPSGGV	683	EGSGSGWYFDF	723
149367	GGSISSGGY	644	YYSGS	684	AGIAARLRGAFDI	724
149368	GGTFSSY	645	IPIFGT	685	RGGYQLLRWDVGLL RSAFDI	725

149369	GDSVSSNSA	646	YYRSKWY	686	SSPEGLFLYWFD	726
BCMA_EBB-C1978-A4	GFTFSSY	647	SGSGGS	687	VEGSGSLDY	727
BCMA_EBB-C1978-G1	GITFSRY	648	SDSGVS	688	RAGSEASDI	728
BCMA_EBB-C1979-C1	GFTFSSY	649	SGSGGS	689	ATYKRELRYYYGMDV	729
BCMA_EBB-C1978-C7	GFTFSSY	650	SGSGGS	690	ATYKRELRYYYGMDV	730
BCMA_EBB-C1978-D10	GFTFDDY	651	SWNSGS	691	VGKAVPDV	731
BCMA_EBB-C1979-C12	GFTFDDY	652	NWKGNS	692	HQGVAYYNYAMD	732
BCMA_EBB-C1980-G4	GFTFSSY	653	SGSGGS	693	VVRDGMDDV	733
BCMA_EBB-C1980-D2	GFTFSSY	654	SGSGGS	694	IPQTGTFDY	734
BCMA_EBB-C1978-A10	GFTFSSY	655	SGSGGS	695	ANYKRELRYYYGMDV	735
BCMA_EBB-C1978-D4	GFTFSSY	656	SGSGGS	696	ALVGATGAFDI	736
BCMA_EBB-C1980-A2	GFTFSSY	657	SGSGGS	697	WFGEGFDP	737
BCMA_EBB-C1981-C3	GFTFSSY	658	SGSGGS	698	VGYDSSGYRDYYGMDV	738
BCMA_EBB-C1978-G4	GFTFSSY	659	SGSGGS	699	MGWSSGYLGAFDI	739
A7D12.2	GYTFTNF	660	NTYTGE	700	GEIYYGYDGGFAY	740
C11D5.3	GYTFTDY	661	NTETRE	701	DYSYAMDY	741
C12A3.2	GYTFRHY	662	NTESGV	702	DYLYSLDF	742
C13F12.1	GYTFTHY	663	NTETGE	703	DYLYSCDY	743

5

Table 23: Light Chain Variable Domain CDRs according to the Chothia numbering scheme (Al-Lazikani et al., (1997) JMB 273,927-948)

Candidate	LCDR1	ID	LCDR2	ID	LCDR3	ID
139109	SQSISSY	754	AAS	794	SYSTPY	834
139103	SQSISSSF	744	GAS	784	YHSSPSW	824
139105	SQSLHNSNGYNY	745	LGS	785	ALQTPY	825
139111	SQSLLRNDGKTP	746	EVS	786	NIQFP	826
139100	SQSLHNSNGYNY	747	LGS	787	ALQTPY	827
139101	SQSISSY	748	GAS	788	SYKRA	828
139102	SQSLLYSNGYNY	749	LGS	789	GRQFPY	829
139104	SQSVSSN	750	GAS	790	YGSSL	830
139106	SQSVSSK	751	GAS	791	YGSSSW	831
139107	SQSVGSTN	752	DAS	792	YGSSPPW	832
139108	SQSISSY	753	AAS	793	SYTL	833
139110	SESLVHNSGKTY	755	EVS	795	GTHWPG	835

139112	SEDINKF	756	DAS	796	YESLPL	836
139113	SQSVGSN	757	GAS	797	YNDWLPV	837
139114	SQSIGSSS	758	GAS	798	YAGSPPF	838
149362	SQDIDDA	759	SAT	799	HDNFPL	839
149363	SQDIYNN	760	AAN	800	YYRFPY	840
149364	SQSLLSNGYNY	761	LGS	801	ALQTPY	841
149365	NNIGTKS	762	DDS	802	WSDSEHV	842
149366	DGLSKKY	763	RDK	803	WDDTTV	843
149367	SQGIRNW	764	AAS	804	YNSAPF	844
149368	NNIGSKS	765	GKN	805	RDSSGDHLR	845
149369	DSLGNYY	766	GTN	806	RDSSGHHL	846
BCMA_EBB-C1978-A4	SQSVSSAY	767	GAS	807	YGSSFNGSSLF	847
BCMA_EBB-C1978-G1	SQSVSNS	768	DAS	808	FGTSSGL	848
BCMA_EBB-C1979-C1	SQSVSSSF	769	GAS	809	YHSSPSW	849
BCMA_EBB-C1978-C7	SQSVSTTF	770	GSS	810	YHSSPSW	850
BCMA_EBB-C1978-D10	SQSISSY	771	AAS	811	SYSTPY	851
BCMA_EBB-C1979-C12	TQSIGSSF	772	GAS	812	YESSPSW	852
BCMA_EBB-C1980-G4	SQSVSSSY	773	GAS	813	YGSPPRF	853
BCMA_EBB-C1980-D2	SQSVSSSY	774	GAS	814	YGSSPSW	854
BCMA_EBB-C1978-A10	SQRVASNY	775	GAS	815	YDSSPSW	855
BCMA_EBB-C1978-D4	SQSLSSNF	776	GAS	816	YGTSPMY	856
BCMA_EBB-C1980-A2	SQSLLSNGYNY	777	LGS	817	ALQTPL	857
BCMA_EBB-C1981-C3	SQSVSSSY	778	GTS	818	YGNSPPKF	858
BCMA_EBB-C1978-G4	SQSVASSF	779	GAS	819	YGGSPRL	859
A7D12.2	SQDVNTA	780	SAS	820	HYSTPW	860
C11D5.3	SESVSVIG AHL	781	LAS	821	SRIFPR	861
C12A3.2	SESVTILGSHL	782	LAS	822	SRTIPR	862
C13F12.1	SESVTILGSHL	783	LAS	823	SRTIPR	863

5

Table 24. Heavy Chain Variable Domain CDRs according to a combination of the Kabat numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD) and the Chothia numbering scheme (Al-Lazikani et al., (1997) JMB 273,927-948).

10

Candidate	HCDR1	ID	HCDR2	ID	HCDR3	ID
139109	GFALSNHGMS	874	GIVYSGSTYYAAS VKG	914	HGGESDV	954
139103	GFTFSNYAMS	864	GISRSGENTYYAD SVKG	904	SPAHHYGGMDV	944
139105	GFTFDDYAMH	865	GISWNSGSIGYAD SVKG	905	HSFLAY	945
139111	GFALSNHGMS	866	GIVYSGSTYYAAS VKG	906	HGGESDV	946
139100	GYIFDNFGIN	867	WINPKNNNTNYA QKFQG	907	GPYYYQSYMDV	947
139101	GFTFSSDAMT	868	VISGSGGTTYAD SVKG	908	LDSSGYYYARGPR Y	948
139102	GYTFSNYGIT	869	WISAYNGNTNYA QKFQG	909	GPYYYYMDV	949
139104	GFALSNHGMS	870	GIVYSGSTYYAAS VKG	910	HGGESDV	950
139106	GFALSNHGMS	871	GIVYSGSTYYAAS VKG	911	HGGESDV	951
139107	GFALSNHGMS	872	GIVYSGSTYYAAS VKG	912	HGGESDV	952
139108	GFTFSDYYMS	873	YISSSGSTIYYADS VKG	913	ESGDGMDV	953
139110	GFTFSDYYMS	875	YISSSGNTIYYAD SVKG	915	STMVREDY	955
139112	GFALSNHGMS	876	GIVYSGSTYYAAS VKG	916	HGGESDV	956
139113	GFALSNHGMS	877	GIVYSGSTYYAAS VKG	917	HGGESDV	957
139114	GFALSNHGMS	878	GIVYSGSTYYAAS VKG	918	HGGESDV	958
149362	GGSISSSYYYW G	879	SIYYSGSAYYNPS LKS	919	HWQEWPAFDI	959
149363	GFSLRTSGMC VS	880	RIDWDEDKFYSTS LKT	920	SGAGGTSATAFDI	960
149364	GFTFSSYSMN	881	SISSSSYIYYADS VKG	921	TIAAVYAFDI	961
149365	GFTFSDYYMS	882	YISSSGSTIYYADS VKG	922	DLRGAFDI	962
149366	GYTVTSHYIH	883	MINPSGGVTAYS QTLQG	923	EGSGSGWYFDF	963
149367	GGSISSGGYY WS	884	YIYYSGSTYYNPS LKS	924	AGIAARLRGAFDI	964
149368	GGTFSSY AIS	885	GIPIFGTANYAQ KFQG	925	RGGYQLLRWDVG LLRSAFDI	965
149369	GDSVSSNSAA WN	886	RTYYRSKWYSFY AISLKS	926	SSPEGLFLYWFDP	966
BCMA_EBB -C1978-A4	GFTFSSYAMS	887	AISGSGGSTYYAD SVKG	927	VEGSGSLDY	967
BCMA_EBB -C1978-G1	GITFSRYPMS	888	GISDSGVSTYYAD SAKG	928	RAGSEASDI	968
BCMA_EBB -C1979-C1	GFTFSSYAMS	889	AISGSGGSTYYAD SVKG	929	ATYKRELRYYYG MDV	969
BCMA_EBB -C1978-C7	GFTFSSYAMS	890	AISGSGGSTYYAD SVKG	930	ATYKRELRYYYG MDV	970

BCMA_EBB -C1978-D10	GFTFDDYAMH	891	GISWNSGSIGYAD SVKG	931	VGKAVPDV	971
BCMA_EBB -C1979-C12	GFTFDDYAMH	892	SINWKGNSLAYG DSVKG	932	HQGVAYYNYAM DV	972
BCMA_EBB -C1980-G4	GFTFSSYAMS	893	AISGSGGSTYYAD SVKG	933	VVRDGMMDV	973
BCMA_EBB -C1980-D2	GFTFSSYAMS	894	AISGSGGSTYYAD SVKG	934	IPQTGTFDY	974
BCMA_EBB -C1978-A10	GFTFSSYAMS	895	AISGSGGSTYYAD SVKG	935	ANYKRELRYYYG MDV	975
BCMA_EBB -C1978-D4	GFSFSSYAMS	896	AISGSGGSTYYAD SVKG	936	ALVGATGAFDI	976
BCMA_EBB -C1980-A2	GFTFSSYAMS	897	AISGSGGSTYYAD SVKG	937	WFGEGFDP	977
BCMA_EBB -C1981-C3	GFTFSSYAMS	898	AISGSGGSTYYAD SVKG	938	VGYDSSGYRDI YGMMDV	978
BCMA_EBB -C1978-G4	GFTFSSYAMS	899	AISGSGGSTYYAD SVKG	939	MGWSSGYLGAFD I	979
A7D12.2	GYTFTNFGMN	900	WINTYTGESYFA DDFKG	940	GEIYYGYDGGFAY	980
C11D5.3	GYTFTDYSIN	901	WINTETREPAYA YDFRG	941	DYSYAMDY	981
C12A3.2	GYTFRHYSMN	902	RINTESGVPIYAD DFKG	942	DYLYSLDF	982
C13F12.1	GYTFTHYSMN	903	RINTETGEPLYAD DFKG	943	DYLYSCDY	983

5

Table 25. Light Chain Variable Domain CDRs according to a combination of the Kabat numbering scheme (Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD) and the Chothia numbering scheme (Al-Lazikani et al., (1997) JMB 273,927-948).

Candidate	LCDR1	ID	LCDR2	ID	LCDR3	ID
139109	RASQSISSYLN	994	AASSLQS	1034	QQSYSTPYT	1074
139103	RASQSISSSFLA	984	GASRRAT	1024	QQYHSSPSWT	1064
139105	RSSQSLLHNSNGYNYLD	985	LGSNRAS	1025	MQALQTPYT	1065
139111	KSSQSLLRNDGKTPLY	986	EVSNRFS	1026	MQNIQFPS	1066
139100	RSSQSLLHNSNGYNYLN	987	LGSKRAS	1027	MQALQTPYT	1067
139101	RASQSISSYLN	988	GASTLAS	1028	QQSYKRAS	1068
139102	RSSQSLLYNSNGYNYVD	989	LGSNRAS	1029	MQGRQFPYS	1069
139104	RASQSVSSNLA	990	GASTRAS	1030	QQYGSSLT	1070
139106	RASQSVSSKLA	991	GASIRAT	1031	QQYGSSSWT	1071
139107	RASQSVGSTNLA	992	DASNRAT	1032	QQYGSSPPWT	1072
139108	RASQSISSYLN	993	AASSLQS	1033	QQSYTLA	1073
139110	KSESLSVHNSGKTYLN	995	EVSNRDS	1035	MQGTHWPGT	1075
139112	QASEDINKFLN	996	DASTLQT	1036	QQYESLPLT	1076
139113	RASQSVGSNLA	997	GASTRAT	1037	QQYNDWLPV T	1077
139114	RASQSIGSSSLA	998	GASSRAS	1038	QQYAGSPFFT	1078

149362	KASQDIDDAMN	999	SATSPVP	1039	LQHDNFPLT	1079
149363	RASQDIYNNLA	1000	AANKSQS	1040	QHYYRFPYS	1080
149364	RSSQSLHSHNGYNYLD	1001	LGSNRAS	1041	MQALQTPYT	1081
149365	GGNNIGTKSVH	1002	DDSVRPS	1042	QVWDSDSEHVV	1082
149366	SGDGLSKKYVS	1003	RDKERPS	1043	QAWDDTTVV	1083
149367	RASQGIRNWLA	1004	AASNLQS	1044	QKYNAPFT	1084
149368	GGNNIGSKSVH	1005	GKNNRPS	1045	SSRDSSGDHLRV	1085
149369	QGDSLGNYYAT	1006	GTNNRPS	1046	NSRDSSGHHL	1086
BCMA_EBB-C1978-A4	RASQSVSSAYLA	1007	GASTRAT	1047	QHYGSSFNGLSLFT	1087
BCMA_EBB-C1978-G1	RASQSVSNSLA	1008	DASSRAT	1048	QQFGTSSGLT	1088
BCMA_EBB-C1979-C1	RASQSVSSSFLA	1009	GASSRAT	1049	QQYHSSPSWT	1089
BCMA_EBB-C1978-C7	RASQSVSTTFLA	1010	GSSNRAT	1050	QQYHSSPSWT	1090
BCMA_EBB-C1978-D10	RASQSISSYLN	1011	AASSLQS	1051	QQSYSTPYS	1091
BCMA_EBB-C1979-C12	RATQSIGSSFLA	1012	GASQRAT	1052	QHYESSPSWT	1092
BCMA_EBB-C1980-G4	RASQSVSSSYLA	1013	GASSRAT	1053	QQYGSPPRFT	1093
BCMA_EBB-C1980-D2	RASQSVSSSYLA	1014	GASSRAT	1054	QHYGSSPSWT	1094
BCMA_EBB-C1978-A10	RASQRVASNYLA	1015	GASSRAT	1055	QHYDSSPSWT	1095
BCMA_EBB-C1978-D4	RASQSLSSNFLA	1016	GASNWAT	1056	QYYGTSPMYT	1096
BCMA_EBB-C1980-A2	RSSQSLHSHNGYNYLD	1017	LGSNRAS	1057	MQALQTPLT	1097
BCMA_EBB-C1981-C3	RASQSVSSSYLA	1018	GTSSRAT	1058	QHYGNSPPKFT	1098
BCMA_EBB-C1978-G4	RASQSVASSFLA	1019	GASGRAT	1059	QHYGGSPRLT	1099
A7D12.2	RASQDVNTAVS	1020	SASYRYT	1060	QQHYSTPWT	1100
C11D5.3	RASESVSVIGAHLIH	1021	LASNLET	1061	LQSRIFPRT	1101
C12A3.2	RASESVTILGSHLIY	1022	LASNVQT	1062	LQSRITPRT	1102
C13F12.1	RASESVTILGSHLIY	1023	LASNVQT	1063	LQSRITPRT	1103

5

In certain embodiments, the CAR molecule described herein (*e.g.*, the CAR nucleic acid or the CAR polypeptide) or a BCMA binding domain includes:

(1) one, two, or three light chain (LC) CDRs chosen from one of the following:

10 (i) a LC CDR1 of SEQ ID NO: 504, LC CDR2 of SEQ ID NO: 544 and LC CDR3 of SEQ ID NO: 584 of BCMA-4 CAR (139103);

5 (ii) a LC CDR1 of SEQ ID NO: 514, LC CDR2 of SEQ ID NO: 554 and LC CDR3 of SEQ ID NO: 594 of BCMA-10 CAR (139109);

(iii) a LC CDR1 of SEQ ID NO: 516, LC CDR2 of SEQ ID NO: 556 and LC CDR3 of SEQ ID NO: 596 of BCMA-13 CAR (139112); or

10 (iv) a LC CDR1 of SEQ ID NO: 518, LC CDR2 of SEQ ID NO: 558 and LC CDR3 of SEQ ID NO: 598 of BCMA-15 CAR (139114), and/or

(2) one, two, or three heavy chain (HC) CDRs from one of the following:

(i) a HC CDR1 of SEQ ID NO: 384, HC CDR2 of SEQ ID NO: 424 and HC CDR3 of SEQ ID NO: 464 of BCMA-4 CAR (139103);

15 (ii) a HC CDR1 of SEQ ID NO: 394, HC CDR2 of SEQ ID NO: 434 and HC CDR3 of SEQ ID NO: 474 of BCMA-10 CAR (139109);

(iii) a HC CDR1 of SEQ ID NO: 396, HC CDR2 of SEQ ID NO: 436 and HC CDR3 of SEQ ID NO: 476 of BCMA-13 CAR (139112); or

(iv) a HC CDR1 of SEQ ID NO: 398, HC CDR2 of SEQ ID NO: 438 and HC CDR3 of SEQ ID NO: 478 of BCMA-15 (139114).

20 In certain embodiments, the CAR molecule described herein (*e.g.*, the CAR nucleic acid or the CAR polypeptide) includes:

(1) one, two, or three light chain (LC) CDRs chosen from one of the following:

25 (i) a LC CDR1 of SEQ ID NO: 744, LC CDR2 of SEQ ID NO: 784 and LC CDR3 of SEQ ID NO: 824 of BCMA-4 CAR (139103);

(ii) a LC CDR1 of SEQ ID NO: 754, LC CDR2 of SEQ ID NO: 794 and LC CDR3 of SEQ ID NO: 834 of BCMA-10 CAR (139109);

(iii) a LC CDR1 of SEQ ID NO: 756, LC CDR2 of SEQ ID NO: 796 and LC CDR3 of SEQ ID NO: 836 of BCMA-13 CAR (139112); or

30 (iv) a LC CDR1 of SEQ ID NO: 758, LC CDR2 of SEQ ID NO: 798 and LC CDR3 of SEQ ID NO: 838 of BCMA-15 CAR (139114); and/or

(2) one, two, or three heavy chain (HC) CDRs chosen from one of the following:

(i) a HC CDR1 of SEQ ID NO: 624, HC CDR2 of SEQ ID NO: 664 and HC CDR3 of SEQ ID NO: 704 of BCMA-4 CAR (139103);

35 (ii) a HC CDR1 of SEQ ID NO: 634, HC CDR2 of SEQ ID NO: 674 and HC CDR3 of SEQ ID NO: 714 of BCMA-10 CAR (139109);

5 (iii) a HC CDR1 of SEQ ID NO: 636, HC CDR2 of SEQ ID NO: 676 and HC CDR3 of SEQ ID NO: 716 of BCMA-13 CAR (139112); or

(iv) a HC CDR1 of SEQ ID NO: 638, HC CDR2 of SEQ ID NO: 678 and HC CDR3 of SEQ ID NO: 718 of BCMA-15 CAR (139114).

10 In certain embodiments, the CAR molecule described herein (*e.g.*, the CAR nucleic acid or the CAR polypeptide) includes:

(1) one, two, or three light chain (LC) CDRs chosen from one of the following:

(i) a LC CDR1 of SEQ ID NO: 984 LC CDR2 of SEQ ID NO: 1024 and LC CDR3 of SEQ ID NO: 1064 of BCMA-4 CAR (139103);

15 (ii) a LC CDR1 of SEQ ID NO: 994, LC CDR2 of SEQ ID NO: 1034 and LC CDR3 of SEQ ID NO: 1074 of BCMA-10 CAR (139109);

(iii) a LC CDR1 of SEQ ID NO: 996, LC CDR2 of SEQ ID NO: 1036 and LC CDR3 of SEQ ID NO: 1076 of BCMA-13 CAR (139112); or

(iv) a LC CDR1 of SEQ ID NO: 998, LC CDR2 of SEQ ID NO: 1038 and LC CDR3 of SEQ ID NO: 1078 of BCMA-15 CAR (139114); and/or

(2) one, two, or three heavy chain (HC) CDRs chosen from one of the following:

(i) a HC CDR1 of SEQ ID NO: 864, HC CDR2 of SEQ ID NO: 904 and HC CDR3 of SEQ ID NO: 944 of BCMA-4 CAR (139103);

(ii) a HC CDR1 of SEQ ID NO: 874, HC CDR2 of SEQ ID NO: 914 and HC CDR3 of SEQ ID NO: 954 of BCMA-10 CAR (139109);

(iii) a HC CDR1 of SEQ ID NO: 876, HC CDR2 of SEQ ID NO: 916 and HC CDR3 of SEQ ID NO: 956 of BCMA-13 CAR (139112);

(iv) a HC CDR1 of SEQ ID NO: 878, HC CDR2 of SEQ ID NO: 918 and HC CDR3 of SEQ ID NO: 958 of BCMA-15 CAR (139114).

30 In embodiments, anti-BCMA CAR constructs, *e.g.*, human or humanized anti-BCMA CAR constructs, are generated using a method described herein, *e.g.*, as described in Example 4. Exemplary anti-BCMA scFvs include but are not limited to BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, and BCMA-15. The sequences of human anti-BCMA scFv

5 fragments (SEQ ID NOS: 39-52), are provided in Table 1 (and the name designations are provided in Table 2).

In embodiments, full BCMA CAR constructs (e.g., SEQ ID NOS: 99-113) are generated using scFv fragments, e.g., the human scFv fragments (e.g., SEQ ID NOS: 39-52), in combination with additional sequences, such as those shown below.

10 It is noted that the scFv fragments described herein, e.g., in Tables 1 and 16 or in SEQ ID NOS: 39-53, 129-149, 263-266, 271 or 273, without a leader sequence (e.g., without the amino acid sequence of SEQ ID NO: 1 or the nucleotide sequence of SEQ ID NO:12), are encompassed by the present invention. In other embodiments, scFv fragments described
 15 leader sequence (e.g., without the amino acid sequence of SEQ ID NO: 1 or the nucleotide sequence of SEQ ID NO:12), are also encompassed by the present invention.

leader (amino acid sequence) (SEQ ID NO: 1)

20 MALPVTALLPLALLHAARP

leader (nucleic acid sequence) (SEQ ID NO: 12)

ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCATGCCGCTAGACC
 C

25 CD8 hinge (amino acid sequence) (SEQ ID NO: 2)

TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD

CD8 hinge (nucleic acid sequence) (SEQ ID NO: 13)

ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCACCATCGCGTCGCAGCCCCTG
 TCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGACACGAGGGGGGCTG
 30 GACTTCGCCTGTGAT

CD8 transmembrane (amino acid sequence) (SEQ ID NO: 6)

IYIWAPLAGTCGVLLLSLVITLYC

35 CD8 transmembrane (nucleic acid sequence) (SEQ ID NO: 17)

ATCTACATCTGGGCGCCCTTGCCGGGACTTGTGGGGTCTTCTCTGTCACCTGGTTATCAC
 CCTTTACTGC

5

4-1BB Intracellular domain (amino acid sequence) (SEQ ID NO: 7)

KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL

4-1BB Intracellular domain (nucleic acid sequence) (SEQ ID NO: 18)

AAACGGGGCAGAAAGAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAA
 10 ACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCAGAAGAAGAAGGAGGATGT
 GAACTG

CD28 Intracellular domain (amino acid sequence) (SEQ ID NO: 1104)

RSKRSRLLHSDYMNMTPRRPGPTRKHYPYAPPRDFAAYRS (SEQ ID NO: 1104)

15

CD28 Intracellular domain (nucleotide sequence) (SEQ ID NO: 1105)

AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCG
 CCGCCCCGGGCCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCG
 CAGCCTATCGCTCC (SEQ ID NO: 1105)

20

ICOS Intracellular domain (amino acid sequence) (SEQ ID NO: 1106)

T K K K Y S S S V H D P N G E Y M F M R A V N T A K K S R L T D V T L
 (SEQ ID NO: 1106)

25

ICOS Intracellular domain (nucleotide sequence) (SEQ ID NO: 1107)

ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACATGTTTCATGA
 GAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGACCCTA (SEQ ID NO: 1107)

30

CD3 zeta domain (amino acid sequence) (SEQ ID NO: 9)

RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
 LQKDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQUALPPR

CD3 zeta (nucleic acid sequence) (SEQ ID NO: 20)

AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCAGAACCAGCTC
 35 TATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGC
 CGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAA
 TGAAGTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCG
 CCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACAC
 CTACGACGCCCTTACATGCAGGCCCTGCCCCCTCGC

5

CD3 zeta domain (amino acid sequence; NCBI Reference Sequence NM_000734.3) (SEQ ID NO:10)

RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE
LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR

10

CD3 zeta (nucleic acid sequence; NCBI Reference Sequence NM_000734.3); (SEQ ID NO:21)

AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAG
AACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTT
TGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGA
15 AGAACCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGG
AGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGC
ACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGC
CCTTCACATGCAGGCCCTGCCCCCTCGC

20

IgG4 Hinge (amino acid sequence) (SEQ ID NO:36)

ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGV
EVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE
PQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHLEALHNHYTQKSLSLSLGKM

25

IgG4 Hinge (nucleotide sequence) (SEQ ID NO:37)

GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGGACCCA
GCGTGTTCTGTGTTCCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAGGT
GACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCAGTTCAACTGGTACGTG
30 GACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACC
TACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAATAC
AAGTGTAAGGTGTCCAACAAGGGCCTGCCAGCAGCATCGAGAAAACCATCAGCAAGGCC
AAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAGAGGAGATGACC
AAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCAGCGACATCGCCGTGG
35 AGTGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACA
GCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGG
GCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGAG
CCTGAGCCTGTCCCTGGGCAAGATG

5

In embodiments, the CAR scFv fragments are cloned into lentiviral vectors to create a full length CAR construct in a single coding frame, and using a promoter, e.g., EF1 alpha promoter, for expression (SEQ ID NO: 11).

EF1 alpha promoter

10 CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCACAGTCCCGAGAAGTTGGGGGGAGGGGTCGG
CAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTT
CCCCAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTTCGCAACGGGTTTGCCGCCA
GAACACAGGTAAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAAT
15 TACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCT
TGCGCTTAAGGAGCCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCT
GGTGGCACCTTCGCGCCTGTCTCGCTGCTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGAC
GCTTTTTTCTGGCAAGATAGTCTTGTAATGCGGGCCAAGATCTGCACACTGGTATTTTCGGTTTTTGGGGCCGCG
GGCGGCGACGGGGCCCGTGGTCCAGCGCACATGTTCCGGCGAGGCGGGGCCCTGCCAGCGCGGCCACCGAGAATCG
20 GACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGC
GGCAAGGCTGGCCCCGGTCGGCACCAAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCA
AAATGGAGGACCGGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCTCAG
CCGTGCTTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGAGTAC
GTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGG
25 CCAGCTTGGCACTTGATGTAATTCTCCTTGGAAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCACTTCAAGCCTC
AGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTTGCTGA (SEQ ID NO: 11).

Gly/Ser (SEQ ID NO:25)

GGGGS

Gly/Ser (SEQ ID NO:26): This sequence may encompass 1-6 "Gly Gly Gly Gly Ser" repeating
30 units

GGGGSGGGGS GGGGSGGGGS GGGGSGGGGS

Gly/Ser (SEQ ID NO:27)

GGGGSGGGGS GGGGSGGGGS

35

Gly/Ser (SEQ ID NO:28)

GGGGSGGGGS GGGGS

Gly/Ser (SEQ ID NO:29)

40 GGGS

PolyA: (A)₅₀₀₀ (SEQ ID NO:30)

5

PolyA: (T)₁₀₀ (SEQ ID NO:31)**PolyA: (T)₅₀₀₀ (SEQ ID NO:32)**10 **PolyA: (A)₅₀₀₀ (SEQ ID NO:33)****PolyA: (A)₄₀₀ (SEQ ID NO:34)****PolyA: (A)₂₀₀₀ (SEQ ID NO:35)**

15

Gly/Ser (SEQ ID NO:38): This sequence may encompass 1-10 "Gly Gly Gly Ser" repeating units

GGGSGGGSGG GSGGGSGGGS GGGSGGGSGG GSGGGSGGGS

20 The amino acid and nucleic acid sequences of exemplary BCMA scFv domains and
exemplary BCMA CAR molecules are provided in Table 1.

Table 2 below designates the nicknames for the BCMA CAR constructs with
respect to the DNA ID number, also listed in Table 1.

Table 2: CAR construct IDs

Nickname	Novartis ID	DNA2.0 ID
BCMA-1	ER95-03VA	139100
BCMA-2	UR96-08PA	139101
BCMA-3	KR98-03KA	139102
BCMA-4	JF32-78IB	139103
BCMA-5	AR99-08FA	139104
BCMA-6	ZF34-73CB	139105
BCMA-7	QR91-12ZA	139106
BCMA-8	GR92-17UA	139107
BCMA-9	OG62-93QB	139108
BCMA-10	EG63-98LB	139109
BCMA-11	UG65-93FB	139110
BCMA-12	HU13-58ZB	139111
BCMA-13	KG66-98AB	139112
BCMA-14	HJ64-62PB	139113

BCMA-15 PY43-48LB 139114

5

Table 1. Amino Acid and Nucleic Acid Sequences of exemplary anti-BCMA scFv domains and BCMA CAR molecules

The amino acid sequences variable heavy chain and variable light chain sequences for each

10 scFv is also provided. Table 2 lists names and CAR construct IDs for several BCMA CARs.

Name/ Description	SEQ ID NO:	Sequence
139109		
139109- aa ScFv domain	49	EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVITITCRASQ SISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSSSLQP EDFATYYCQQSYSTPYTFGQGTKVEIK
139109- nt ScFv domain	64	GAAGTGCAATTGGTGAATCAGGGGGAGGACTTGTGCAGCCTGGAGGATCGCT GAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCACGGGATGTCCT GGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTGGGTATTGTGTAC AGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTACCATCAGCCG GGACAACCTCCAGGAACACTCTGTACCTCCAAATGAATTGCTGAGGCCAGAGG ACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGACGTCTGGGGA CAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCGGCAGCGGGGG TCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCACCAGTCCCCGAGCT CGCTGTCCGCCTCCGTGGGAGATCGGGTCAACATCACGTGCCGCGCCAGCCAG TCGATTTCCCTCCTACCTGAACTGGTACCAACAGAAGCCCCGAAAAGCCCCGAA GCTTCTCATCTACGCCGCTCGAGCCTGCAGTCAGGAGTGGCCTCACGGTTCT CCGGCTCCGGTTCCGGTACTGATTTACCCCTGACCATTTCCTCCCTGCAACCG GAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCCCTACACTTT CGGACAAGGCACCAAGGTCGAAATCAAG
139109- aa VH	79	EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139109- aa VL	94	DIQLTQSPSSLSASVGDRVITITCRASQSISSYLNWYQQKPGKAPKLLIYAASS LQSGVPSRFSGSGSGTDFTLTITSSSLQPEDFATYYCQQSYSTPYTFGQGTKVEI K
139109- aa Full CAR	109	MALPVTALLLPLALLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNH GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQLTQ SPSSLSASVGDRVITITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVP SRFSGSGSGTDFTLTITSSSLQPEDFATYYCQQSYSTPYTFGQGTKVEIKTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREYDVLDRGRDPEMGGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHM QALPPR
139109- nt	124	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC

Full CAR		CGCTCGGCCCCGAAGTGCAATTGGTGGAATCAGGGGGAGGACTTGTGCAGCCTG GAGGATCGCTGAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCAC GGGATGTCCTGGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTCCGG TATTGTGTACAGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTCA CCATCAGCCGGGACAACTCCAGGAACACTCTGTACCTCCAAATGAATTCGCTG AGGCCAGAGGACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGA CGTCTGGGGACAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCG GCAGCGGGGGTCCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCAGCCAG TCCCCGAGCTCGCTGTCCGCCTCCGTGGGAGATCGGGTCACCATCACGTGCCG CGCCAGCCAGTCGATTTCTCCTACCTGAACTGGTACCAACAGAAGCCCGGAA AAGCCCCGAAGCTTCTCATCTACGCCGCCTCGAGCCTGCAGTCAGGAGTGCCC TCACGGTTCTCCGGCTCCGGTTCCGGTACTGATTTACCCTGACCATTTCCTC CCTGCAACCGGAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCC CCTACACTTTTCGGACAAGGCACCAAGGTGAAATCAAGACCACTACCCAGCA CCGAGGCCACCCACCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG ACTTCGCCTGCGATATCTACATTTGGGCCCTCTGGCTGGTACTTGCGGGGTC CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCCGAAGAAGCT GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG AGGACGGCTGTTTCATGCCGGTTCAGAGAGGAGGAGGAAGCGGCTGCGAACTG CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGGCAAAGGCCACGACGGAC TGTACCAGGGAAGCTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG CAGGCCCTGCCGCCTCGG
139103		
139103- aa ScFv domain	39	QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISR SGENTYYADSVKGRFTISRDNKNTLYLQMNSLRDEDTAVYYCARSPAHYYGG MDVWGQGTITVTVSSASGGGSGGRASGGGSDIVLTQSPGTLSPGERATLS CRASQSISSSFLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLT ISRLEPEDSAVYYCQQYHSSPSWTFGQGTKLEIK
139103- nt ScFv domain	54	CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGAAGATCGCT TAGACTGTCTGTGCGCCAGCGGGTTCACTTTCTCGAACTACGCGATGTCTT GGGTCCGCCAGGCACCCGGAAGGGACTCGGTGGGTGTCCGGCATTTCCTCGG TCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTC AAGGGACAACAGCAAAAACACCTGTACTTGCAAATGAACTCCCTGCGGGATG AAGATACAGCCGTGTACTATTGCGCCCGGTGCGCTGCCATTACTACGGCGGA ATGGACGTCTGGGGACAGGGAACCACTGTGACTGTCAGCAGCGCGTCGGGTGG CGGCGGCTCAGGGGGTCCGGGCCTCCGGGGGGGAGGGTCCGACATCGTGCTGA CCCAGTCCCCGGGAACCTGAGCCTGAGCCCGGGAGAGCGCGCGACCCCTGTCA TGCCGGGCATCCAGAGCATTAGCTCCTCCTTCTCGCCTGGTATCAGCAGAA GCCCGGACAGGCCCCGAGGCTGTGATCTACGGCGCTAGCAGAAGGGCTACCG GAATCCCAGACCGGTTCTCCGGCTCCGGTTCGGGACCGATTTCACCTTACT ATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCCAGCAGTACCA CTCATCCCCGTGCTGGACGTTCCGGACAGGGCACCAAGCTGGAGATTAAG
139103- aa VH	69	QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISR SGENTYYADSVKGRFTISRDNKNTLYLQMNSLRDEDTAVYYCARSPAHYYGG MDVWGQGTITVTVSS
139103- aa VL	84	DIVLTQSPGTLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGAS RRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTKL

		EIK
139103- aa Full CAR	99	MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFSNY AMSWVRQAPGKGLGWVSGISRSRGENTYYADSVKGRFTISRDN SKNTLYLQMN LRDEDTAVYYCARSPAHYYGMDVWGQGTITVTVSSASGGGSGGRASGGGSD IVLTQSPGTLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASR RATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQYHSSPSWTFGQGTKLE IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCELRVKFSRSADAPAYKQGQNLNELNLGRREEYDVLDRRGRDPFEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR
139103- nt Full CAR	114	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCG GAAGATCGCTTAGACTGTCTGTGCGGCCAGCGGGTTCACTTCTCGAACTAC GCGATGTCCTGGGTCCGCCAGGCACCCGAAAGGGAAGGACTCGGTTGGGTGTCCGG CATTTCGGGTCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCT TCACCATCTCAAGGGACAACAGCAAAAACACCCTGTACTTGCAAATGAAGTCC CTGCGGGATGAAGATACAGCCGTGTACTATTGCGCCCGGTGCGCTGCCATTA CTACGGCGGAATGGACGTCTGGGGACAGGGAACCACTGTGACTGTGAGCAGCG CGTCGGGTGGCGGCGGCTCAGGGGGTCCGGCCCTCCGGGGGGGAGGGTCCGAC ATCGTGCTGACCCAGTCCCCGGGAACCCGTAGCCCTGAGCCCGGGAGAGCGCGC GACCCTGTCTATGCCGGGCATCCCAGAGCATTAGCTCCTCCTTCTCGCCTGGT ATCAGCAGAAGCCCGGACAGGCCCCGAGGCTGCTGATCTACGGCGCTAGCAGA AGGGCTACCGGAATCCCAGACCGGTTCTCCGGCTCCGGTTCCGGGACCGATT CACCTTACTATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCC AGCAGTACCACTCATCCCCGTCTGTGGACGTTCCGACAGGGCACCAAGCTGGAG ATTAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGAGCTGGTGGGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCT CTGGCTGGTACTTGCGGGGTCTGTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGCAGAACCAAGCTCTACAACGAACCTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGAAGTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
139105		
139105- aa ScFv domain	40	QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW NSGSIGYADSVKGRFTISRDNKNSLYLQMNLSRAEDTALYYCSVHSFLAYWG QGTLVTVSSASGGGSGGRASGGGSDIVMTQTPLSLPTVPEPASISCRSSQ SLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK
139105- nt ScFv domain	55	CAAGTGCAACTCGTCAATCCGGTGGAGGTCTGGTCCAACCTGGTAGAAGCCT GAGACTGTCTGTGCGGCCAGCGGATTACCTTTGATGACTATGCTATGCACT GGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTGCGGAATTAGCTGG AACTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTC CCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCGCTCAGGGCTG AGGATACCGCGCTGTACTACTGCTCCGTGCATTCTTCTGGCCTACTGGGGA CAGGGAAGTCTGGTCACCGTGTGAGCGCCTCCGGCGGCGGGGGCTCGGGTGG

		ACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAGACCCCGCTGA GCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCGGTCATCCAG TCCCTTCTCCACTCCAACGGATACAACCTACCTCGACTGGTACCTCCAGAAGCC GGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGAGCCTCAGGAG TGCCGGATCGGTTTACGCGGATCTGGTTCCGGAACTGATTTCACTCTGAAGATT TCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGCAGGCGCTGCA GACCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAG
139105- aa VH	70	QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW NSGSIQYADSVKGRFTISRDNKNSLYLQMNSLRAEDTALYYCSVHSFLAYWG QGTLVTVSS
139105- aa VL	85	DIVMTQTPLSLPVTGPGEPAISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLLI YLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQG TKVEIK
139105- aa Full CAR	100	MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFDDY AMHWVRQAPGKGLEWVSGISWNSGSIQYADSVKGRFTISRDNKNSLYLQMNS LRAEDTALYYCSVHSFLAYWGQGTLVTVSSASGGGGSGGRASGGGSDIVMTQ TPLSLPVTGPGEPAISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLLIYLGSNR ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSRFPPEEEE GGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATKDTY DALHMQALPPR
139105- nt Full CAR	115	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAACTCGTCGAATCCGGTGGAGGTCTGGTCCAACCTG GTAGAAGCCTGAGACTGTCGTGTGCGGCCAGCGGATTACCTTTGATGACTAT GCTATGCACTGGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTGCGG AATTAGCTGGAACCTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCT TCACCATCTCCCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCG CTCAGGGCTGAGGATACCGCGCTGTACTACTGCTCCGTGCATTCTTCTGCTGGC CTACTGGGGACAGGGAACCTCTGGTCACCGTGTGAGCGCCTCCGGCGGCGGGG GCTCGGGTGGACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAG ACCCCGCTGAGCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCG GTCATCCCAGTCCCTTCTCCACTCCAACGGATACAACCTACCTCGACTGGTACC TCCAGAAGCCGGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGA GCCTCAGGAGTGCCGGATCGGTTACGCGGATCTGGTTCCGGAACTGATTTTAC TCTGAAGATTTCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGC AGGCGCTGCAGACCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAG ACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGGCCCTCTGGCT GGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG CGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGC AGACTACTCAAGAGGAGGACGGCTGTTTATGCCGGTTCCAGAGGAGGAGGAA GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA CAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTTCGGAGAGAGG AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG CCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAA GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA AAGGCCACGACGGAATGTACCAGGGACTCAGCACCGCCACCAAGGACACCTAT GACGCTCTTACATGCAGGCCCTGCCGCCTCGG
139111		

139111- aa ScFv domain	41	EVQLLESGGGLVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLSVTPGQPASISCKSSQ SLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNNRFSGVDPDRFSGSGSGTDFTLKI SRVEAEDVGAYYCMQNIQFSPFSGGGTKLEIK
139111- nt ScFv domain	56	GAAGTGC AATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTGGAGGATCACT GAGACTTTCGTGTGCGGTGTGAGGCTTCGCCCTGAGCAACCACGGCATGAGCT GGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGGGATCGTCTAC TCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTTCGCTTACCATTTCCTG CGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTGCGGCCCCGAGG ACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGATGTCTGGGGA CAGGGCACTACCGTGACCGTGTGAGCGCCTCGGGGGGAGGAGGCTCCGGCGG TCGCGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAGACTCCACTCT CGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAAGAGCTCCAG AGCCTGCTGAGGAACGACGGAAGACTCCTCTGTATTGGTACCTCCAGAAGGC TGGACAGCCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGCTTCTCCGGGG TGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCAGACTTACCCTGAAAATC TCCAGGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGCAAAACATCCA GTTCCCTTCCTTCGGCGCGGCACAAAGCTGGAGATTAAG
139111- aa VH	71	EVQLLESGGGLVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139111- aa VL	86	DIVMTQTPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLI YEVSNNRFSGVDPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFSPFSGGT KLEIK
139111- aa Full CAR	101	MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAVSGFALSNGTH MSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSNTLYLQMNSLR PEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVMTQ TPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNNR FSGVDPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFSPFSGGGTKLEIKT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG GCELRVKFSRSADAPAYKQGQNLQYLNELNLRREEYDVLDKRRGRDPPEMGGK RRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGKGDGLYQGLSTATKDTYD ALHMQALPPR
139111- nt Full CAR	116	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTG GAGGATCACTGAGACTTTCGTGTGCGGTGTGAGGCTTCGCCCTGAGCAACCAC GGCATGAGCTGGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGG GATCGTCTACTCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTTCGCTTCA CCATTTCCTCGGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTG CGGCCCGAGGACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGA TGTCTGGGGACAGGGCACTACCGTGACCGTGTGAGCGCCTCGGGGGGAGGAG GCTCCGGCGGTGCGGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAG ACTCCACTCTCGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAA GAGCTCCCAGAGCCTGCTGAGGAACGACGGAAGACTCCTCTGTATTGGTACC TCCAGAAGGCTGGACAGCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGC TTCTCCGGGGTGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCAGACTTCAC CCTGAAAATCTCCAGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGC AAAACATCCAGTTCCCTTCCTTCGGCGGCGGCACAAAGCTGGAGATTAAGACC ACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCC TCTGTCCCTGCGTCCGGAGGCATGTAGACCCCGAGCTGGTGGGGCCGTGCATA

		CCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCTCTGGCTGGT ACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGG TCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCCTTCATGAGGCCTGTGCAGA CTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCCCAGAGGAGGAGGAAGGC GGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAA GCAGGGGCAGAACCCAGCTCTACAACGAACTCAATCTTGGTTCGGAGAGAGGAGT ACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCG CGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGAT GGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCCAAAG GCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGAC GCTCTTCACATGCAGGCCCTGCCGCCTCGG
139100		
139100- aa ScFv domain	42	QVQLVQSGAEVRKTGASVKVSKASGYIFDNFGINWVRQAPGQGLEWMGWINP KNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDVAVYYCARGPYYYQSY MDVWGQGTMTVTVSSASGGGSGGRASGGGSDIVMTQTPLSLPVTGPGEPA SISRSSQSLLSHNGYNYLNWYLQKPGQSPQLLIYLGSKRASGVPDRFSGSGS GTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGTKLEIK
139100- nt ScFv domain	57	CAAGTCCAACCTCGTCCAGTCCGGCGCAGAAAGTCAGAAAAACCGGTGCTAGCGT GAAAGTGTCCTGCAAGGCCTCCGGCTACATTTTCGATAACTTCGGAATCAACT GGGTCAGACAGGCCCCGGGCCAGGGGCTGGAATGGATGGGATGGATCAACCCC AAGAACAACAACACCAACTACGCACAGAAGTTCAGGGCCGCGTGACTATCAC CGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCTCCCTGCGGTTCGG AGGACACTGCCGTGTATTACTGCGCGAGGGGCCATACTACTACCAAAGCTAC ATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTTCATCCGCCTCCGGTGG TGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGATATTGTGATGA CCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCGGCCTCCATTTC TGCCGGTCTTCGCAATCACTCCTGCATTCCAACGGTTACAACCTACCTGAATTG GTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTATCTGGGCTCGA AGCGCGCTCCGGGGTGCCGTGACCGGTTTAGCGGATCTGGGAGCGGCACGGAC TTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAGTGTACTACTG TATGCAGGCGCTGCAGACTCCGTACACATTCGGACAGGGCACCAAGCTGGAGA TCAAG
139100- aa VH	72	QVQLVQSGAEVRKTGASVKVSKASGYIFDNFGINWVRQAPGQGLEWMGWINP KNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDVAVYYCARGPYYYQSY MDVWGQGTMTVTVSS
139100- aa VL	87	DIVMTQTPLSLPVTGPGEPA SISRSSQSLLSHNGYNYLNWYLQKPGQSPQLLI YLGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQG TKLEIK
139100- aa Full CAR	102	MALPVTALLLPLALLLHAARPQVQLVQSGAEVRKTGASVKVSKASGYIFDNF GINWVRQAPGQGLEWMGWINPKNNNTNYAQKFQGRVTITADESTNTAYMEVSS LRSEDVAVYYCARGPYYYQSYMDVWGQGTMTVTVSSASGGGSGGRASGGGSD IVMTQTPLSLPVTGPGEPA SISRSSQSLLSHNGYNYLNWYLQKPGQSPQLLIY LGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGT KLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF PEEEEGGCELRVKFSRSADAPAYKQGQNLYNELNLGRREEYDVLDRKRRDP EMGGKPRRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGKGHGDLGYQLSTA TKDITYDALHMQALPPR
139100- nt Full CAR	117	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTCCAACCTCGTCCAGTCCGGCGCAGAAAGTCAGAAAAACCG GTGCTAGCGTGAAAGTGTCTGCAAGGCCTCCGGCTACATTTTCGATAACTTC GGAATCAACTGGGTGAGACAGGCCCGGGCCAGGGGCTGGAATGGATGGGATG

		GATCAACCCCAAGAACAACAACACCAACTACGCACAGAAGTTCAGGGGCCGCG TGACTATCACCGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCTCC CTGCGGTTCGGAGGACACTGCCGTGTATTACTGCGCGAGGGGCCATACTACTA CCAAAGCTACATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTCTATCCG CCTCCGGTGGTGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGAT ATTGTGATGACCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCAGGC CTCCATTTCTGCCGGTCTTCGCAATCACTCCTGCATTCCAACGGTTACAACCT ACCTGAATTGGTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTAT CTGGGCTCGAAGCGCGCCTCCGGGGTGCTGACCGGTTTAGCGGATCTGGGAG CGGCACGGACTTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAG TGTACTACTGTATGCAGGCGCTGCAGACTCCGTACACATTTCGGACAGGGCACC AAGCTGGAGATCAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCC TACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCGAG CTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATT TGGGCCCCCTCTGGCTGGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCAC TCTTTACTGTAAGCGCGGTTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCT TCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTC CCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGC AGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACCTCAATC TTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCA GAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGA GCTCCAAAAGGATAAGATGGCAGAAAGCCTATAGCGAGATTGGTATGAAAGGGG AACGCAGAAGAGGCCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCC ACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
139101		
139101- aa ScFv domain	43	QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISG SGGTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYY ARGPRYWQGTLVTVSSASGGGSGGRASGGGSDIQLTQSPSSLASVGD RV TITCRASQSISSYLNWYQQKPKAPKLLIYGASTLASGVPARFSGSGSGTHFT LTINSLQSEDSATYYCQQSYKRA SFGQGTKVEIK
139101- nt ScFv domain	58	CAAGTGC AACTTCAAGAATCAGGCGGAGGACTCGTG CAGCCCGGAGGATCATT GCGGCTCTCGTGCGCCGCTCGGGCTTACCTTCTCGAGCGACGCCATGACCT GGGTCCGCCAGGCCCCGGGGAAGGGGCTGGAATGGGTGTCTGTGATTTCCGGC TCCGGGGGA ACTACGTACTACGCCGATTCCGTGAAAGGTCGCTTCACTATCTC CCGGGACAACAGCAAGAACACCCCTTTATCTGCAAATGAATCCCTCCGCGCCG AGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGGCTACTACTAT GCCCCGGGTCCGAGATACTGGGGACAGGGAACCCCTCGTGACCGTGTCTCCGC GTCCGGCGGAGGAGGGTCGGGAGGGCGGGCCTCCGGCGGCGGCGGTTCCGGACA TCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGGGCGACAGAGTC ACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGAACTGGTACCA ACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCTTCGACCCTGG CATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCACCTCACTTCACT CTGACCATTAAACAGCCTCCAGTCCGAGGATTACGCCACTTACTACTGTCAGCA GTCCTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTCGAGATCAAG
139101- aa VH	73	QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISG SGGTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYY ARGPRYWQGTLVTVSS
139101- aa VL	88	DIQLTQSPSSLASVGD RV TITCRASQSISSYLNWYQQKPKAPKLLIYGAST LASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRA SFGQGTKVEIK
139101- aa Full CAR	103	MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGFTFSSD AMTWVRQAPGKGLEWVSVISGSGGTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKLDSSGYYYARGPRYWQGTLVTVSSASGGGSGGRASGGG

		GSDIQLTQSPSSLSASVGDRTITCRASQSISSYLNWYQQKPGKAPKLLIYGA STLASGVPARFSGSGSGTHFTLTINSLOSEDSATYYCQOSYKRASFGQGTKVE IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCELRVKFSRSADAPAYKQGQONQLYNELNLGRREEYDVLDRRRGRDPEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKD TYDALHMQALPPR
139101- nt Full CAR	118	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAACTTCAAGAATCAGGCGGAGGACTCGTGCGAGCCG GAGGATCATTGCGGCTCTCGTGCGCCGCTCGGGCTTACCTTCTCGAGCGAC GCCATGACCTGGGTCCGCCAGGCCCGGGGAAGGGGTGGAATGGGTGTCTGT GATTTCCGGCTCCGGGGGAACACTACGTACTACGCCGATTCCGTGAAAGGTGCT TCACTATCTCCCGGGACAACAGCAAGAACACCCTTTATCTGCAAATGAATTCC CTCCGCGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGG CTACTACTATGCCCCGGGTCCGAGATACTGGGGACAGGGAACCCTCGTGACCG TGTCCTCCGCGTCCGGCGGAGGAGGTGCGGAGGGCGGGCTCCGGCGGCGGC GGTTCGGACATCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGCG CGACAGAGTCACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGA ACTGGTACCAACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCT TCGACCCTGGCATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCAC TCACTTCACTCTGACCATTAAACAGCCTCCAGTCCGAGGATTCAGCCACTTACT ACTGTCAGCAGTCTTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTGAG ATCAAGACCACTACCCAGCACCAGGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGAGCTGGTGCGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCT CTGGCTGGTACTTGCGGGGTCTGTCTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGGCAGAACCAGCTCTACAACGAACCTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGAAGTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTACATGCAGGCCCTGCCGCTCGG
139102		
139102- aa ScFv domain	44	QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISA YNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDYAVYYCARGPYYYMD VWGKGTMTVSSASGGGSGGRASGGGGSEIVMTQSPLSLPVTGPGEPAISCR SSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLGSNRASGVDPDRFSGSGSGTDFK LQISRVEAEDVGIYYCMQGRQFPYSFGQGTKVEIK
139102- nt ScFv domain	59	CAAGTCCAAGTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCGGAGCGAGCGT GAAAGTGTCTGCAAGGCTTCCGGGTACACCTTCTCCAAGTACGGCATCACTT GGGTGCGCCAGGCCCGGGACAGGGCCTGGAATGGATGGGGTGGATTTCCGCG TACAACGGCAATACGAAGTACGCTCAGAAGTTCAGGGTAGAGTGACCATGAC TAGGAACACCTCCATTTCCACCGCTACATGGAAGTGTCTCCCTGCGGAGCG AGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTACTACATGGAT GTCTGGGGGAAGGGGACTATGGTCAACGTGTCATCCGCTCGGGAGGCGGCGG ATCAGGAGGACGCGCTCTGGTGGTGGAGGATCGGAGATCGTGATGACCCAGA GCCCTCTCTCCTTGCCCGTGAAGTCTGGGGAGCCCGCATCCATTTTCATGCCG AGCTCCCAGTCACTTCTTACTCCAACGGCTATAACTACGTGGATTGGTACCT CCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGCTCGAACAGGG

		CCAGCGGAGTGCCTGACCGGTTCTCCGGGTCGGGAAGCGGGACCGACTTCAAG CTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACTACTGTATGCA GGGCCGCCAGTTTCCGTA CTCTCGGACAGGGCACCAAAGTGGAAATCAAG
139102- aa VH	74	QVQLVQSGAEVKKPGASVKVSKASGYTFSNYGITWVRQAPGQGLEWMGWISA YNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSED TAVYYCARGPYYYMD VWGKGTMTVSS
139102- aa VL	89	EIVMTQSPLSLPVTGPGEPA SISRSSQSLLYSNGYNYVDWYLQKPGQSPQLLI YLGSNRASGVDPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQG TKVEIK
139102- aa Full CAR	104	MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSKASGYTFSNY GITWVRQAPGQGLEWMGWISAYNGNTNYAQKFQGRVTMTRNTSISTAYMELSS LRSED TAVYYCARGPYYYMDVWGKGTMTVSSASGGGSGGRASGGGGSEIV MTQSPLSLPVTGPGEPA SISRSSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLG SNRASGVDPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQGTKV EIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPE EEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATK DTYDALHMQALPPR
139102- nt Full CAR	119	ATGGCCCTCCCTGTCAACGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCAAGTCCA ACTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCCG GAGCGAGCGTGAAAGTGTCTTGCAAGGCTTCCGGGTACACCTTCTCCA ACTAC GGCATCACTTGGGTGCGCCAGGCCCGGGACAGGGCCTGGAATGGATGGGGTG GATTTCGCGGTACAACGGCAATACGA ACTACGCTCAGAAGTTCAGGGTAGAG TGACCATGACTAGGAACACCTCCATTTCCACCGCCTACATGGA ACTGTCTCTCC CTGCGGAGCGAGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTA CTACATGGATGTCTGGGGGAAGGGGACTATGGTCACCGTGTATCCGCCTCGG GAGGCGGCGGATCAGGAGGACGCGCCTCTGGTGGTGGAGGATCGGAGATCGTG ATGACCCAGAGCCCTCTCTCCTTGCCCGTGACTCCTGGGGAGCCCGCATCCAT TTCATGCCGAGCTCCCAGTCACTTCTCTACTCCAACGGCTATAACTACGTGG ATTGGTACCTCCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGC TCGAACAGGGCCAGCGGAGTGCCTGACCGGTTCTCCGGGTGCGGAAGCGGGAC CGACTTCAAGCTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACT ACTGTATGCAGGGCCGCCAGTTTCCGTACTCGTTCCGACAGGGCACCAAAGTG GAAATCAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCAT CGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTG GGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCC CCTCTGGCTGGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTA CTGTAAGCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGA GGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCACAGAG GAGGAGGAAGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGC TCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGA ACTCAATCTTGGTC GGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATG GGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCA AAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCA GAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAG GACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
139104		
139104- aa ScFv domain	45	EVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDN SRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGSGGRASGGGGSEIVLTQSPATLSVSPGESATLSRASQ SVSSNLAWYQQKPGQAPRLLIYGASTRASGIPDRFSGSGSGTDFLTITSSLQA

		EDVAVYYCQQYGSSSLTFGGGTKVEIK
139104- nt ScFv domain	60	GAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTGGAGGATCACT TCGCCTGTCTGCGCCGTGTGCGGCTTTGCCCTGTCCAACCATGGAATGAGCT GGGTCCGCCGCGCGCCGGGAAGGGCCTCGAATGGGTGTCCGGCATCGTCTAC TCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCACGATTTACG GGACAACTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTTCGGCCGGAGG ATACTGCCATCTACTACTGCTCCGCCACGGTGGCGAATCCGACGTCTGGGGC CAGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAGGAAGCGGGGG TAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAGTCCCCGCCA CCTTGAGCGTGTACCAGGAGAGTCCGCCACCCTGTATGCCGCGCCAGCCAG TCCGTGTCTCCAACTGGCTTGGTACCAGCAGAAGCCGGGGCAGGCCCCCTAG ACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCGGATAGGTTCA GCGGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTCGCTGCAAGCC GAGGACGTGGCTGTGTACTACTGTGTCAGCAGTACGGAAGCTCCCTGACTTTCGG TGGCGGGACCAAAGTCGAGATTAAG
139104- aa VH	75	EVQLLETGGGLVQPGGSLRLSCAVSGFALSNGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139104- aa VL	90	EIVLTQSPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAST RASGIPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQYGSSSLTFGGGTKVEIK
139104- aa Full CAR	105	MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAVSGFALSNG GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQ SPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRASGIP DRFSGSGSGTDFTLTISLQAEDVAVYYCQQYGSSSLTFGGGTKVEIKTTTPAP RPPTPAPTIIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVL LLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCELR VKFSRSADAPAYKQGQNLQYLNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKHGHDGLYQGLSTATKDTYDALHMQ ALPPR
139104- nt Full CAR	120	ATGGCCCTCCCTGTACCCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTG GAGGATCACTTCGCCTGTCTGCGCCGTGTGCGGCTTTGCCCTGTCCAACCAT GGAATGAGCTGGGTCCGCCGCGCGCCGGGAAGGGCCTCGAATGGGTGTCCGG CATCGTCTACTCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCA CGATTTACGGGACAACCTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTT CGGCCGGAGGATACTGCCATCTACTACTGCTCCGCCACGGTGGCGAATCCGA CGTCTGGGGCCAGGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAG GAAGCGGGGGTAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAG TCCCCCGCCACCTTGAGCGTGTACACAGGAGAGTCCGCCACCCTGTATGCCG CGCCAGCCAGTCCGTGTCTCCAACCTGGCTTGGTACCAGCAGAAGCCGGGGC AGGCCCTAGACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCCC GATAGGTTACAGCGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTC GCTGCAAGCCGAGGACGTGGCTGTGTACTACTGTGTCAGCAGTACGGAAGCTCCC TGACTTTCCGTGGCGGGACCAAAGTCGAGATTAAGACCACTACCCAGCACCG AGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTCCCTGCGTCC GGAGGCATGTAGACCCGAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACT TCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGCGGGGTCTG CTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAAGAAGCTGCT GTACATCTTTAAGCAACCCTTCATGAGGCCTGTGTCAGACTACTCAAGAGGAGG ACGGCTGTTTCATGCCGTTCCAGAGGAGGAGGAAGGCGGTGCGAACTGCGC GTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCA

		GCTCTACAACGAACTCAATCTTGGTCCGAGAGAGGAGTACGACGTGCTGGACA AGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCC CAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAG CGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCCAAAGGCCACGACGGACTGT ACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAG GCCCTGCCGCCTCGG
139106		
139106- aa ScFv domain	46	EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGGSGGRASGGGGSEIVMTQSPATLSVSPGERATLSCRASQ SVSSKLAWYQQKPGQAPRLLMYGASIRATGIPDRFSGSGSGTEFTLTITSSLEP EDFAVYYCQQYGSSSWTFGQGTKVEIK
139106- nt ScFv domain	61	GAAGTGCAATTGGTGGAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATT GAGACTGAGCTGCGCAGTGTGCGGATTGCCCCGAGCAACCATGGAATGTCTT GGGTCAGAAGGGCCCCCTGGAAGAGGCCTCGAATGGGTGTGAGGGATCGTGAC TCCGGTTCCACTTACTACGCCGCTCCGTGAAGGGGCGCTTCACTATCTCACG GGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTGCGGCCGGAGG ATACCGCCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGACGTCTGGGGC CAGGGAAGTACCGTGACCGTGTCTCCGCGTCCGGCGGTGGAGGGAGCGGCGG CCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAGAGCCCCGCTA CTCTGTGCGGTGTGCGCCGGAGAAAGGGCGACCCCTGTCTGCGGGGCGTTCGAG TCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCCAGGCACCACG CCTGCTTATGTACGGTGCCTCCATTCCGGGCCACCGGAATCCCGGACCGGTTCT CGGGGTCGGGGTCCGGTACCGAGTTCACACTGACCATTCTCTCGCTCGAGCCC GAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCTCATGGACGTT CGGCCAGGGGACCAAGGTCGAAATCAAG
139106- aa VH	76	EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139106- aa VL	91	EIVMTQSPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASI RATGIPDRFSGSGSGTEFTLTITSSLEPEDFAVYYCQQYGSSSWTFGQGTKVEI K
139106- aa Full CAR	106	MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNH GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVMTQ SPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASIRATGIP DRFSGSGSGTEFTLTITSSLEPEDFAVYYCQQYGSSSWTFGQGTKVEIKTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYKQGQNLNELNLGRREEYDVLDRRRGRDPEMGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATKDTYDALHM QALPPR
139106- nt Full CAR	121	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGGTGGAACTGGAGGAGGACTTGTGCAACCTG GAGGATCATTGAGACTGAGCTGCGCAGTGTGCGGATTGCCCCGAGCAACCAT GGAATGTCCTGGGTGAGAAGGGCCCCCTGGAAGAGGCCTCGAATGGGTGTGAGG GATCGTGTACTCCGGTTCCTTACTACGCCGCTCCGTGAAGGGGCGCTTCA CTATCTCACGGGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTG CGGCCGGAGGATAACCGCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGA CGTCTGGGGCCAGGGAAGTACCGTGACCGTGTCTCCGCGTCCGGCGGTGGAG GGAGCGGCGGCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAG AGCCCCGCTACTCTGTGCGGTGTGCGCCGGAGAAAGGGCGACCCGTGCTCGCCG

		GGCGTCGCAGTCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCC AGGCACCACGCCTGCTTATGTACGGTGCCTCCATTCCGGGCCACCGGAATCCCG GACCGGTTCTCGGGGTCCGGGTACCGAGTTACACTGACCATTTCCTC GCTCGAGCCCCGAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCT CATGGACGTTCCGGCCAGGGGACCAAGGTCGAAATCAAGACCACTACCCAGCA CCGAGGCCACCCACCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG ACTTCGCCTGCGATATCTACATTGGGGCCCTCTGGCTGGTACTTGCGGGGTC CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCCGAAGAAGCT GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG AGGACGGCTGTTTCATGCCGGTTCAGAGGAGGAGGAAGGCGGTGCGAACTG CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA CCAGCTCTACAACGAACCTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCCAAAGGCCACGACGGAC TGTACCAGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG CAGGCCCTGCCGCTCGG
139107		
139107- aa ScFv domain	47	EVQLVETGGGVVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGSGGRASGGGGSEIVLTQSPGTLSPGERATLSCRASQ SVGSTNLAWYQQKPGQAPRLLIYDASNRTATGIPDRFSGGGSGTDFTLTISRLE PEDFAVYYCQQYGSSPPWTFGQGTKVEIK
139107- nt ScFv domain	62	GAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTGGAGGAAGCCT GAGACTGTCATGCGCGGTGTCCGGCTTCGCCCTCTCCAACCACGGAATGTCCT GGGTCCGCCGGGCCCCCTGGGAAAGGACTTGAATGGGTGTCCGGCATCGTGAC TCGGGTTCCACCTACTACGCGGCTCAGTGAAGGGCCGGTTTACTATTAGCCG CGACAACTCCAGAAACACACTGTACCTCCAAATGAACCTCGCTGCGGCCCGGAAG ATACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGACGTCTGGGGA CAGGGCACCCTGTCACTGTGTCCAGCGCTTCGGCGGTGGTGAAGCGGGGG ACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAGTCCCCCGGGA CCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCCTGTGCGGCATCCAG TCCGTGGGGTCTACTAACCTTGCAATGGTACCAGCAGAAGCCCGGCCAGGCCCC TCGCCTGCTGATCTACGACGCTCCAATAGAGCCACCGGCATCCCGGATCGCT TCAGCGGAGGCGGATCGGGCACCAGCTTCAACCTCACCATTCAAGGCTGGAA CCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCTGTCGCCACCCTG GACGTTCCGCCAGGGGACTAAGGTCGAGATCAAG
139107- aa VH	77	EVQLVETGGGVVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139107- aa VL	92	EIVLTQSPGTLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDAS NRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKV EIK
139107- aa Full CAR	107	MALPVTALLLPLALLLHAARPEVQLVETGGGVVQPGGSLRLSCAVSGFALSNGTH MSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGSGGRASGGGGSEIVLTQ SPGTLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDASNRTATG IPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIKTTT PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGC ELRVKFSRSADAPAYKQGGNQLYNELNLRREEYDVLDRRGRDPEMGGKPRR

		KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDLGYQGLSTATKDTYDAL HMQALPPR
139107- nt Full CAR	122	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTG GAGGAAGCCTGAGACTGTCATGCGCGGTGTCGGGCTTCGCCCTCTCCAACCAC GGAATGTCCTGGGTCCGCCGGGCCCCCTGGGAAAGGACTTGAATGGGTGTCCGG CATCGTGTACTCGGGTTCACCTACTACGCGGCCTCAGTGAAGGGCCGGTTTA CTATTAGCCGCGACAACCTCCAGAAACACACTGTACCTCCAAATGAACTCGCTG CGGCCGGAAGATAACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGA CGTCTGGGGACAGGGCACCCTGTCACTGTGTCCAGCGCTTCCGGCGGTGGTG GAAGCGGGGGACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAG TCCCCCGGGACCCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCTGTGCG GGCATCCCAGTCCGTGGGGTCTACTAACCTTGATGGTACCAGCAGAAGCCCCG GCCAGGCCCCCTCGCCTGCTGATCTACGACGCGTCCAATAGAGCCACCGGCATC CCGGATCGCTTCAGCGGAGGCGGATCGGGCACCAGACTTCACCCTCACCATTTC AAGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCGT CCCCACCCTGGACGTTTCGGCCAGGGGACTAAGGTCGAGATCAAGACCACTACC CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTC CCTGCGTCCGGAGGCATGTAGACCCGCGAGCTGGTGGGGCCGTGCATACCCGGG GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCTCTGGCTGGTACTTGC GGGGTCCTGCTGCTTTCACCTCGTGATCACTCTTTACTGTAAGCGCGGTTCGAA GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC AAGAGGAGGACGGCTGTTTCATGCCGGTTCAGAGGAGGAGGAAGGCGGCTGC GAACTGCGCGTGAAATTCAGCCGCGAGCGCAGATGCTCCAGCCTACAAGCAGGG GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG ACGGA CTGTACCAGG GACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT CACATGCAGGCCCTGCCGCCTCGG
139108		
139108- aa ScFv domain	48	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYMSWIRQAPGKGLEWVSYISS SGSTIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARESGDGM DV WGQGT TVTVSSASGGGSGGRASGGGSDIQMTQSPSSLSASVGRVTITCRA SQSISSYLNWYQQKPKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISL QPEDFATYYCQSYTLAFGQGTKVDIK
139108- nt ScFv domain	63	CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTGGAGGATCATT GAGACTGTCATGCGCGGCCTCGGGATTACGTTCTCCGATTACTACATGAGCT GGATTCCGCCAGGCTCCGGGGAAGGGACTGGAATGGGTGTCTTACATTTCTCA TCCGGCTCCACCATCTACTACGCGGACTCCGTGAAGGGGAGATTACCATTAG CCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACTCCCTGCGGGCTG AAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGGGATGGACGTC TGGGGACAGGGTACCACTGTGACCGTGTCTGTCGGCCTCCGGCGGAGGGGGTTC GGGTGGAAGGGCCAGCGCGGCGGAGGCAGCGACATCCAGATGACCCAGTCCC CCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCACATGCCGGGCC TCACAGTCGATCTCTCTACCTCAATTGGTATCAGCAGAAGCCCGGAAAGGC CCCTAAGCTTCTGATCTACGACGCTCCTCCCTGCAATCCGGGGTCCCATCTC GGTTCCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCATCTCGAGCCTG CAGCCGGAGGACTTCGCCACTTACTACTGTAGCAAAGCTACACCCTCGCGTT TGGCCAGGGCACCAAAGTGGACATCAAG
139108- aa VH	78	QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYMSWIRQAPGKGLEWVSYISS SGSTIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARESGDGM DV

		WGQGTTVTVSS
139108- aa VL	93	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASS LQSGVPSRFSGSGSGTDFTLTISSSLQPEDFATYYCQQSYTLAFGGQGTKVDIK
139108- aa Full CAR	108	MALPVTALLLPLALLLHAARPQVQLVESGGGLVKGPGSLRLSCAASGFTFSDY YMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNANKNSLYLQMNS LRAEDTAVYYCARESGDGMVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQM TQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSSLQPEDFATYYCQQSYTLAFGGQGTKVDIKTTTPA PRPPTPAPTIIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRGRDPEMGGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHM QALPPR
139108- nt Full CAR	123	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTG GAGGATCATTGAGACTGTCATGCGCGGCCTCGGGATTACGTTCTCCGATTAC TACATGAGCTGGATTGCCAGGCTCCGGGAAGGGACTGGAATGGGTGTCCTA CATTTCTCATCCGGCTCCACCCTCTACTACGCGGACTCCGTGAAGGGGAGAT TCACCATTAGCCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACCTC CTGCGGGCTGAAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGG GATGGACGTCTGGGGACAGGGTACCACTGTGACCGTGTCTGTCGGCCTCCGGCG GAGGGGGTTCGGGTGGAAGGGCCAGCGGCGGCGGAGGCAGCGACATCCAGATG ACCCAGTCCCCCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCAC ATGCCGGGCTCACAGTCGATCTCCTCCTACCTCAATTGGTATCAGCAGAAGC CCGGAAGGCCCTAAGCTTCTGATCTACGCAGCGTCTCCTCCGTGCAATCCGGG GTCCCATCTCGGTTCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCAT CTCGAGCCTGCAGCCGGAGGACTTCGCCACTTACTACTGTGAGCAAGCTACA CCCTCGCGTTTGGCCAGGGCACCAAGTGGACATCAAGACCACTACCCAGCA CCGAGGCCACCCACCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG ACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGCGGGGTC CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAAGAAGCT GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG AGGACGGCTGTTTATGCCGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA CCAGCTCTACAACGAACCTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC TGTACCAGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG CAGGCCCTGCCGCTCGG
139110		
139110- aa ScFv domain	50	QVQLVQSGGGLVKGPGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS SGNTIYYADSVKGRFTISRDNANKNSLYLQMNSLRAEDTAVYYCARSTMVREDY WGQGTTLTVTVSSASGGGGSGGRASGGGGSDIVLTQSPSLPVTLGQPASISCKS SESLVHNSGKTYLNWFHQRPQGQSPRRLIYEVSNRDSGVDPDRFTGSGSGTDFTL KISRVEAEDVGVYYCMQGTHTWPGTFGGQGTKLEIK
139110- nt ScFv domain	65	CAAGTGCAACTGGTGCAAGCGGAGGAGGATTGGTCAAACCCGGAGGAAGCCT GAGACTGTCATGCGCGGCCTCTGGATTACCTTCTCCGATTACTACATGTCAT GGATCAGACAGGCCCCGGGAAGGGCCTCGAATGGGTGTCTACATCTCGTCC TCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCTTTACCATTTC CCGCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATCCCTGCGGGCTG

		AAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCGGGAGGACTAC TGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGGGTGGAGGCAG CGGTGGACGCGCCTCCGGCGGCGGCGGTTTCAGACATCGTGCTGACTCAGTCGC CCCTGTCGCTGCCGGTCAACCTGGGCCAACCGGCCTCAATTAGCTGCAAGTCC TCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACTGGTTCCATCA GCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTCCAACAGGGATT CGGGGGTGGCCGACCGCTTCACTGGCTCCGGGTCCGGCACCGACTTCACCTTG AAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTATGCAGGG TACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAGATTAAG
139110- aa VH	80	QVQLVQSGGGLVLPKPGSLRLSCAASGFTFSDYMSWIRQAPGKGLEWVSYISS SGNTIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARSTMVREDY WGQGLTVTVSS
139110- aa VL	95	DIVLTQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPQGSPRRLI YEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQG TKLEIK
139110- aa Full CAR	110	MALPVTALLLPLALLLHAARPQVQLVQSGGGLVLPKPGSLRLSCAASGFTFSDY YMSWIRQAPGKGLEWVSYISSSGNTIYYADSVKGRFTISRDNKNSLYLQMNS LRAEDTAVYYCARSTMVREDYWGQGLTVTVSSASGGGGSGGRASGGGGSDIVL TQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPQGSPRRLIYEV NRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQGT IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEDGCS CRFPFEEEGGCELRVKFSRSADAPAYKQGQNLNELNLGRREEYDVL DKRRGRDPFMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKD TYDALHMQALPPR
139110- nt Full CAR	125	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAACTGGTGCAAAGCGGAGGAGGATTGGTCAAACCCG GAGGAAGCCTGAGACTGTATGCGCGGCCTCTGGATTACCTTCTCCGATTAC TACATGTCATGGATCAGACAGGCCCGGGGAAGGGCCTCGAATGGGTGTCTTA CATCTCGTCCCTCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCT TTACCATTTCGCCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATTCC CTGCGGGCTGAAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCG GGAGGACTACTGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGG GTGGAGGCAGCGGTGGACGCGCCTCCGGCGGCGGCGGTTCAGACATCGTGCTG ACTCAGTCGCCCCGTGCTGCTGCCGGTCAACCTGGGCCAACCGGCCTCAATTAG CTGCAAGTCCTCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACT GGTTCCATCAGCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTC AACAGGGATTGCGGGGTGCCCGACCGCTTCACTGGCTCCGGGTCCGGCACC GA CTTACCTTGAAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACT GTATGCAGGGTACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAG ATTAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCT CTGGCTGGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTATGCCGTTCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGCAGAACAGCTCTACAACGAACTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC

		ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
139112		
139112- aa ScFv domain	51	QVQLVESGGGLVQPGGSLRLSCAVSGFALS NHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDN SRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGGSGGRASGGGSDIRLTQSPSPLSASVGDRVTITCQASE DINKFLNWHQTPGKAPKLLIYDASTLQTGVPSRFSGSGSGTDFTLTINSLQP EDIGTYYCQQYESLPLTFGGGKVEIK
139112- nt ScFv domain	66	CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGTGGAAGCCT TAGGCTGTCGTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCATGGAATGTCCT GGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGGCATCGTGAC AGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCACTATCTCAAG AGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTGCGCCCCGAGG ACACCGCCATCTACTACTGCTCCGCCACGGAGGAGAGTCGGACGTGTGGGGC CAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGTGGTTCGGGCGG CCGGGCCTCGGGGGGAGGAGGTTCCGACATTCCGGCTGACCCAGTCCCCGTCCC CACTGTCGGCCTCCGTCCGCGACCGCGTGACCATCACTTGTGAGGCGTCCGAG GACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAAAGGCCCCCAA GCTGCTGATCTACGATGCCTCGACCCTTCAAAGTGGAGTGCCTAGCCGGTTCT CCGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTCATTGCAGCCG GAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCCCGCTCACATT CGGCGGGGGAACCAAGGTCGAGATTAAG
139112- aa VH	81	QVQLVESGGGLVQPGGSLRLSCAVSGFALS NHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDN SRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139112- aa VL	96	DIRLTQSPSPLSASVGDRVTITCQASEDINKFLNWHQTPGKAPKLLIYDAST LQTGVPSRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGKVEI K
139112- aa Full CAR	111	MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAVSGFALS NH GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDN SRNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGSDIRLTQ SPSPLSASVGDRVTITCQASEDINKFLNWHQTPGKAPKLLIYDASTLQTGVPS SRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGKVEIKTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRRGRDPEMGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR
139112- nt Full CAR	126	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCG GTGGAAGCCTTAGGCTGTGCTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCAT GGAATGTCCTGGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGG CATCGTGTACAGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCA CTATCTCAAGAGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTG CGCCCCGAGGACACCGCCATCTACTACTGCTCCGCCACGGAGGAGAGTCGGA CGTGTGGGGCCAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGGTG GTTCCGGCGGGCCGGGCTCGGGGGGAGGAGGTTCCGACATTCGGCTGACCCAG TCCCCGTCCCCACTGTCCGCCTCCGTCCGCGACCGCGTGACCATCACTTGTC GGCGTCCGAGGACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAA AGGCCCCCAAGCTGCTGATCTACGATGCCTCGACCCTTCAAAGTGGAGTGCCT AGCCGGTTCTCCGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTC ATTGCAGCCGGAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCC CGCTCACATTCGGCGGGGGAACCAAGGTCGAGATTAAGACCACTACCCAGCA

		CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGTCTTG ACTTCGCCTGCGATATCTACATTGGGCCCTCTGGCTGGTACTTGCGGGGTC CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT GCTGTACATCTTTAAGCAACCCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG AGGACGGCTGTTTCATGCCGGTTCAGAGAGGAGGAGGAAGGCGGCTGCGAACTG CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA CCAGCTCTACAACGAACCTCAATCTTGGTTCGAGAGAGGAGTACGACGTGCTGG ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG CAGGCCCTGCCGCTCGG
139113		
139113- aa ScFv domain	52	EVQLVETGGGLVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNSTNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGGSGGRASGGGGSETTLTQSPATLSVSPGERATLSCRASQ SVGSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGSGSGTEFTLTISLQ EDFAVYYCQQYNDWLPVTFGQGTKVEIK
139113- nt ScFv domain	67	GAAGTGCAATTGGTGGAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATT GCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCACGGGATGTCGT GGGTGAGACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTGCGGGGATTGTGTAC AGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCACTATTTACG GGACAACAGCCGCAACACCCTCTATCTGCAATGAACCTCTCTCCGCCCGGAGG ATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGACGTGTGGGGA CAGGGAACCACTGTCACCGTGTGTCGCGCATCCGGTGGCGGAGGATCGGGTGG CCGGGCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAGTCCCCTGCCA CTCTGTCCGTGAGCCCCGGGAGAGAGAGCCACCCTTAGCTGCCGGGCCAGCCAG AGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGGTCCCAG GCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCCGCGAGGTTCT CCGGGTCGGGTTCCGGGACCGAGTTCACCCTGACCATCTCCTCCCTCCAACCG GAGGACTTCGCGGTGTACTACTGTCAGCAGTACAACGATTGGCTGCCCGTGAC ATTTGGACAGGGGACGAAGGTGGAAATCAAA
139113- aa VH	82	EVQLVETGGGLVQPGGSLRLSCAVSGFALSNGTHMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNSTNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139113- aa VL	97	ETTLTQSPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGAST RATGIPARFSGSGSGTEFTLTISLQPEDFAVYYCQQYNDWLPVTFGQGTKVE IK
139113- aa Full CAR	112	MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNT HMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSTNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSETTLTQ SPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGIP ARFSGSGSGTEFTLTISLQPEDFAVYYCQQYNDWLPVTFGQGTKVEIKTTTP APRPPTPAPTIIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG VLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCE LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHGDLGYQLGLSTATKDTYDALH MQALPPR
139113- nt Full CAR	127	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGGTGGAACTGGAGGAGGACTTGTGCAACCTG GAGGATCATTGCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCAC

		GGGATGTCGTGGGTGACACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTCGGG GATTGTGTACAGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCA CTATTTACGGGACAACAGCCGCAACACCCTCTATCTGCAAATGAACTCTCTC CGCCCGGAGGATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGA CGTGTGGGGACAGGGAACCACTGTCACCGTGTGTCGCCATCCGGTGGCGGAG GATCGGGTGGCCGGGCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAG TCCCCTGCCACTCTGTCCGTGAGCCCCGGGAGAGAGAGCCACCCTTAGCTGCCG GGCCAGCCAGAGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGAC AGGGTCCCAGGCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCC GCGAGGTTCTCCGGGTCGGGTTCCGGGACCGAGTTACCCCTGACCATCTCCTC CCTCCAACCGGAGGACTTCGCGGTGTACTACTGTGTCAGCAGTACAACGATTGGC TGCCCGTGACATTTGGACAGGGGACGAAGGTGGAATCAAAACCACTACCCCA GCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTCCCT GCGTCCGGAGGCATGTAGACCCGCGAGCTGGTGGGGCCGTGCATACCCGGGGTC TTGACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGCGGG GTCTGTGCTTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAAGAA GCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAG AGGAGGACGGCTGTTTCATGCCGTTCCAGAGGAGGAGGAAGCGGCTGCGAA CTGCGCGTGAAATTCAGCCGCGAGCGCAGATGCTCCAGCCTACAAGCAGGGGCA GAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGC TGGAACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAG AATCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGC CTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACG GACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCAC ATGCAGGCCCTGCCGCTCGG
139114		
139114- aa ScFv domain	53	EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSSASGGGSGGRASGGGGSEIVLTQSPGTLSSLSPGERATLSCRASQ SIGSSSLAWYQQKPGQAPRLLMYGASSRASGIPDRFSGSGSGTDFTLTISRLE PEDFAVYYCQQYAGSPFFTFGQGTKVEIK
139114- nt ScFv domain	68	GAAGTGCAATTGGTGAATCTGGTGGAGGACTTGTGCAACCTGGAGGATCACT GAGACTGTCATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCATGGGATGTCTGT GGGTCCGGCGCGCCCCCGGAAAGGGTCTGGAATGGGTGTGGGTATCGTCTAC TCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTACCATTTCCTG CGATAACTCCGCAACACCCTGTACTTGCAATGAACTCGCTCCGGCCTGAGG ACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGACGTGTGGGGC CAGGGAATAACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGGGCTCAGGCGG ACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGCTGACCCAGTCGCTGGCA CTCTCTCGCTGAGCCCCGGGAAAGGGCAACCCTGTCTGTGGGGCCAGCCAG TCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGGGACAGGCTCC GCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATTCCTGACCGGT TCTCCGGGTCCGGTTCGGGCACCGATTTCACCCTGACTATCTCGAGGCTGGAG CCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGTCCCCGCCGT CACGTTCCGACAGGGAACCAAGGTCGAGATCAAG
139114- aa VH	83	EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY SGSTYYAASVKGRFTISRDNRSNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG QGTTVTVSS
139114- aa VL	98	EIVLTQSPGTLSSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGAS SRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPFFTFGQGTKV EIK
139114- aa	113	MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNH

Full CAR		GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNRSRNTLYLQMNSL RPEDTAIYYCSAHGGESDVWGQTTVTVSSASGGGGSGGRASGGGGSEIVLTQ SPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGASSRASGI PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPPTFGQGTKVEIKTTT PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC ELRVKFSRSADAPAYKQGQNLQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL HMQALPPR
139114- nt Full CAR	128	ATGGCCCTCCCTGTACCCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAATTGGTGGAATCTGGTGGAGGACTTGTGCAACCTG GAGGATCACTGAGACTGTCTATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCAT GGGATGTCTGTGGGTCCGGCGCGCCCCCGAAAGGGTCTGGAATGGGTGTCTGGG TATCGTCTACTCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTCA CCATTTCCCGCGATAACTCCCGCAACACCCTGTACTTGCAAATGAACTCGCTC CGGCCTGAGGACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGA CGTGTGGGGCCAGGGAACCTACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGG GCTCAGGCGGACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGTGACCCAG TCGCCTGGCACTCTCTCGCTGAGCCCCGGGAAAGGGCAACCCTGTCTGTCTG GGCCAGCCAGTCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGG GACAGGCTCCGCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATT CCCGACCGGTTCTCCGGGTCCGGTCCGGCACCGATTTCACCCTGACTATCTC GAGGCTGGAGCCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGT CCCCGCCGTTACGTTCCGACAGGGAACCAAGGTCGAGATCAAGACCACTACC CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTCT CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGC GGGGTCCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTTCGGAA GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC AAGAGGAGGACGGCTGTTTCATGCCGGTTCAGAGAGGAGGGAAGGCGGCTGC GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG GCAGAACCAGCTCTACAACGAACCTCAATCTTGGTTCGGAGAGAGGAGTACGACG TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAAGCCGCGCAGA AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG ACGGACTGTACCAGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT CACATGCAGGCCCTGCCGCCTCGG
149362		
149362-aa ScFv domain	129	QVQLQESGPGLVKPSSETLSLTCTVSGGSISSSYYYWGWIROPPEGKLEWIGSI YYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPD AFDIWGQGTMTVTSSGGGSGGGGSGGGGSETTLTQSPAFMSATPGDKVIISC KASQDIDDAMNWWYQQKPGEAPLFIIQSATSPVPGIPPRFSGSGFGTDFSLTIN NIESEDAAYYFCLQHDNFPLTFGQGTKLEIK
149362-nt ScFv domain	150	CAAGTGCACTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCATCCGAAACTCT CTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCTGTAATACTACT GGGGCTGGATTAGGCAGCCGCGCGGAAAGGGACTGGAGTGGATCGGAAGCATC TACTATTCCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGAGAGTGACCAT CTCCGTGGATACTCCAAGAACCAGTTTTCCCTGCGCCTGAGCTCCGTGACCG CCGCTGACACCGCCGTGTACTACTGTCTCGGCATTGGCAGGAATGGCCCGAT GCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGTATCCGGGGGTGG AGGCAGCGGGGAGGAGGTTCCGGGGGGGAGGTTTCAGAGACAACCTTGACCC AGTCACCCGCATTTCATGTCCGCCACTCCGGGAGACAAGGTCATCATCTCGTGC

		AAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGCAGAAGCCTGG CGAAGCGCCGCTGTTTCATTATCCAATCCGCAACCTCGCCCGTGCCTGGAATCC CACC GCGGTT CAGCGGCAGCGGTTTCGGAACCGACTTTTCCCTGACCATT AAC AACATTGAGTCCGAGGACGCCGCTACTACTTCTGCCTGCAACACGACAACCTT CCCTCTCACGTT CGGCCAGGGAACCAAGCTGGAAATCAAG
149362-aa VH	171	QVQLQESGPGLVKPSSETLSLTCTVSGGSISSSYYYWGWI RQPPGKGLEWIGSI YYSGSAYYNPSLKSRTVISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPD AFDIWGQGTMTVSS
149362-aa VL	192	ETTLTQSPAFMSATPGDKV IISCKASQDIDDAMN WYQOKPGEAPLFIIQSATS PVP GIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFP LTFGQGTKLEI K
149362-aa Full CAR	213	MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSSETLSLTCTVSGGSISS YYYWGWI RQPPGKGLEWIGSIYYSGSAYYNPSLKSRTVISVDTSKNQFSLRLS SVTAADTAVYYCARHWQEWPD AFDIWGQGTMTVSSGGGGSGGGSGGGGSET TLTQSPAFMSATPGDKV IISCKASQDIDDAMN WYQOKPGEAPLFIIQSATSPV PGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFP LTFGQGTKLEIKT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG GCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKP RRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYD ALHMQALPPR
149362-nt Full CAR	234	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAGCTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCAT CCGAAACTCTCTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCG TACTACTACTGGGGCTGGATTAGGCAGCCGCCCGGAAAGGGACTGGAGTGGAT CGGAAGCATCTACTATTCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGA GAGTGACCATCTCCGTGGATACCTCCAAGAACCAGTTTTTCCCTGCGCCTGAGC TCCGTGACCGCCGCTGACACCGCCGTGTACTACTGTGCTCGGCATTGGCAGGA ATGGCCCGATGCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGT CAT CCGGGGGTGGAGGCAGCGGGGGAGGAGGGTCCGGGGGGGGAGGTT CAGAGACA ACCTTGACCCAGTCACCCGCATTCATGTCCGCCACTCCGGGAGACAAGGTCAT CATCTCGTGCAAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGC AGAAGCCTGGCGAAGCGCCGCTGTTTCATTATCCAATCCGCAACCTCGCCCGTG CCTGGAATCCCACCGCGGTT CAGCGGCAGCGGTTTCGGAACCGACTTTTCCCT GACCATTAAACAACATTGAGTCCGAGGACGCCGCTACTACTTCTGCCTGCAAC ACGACAACCTCCCTCTCACGTTCCGGCCAGGGAACCAAGCTGGAAATCAAGACC ACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCC TCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATA CCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGT ACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGG TCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA CTACTCAAGAGGAGGACGGCTGTT CATGCCGTTCCAGAGGAGGAGGAAGGC GGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAA GCAGGGGCAGAACCGACTCTACAACGAACTCAATCTTGGTCCGAGAGAGGAGT ACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCG CGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGAT GGCAGAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAG GCCACGACGGA CTGTACCAGGGA CTGACACCGCCACCAAGGACACCTATGAC GCTCTTCACATGCAGGCCCTGCCGCTCGG
149363		
149363-aa ScFv domain	130	VNLRESGPALVKPTQTLLTCTFSGFSLRTSGMCSWIRQPPGKALEWLARID WDEDKFYSTSLKTRLTISKDTS DNQVLRMTNMDPADTATYYCARSGAGGTS A

		TAFDIWGPMTMTVSSGGGGSGGGSGGGGSDIQMTQSPSSLSASVGDRVITITCRASQDIYNNLAWFQLKPGSAPRSLMYAANKSQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYRFPYSFGQGTKLEIK
149363-nt ScFv domain	151	CAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTACCCAGACCCTCACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCCGGGATGTGCGTGTCCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCTCGCTCGCATTGACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCAGGCTGACCATCAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACCAACATGGACCAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGGCGGAACCTCCGCCACCGCCTTCGATATTTGGGGCCCCGGGTACCATGGTCACCGTGTCAAGCGGAGGAGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCGGACATTGAGATGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAGAGTGACAATCACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCCTGGTTCAGCTGAA GCCTGGTTCGCGACCGCGGTCACTTATGTACGCCGCCAACAAGAGCCAGTCGGGAGTGCCGTCCCGGTTTTCCGGTTCGGCCTCGGGAAGTACTTACCCTGACGATCTCCAGCCTGCAACCCGAGGATTCGCCACCTACTACTGCCAGCACTACTA CCGCTTCCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATCAAG
149363-aa VH	172	QVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARI DWDEDKFYSTSLKTRLTISKDTSDNQVVLRTNMDPADTATYYCARSGAGGTSATAFDIWGPMTMTVSS
149363-aa VL	193	DIQMTQSPSSLSASVGDRVITITCRASQDIYNNLAWFQLKPGSAPRSLMYAANK SQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYRFPYSFGQGTKLEIK
149363-aa Full CAR	214	MALPVTALLLPLALLLHAARPQVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARIDWDEDKFYSTSLKTRLTISKDTSDNQVVLRTNMDPADTATYYCARSGAGGTSATAFDIWGPMTMTVSSGGGGSGGGSGGGGSDIQMTQSPSSLSASVGDRVITITCRASQDIYNNLAWFQLKPGSAPRSLMYAANK SQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYRFPYSFGQGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEE EGGCELRVKFSRSADAPAYKQGNQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
149363-nt Full CAR	235	ATGGCCCTCCCTGTACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTA CCCAGACCCTCACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCC GGGATGTGCGTGTCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCT CGCTCGCATTGACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCA GGCTGACCATCAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACC AACATGGACCCAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGG CGGAACCTCCGCCACCGCCTTCGATATTTGGGGCCCCGGGTACCATGGTCACCG TGTCAAGCGGAGGAGGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCG GACATTGAGATGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAG AGTGACAATCACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCCTGGT TCCAGCTGAAGCCTGGTTCCGCACCGCGGTCACTTATGTACGCCGCCAACAAG AGCCAGTCGGGAGTGCCGTCCCGTTTTCCGGTTCGGCCTCGGGAAGTACTT CACCCTGACGATCTCCAGCCTGCAACCCGAGGATTCGCCACCTACTACTGCC AGCACTACTACCGCTTTCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATC AAGACCACTACCCAGCACCAGGCCACCCACCCGGCTCCTACCATCGCCTC CCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCG TGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCTCTG GCTGGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAA

		GCGCGGTCCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTG TGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCAGAGGAGGAG GAAGGCGGCTGCGAACTGCGCGTGAATTCAGCCGAGCGCAGATGCTCCAGC CTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAG AGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGG AAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGA TAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAG GCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACC TATGACGCTCTTCACATGCAGGCCCTGCCGCCCTCGG
149364		
149364-aa ScFv domain	131	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISS SSSYIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAF DIWGQGTITVTVSSGGGGSGGGSGGGGSEIVLTQSPLSLPVTPEEPASISCRS SQSLHLSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTL KISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK
149364-nt ScFv domain	152	GAAGTGCAGCTTGTGCAATCCGGGGGGGACTGGTCAAGCCGGGCGGATCACT GAGACTGTCTGCGCCGCGAGCGGCTTCACGTTCTCTCTCTACTCCATGAACT GGGTCCGCCAAGCCCCCGGAAGGGACTGGAATGGGTGTCTCTATCTCTCTCG TCGTCTCTCTACTACTACGCCGACTCCGTGAAGGGAAGATTACCATTTTC CCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCACTCCGGGCCG AAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCCGCGTCTACGCTTTC GACATCTGGGGCCAGGGAACCAACCGTGACTGTGTCTCGGTGGTGGTGGCTC GGGCGGAGGAGGAAGCGGCGGGGGGGTCCGAGATTGTGTGACCCAGTCGC CACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAGCTGCCGGTCC AGCCAGTCCCTGCTCCACTCCAACGGATAACAATTACCTCGATTGGTACCTTCA GAAGCCTGGACAAAGCCCGCAGCTGCTCATCTACTTGGGATCAAACCGCGCGT CAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGATTTCACCTG AAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACTGTATGCAGGC GCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAGATCAAG
149364-aa VH	173	EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISS SSSYIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAF DIWGQGTITVTVSS
149364-aa VL	194	EIVLTQSPLSLPVTPEEPASISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLLI YLGSNRASGVPDRFSGSGSGTDFTLTKISRVEAEDVGVYYCMQALQTPYTFGQ TKLEIK
149364-aa Full CAR	215	MALPVTALLLPLALLLHAARPEVQLVESGGGLVKPGGSLRLSCAASGFTFSSY SMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNKNSLYLQMNS LRAEDTAVYYCAKTIAAVYAFDIWGQGTITVTVSSGGGGSGGGSGGGGSEIVL TQSPLSLPVTPEEPASISCRSSQSLHLSNGYNYLDWYLQKPGQSPQLLIYLG NRASGVPDRFSGSGSGTDFTLTKISRVEAEDVGVYYCMQALQTPYTFGQGTKLE IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRGRDPEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATKD TYDALHMQALPPR
149364-nt Full CAR	236	ATGGCCCTCCCTGTACCCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTTGTGCAATCCGGGGGGGGACTGGTCAAGCCGG GCGGATCACTGAGACTGTCTGCGCCGCGAGCGGCTTCACGTTCTCTCTCTAC TCCATGAACTGGGTCCGCCAAGCCCCCGGAAGGGACTGGAATGGGTGTCTC TATCTCTCTGTCGTCGTCCTACATCTACTACGCCGACTCCGTGAAGGGAAGAT TCACCATTTCCCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCA CTCCGGGCCGAAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCGCCGT

		CTACGCTTTCGACATCTGGGGCCAGGGAACCAACCGTGA CTGTGTCGTCCGGTG GTGGTGGCTCGGGCGGAGGAGGAAGCGGCGGGGGGGTCCGAGATTGTGCTG ACCCAGTCGCCACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAG CTGCCGGTCCAGCCAGTCCCTGCTCCACTCCAACGGATACAATTACCTCGATT GGTACCTTCAGAAGCCTGGACAAAGCCCCGAGCTGCTCATCTACTTGGGATCA AACCGCGCGTCAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGA TTTCACCCTGAAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACT GTATGCAGGCGCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAG ATCAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCGAGCTGGTGGGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCT CTGGCTGGTACTTGCGGGGTCTGTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTCCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGTTCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCGAGCGCAGATGCTCC AGCCTACAAGCAGGGGCAGAACAGCTCTACAACGAATCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
149365		
149365-aa ScFv domain	132	EVQLVESGGGLVLPKPGGSLRLSCAASGFTTFSDYYMSWIRQAPGKGLEWVSYISS SGSTIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARDLRGAFDI WGQGTMTVTVSSGGGGSGGGGSGGGSSSYVLTQSPSVSAAPGYTATISCGGNNI GTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPGRFSGSNSGNMATLTIISGVQAG DEADFCQVWDSSEHVVFGGGTKLTVL
149365-nt ScFv domain	153	GAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCTTGTGAAGCCTGGAGGTTTCGCT GAGACTGTCCTGCGCCGCTCCGGCTTACCTTCTCCGACTACTACATGTCCT GGATCAGACAGGCCCCGGGAAAGGGCCTGGAATGGGTGTCTACATCTCGTCA TCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGTTACCATTTT CCGGGATAACCGGAAGAACTCGCTGTATCTGCAAATGAATCACTGAGGGCCG AGGACACCGCCGTGTACTACTGCGCCCGGATCTCCGCGGGGCATTTGACATC TGGGGACAGGGAACCATGGTCACAGTGTCCAGCGGAGGGGGAGGATCGGGTGG CGGAGGTTCCGGGGGTGGAGGCTCCTCTACGTGCTGACTCAGAGCCCAAGCG TCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGGAAACAACATT GGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAGCTCCCCTGTT GGTGATCCGCGATGACTCCGTGCGGCCTAGCAAAATTCGGGACGGTTCTCCG GCTCCAACAGCGCAATATGGCCACTCTCACCATCTCGGGAGTGCAGGCCGGA GATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCGAGCATGTGGT GTTCCGGGGGCGGAACCAAGCTGACTGTGCTC
149365-aa VH	174	EVQLVESGGGLVLPKPGGSLRLSCAASGFTTFSDYYMSWIRQAPGKGLEWVSYISS SGSTIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARDLRGAFDI WGQGTMTVTVSS
149365-aa VL	195	SYVLTQSPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVR PSKIPGRFSGSNSGNMATLTIISGVQAGDEADFCQVWDSSEHVVFGGGTKLTVL
149365-aa Full CAR	216	MALPVTALLLPLALLLHAARPEVQLVESGGGLVLPKPGGSLRLSCAASGFTTFSDY YMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNKNSLYLQMNS LRAEDTAVYYCARDLRGAFDIWGQGTMTVTVSSGGGGSGGGGSGGGSSSYVLTQ SPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPG RFSGSNSGNMATLTIISGVQAGDEADFCQVWDSSEHVVFGGGTKLTVLTTTP

		APRPPTPAPTIIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG VLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE LRVKFSRSADAPAYKQGQNLQLYNELNLGRREEYDVLDRRGRDPEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH MQALPPR
149365-nt Full CAR	237	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCCTTGTGAAGCCTG GAGGTTCGCTGAGACTGTCCTGCGCCGCCCTCCGGCTTCACCTTCTCCGACTAC TACATGTCCTGGATCAGACAGGCCCGGGAAAGGGCCTGGAATGGGTGTCCTA CATCTCGTCATCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGT TCACCATTTCCCGGGATAACGCGAAGAACTCGCTGTATCTGCAAATGAACTCA CTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCCGCGATCTCCGCGGGGC ATTTGACATCTGGGGACAGGGAACCATGGTTCACAGTGTCCAGCGGAGGGGGAG GATCGGGTGGCGGAGGTTCCGGGGGTGGAGGCTCCTCCTACGTGCTGACTCAG AGCCCAAGCGTCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGG AAACAACATTGGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAG CTCCCTGTTGGTGATCCGCGATGACTCCGTGCGGCCCTAGCAAAATTCCGGGA CGGTTCTCCGGCTCCAACAGCGGCAATATGGCCACTCTCACCATCTCGGGAGT GCAGGCCGGAGATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCG AGCATGTGGTGTTCGGGGGCGGAACCAAGCTGACTGTGCTCACCCTACCCCA GCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTCCCT GCGTCCGGAGGCATGTAGACCCGAGCTGGTGGGGCCGTGCATACCCGGGGTC TTGACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGCGGG GTCTGTGCTTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGGAAGAA GCTGCTGTACATCTTTAAGCAACCCCTTCATGAGGCCTGTGCAGACTACTCAAG AGGAGGACGGCTGTTTCATGCCGTTTCCCAGAGGAGGAGGAAGCGGGCTGCGAA CTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCA GAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGC TGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAG AATCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAAGC CTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACG GACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCAC ATGCAGGCCCTGCCGCTCGG
149366		
149366-aa ScFv domain	133	QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINP SGGVTAYSQTLQGRVTMTSDTSSSTVYMEISSLRSEDTAMYICAREGSGSGWY FDFWGRGTLVTVSSGGGGSGGGGSGGGSSVYLTQPPSVSVSPGQTASITCSG DGLSKKYVSWYQQKAGQSPVVLISRDKERPSPGIPDRFSGSNSADTATLTISGT QAMDEADYYCQAWDDTTVVFGGGKLTVL
149366-nt ScFv domain	154	CAAGTGCAGCTGGTGCAGAGCGGGGCCGAAGTCAAGAAGCCGGGAGCCTCCGT GAAAGTGTCTGCAAGCCTTCGGGATACACCGTGACCTCCCACTACATTCATT GGGTCCGCCGCGCCCCCGGCCAAGGACTCGAGTGGATGGGCATGATCAACCCT AGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCGTGACTATGAC CTCGGATACCTCCTCCTCCACCGTCTATATGGAAGTGTCCAGCCTGCGGTCCG AGGATACCGCCATGTACTACTGCGCCCGGAAGGATCAGGCTCCGGGTGGTAT TTCGACTTCTGGGAAGAGGCACCCTCGTGACTGTGTCTCTGGGGGAGGGGG TTCCGGTGGTGGCGGATCGGGAGGAGGCGGTTTCATCCTACGTGCTGACCCAGC CACCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTACATGTAGCGGC GACGGCCTCTCCAAGAAATACGTGTCTGGTACCAGCAGAAGGCCGGACAGAG CCCGGTGGTGTGATCTCAAGAGATAAGGAGCGGCCTAGCGGAATCCCGGACA GGTTCTCGGGTTCCAACCTCCGCGGACACTGCTACTCTGACCATCTCGGGGACC CAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACGACACTACTGT

		CGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTT
149366-aa VH	175	QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINP SGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWY FDFWGRGTLVTVSS
149366-aa VL	196	SYVLTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKER PSGIPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVL
149366-aa Full CAR	217	MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKPSGYTVTSH YIHWVRRAPGQGLEWMGMINPSSGGVTAYSQTLQGRVTMTSDTSSSTVYMELSS LRSEDTAMYYCAREGSGSGWYFDFWGRGTLVTVSSGGGGSGGGSGGGSSSYV LTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKERPSG IPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVLTTT PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGC ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRRGRDPGEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL HMQUALPPR
149366-nt Full CAR	238	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAGCTGGTGCAGAGCGGGGCCAAGTCAAGAAGCCGG GAGCCTCCGTGAAAGTGTCTTCAAGCCTTCGGGATACACCGTGACCTCCCAC TACATTCAATTGGGTCCGCCGCGCCCCCGCCAAGGACTCGAGTGGATGGGCAT GATCAACCCTAGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCG TGACTATGACCTCGGATACCTCCTCCTCCACCGTCTATATGGAAGTGTCCAGC CTGCGGTCCGAGGATACCGCCATGTACTACTGCGCCCGGGAAGGATCAGGCTC CGGGTGGTATTTTCTGACTTCTGGGGAAGAGGCACCCTCGTGAAGTGTGTCTCTG GGGGAGGGGGTTCGGTGGTGGCGGATCGGGAGGAGGCGGTTTCATCCTACGTG CTGACCCAGCCACCCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTAC ATGTAGCGGCGACGGCCTCTCCAAGAAATACGTGTCTGTGGTACCAGCAGAAGG CCGGACAGAGCCCGGTGGTGTCTCAAGAGATAAGGAGCGGCCTAGCGGA ATCCCGGACAGGTTCTCGGGTTCCTCAACTCCGCGGACACTGCTACTCTGACCAT CTCGGGGACCCAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACG ACACTACTGTCTGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTTACCACTACC CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTC CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCTCTGGCTGGTACTTGC GGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAA GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC AAGAGGAGGACGGCTGTTTCATGCCGTTCCAGAGGAGGAGGAAGGCGGCTGC GAACTGCGCGTGAAATTCAGCCGCGAGCGCAGATGCTCCAGCCTACAAGCAGGG GCAGAACCAGCTCTACAACGAACCTCAATCTTGGTTCGGAGAGAGGAGTACGACG TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT CACATGCAGGCCCTGCCGCTCGG
149367		
149367-aa ScFv domain	134	QVQLQESGPGLVKPSQTLSTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYI YYSGSTYYNPSLKSRTVISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARL RGAFDIWGQGTMTVTVSSGGGGSGGGSGGGSDIVMTQSPSSVSASVGDRIII TCRASQGIRNWLAWYQQKPGKAPNLLIYAASNLQSGVPSRFSGSGSGADFTLT ISSLQPEDVATYYCQKYNAPFTFGPGTKVDIK
149367-nt ScFv domain	155	CAAGTGCAGCTTCAGGAGAGCGGCCCGGACTCGTGAAGCCGTCCCAGACCCT GTCCCTGACTTGACCGGTGTGCGGAGGAAGCATCTCGAGCGGAGGCTACTATT

		GGTCGTGGATTTCGGCAGCACCCCTGGAAAGGGCCTGGAATGGATCGGCTACATC TACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCAGAGTGACAAT CTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCTTCCGTGACTG CGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGCCGCCCGGCTG AGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCGTGTCTCCGG CGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGTCCGACATCGTCA TGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTGCGGGACAGAGTGATCATC ACCTGTCGGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGTATCAGCAGAA GCCCCGAAAGGCCCCCAACCTGTTGATCTACGCCGCTCAAACCTCCAATCCG GGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTTACTCTGACC ATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCCAAAAGTACAA CTCCGCACCTTTTACTTTTCGGACCGGGGACCAAAGTGGACATTAAG
149367-aa VH	176	QVQLQESGPGLVKPSQTLSTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYI YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSVTAADTAVYYCARAGIAARL RGAFDIWGQGTMTVSS
149367-aa VL	197	DIVMTQSPSSVSASVGDRIITCRASQGIRNLAWYQQKPGKAPNLLIYAASN LQSGVPSRFSGSGSGADFTLTISLQPEDVATYYCQKYNAPFTFGPGTKVDI K
149367-aa Full CAR	218	MALPVTALLPLALLHAARPQVQLQESGPGLVKPSQTLSTCTVSGGSISSG GYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS SVTAADTAVYYCARAGIAARLRGAFDIWGQGTMTVSSGGGSGGGGSGGGGS DIVMTQSPSSVSASVGDRIITCRASQGIRNLAWYQQKPGKAPNLLIYAASN LQSGVPSRFSGSGSGADFTLTISLQPEDVATYYCQKYNAPFTFGPGTKVDI KTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEE EGGCELRVKFSRSADAPAYKQGQNLQYLNELNLGRREEYDVLDRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGHDLGYQLSTATKDT YDALHMQALPPR
149367-nt Full CAR	239	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCCAAGTGCAGCTTCAGGAGAGCGGCCCGGGACTCGTGAAGCCGT CCCAGACCCTGTCCCTGACTTGCACCGTGTGCGGAGGAAGCATCTCGAGCGGA GGCTACTATTGGTCGTGGATTTCGGCAGCACCCCTGGAAAGGGCCTGGAATGGAT CGGCTACATCTACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCA GAGTGACAATCTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCT TCCGTGACTGCGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGC CGCCCGGCTGAGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCG TGTCCTCCGGCGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGTCC GACATCGTCATGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTGCGGGACAG AGTGATCATCACCTGTGCGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGT ATCAGCAGAAGCCCGGAAAGGCCCCCAACCTGTTGATCTACGCCGCTCAAAC CTCCAATCCGGGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTT CACTCTGACCATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCC AAAAGTACAACCTCCGCACCTTTTACTTTTCGGACCGGGGACCAAAGTGGACATT AAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTC CCAGCCTCTGTCCCTGCGTCCGAGGCATGTAGACCCGAGCTGGTGGGGCCG TGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTGGGCCCTCTG GCTGGTACTTGCGGGGTCTGTGCTTTTCACTCGTGATCACTCTTTACTGTAA GCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTG TGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCAGAGGAGGAG GAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGC CTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTTCGGAGAG AGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGG

		AAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGA TAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAG GCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACC GCCACCAAGGACACC TATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
149368		
149368-aa ScFv domain	135	QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAI SWVRQAPGQGLEWMGGIIP IFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLR WDVGLLRSAFDIWGQGTMTVTVSSGGGGSGGGSGGGSSSYVLTQPPSVSVAPG QTARITCGGNNIGSKSVHWYQQKPGQAPVFLVLYGKNNRPSGVPDRFSGSRSGT TASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTGKVTVL
149368-nt ScFv domain	156	CAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCGGGAGCTCTGT GAAAGTGTCTTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTACGCCATCTCCT GGGTCCGCCAAGCACCGGTCAAGGCCTGGAGTGGATGGGGGAATTATCCCT ATCTTCGGCACTGCCAACTACGCCCAGAAGTTCAGGGACGCGTGACCATTAC CGCGGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGCTTGCCTCGG AAGATACCGCCGTGTACTACTGCGCCCGAGGGGTGGATAACAGCTGCTGAGA TGGGACGTGGGCCTCCTGCGGTGCGCGTTTCGACATCTGGGGCCAGGGCACTAT GGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGCGGATCAGGGGGAG GCGGTTCCAGCTACGTGCTTACTCAACCCCTTCGGTGTCCGTGGCCCCGGGA CAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCAAGAGCGTGCA TTGGTACCAGCAGAAGCCAGGACAGGCCCCCTGTGCTGGTGTCTACGGGAAGA ACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACGCTCCGGTACA ACCGCTTCACTGACTATCACCGGGGCCAGGCAGAGGATGAAGCGGACTACTA CTGTTCTCCCGGGATTTCATCCGGCGACCACCTCCGGGTGTTCGGAACCGGAA CGAAGGTCACCGTGCTG
149368-aa VH	177	QVQLVQSGAEVKKPGSSVKVSKASGGTFSSYAI SWVRQAPGQGLEWMGGIIP IFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLR WDVGLLRSAFDIWGQGTMTVTVSS
149368-aa VL	198	SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVFLVLYGKNNR PSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTGK TVL
149368-aa Full CAR	219	MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGSSVKVSKASGGTFSSY AISWVRQAPGQGLEWMGGIIP IFGTANYAQKFQGRVTITADESTSTAYMELSS LRSEDTAVYYCARRGGYQLLRWDVGLLRSAFDIWGQGTMTVTVSSGGGGSGGGG SGGGSSSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVFLV YGKNNRPSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVF GTGKVTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGC SCRFEEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRR GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKHDGLYQG LSTATKDTYDALHMQALPPR
149368-nt Full CAR	240	ATGGCCCTCCCTGTACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCG GGAGCTCTGTGAAAGTGTCTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTAC GCCATCTCCTGGGTCCGCCAAGCACCGGGTCAAGGCCTGGAGTGGATGGGGGG AATTATCCCTATCTTCGGCACTGCCAACTACGCCCAGAAGTTCAGGGACGCG TGACCATTACCGCGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGC TTGCGCTCGGAAGATAACCGCCGTGTACTACTGCGCCCGAGGGGTGGATACCA GCTGCTGAGATGGGACGTGGGCCTCCTGCGGTGCGCGTTTCGACATCTGGGGCC AGGGCACTATGGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGGCGGA TCAGGGGGAGGCGGTTCCAGCTACGTGCTTACTCAACCCCTTCGGTGTCCGT GGCCCCGGGACAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCA

		AGAGCGTGCAATTGGTACCAGCAGAAGCCAGGACAGGCCCTGTGCTGGTGCTC TACGGGAAGAACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACG CTCCGGTACAACCGCTTCACTGACTATCACCAGGGGCCCAGGCAGAGGATGAAG CGGACTACTACTGTTCTCCCGGGATTTCATCCGGCGACCACCTCCGGGTGTTT GGAACCGGAACGAAGGTCACCGTGCTGACCACTACCCAGCACCGAGGCCACC CACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCAT GTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGC GATATCTACATTTGGGCCCCCTCTGGCTGGTACTTGCGGGGTCTGCTGCTTTC ACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAAGAAGCTGCTGTACATCT TTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGT TCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATT CAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACA ACGAACCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGA GGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGG CCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTG GTATGAAAGGGGAACGCAGAAGAGGCCAAGGCCACGACGGACTGTACCAGGGA CTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCC GCCTCGG
149369		
149369-aa ScFv domain	136	EVQLQQSGPGLVKPSQTLSTLCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRT YYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEG LFLYWFDWPWGQGTILVTVSSGGDGSGGGGSSGGSSSELTQDPAVSVALGQTIR ITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNRPSGIPDRFSASSSGNTASL TITGAQAEDEADYYCNSRDSSGHLLFGTGTKVTVL
149369-nt ScFv domain	157	GAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCATCCCAGACCT GTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTATCGAACTCCGCCGCT GGAAGTGGATTCCGGCAGAGCCCGTCCCGCGGACTGGAGTGGCTTGGAAGGACC TACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGAAGTCCCGCAT TATCATTAACCTGATACCTCCAAGAATCAGTTCTCCCTCCAAGTGAATCCG TCACCCCGGAGGACACAGCAGTGTATTACTGCGCACGGAGCAGCCCCGAAGGA CTGTTCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTGTGACCGTGTG GAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGCGGATCATCAT CCGAAGTGAACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACAAACCATCCGC ATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTTGGTACCAGCA GAAGCCGGGCCAAGCCCTGTGTTGGTTCATCTACGGGACCAACAACAGACCTT CCGGCATCCCCGACCGGTTTACGCGCTTCGTCTCCGGCAACACTGCCAGCCTG ACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACTGCAACAGCAG AGACTCCTCGGGTCATCACCTCTTGTTCGGAAGTGAACCAAGGTCACCGTGC TG
149369-aa VH	178	EVQLQQSGPGLVKPSQTLSTLCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRT YYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEG LFLYWFDWPWGQGTILVTVSS
149369-aa VL	199	SSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNR PSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHLLFGTGTKVT VL
149369-aa Full CAR	220	MALPVTALLLPLALLLHAARPEVQLQQSGPGLVKPSQTLSTLCAISGDSVSSN SAAWNWIRQSPSRGLEWLGRTYYRSKWYSFYAISLKSRIIINPDTSKNQFSLQ LKSVTPEDTAVYYCARSSPEGLFLYWFDWPWGQGTILVTVSSGGDGSGGGGSSGG GSSSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTN NRPSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHLLFGTGTK VTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP

		EEEEGGCELRVKFSRSADAPAYKQGQNLNLYNELNLGRREEYDVLDKRRGRDPE MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHGGLYQGLSTAT KDTYDALHMQALPPR
149369-nt Full CAR	241	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCGAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCAT CCCAGACCCTGTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTTCATCGAAC TCCGCCGCCTGGAACCTGGATTTCGGCAGAGCCCCGTCCCGCGGACTGGAGTGGCT TGGAAGGACCTACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGA AGTCCCGCATTATCATTAAACCCTGATACCTCCAAGAATCAGTTCTCCCTCCAA CTGAAATCCGTCACCCCCGAGGACACAGCAGTGTATTACTGCGCACGGAGCAG CCCCGAAGGACTGTTCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTG TGACCGTGTTCGAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGC GGATCATCATCCGAACCTGACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACA AACCATCCGCATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTT GGTACCAGCAGAAGCCGGGCCAAGCCCCCTGTGTTGGTCATCTACGGGACCAAC AACAGACCTTCCGGCATCCCCGACCGGTTTCAGCGCTTCGTCTCCGGCAACAC TGCCAGCCTGACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACT GCAACAGCAGAGACTCCTCGGGTCATCACCTCTTGTTCCGGAACCTGGAACCAAG GTCACCGTGCTGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTAC CATCGCCTCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTGG GCCCCCTGTGGCTGGTACTTGCGGGGTCTGTCTGCTTTCACTCGTGATCACTCT TTACTGTAAGCGCGGTCCGAAGAAGCTGCTGTACATCTTTAAGCAACCCCTCA TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCCCA GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTACGCCGCAGCGCAGA TGCTCCAGCCTACAAGCAGGGGCAGAACAGCTCTACAACGAACCTCAATCTTG GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT CCAAAAGGATAAGATGGCAGAACCTATAGCGAGATTGGTATGAAAGGGGAAC GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
BCMA_EBB-C1978-A4		
BCMA_EBB- C1978-A4 - aa ScFv domain	137	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLD YWGQGLTVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSPGERATLSCRAS QSVSSAYLAWYQQKPGQPPRLISGASTRATGIPDRFGGSGSGTDFTLTISRL EPEDFAVYYCQHYGSSFNSSSLFTFGQGRLEIK
BCMA_EBB- C1978-A4 - nt ScFv domain	158	GAAGTGCAGCTCGTGGAGTCAGGAGGCGGCCTGGTCCAGCCGGGAGGGTCCCT TAGACTGTTCATGCGCCGCAAGCGGATTCACTTTCTCCTCCTATGCCATGAGCT GGGTCCGCCAAGCCCCCGAAAGGGACTGGAATGGGTGTCCGCCATCTCGGGG TCTGGAGGCTCAACTTACTACGTGACTCCGTGAAGGGACGGTTCACCATTAG CCGCGACAACCTCCAAGAACACCCTCTACCTCCAAATGAACTCCCTGCGGGCCG AGGATACCGCCGTCTACTACTGCGCCAAAGTGGAAGGTTTCAGGATCGCTGGAC TACTGGGGACAGGGTACTCTCGTGACCGTGTTCATCGGGCGGAGGAGTTCCGG CGGTGGCGGCTCCGGCGGCGGAGGGTTCGGAGATCGTGATGACCCAGAGCCCTG GTACTCTGAGCCCTTCGCCGGGAGAAAGGGCCACCCTGTCTGCGCGCTTCC CAATCCGTGTCTCCGCGTACTTGGCGTGGTACCAGCAGAAGCCGGGACAGCC CCCTCGGCTGTCTGATCAGCGGGGCCAGCACCCGGGCAACCGGAATCCCAGACA GATTCGGGGGTTCCGGCAGCGGCACAGATTTACCCCTGACTATTTTCAGGTTG GAGCCCGAGGACTTTGCGGTGTATTACTGTGCACTACGGGTGCTCCTTTAA TGGCTCCAGCCTGTTACGTTTCGGACAGGGGACCCGCCTGGAAATCAAG
BCMA_EBB-	179	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG

C1978-A4 - aa VH		SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLD YWQGTLTVTVSS
BCMA_EBB-C1978-A4 - aa VL	200	EIVMTQSPGTL SLSPGERATL SCRASQSVSSAYLAWYQQKPGQPRL LISGAS TRATGIPDRFGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFN GSSSLFTFGQ GTRLEIK
BCMA_EBB-C1978-A4 - aa Full CART	221	MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKVEGSGSLDYWGQTLTVTVSSGGGGSGGGSGGGGSEIVMT QSPGTL SLSPGERATL SCRASQSVSSAYLAWYQQKPGQPRL LISGASTRATG IPDRFGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFN GSSSLFTFGQ GTRLE IKTTTTAPRPPTPAPT IASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCEL RVKFSRSADAPAYKQGNQLYNELNLGRREEYDVL DKRRGRDP EMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR
BCMA_EBB-C1978-A4 - nt Full CART	242	ATGGCCCTCCCTGTCAACGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTCGTGGAGTCAGGAGCGGCCCTGGTCCAGCCGG GAGGGTCCCTTAGACTGT CATGCGCCGCAAGCGGATTCACTTTCTCCTCCTAT GCCATGAGCTGGGTCCGCCAAGCCCCCGGAAAGGGACTGGAATGGGTGTCCGC CATCTCGGGGTCTGGAGGCTCAACTTACTACGCTGACTCCGTGAAGGGACGGT TCACCATTAGCCGCGACAACCTCCAAGAACACCCTCTACCTCCAAATGAACTCC CTGCGGGCCGAGGATACCGCCGTCTACTACTGCGCCAAAGTGAAGGTTT CAGG ATCGCTGGACTACTGGGGACAGGGTACTCTCGTGACCGTGT CATCGGGCGGAG GAGGTTCCGGCGGTGGCGGCTCCGGCGGCGGAGGGTTCGGAGATCGTGATGACC CAGAGCCCTGGTACTCTGAGCCTTTGCGCGGGAGAAAGGGCCACCCTGTCTTG CCGCGCTTCCCAATCCGTGTCTTCCGCGTACTTGGCGTGGTACCAGCAGAAGC CGGGACAGCCCCCTCGGCTGTGTGATCAGCGGGGCCAGCACCCGGGCAACCGGA ATCCCAGACAGATTCGGGGGTTCCGGGCAGCGGCACAGATTTACCCTGACTAT TTCGAGGTTGGAGCCCGAGGACTTTGCGGTGTATTACTGT CAGCACTACGGGT CGTCCTTTAATGGCTCCAGCCTGTTACGTTTCGGACAGGGGACCCGCTTGAA ATCAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCG CAGCTGGTGGGG CCGTGCATACCCGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCT CTGGCTGGTACTTGCGGGGTCTGTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTTCGGAAGAAGCTGTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGCAGAACCCAGCTCTACAACGAACTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
BCMA_EBB-C1978-G1		
BCMA_EBB-C1978-G1 - aa ScFv domain	138	EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPM SWVRQAPGKGLEW VSGISDSGVSTYYADSAKGRFTISRDN SKNTLFLQMSSLRDEDTAVYY CVTRAGSEASDIWGQGMVTVSSGGGGSGGGSGGGGSEIVLTQSPAT LSLSPGERATL SCRASQSVSN SLAWYQQKPGQAPRL LIYDASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGT KLEIK
BCMA_EBB-	159	GAAGTGCAACTGGTGGAAACCGGTGGCGGCCTGGTGCAGCCTGGAGGATCATT

C1978-G1 - nt ScFv domain		GAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTACCCCATGTCCT GGGTGAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGGGATCTCGGAC TCCGGTGTGAGCACTTACTACGCCGACTCCGCCAAGGGACGCTTCACCATTTT CCGGGACAACCTCGAAGAACACCCTGTTCTCTCCAAATGAGCTCCCTCCGGGACG AGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGAGGCGTCTGAC ATTTGGGGACAGGGCACTATGGTCAACCGTGTGCTCCGGCGGAGGGGGCTCGGG AGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACCCAATCCCCGG CCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCTGTGCGCGGAGC CAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCTCC GAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATCCCCGACCGCT TTTCGGGGTCCGGCTCAGGAACCGATTTACCCCTGACAATCTCACGGCTGGAG CCAGAGGATTTGCGCATCTATTACTGCCAGCAGTTCGGTACTTCTCTCCGGCCT GACTTTCGGAGGCGGCACGAAGCTCGAAATCAAG
BCMA_EBB- C1978-G1 - aa VH	180	EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWVSGISD SGVSTYYADSAKGRFTISRDNKNTLFLQMSSLRDEDTAVYYCVTRAGSEASD IWQGTMVTVSS
BCMA_EBB- C1978-G1 - aa VL	201	EIVLTQSPATLSLSPGERATLSCRASQSVSNLAWYQQKPGQAPRLLIYDASS RATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGTKLE IK
BCMA_EBB- C1978-G1 - aa Full CART	222	MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGI TFSRYPMSWVRQAPGKGLEWVSGISDSGVSTYYADSAKGRFTISRDN KNTLFLQMSSLRDEDTAVYYCVTRAGSEASDIWQGTMVTVSSGGGG SGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSNLAWYQQ KPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQ QFGTSSGLTFGGGTKEIKTTTTAPRPPTPAPTIASQPLSLRPEACRPAAG GAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFK QPFMRPVQTTQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYKQGQN QLYNELNLGRREEYDVLDKRRGRDPENMGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALP PR
BCMA_EBB- C1978-G1 - nt Full CART	243	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAACTGGTGGAACCGGTGGCGGCCTGGTGACGCTG GAGGATCATTGAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTAC CCCATGTCCTGGGTGAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGG GATCTCGGACTCCGGTGTGAGCACTTACTACGCCGACTCCGCCAAGGGACGCT TCACCATTTCCCGGACAACCTCGAAGAACACCCTGTTCTCTCCAAATGAGCTCC CTCCGGGACGAGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGA GGCGTCTGACATTTGGGGACAGGGCACTATGGTCAACCGTGTGCTCCGGCGGAG GGGGCTCGGGAGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACC CAATCCCCGGCCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCTG TCGCGCGAGCCAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCG GACAGGCTCCGAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATC CCCGACCGCTTTTCGGGGTCCGGCTCAGGAACCGATTTACCCCTGACAATCTC ACGGCTGGAGCCAGAGGATTTGCGCATCTATTACTGCCAGCAGTTCGGTACTT CCTCCGGCCTGACTTTCGGAGGCGGCACGAAGCTCGAAATCAAGACCACTACC CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTC CCTGCGTCCGGAGGCATGTAGACCCGCGAGCTGGTGGGGCCGTGCATACCCGGG GTCTTGACTTCGCTGCGATATCTACATTTGGGCCCTCTGGCTGGTACTTGC GGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCCGAA

		GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC AAGAGGAGGACGGCTGTTTCATGCCGGTTCAGAGGAGGAGGAAGGCGGCTGC GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA AAGAATCCCCAAGAGGGGCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT CACATGCAGGCCCTGCCGCCTCGG
BCMA_EBB-C1979-C1		
BCMA_EBB-C1979-C1 - aa ScFv domain	139	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAIYYCARATYKREL YYYGMDVWGQGTMTVSSGGGGSGGGSGGGGSEIVMTQSPGTVSLSPGERAT LSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFT LTISRLEPEDSAVYYCQYHSSPSWTFGQGRLEIK
BCMA_EBB-C1979-C1 - nt ScFv domain	160	CAAGTGCAGCTCGTGGAAATCGGGTGGCGGACTGGTGCAGCCGGGGGGCTCACT TAGACTGTCTCGCGCGGCCAGCGGATTCACTTTCTCCTCCTACGCCATGTCTT GGGTCAGACAGGCCCCCTGGAAAGGGCCTGGAATGGGTGTCCGCAATCAGCGGC AGCGGCGGCTCGACCTATTACGCGGATTCAGTGAAGGGCAGATTCACCATTTT CCGGGACAACGCCAAGAACTCCTTGTACCTTCAAATGAACTCCCTCCGCGCGG AAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAGGGAAGTGC TACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCACCGTGTCCAG CGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGGTCCGAGATCG TGATGACCCAGTCCCCGGCACTGTGTGCTGTCCCCCGGCGAACGGGCCACC CTGTCTGTGCGGGCCAGCCAGTCAGTGTGCTCAAGCTTCTCCTCGCCTGGTACCA GCAGAAACCGGGACAAGCTCCCCGCTGCTGATCTACGGAGCCAGCAGCCGGG CCACCGGTATTCTGACCGGTTCTCCGGTTCGGGGTCCGGGACCGACTTTACT CTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATTACTGCCAGCA GTACCACTCCTCCCCGTCTTGGACGTTCCGGACAGGGCACAAAGGCTGGAGATTA AG
BCMA_EBB-C1979-C1 - aa VH	181	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAIYYCARATYKREL YYYGMDVWGQGTMTVSS
BCMA_EBB-C1979-C1 - aa VL	202	EIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQYHSSPSWTFGQGRLE EIK
BCMA_EBB-C1979-C1 - aa Full CART	223	MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNKNSLYLQMNS LRAEDTAIYYCARATYKRELRYYYGMDVWGQGTMTVSSGGGGSGGGSGGGG SEIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGAS SSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQYHSSPSWTFGQGR LEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF EEEEGGCELRVKFSRSADAPAYKQGQNLNELNLGRREEYDVLDRGRDPE MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGDGLYQGLSTAT KDTYDALHMQALPPR
BCMA_EBB-C1979-C1 - nt Full CART	244	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAGCTCGTGGAAATCGGGTGGCGGACTGGTGCAGCCGG GGGGCTCACTTAGACTGTCTGCGCGGCCAGCGGATTCACTTTCTCCTCCTAC

		<p>GCCATGTCCTGGGTCAGACAGGCCCTGGAAAGGGCCTGGAATGGGTGTCCGC AATCAGCGGCAGCGCGGCTCGACCTATTACGCGGATTAGTGAAGGGCAGAT TCACCATTTCCTGGGACACGCCAAGAACTCCTTGTACCTTCAAATGAACTCC CTCCGCGCGGAAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAG GGAAGTGCCTACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCA CCGTGTCCAGCGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGG TCGGAGATCGTGATGACCCAGTCCCCCGGCACTGTGTCTGCTGTCCCCCGGCGA ACGGGCCACCCTGTCTGTCTGGGCCAGCCAGTCAGTGTCTGCAAGCTTCCTCG CCTGGTACCAGCAGAAACCGGGACAAGCTCCCCGCCTGTGTATCTACGGAGCC AGCAGCCGGGGCCACCGGTATTCCTGACCGGTTCTCCGGTTCGGGGTCCGGGAC CGACTTTACTCTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATT ACTGCCAGCAGTACCCTCCTCCCCGTCTGGACGTTTCGGACAGGGCACAAGG CTGGAGATTAAGACCACTACCCAGCACCAGGAGGCCACCCACCCGGCTCCTAC CATCGCCTCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG GCCCCCTCTGGCTGGTACTTGCGGGGTCTGTCTGCTTTTACTCGTGATCACTCT TTACTGTAAGCGCGGTTCGGAAGAAGCTGTGTACATCTTTAAGCAACCCTTCA TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTATGCCGGTTCCCA GAGGAGGAGGAAGGCGGCTGCGAAGTGCCTGAAATTCAGCCGCAGCGCAGA TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTG GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT CCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGAAGTACGACCGCCACC AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG</p>
BCMA_EBB-C1978-C7		
BCMA_EBB-C1978-C7 - aa ScFv domain	140	<p>EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNTLYLQMNTLKAEDTAVYYCARATYKRELRL YYYGMDVWVGQGTITVTVSSGGGGSGGGSGGGGSEIVLTQSPSTLSLSPGESAT LSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDFIT LTIRRLPEDFAVYYCQYHSSPSWTFGQGTKVEIK</p>
BCMA_EBB-C1978-C7 - nt ScFv domain	161	<p>GAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCGGAGGAAGCCT CAGGCTGTCTGCGCCGCGTCCGGCTTACCTTCTCCTCGTACGCCATGTCTCT GGGTCCGCCAGGCCCCCGGAAAGGGCCTGGAATGGGTGTCCGCCATCTCTGGA AGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGTTCAATCTC CCGCGATAATTGGAAGAACACTCTGTACCTTCAAATGAACACCCTGAAGGCCG AGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAGAGAGCTCCGG TACTACTACGGAATGGACGTCTGGGGCCAGGGAAGTGTGACCGTGTCTCTC GGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGTTCCGAGATTG TGCTGACCCAGTCACCTTCAACTCTGTCTGCTGTCCCCGGGAGAGAGCGCTACT CTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCTCGCCTGGTATCA GCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCAAGCAACAGAG CGACCGGAATTCTGACCGCTTCTCGGGGAGCGGTTACAGGCACCGACTTCACC CTGACTATCCGGCGCTGGAACCCGAAGATTTCCGCGTGTATTACTGTCAACA GTACCCTCTCTCGCGTCTCTGGACCTTTGGCCAAGGAACCAAAGTGGAAATCA AG</p>
BCMA_EBB-C1978-C7 - aa VH	182	<p>EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNTLYLQMNTLKAEDTAVYYCARATYKRELRL YYYGMDVWVGQGTITVTVSS</p>
BCMA_EBB-C1978-C7 -	203	<p>EIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSS</p>

aa VL		NRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTKV EIK
BCMA_EBB- C1978-C7 - aa Full CART	224	MALPVTALLLPLALLLHAARPEVOLVETGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNT LKAEDTAVYYCARATYKRELRYYYGMDVWGQGTITVTVSSGGGSGGGGSGGGG SEIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGS SNRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTK VEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW APLAGTCGVLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFP EEEEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVL DKRRGRDPE MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHGHDGLYQGLSTAT KDTYDALHMQALPPR
BCMA_EBB- C1978-C7 - nt Full CART	245	ATGGCCCTCCCTGTACCCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCG GAGGAAGCCTCAGGCTGTCTGCGCCGCGTCCGGCTTCACCTTCTCCTCGTAC GCCATGTCTGGGTCCGCCAGGCCCGGAAAGGGCCTGGAATGGGTGTCCGC CATCTCTGGAAGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGT TCACAATCTCCCGCGATAATTGGAAGAACACTCTGTACCTTCAAATGAACACC CTGAAGGCCGAGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAG AGAGCTCCGGTACTACTACGGAATGGACGTCTGGGGCCAGGGAACACTACTGTGA CCGTGTCTCTCGGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGT TCCGAGATTGTGCTGACCCAGTCACCTTCAACTCTGTCTGCTGTCCCCGGGAGA GAGCGCTACTCTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCTCTCG CCTGGTATCAGCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCA AGCAACAGAGCGACCGGAATTCCTGACCGCTTCTCGGGGAGCGGTT CAGGCAC CGACTTCACCCTGACTATCCGGCGCCTGGAACCCGAAGATTTCCGCCGTGTATT ACTGTCAACAGTACCCTCCTCGCCGTCTTGACCTTTGGCCAAGGAACCAAA GTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCGGCTCCTAC CATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG GCCCCCTCTGGCTGGTACTTGCGGGGTCTTGCTGCTTTCACTCGTGATCACTCT TTACTGTAAGCGCGGTGCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTT CATGCCGGTTCCCA GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGA TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACCTCAATCTTG GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA ATGGGCGGGAAGCCGCGCAGAAAGAATCCCAAGAGGGCCTGTACAACGAGCT CCAAAAGGATAAGATGGCAGAAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGAACCTCAGCACCGCCACC AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
BCMA_EBB-C1978-D10		
BCMA_EBB- C1978-D10 - aa ScFv domain	141	EVQLVETGGGLVQPGRSRLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW NSGSGIYADSVKGRFTISRDN AKNSLYLQMN SLRDEDTAVYYCARVGKAVPDV WGQGTITVTVSSGGGSGGGGSGGGGSDIVMTQTPSSLSASVGDRVITICRASQ SISYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISLQPF EDFATYYCQQSYSTPYSGGQTRLEIK
BCMA_EBB- C1978-D10- nt ScFv domain	162	GAAGTGCAGCTCGTGGAACTGGAGGTGGACTCGTGCAGCCTGGACGGTCGCT GCGGCTGAGCTGCGCTGCATCCGGCTTACCTTCGACGATTATGCCATGCACT GGGT CAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGGTATCAGCTGG AATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGTTCAACATTTT CCGCGACAACGCCAAGAACTCCCTGTACTTGCAAATGAACAGCCTCCGGGATG

		AGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGTGCCCGACGTC TGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGCGGGGGTGGATCGGGCGG TGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAGACCCCTCGT CCCTGTCCGCCTCGGTCCGGCACC GCCTGACTATCACATGTAGAGCCTCGCAG AGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGAAGGCCCCGAA GCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCGAGCCGGTTTT CCGGTCCGGCTCCGGCACC GACTTCACGCTGACCATTCTTCCCTGCAACCC GAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCCCTTACTCCTT CGGCCAAGGAACCAGGCTGGAAATCAAG
BCMA_EBB- C1978-D10 - aa VH	183	EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW NSGSIGYADSVKGRFTISRDNANKNSLYLQMNSLRDEDTAVYYCARVGKAVPDV WGQGTITVTVSS
BCMA_EBB- C1978-D10- aa VL	204	DIVMTQTPSSLSASVGDRVITICRASQSISSYLNWYQQKPKAPKLLIYAASS LQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQSYSTPYSGQGTRLEI K
BCMA_EBB- C1978-D10 - aa Full CART	225	MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGRSLRLSCAASGFTFDDY AMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNANKNSLYLQMNS LRDEDTAVYYCARVGKAVPDVWGQGTITVTVSSGGGGSGGGSGGGSDIVMTQ TPSSLSASVGDRVITICRASQSISSYLNWYQQKPKAPKLLIYAASSLQSGVP SRFSGSGSGTDFTLTISLQPEDFATYYCQQSYSTPYSGQGTRLEIKTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV LLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR
BCMA_EBB- C1978-D10 - nt Full CART	246	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTCGTGGAAGCTGGAGGTGGACTCGTGCAGCCTG GACGGTCGCTGCGGCTGAGCTGCGCTGCATCCGGCTTCACCTTCGACGATTAT GCCATGCACTGGGTGAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGG TATCAGCTGGAATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGT TCACCATTTCGCGGACAACGCCAAGAACTCCCTGTACTTGCAATGAACAGC CTCCGGGATGAGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGT GCCCGACGTCTGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGCGGGGGTG GATCGGGCGGTGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAG ACCCCTCGTCCCTGTCCGCCTCGGTCCGCGACCGCGTGAATATCACATGTAG AGCCTCGCAGAGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGA AGGCCCCGAAGCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCG AGCCGGTTTTCCGGGTCCGGCTCCGGCACC GACTTCACGCTGACCATTCTTC CCTGCAACCCGAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCC CTTACTCCTTCGGCCAAGGAACCAGGCTGGAAATCAAGACCACTACCCAGCA CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTCCCTGCG TCCGGAGGCATGTAGACCCGAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG ACTTCGCCTGCGATATCTACATTGGGGCCCTCTGGCTGGTACTTGCGGGGTC CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCGAAGAAGCT GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG AGGACGGCTGTTTATGCGGTTCCAGAGGAGGAGGAAGGCGGCTGCGAACTG CGCGTGAAATTCAGCCGAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA

		TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGGCAAAGGCCACGACGGAC TGTACCAGGGACTCAGCACC GCCACCAAGGACACCTATGACGCTCTTCACATG CAGGCCCTGCCGCTCGG
BCMA_EBB-C1979-C12		
BCMA_EBB-C1979-C12-aa ScFv domain	142	EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPKGLEWVASINW KGNLAYGDSVKGRFAISRDNKNTVFLQMNSLRTEDTAVYYCASHQGVAYYN YAMDVWGRGTLVTVSSGGGGSGGGSGGGGSEIVLTQSPGTLSPGERATLS CRATQSIGSSFLAWYQQRPGQAPRLLIYGASQRATGIPDRFSGRGSGTDFTLT ISRVEPEDSAVYYCQHYESSPSWTFGQGTKVEIK
BCMA_EBB-C1979-C12-nt ScFv domain	163	GAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCGGAAGGTCCCT GCGGCTCTCCTGCACTGCGTCTGGCTTACCTTCGACGACTACGCGATGCACT GGGTGAGACAGCGCCCGGAAAGGGCCTGGAATGGGTGCGCTCAATCAACTGG AAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCTTCGCCATTTT GCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCCCTGCGGACCG AGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGCATACTATAAC TACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGTCTCCGGGGG CGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAAATCGTGCTGA CTCAGAGCCCGGGAACCTCTTTCCTGTCCCCGGGAGAACGGGCCACTCTCTCG TGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCTGGTACCAGCAGAG GCCAGGACAGGCGCCCGCCTGCTGATCTACGGTGTCTCCCAACGCGCCACTG GCATTCCTGACCGGTTACGCGGCAGAGGGTCGGAACCGATTTCACACTGACC ATTTCCCGGTGGAGCCCGAAGATTCCGCAGTCTACTACTGTCAGCATTACGA GTCTCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAGATCAAG
BCMA_EBB-C1979-C12-aa VH	184	EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPKGLEWVASINW KGNLAYGDSVKGRFAISRDNKNTVFLQMNSLRTEDTAVYYCASHQGVAYYN YAMDVWGRGTLVTVSS
BCMA_EBB-C1979-C12-aa VL	205	EIVLTQSPGTLSPGERATLSRATQSIGSSFLAWYQQRPGQAPRLLIYGAS QRATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKV EIK
BCMA_EBB-C1979-C12-aa Full CART	226	MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGRSLRLSCTASGFTFDDY AMHWVRQRPKGLEWVASINWKGNLAYGDSVKGRFAISRDNKNTVFLQMNS LRTEDTAVYYCASHQGVAYYNYAMDVWGRGTLVTVSSGGGGSGGGSGGGGSE IVLTQSPGTLSPGERATLSRATQSIGSSFLAWYQQRPGQAPRLLIYGASQ RATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKVE IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA LAGTCGVLLLSLVITLYCKRGRKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCELRVKFSRSADAPAYKQGQNQLYNEINLGRREEYDVLDRGRDPEMG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGDGLYQGLSTATKD TYDALHMQALPPR
BCMA_EBB-C1979-C12-nt Full CART	247	ATGGCCCTCCCTGTACCCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCG GAAGGTCCCTGCGGCTCTCCTGCACTGCGTCTGGCTTACCTTCGACGACTAC GCGATGCACTGGGTGAGACAGCGCCCGGAAAGGGCCTGGAATGGGTGCGCTC AATCAACTGGAAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCT TCGCCATTTTCGCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCC CTGCGGACCGAGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGC ATACTATAACTACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGT CCTCCGGGGGCGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAA ATCGTGCTGACTCAGAGCCCGGGAACCTCTTTCCTGTCCCCGGGAGAACGGGC CACTCTCTCGTGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCTGGT

		ACCAGCAGAGGCCAGGACAGGCGCCCCGCTGCTGATCTACGGTGCTTCCCAA CGCGCCACTGGCATTCCCTGACCGGTTACGCGGCAGAGGGTCGGGAACCGATT CACACTGACCATTTCCTCCGGGTGGAGCCCCAAGATTTCGGCAGTCTACTACTGTC AGCATTACGAGTCTCTCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAG ATCAAGACCACTACCCACGACCCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCT CTGGCTGGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGCGAGAACCAGCTCTACAACGAACCTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
BCMA_EBB-C1980-G4		
BCMA_EBB- C1980-G4- aa ScFv domain	143	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW VSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYY CAKVV RDGMDVWGQGT VTVSSGGGGSGGGGSGGGGSEIVLTQSPA TSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATG IPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKVDI K
BCMA_EBB- C1980-G4- nt ScFv domain	164	GAGGTGCAGTTGGTTCGAAAGCGGGGGCGGGCTTGTGCAGCCTGGCGGATCACT GCGGCTGTCTGCGCGGCATCAGGCTTCACGTTTTCTTCTACGCCATGTCTT GGGTGCGCCAGGCCCTTGAAAGGGACTGGAATGGGTGTCCGCGATTTCGGGG TCCGGCGGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCTTCACTATCTC GCGGGACAACCTCCAAGAACACCTCTACCTCCAAATGAATAGCCTGCGGGCCG AGGATACCGCGTCTACTATTGCGCTAAGGTCTGCGCGACGGAATGGACGTG TGGGGACAGGGTACCACCGTGACAGTGTCTCGGGGGGAGGCGGTAGCGGCGG AGGAGGAAGCGGTGGTGGAGGTTCCGAGATTGTGCTGACTCAATCACCCGCGA CCCTGAGCCTGTCCCCCGCGCAAAGGGCCACTCTGTCTGTGCGGGCCAGCCAA TCAGTCTCCTCCTCGTACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGCTCC GAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATCCCGGATAGGT TCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTCCCGGCTGGAA CCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCCCGCCTAGATT CACTTTCGGCCCCGGCACCAAAGTGGACATCAAG
BCMA_EBB- C1980-G4- aa VH	185	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKVV RDGMDV WGQGT VTVSS
BCMA_EBB- C1980-G4- aa VL	206	EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAS SRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKV DIK
BCMA_EBB- C1980-G4- aa Full CART	227	MALPVTALLLPLALLHAARPEVQLVESGGGLVQPGGSLRLSCAASGF TFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKVV RDGMDVWGQGT VTVSSGGG SGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWY QQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVY YCQQYGSPPRFTFGPGTKVDIKTTTPAPRPPTPAPTIASQPLSLRPEACRP AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKLL YIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCEL RVKFSRSADAPAYK

		QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR
BCMA_EBB- C1980-G4- nt Full CART	248	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAGGTGCAGTTGGTCGAAAGCGGGGGCGGGCTTGTGCAGCCTG GCGGATCACTGCGGCTGTCTGCGCGGCATCAGGCTTCACGTTTTCTTCTCTAC GCCATGTCTCTGGGTGCGCCAGGCCCTGGAAAGGGACTGGAATGGGTGTCCGC GATTTGCGGGTCCGCGCGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCT TCACTATCTCGCGGGACAACCTCCAAGAACACCCTCTACCTCCAAATGAATAGC CTGCGGGCCGAGGATACCGCCGTCTACTATTGCGCTAAGGTCTGCGCGACGG AATGGACGTGTGGGGACAGGGTACCACCGTGACAGTGTCTCGGGGGGAGGCG GTAGCGGCGGAGGAGGAAGCGGTGGTGGAGGTCCGAGATTGTGCTGACTCAA TCACCCGCGACCCCTGAGCCTGTCCCCCGCGGAAAGGGCCACTCTGTCTGTCTG GGCCAGCCAATCAGTCTCTCTCTCTGACCTGGCTGGTACCAGCAGAAGCCAG GACAGGCTCCGAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATC CCGGATAGGTTTCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTC CCGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCC CGCCTAGATTCACTTTGCGCCCCGGCACCAAAGTGACATCAAGACCACTACC CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCAGCCTCTGTC CCTGCGTCCGGAGGCATGTAGACCCGCGAGCTGGTGGGGCCGTGCATACCCGGG GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCTCTGGCTGGTACTTGC GGGGTCTGTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTTCGGAA GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC AAGAGGAGGACGGCTGTTTCATGCCGGTTCAGAGAGGAGGAGGAAGCGGCTGC GAACTGCGCGTGAAATTCAGCCGCGAGCGCAGATGCTCCAGCCTACAAGCAGGG GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCCGAGAGAGGAGTACGACG TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT CACATGCAGGCCCTGCCGCCTCGG
BCMA_EBB-C1980-D2		
BCMA_EBB- C1980-D2- aa ScFv domain	144	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFD YWGQGLTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSPGERATLSCRAS QSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR LEPEDEFAVYYCQHYGSSPSWTFGQGRLEIK
BCMA_EBB- C1980-D2- nt ScFv domain	165	GAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGGGGGGATCGCT CAGACTGTCCTGTGCGGCGTCAGGCTTACCTTCTCGAGCTACGCCATGTCAT GGGTGAGACAGGCCCTGGAAAGGGTCTGGAATGGGTGTCCGCCATTTCCGGG AGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCTTACCATTTC CCGGGACAACCTCCAAGAACACTCTCTATCTGCAAATGAACTCCCTCCGCGCTG AGGACACTGCCGTGTACTACTGCGCCAAATCCCTCAGACCGGCACCTTCGAC TACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCGGAGGTTCCGG GGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACCCAGTCACCCG GCACTTTGTCCCTGTGCGCTGGAGAAAGGGCCACCCTTCTCTGCCGGGCATCC CAATCCGTGTCTCTCTCTGACCTGGCCTGGTACCAGCAGAGGCCCGGACAGGC CCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGGACCGGTATCCCGGACC GGTTTTCGGGCTCGGGCTCAGGAACCTGACTTACCCTCACCATCTCCCGCCTG GAACCCGAAGATTTGCTGTGTATTACTGCCAGCACTACGGCAGCTCCCCGTC CTGGACGTTCCGGCCAGGGAACCTCGGCTGGAGATCAAG
BCMA_EBB-	186	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG

C1980-D2- aa VH		SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFD YWGQGT LVT VSS
BCMA_EBB- C1980-D2- aa VL	207	EIVLTQSPGTL SLSPGERATL SCRASQSVSSSYLAWYQQRPGQAPRLLIYGAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRL EIK
BCMA_EBB- C1980-D2- aa Full CART	228	MALPVTALLLPLALLLHAARPEVQLLES GGGGLVQPGGSLRLS CAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKIPQTGTFDYWGQGT LVT VSSGGGGSGGGGSGGGGSEIVLT QSPGTL SLSPGERATL SCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATG IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRLEIKTT TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG CELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYDA LHMQALPPR
BCMA_EBB- C1980-D2- nt Full CART	249	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGG GGGATCGCTCAGACTGTCTGTGCGGCGTCAGGCTTCACCTTCTCGAGCTAC GCCATGTCATGGGT CAGACAGGCCCTGGAAAGGGTCTGGAATGGGTGTCCGC CATTTCCGGGAGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCT TCACCATTTCGGGACAACTCCAAGAACACTCTCTATCTGCAAATGAACTCC CTCCGCGCTGAGGACACTGCCGTGTACTACTGCGCCAAAATCCCTCAGACCGG CACCTTCGACTACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCG GAGGTTCGGGGGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACC CAGTCACCCGGCACTTTGTCCCTGTGCGCTGGAGAAAGGGCCACCCTTTCTTG CCGGGCATCCCAATCCGTGTCTCTCGTACCTGGCCTGGTACCAGCAGAGGC CCGGACAGGCCCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGCAGCCGGT ATCCCGGACCGGTTTTTCGGGCTCGGGCTCAGGAACTGACTTCACCCTCACCAT CTCCCGCTGGAACCCGAAGATTTCGCTGTGTATTACTGCCAGCACTACGGCA GCTCCCCGTCTTGACGTTTCGGCCAGGGAACCTCGGCTGGAGATCAAGACCACT ACCCAGCACCAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCT GTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCC GGGTCTTGACTTCGCTGCGATATCTACATTGGGGCCCTCTGGCTGGTACT TGCGGGGTCTGTGCTTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTGCG GAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTA CTCAAGAGGAGGACGGCTGTTTCATGCCGTTTCCAGAGGAGGAGGAAGGCGGC TGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCA GGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACG ACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGC AGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGC AGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAAGAGGCAAAGGCC ACGACGGA CTGTACCAGGGA CTGACACCGCCACCAAGGACACCTATGACGCT CTTCACATGCAGGCCCTGCCGCTCGG
BCMA_EBB-C1978-A10		
BCMA_EBB- C1978-A10- aa ScFv domain	145	EVQLVETGGGLVQPGGSLRLS CAASGFTFSSYAMSWVRQAPGKGLEW VSAISGSGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVY YCARANYKRELRYYYGMDVWGQGTMTVTVSSGGGGSGGGGSGGGGS EIVMTQSPGTL SLSPGESATL SCRASQSVSSSYLAWYQHKPGQAPSLLI SGASSRATGV PDRFSGSGSGTDFTLISRLEPEDSAVYYCQHYDSSPSW TFGQGTKVEIK
BCMA_EBB- C1978-A10-	166	GAAGTGCAACTGGTGGAAACCGGTGGAGGACTCGTGACGCTGGCGGCAGCCT CCGGCTGAGCTGCGCCGCTTCGGGATTACCTTTTCTCTCTACGCGATGTCTT

nt ScFv domain		GGGTCAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGCCATCTCCGGC TCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGTTCACCATGTC GCGCGAGAATGACAAGAACTCCGTGTTCTCTGCAAATGAACTCCCTGAGGGTGG AGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAGAGAGCTGCGG TACTACTACGGAATGGACGTCTGGGGACAGGGAACATGGTGACCGTGTTCATC CGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGGTTCAGAAATTG TCATGACCCAGTCCCCGGGAACCTCTTTCCTCTCCCCCGGGGAATCCGCGACT TTGTCTGCGGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCGCATGGTACCA GCATAAGCCAGGCCAAGCCCCCTTCCCTGCTGATTTCCGGGGCTAGCAGCCGCG CCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTACCGATTTTACC CTGGCAATCTCGCGGCTGGAACCGGAGGATTGGCCGTGTACTACTGCCAGCA CTATGACTCATCCCCCTCTGGACATTGGACAGGGCACCAAGGTCGAGATCA AG
BCMA_EBB- C1978-A10- aa VH	187	EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVIYCARANYKREL YYYGMDVWGQGTMTVSS
BCMA_EBB- C1978-A10- aa VL	208	EIVMTQSPGTLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLILISGAS SRATGVPDRFSGSGSGTDFTLAIISRLEPEDSAVYYCQHYDSSPSWTFGQGTKV EIK
BCMA_EBB- C1978-A10- aa Full CART	229	MALPVTALLPLALLHAARPEVQLVETGGGLVQPGGSLRLSCAASGF TFSSYAMSWVRQAPGKGLEWVSAISGGGSTYYADSVKGRFTMSREN DKNSVFLQMNSLRVEDTGVIYCARANYKRELRYYYGMDVWGQGTMT VTVSSGGGGSGGGSGGGGSEIVMTQSPGTLSPGESATLSCRASQR VASNYLAWYQHKPGQAPSLILISGASSRATGVPDRFSGSGSGTDFTLAI SRLEPEDSAVYYCQHYDSSPSWTFGQGTKVEIKTTTPAPRPPTPAPTIA QPLSLRPEACRPAAGGAVHTRGLDFACDIYWAPLAGTCGVLLLSLVIT LYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCEL RVK FSRSADAPAYKQGQNQLYNELNLGRREEYDVLDRRGRDPEMGGKP RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST ATKDTYDALHMQALPPR
BCMA_EBB- C1978-A10- nt Full CART	250	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAACTGGTGGAACCGGTGGAGGACTCGTGACGCTG GCGGCAGCCTCCGGCTGAGCTGCGCCGCTTCGGGATTACCTTTTCTCTTAC GCGATGTCTTGGGTGAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGC CATCTCCGGCTCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGT TCACCATGTGCGCGAGAATGACAAGAACTCCGTGTTCTGCAAATGAACTCC CTGAGGGTGGAGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAG AGAGCTGCGGTACTACTACGGAATGGACGTCTGGGGACAGGGAACATGGTGA CCGTGTCATCCGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGT TCAGAAATTGTCATGACCCAGTCCCCGGGAACCTCTTTCCTCTCCCCCGGGGA ATCCGCGACTTTGTCTGCGGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCG CATGGTACCAGCATAAGCCAGGCCAAGCCCCCTTCCCTGCTGATTTCCGGGGCT AGCAGCCGCGCCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTAC CGATTTACCCCTGGCAATCTCGCGGCTGGAACCGGAGGATTGGCCGTGTACT ACTGCCAGCACTATGACTCATCCCCCTCTGGACATTGCGACAGGGCACCAAG GTGAGATCAAGACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTAC CATCGCCTCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG GCCCCCTGTGGCTGGTACTTGCGGGGTCTGCTGCTTTTACTCGTGATCACTCT TTACTGTAAGCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA

		TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCCCA GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTACGCCGCAGCGCAGA TGCTCCAGCCTACAAGCAGGGGAGAACAGCTCTACAACGAACTCAATCTTG GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT CCAAAAGGATAAGATGGCAGAAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCCTCGG
BCMA_EBB-C1978-D4		
BCMA_EBB-C1978-D4- aa ScFv domain	146	EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKALVGATGA FDIWGQGTILVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSPGERATLSCR ASQSLSSNFLAWYQQKPGQAPGLLIYGASNWATGTPDRFSGSGSGTDFTLTIT RLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK
BCMA_EBB-C1978-D4- nt ScFv domain	167	GAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAGGGGGCTCCCT GAGGCTTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTACGCCATGTCGT GGGTCCGCCAAGCCCCCTGGAAGGCTGGAATGGGTGTCCGCGATTTCGGGG AGCGGAGGTTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCTTTACCATCTC CCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCGCTGAGAGCCG AGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCGGCGCGACTGGGGCA TTCGACATCTGGGGACAGGGAACCTCTGTGACCGTGTGAGCGGAGGCGGCGG CTCCGGCGGAGGAGGAGCGGGGGCGGTGGTTCGAAATCGTGTTGACTCAGT CCCCGGGAACCCCTGAGCTTGTCACCCGGGGAGCGGGCCACTCTCTCCTGTCCG GCCTCCCAATCGCTCTCATCCAATTTCTTGGCCTGGTACCAGCAGAAGCCCGG ACAGGCCCCGGGCTGCTCATCTACGGCGCTTCAAACCTGGGCAACGGGAACCC CTGATCGGTTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCTGACCATCACC AGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACTACGGCACCTC CCCCATGTACACATTCCGACAGGGTACCAAGGTCGAGATTAAG
BCMA_EBB-C1978-D4- aa VH	188	EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKALVGATGA FDIWGQGTILVTVSS
BCMA_EBB-C1978-D4- aa VL	209	EIVLTQSPGTLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGAS NWATGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKV EIK
BCMA_EBB-C1978-D4- aa Full CART	230	MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAASGFSFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKALVGATGAFDIWGQGTILVTVSSGGGGSGGGGSGGGGSEIV LTQSPGTLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGASNWA TGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSRFPPEEEE GGCELRVKFSRSADAPAYKQGNQLYNELNLGRREEYDVLDRRGRDPPEMGGK PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATKDTY DALHMQALPPR
BCMA_EBB-C1978-D4- nt Full CART	251	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAG GGGGCTCCCTGAGGCTTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTAC GCCATGTCGTGGGTCCGCCAAGCCCCTGGAAGGCTGGAATGGGTGTCCGC GATTTCCGGGAGCGGAGGTTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCT TTACCATCTCCCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCG

		CTGAGAGCCGAGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCCGGCGC GACTGGGGCATTTCGACATCTGGGGACAGGGAACCTCTTGTGACCGTGTGAGCGG GAGGCGGCGGCTCCGGCGGAGGAGGGAGCGGGGGCGGTGGTTCCGAAATCGTG TTGACTCAGTCCCCGGAACCCCTGAGCTTGTACCCGGGGAGCGGGGCCACTCT CTCCTGTGCGGCCTCCCAATCGCTCTCATCCAATTTCTTGGCCTGGTACCAGC AGAAGCCCCGACAGGCCCCGGGCCTGCTCATCTACGGCGCTTCAAACCTGGGCA ACGGGAACCCCTGATCGGTTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCT GACCATCACCAGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACT ACGGCACCTCCCCCATGTACACATTCGGACAGGGTACCAAGGTCGAGATTAAG ACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGGCCCTCTGGCT GGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG CGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCCTTCATGAGGCCTGTGC AGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCACAGAGGAGGAGGAA GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA CAAGCAGGGGCAGAACCAGCTCTACAACGAACCTCAATCTTGGTCGGAGAGAGG AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG CCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAA GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA AAGGCCACGACGGAAGTGTACAGGGACTCAGCACCGCCACCAAGGACACCTAT GACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
BCMA_EBB-C1980-A2		
BCMA_EBB-C1980-A2- aa ScFv domain	147	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDP WGQGT LVT VSSGGGGSGGGSGGGSDIVLTQSP LSLPVT PGEPA SISRSSQ SLLHSNGYNYLDWYLQKPGQSPQLLIYLG SNRASGV PDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQALQ TPLTFGGGTKVDIK
BCMA_EBB-C1980-A2- nt ScFv domain	168	GAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCGGGGGATCACT GCGCCTGTCTGTGCCGCGTCCGGTTTCACTTTCTCTCTGTACGCCATGTCTGT GGGTGAGACAGGCACCGGGAAGGGACTGGAATGGGTGTACGCCATTTCCGGT TCGGGGGGGAGCACCTACTACGCTGACTCCGTGAAGGGCCGGTTCACCATTTT CCGCGACAACCTCCAAGAACACCTTGTACCTCCAAATGAACCTCCGTGCGGGCCG AAGATACCGCCGTGTATTACTGCGTGTCTGTGGTTCGGAGAGGGATTGACCCG TGGGGACAAGGAACACTCGTGACTGTGTATCCGGCGGAGGCGGCAGCGGTGG CGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTGACCCAGTCCCTCTGA GCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCGGTTCAGCCAG TCCCTCCTGCACTCCAATGGGTACAACCTACCTCGATTGGTATCTGCAAAAGCC GGGCCAGAGCCCCCAGCTGCTGATCTACCTGGGTCAAACCGCGCTTCCGGGG TGCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTACCCTGAAAATC TCGAGGGTGGAGGCCGAGGACGTCCGAGTGTACTACTGCATGCAGGCGCTCCA GACTCCCCTGACCTTCGGAGGAGGAACGAAGGTCGACATCAAGA
BCMA_EBB-C1980-A2- aa VH	189	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDP WGQGT LVT VSS
BCMA_EBB-C1980-A2- aa VL	210	DIVLTQSP LSLPVT PGEPA SISRSSQ SLLHSNGYNYLDWYLQKPGQSPQLLI YLG SNRASGV PDRFSGSGSGTDFTLKI SRVEAEDVGVYYCMQALQ TPLTFGG TKVDIK
BCMA_EBB-C1980-A2- aa Full CART	231	MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCVLWFGEGFDPWGQGT LVT VSSGGGGSGGGSGGGSDIVLTQ SP LSLPVT PGEPA SISRSSQ SLLHSNGYNYLDWYLQKPGQSPQLLIYLG SNR

		ASGVPDFRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIK TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEEDGCSRFPEEEEE GGCELRVKFSRSADAPAYKQGQNLQLYNELNLGRREEYDVLDRGRDPEMGGK PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY DALHMQALPPR
BCMA_EBB- C1980-A2- nt Full CART	252	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCCGAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCCG GGGGATCACTGCGCCTGTCTGTGCCGCGTCCGGTTTCACTTTCTCCTCGTAC GCCATGTCTGTGGGTGAGACAGGCACCGGGAAGGGACTGGAATGGGTGTCAGC CATTTCCGGTTCCGGGGGCGAGCACCTACTACGCTGACTCCGTGAAGGGCCGGT TCACCATTTCCCGCGACAACCTCCAAGAACACCTTGTACCTCCAAATGAACTCC CTGCGGGCCGAAGATACCGCCGTGTATTACTGCGTGCTGTGGTTCGGAGAGGG ATTGACCCGTGGGGACAAGGAACACTCGTGACTGTGTATCCGGCGGAGGCG GCAGCGGTGGCGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTGACCCAG TCCCTCTGAGCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCG GTCGAGCCAGTCCCTCCTGCACTCCAATGGGTACAACCTACCTCGATTGGTATC TGCAAAAGCCGGGCCAGAGCCCCAGCTGCTGATCTACCTTGGGTCAAACCGC GCTTCCGGGGTGCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTAC CCTGAAAATCTCGAGGGTGGAGGCCGAGGACGTCGGAGTGTACTACTGCATGC AGGCGCTCCAGACTCCCCTGACCTTCGGAGGAGGAACGAAGGTGCACATCAAG ACCACTACCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCTCTGGCT GGTACTTGCGGGGTCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG CGGTGCGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGC AGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGGTTCACAGAGGAGGAGGAA GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA CAAGCAGGGGCAGAACCAGCTCTACAACGAACCAATCTTGGTCCGAGAGAGG AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG CCGCGCAGAAAGAATCCCCAAGAGGGCCCTGTACAACGAGCTCCAAAAGGATAA GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA AAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTAT GACGCTCTTCACATGCAGGCCCTGCCGCCTCGG
BCMA_EBB-C1981-C3		
BCMA_EBB- C1981-C3- aa ScFv domain	148	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGY YRDYYGMDVWQGTTVTVSSGGGGSGGGSGGGGSEIVLTQSPGTLSPGER ATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGISDRFSGSGSGTD FTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTKLEIK
BCMA_EBB- C1981-C3- nt ScFv domain	169	CAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCGGGGGCTCCCT GAGACTTTCCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTATGCTATGTCCT GGGTGCGCCAGGCCCCGGGAAAGGGACTGGAATGGGTGTCCGCAATCAGCGGT AGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTCCGTTCACTATTTT CCGGGACAACCTCCAAGAATACCTGTACCTCCAAATGAACAGCCTCAGGGCCG AGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAGCTCCGGTTAC TACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCAACCGTGACCGT GTCAAGCGGCGGAGGCGGTTTCAGGAGGGGGAGGCTCCGGCGGTGGAGGGTCCG

		AAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCTGTTGTCCCCGGGGGAGCGC GCTACCCTGTCTGTCTCGGGCGTCGCAGTCCGTGTCTGAGCTCCTACCTCGCGTG GTACCAGCAGAAGCCCGGACAGGCCCTAGACTTCTGATCTACGGCACTTCTT CACGCGCCACCGGGATCAGCGACAGGTTTACGCGGCTCCGGCTCCGGGACCGAC TTCACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCCGCCGTGTATTACTG CCAACACTACGGAACTCGCCGCCAAAGTTCACGTTCCGACCCGGAACCAAGC TGGAAATCAAG
BCMA_EBB- C1981-C3- aa VH	190	QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKVG YDSSGY YRDYYGMDVWGQGT TVTVSS
BCMA_EBB- C1981-C3- aa VL	211	EIVLTQSPGTL SLSPGERATL SCRASQSVSSSYLAWYQQKPGQAPRLLIYGTS SRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTK LEIK
BCMA_EBB- C1981-C3- aa Full CART	232	MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKVG YDSSGYRDYYGMDVWGQGT TVTVSSGGGGSGGGGSGG GGSEIVLTQSPGTL SLSPGERATL SCRASQSVSSSYLAWYQQKPGQAPRLLIY GTSSRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGP GTKLEIKTTTTAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI YIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC RFPEEEEGGCEL RVKFSRSADAPAYKQGNQLYNELNLGRREEYDVL DKRRGR DPEMGGKPRKPNQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLS TATKDTYDALHMQALPPR
BCMA_EBB- C1981-C3- nt Full CART	253	ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCG GGGGCTCCCTGAGACTTTCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTAT GCTATGTCCTGGGTGCGCCAGGCCCGGGAAAGGGACTGGAATGGGTGTCCGC AATCAGCGGTAGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTGCCT TCACTATTTCCCGGGACAACCTCCAAGAATACCCTGTACCTCCAAATGAACAGC CTCAGGGCCGAGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAG CTCCGGTTACTACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCA CCGTGACCGTGTCAAGCGGCGGAGGCGGTTCAGGAGGGGGAGGCTCCGGCGGT GGAGGGTCCGAAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCTGTTGTCCC GGGGGAGCGCGCTACCCTGTCTGTCTCGGGCGTCGCAGTCCGTGTCTGAGCTCCT ACCTCGCGTGGTACCAGCAGAAGCCCGGACAGGCCCTAGACTTCTGATCTAC GGCACTTCTTACGCGCCACCGGGATCAGCGACAGGTTTACGCGGCTCCGGCTC CGGGACCGACTTCAACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCCGCCG TGTATTACTGCCAACACTACGGAACTCGCCGCCAAAGTTCACGTTCCGGACCC GGAACCAAGCTGGAAATCAAGACCACTACCCACGACCCGAGGCCACCCACCCC GGCTCCTACCATCGCCTCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGAC CCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATC TACATTTGGGCCCCCTCTGGCTGGTACTTGCGGGGTCTGCTGCTTTTCACTCGT GATCACTCTTTACTGTAAGCGCGGTGCGAAGAAGCTGCTGTACATCTTTAAGC AACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTATGC CGGTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCG CAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACAGCTCTACAACGAAC TCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGG GACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTA CAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGA

		AAGGGGAACGCAGAAGAGGCCAAAGGCCACGACGGACTGTACCAGGGACTCAGC ACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCG G
BCMA_EBB-C1978-G4		
BCMA_EBB-C1978-G4- aa ScFv domain	149	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYL GAFDIWGQGTTTVTVSSGGGGSGGGSGGGGSEIVLTQSPGTLSPGERATLS CRASQSVASSFLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLT ISRLEPEDFAVYYCQHYGGSPLRTFGGGTKVDIK
BCMA_EBB-C1978-G4- nt ScFv domain	170	GAAGTCCAACCTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCGGAGGCAGCCT TCGGCTGTCTGCGCCGCTCCGGGTTACGTTCTCATCTACCGCATGTCTGT GGGTCAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGCCATTAGCGGC TCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGTTCACTATCTC CCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCTCTGCGGGCCG AGGATACCGCGGTGTACTATTGCGCCAAGATGGGTGGTCCAGCGGATACTTG GGAGCCTTCGACATTGTTGGGACAGGGCACTACTGTGACCGTGTCTCCGGGGG TGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAAATCGTGTGTA CCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGCTACACTGTCA TGTAGAGCGTCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGTACCAGCAGAA GCCGGGACAGGCACCCGCTGCTCATCTACGGAGCCAGCGCCGGGCGACCG GCATCCCTGACCGCTTCTCCGGTTCGGGCTCGGGCACCAGCTTTACTCTGACC ATTAGCAGGCTTGAGCCCGAGGATTTGCCGTGTACTACTGCCAACACTACGG GGGAGCCCTCGCTGACCTTCGGAGCGGAACCTAAGGTCGATATCAAAA
BCMA_EBB-C1978-G4- aa VH	191	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG SGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYL GAFDIWGQGTTTVTVSS
BCMA_EBB-C1978-G4- aa VL	212	EIVLTQSPGTLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGAS GRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPLRTFGGGTKV DIK
BCMA_EBB-C1978-G4- aa Full CART	233	MALPVTALLLPLALLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSY AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNS LRAEDTAVYYCAKMGWSSGYLGAFDIWGQGTTTVTVSSGGGGSGGGSGGGGSE IVLTQSPGTLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGASG RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPLRTFGGGTKVD IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE EEGGCELRVKFSRSADAPAYKQGNQLYNELNLGRREEYDVLDRRRGRDPENG GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKHDGLYQGLSTATKD TYDALHMQALPPR
BCMA_EBB-C1978-G4- nt Full CART	254	ATGGCCCTCCCTGTACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC CGCTCGGCCCGAAGTCCAACCTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCG GAGGCAGCCTTCGGCTGTCTGTCGCCGCTCCGGGTTACGTTCTCATCTAC GCGATGTCTGTGGGTGAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGC CATTAGCGGCTCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGT TCACTATCTCCCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCT CTGCGGGCCGAGGATACCGCGGTGTACTATTGCGCCAAGATGGGTGGTCCAG CGGATACTTGGGAGCCTTCGACATTTGGGGACAGGGCACTACTGTGACCGTGT CCTCCGGGGGTGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAA ATCGTGTGACCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGC TAACTGTCTATGTAGAGCGTCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGT ACCAGCAGAAGCCGGGACAGGCACCCCGCTGCTCATCTACGGAGCCAGCGGC CGGGCGACCGGCATCCCTGACCGCTTCTCCGGTTCGGGCTCGGGCACCAGCTT

		TACTCTGACCATTAGCAGGCTTGAGCCCGAGGATTTTGCCGTGTACTACTGCC AACACTACGGGGGAGCCCTCGCCTGACCTTCGGAGGCGGAACCTAAGGTCGAT ATCAAAACCACTACCCACAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCCT CTGGCTGGTACTTGCGGGGTCTTGCTGCTTTCACTCGTGATCACTCTTTACTG TAAGCGCGGTTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTTCATGCCGTTCCCAGAGGAG GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC AGCCTACAAGCAGGGGCAGAACCAAGCTCTACAACGAACCTCAATCTTGGTCGGA GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA GGATAAGATGGCAGAACCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCTCGG
--	--	--

5

In embodiments, additional exemplary BCMA CAR constructs are generated using the VH and VL sequences from PCT Publication WO2012/0163805 (the contents of which are hereby incorporated by reference in its entirety), e.g., based upon the results from the pBCMA3 and pBCMA4 CARs described in Examples 2 and 3. A schematic of the exemplary BCMA constructs (BCMA-3NP and BCMA-4NP) is shown in Figure 10A. The two constructs differ in the orientation of the VH and VL chains (Fig. 10B). Exemplary BCMA CAR constructs and their corresponding DNA ID are shown below in Table 3.

10

Table 3. Tool CAR construct IDs

Nickname	Novartis ID	DNA2.0 ID
BCMA-3NP		126022
BCMA-4NP		126021

15

In embodiments, additional exemplary BCMA CAR constructs can also be generated using the VH and VL sequences found in Table 16. The amino acid sequences of exemplary scFv domains comprising the VH and VL domains and a linker sequence, and full-length CARs are also found in Table 16.

20

Table 16. Additional exemplary BCMA CAR sequences

Name	Sequence	SEQ ID NO:

A7D12.2 VH	QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGESYFA DDFKGRFAFSVETSATTAYLQINNLTEDTATYFCARGEIYYGYDGGFAYWGQGLVTVSA	255
A7D12.2 VL	DVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKLLIFSASYRYTGVPDR FTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFTGGGTKLDIK	259
A7D12.2 scFv domain	QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGESYFA DDFKGRFAFSVETSATTAYLQINNLTEDTATYFCARGEIYYGYDGGFAYWGQGLVTVSA GGGGSGGGSGGGSDVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKL LIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFTGGGTKLDIK	263
A7D12.2 Full CART	QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGESYFA DDFKGRFAFSVETSATTAYLQINNLTEDTATYFCARGEIYYGYDGGFAYWGQGLVTVSA GGGGSGGGSGGGSDVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKL LIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFTGGGTKLDIK TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP AYKQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYS EIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR	267
C11D5.3 VH	QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYA YDFRGRFAFSLETSASTAYLQINNLYEDTATYFCALDYSYAMDYWGQGSVTVSS	256
C11D5.3 VL	DIVLTQSPASLMSLGKRATISCRASESVSVIGAHLIHWYQQKPGQPPELLIYLASNLETG VPAFSGSGSGTDFTLTIDPVEEDDVAIYSCLSQSRIFPRTFTGGGTKLEIK	260
C11D5.3 scFv domain	QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYA YDFRGRFAFSLETSASTAYLQINNLYEDTATYFCALDYSYAMDYWGQGSVTVSSGGGGS GGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWI NTETREPAYAYDFRGRFAFSLETSASTAYLQINNLYEDTATYFCALDYSYAMDYWGQGS VTVSS	264
C11D5.3 Full CART	QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETREPAYA YDFRGRFAFSLETSASTAYLQINNLYEDTATYFCALDYSYAMDYWGQGSVTVSSGGGGS GGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWI NTETREPAYAYDFRGRFAFSLETSASTAYLQINNLYEDTATYFCALDYSYAMDYWGQGS VTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR SADAPAYKQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNELQKDKM AEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR	268
C12A3.2 VH	QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGVPIYA DDFKGRFAFSVETSASTAYLVINNLTEDTASYFCSNDYLYSLDFWGQGTALTVSS	257
C12A3.2 VL	DIVLTQSPPSLMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASNVQTG VPAFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFTGGGTKLEIK	261
C12A3.2 scFv domain	QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGVPIYA DDFKGRFAFSVETSASTAYLVINNLTEDTASYFCSNDYLYSLDFWGQGTALTVSSGGGGS GGGGSGGGSDIVLTQSPPSLMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLL IQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFTGGGTKLEIK	265
C12A3.2 Full CART	QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGVPIYA DDFKGRFAFSVETSASTAYLVINNLTEDTASYFCSNDYLYSLDFWGQGTALTVSSGGGGS GGGGSGGGSDIVLTQSPPSLMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLL IQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFTGGGTKLEIKT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLS LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPA YKQGQNQLYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE	269

	IGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQALPPR	
C13F12.1 VH	QIQLVQSGPELKKPGETVKISCKASGYTFTTHYSMNWVKQAPGKGLKWMGRINTETGEPLYA DDFKGRFAFSLETSASTAYLVINNLLKNEDTATFFCSNDYLYSCDYWGQGTTLTVSS	258
C13F12.1 VL	DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPFTLLIQLASNVQTG VPAFSGSGSRIDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK	262
C13F12.1 scFv domain	QIQLVQSGPELKKPGETVKISCKASGYTFTTHYSMNWVKQAPGKGLKWMGRINTETGEPLYA DDFKGRFAFSLETSASTAYLVINNLLKNEDTATFFCSNDYLYSCDYWGQGTTLTVSSGGGGS GGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPFTLL IQLASNVQTGVPARFSGSGSRIDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK	266
C13F12.1 Full CART	QIQLVQSGPELKKPGETVKISCKASGYTFTTHYSMNWVKQAPGKGLKWMGRINTETGEPLYA DDFKGRFAFSLETSASTAYLVINNLLKNEDTATFFCSNDYLYSCDYWGQGTTLTVSSGGGGS GGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPFTLL IQLASNVQTGVPARFSGSGSRIDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIKT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAFLAGTCGVLLLS LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCCELRVKFSRSADAPA YKQGQNLQYLNELNLRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSE IGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQALPPR	270

5

In embodiments, the nucleic acid sequence of an exemplary humanized anti-BCMA

scFv in which VH precedes the VL (H2L, e.g., pBCMA 2 and pBCMA 4) is as follows:

CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAG
GCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCGGACAGGGCCTGGAG
TGGATGGGCGCCACCTACAGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACC
ATCACCGCCGACAAGAGCACCAGCACCAGCCTACATGGAAGTGAAGCAGCCTCAGGAGCGAGGACACCGCT
GTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACCTGGGGCCAGGGCACA
CTAGTGACCGTGTCCAGCGGTGGAGGAGGTAGCGGAGGAGGCGGGAGCGGTGGAGGTGGCTCTGGAGGT
GGCGGAAGCGACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACC
ATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCC
CCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCAGCAGGTTTACGCGGAAGCGGC
AGCGGCACCGATTTACCCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAG
CAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACCTGGAGATCAAGCGT
(SEQ ID NO: 272)

20

The corresponding amino acid sequence for the exemplary humanized anti-BCMA scFv in which Vh precedes the VL (H2L, e.g., pBCMA 2 and pBCMA 4) is as follows:

Q V Q L V Q S G A E V K K P G S S V K V S C K A S G G T F S N Y W M H W V R
Q A P G Q G L E W M G A T Y R G H S D T Y Y N Q K F K G R V T I T A D K S T
S T A Y M E L S S L R S E D T A V Y Y C A R G A I Y N G Y D V L D N W G Q G
T L V T V S S G G G G S G G G G S G G G G S G G G G S D I Q M T Q S P S S L
S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K L L I Y
Y T S N L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y
C Q Q Y R K L P W T F G Q G T K L E I K R (SEQ ID NO: 271)

30

- 5 In embodiments, the nucleic acid sequence of an exemplary humanized anti-BCMA scFv in which VL precedes the VH (L2H, e.g., pBCMA1 and pBCMA3) is as follows:

GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGC
 TCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTG
 CTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCAGCAGGTTTCAGCGGAAGCGGCAGCGGCACC
 10 GATTTACCCCTGACCATCTCCAGCCTGCAGCCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGG
 AAGCTCCCCCTGGACTTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTGGTGGAGGAGGTAGCGGAGGA
 GGCGGGAGCGGTGGAGGTGGCTCTGGAGGTGGCGGAAGCCAGGTGCAGCTGGTCCAGAGCGGCGCCGAA
 GTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGG
 ATGCACTGGGTGAGGCAGGCCCCCGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGC
 15 GACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCC
 TACATGGAAGTGAAGCAGCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTAC
 AACGGCTACGACGTGCTGGACAACCTGGGGCCAGGGCACACTAGTGACCGTGTCCAGC
 (SEQ ID NO: 274)

- 20 The corresponding amino acid sequence of the exemplary humanized anti-BCMA scFv in which VL precedes the VH (L2H, e.g., pBCMA1 and pBCMA3) is as follows:

DIQMTQSPSS LSASVGDRVT ITCSASQDIS NYLNWYQQKP GKAPKLLIYY
 TSNLHSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YRKLPWTFGQ
 GTKLEIKRGG GSGGGGSGGGGSGGGGSQV QLVQSGAEVK KPGSSVKVSC
 25 KASGGTFSNY WMHWVRQAPG QGLEWMGATYRGHSDTYYNQ KFKGRVTITA
 DKSTSTAYME LSSLRSEDTA VYYCARGAIYNGYDVLNWDWGQGTLLVTVSS (SEQ ID
 NO: 273)

The CAR scFv fragments can be cloned into lentiviral vectors to create a full length

- 30 CAR construct in a single coding frame, and using the EF1 alpha promoter for expression (SEQ ID NO: 11).

The CAR construct can include a Gly/Ser linker having one or more of the following sequences: GGGGS (SEQ ID NO:25); encompassing 1-6 "Gly Gly Gly Gly Ser" repeating units, e.g., GGGGSGGGGS GGGGSGGGGS GGGGSGGGGS (SEQ ID NO:26);

- 35 GGGGSGGGGS GGGGSGGGGS (SEQ ID NO:27); GGGGSGGGGS GGGGS (SEQ ID NO:28); GGGGS (SEQ ID NO:29); or encompassing 1-10 "Gly Gly Gly Ser" repeating units, e.g., GGGSGGGSGG GSGGGSGGGGS GGGSGGGSGG GSGGGSGGGGS (SEQ ID NO:38). In embodiments, the CAR construct include a poly A sequence, e.g., a sequence encompassing 50-5000 or 100-5000 adenines (e.g., SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34 or SEQ
 40 ID NO:35), or a sequence encompassing 50-5000 thymines (e.g., SEQ ID NO:31, SEQ ID NO:32). Alternatively, the CAR construct can include, for example, a linker including the sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO: 1108)

5

Bispecific CARs

In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv, or fragment thereof, have binding specificity for a first epitope and a scFv, or fragment thereof, have binding specificity for a second epitope.

In certain embodiments, the antibody molecule is a multi-specific (*e.g.*, a bispecific or a trispecific) antibody molecule. Protocols for generating bispecific or heterodimeric antibody molecules are known in the art; including but not limited to, for example, the “knob in a hole” approach described in, *e.g.*, US 5731168; the electrostatic steering Fc pairing as described in, *e.g.*, WO 09/089004, WO 06/106905 and WO 2010/129304; Strand Exchange Engineered Domains (SEED) heterodimer formation as described in, *e.g.*, WO 07/110205; Fab arm exchange as described in, *e.g.*, WO 08/119353, WO 2011/131746, and WO 2013/060867; double antibody conjugate, *e.g.*, by antibody cross-linking to generate a bi-specific structure

5 using a heterobifunctional reagent having an amine-reactive group and a sulfhydryl reactive group as described in, *e.g.*, US 4433059; bispecific antibody determinants generated by recombining half antibodies (heavy-light chain pairs or Fabs) from different antibodies through cycle of reduction and oxidation of disulfide bonds between the two heavy chains, as described in, *e.g.*, US 4444878; trifunctional antibodies, *e.g.*, three Fab' fragments cross-linked through
10 sulfhydryl reactive groups, as described in, *e.g.*, US5273743; biosynthetic binding proteins, *e.g.*, pair of scFvs cross-linked through C-terminal tails preferably through disulfide or amine-reactive chemical cross-linking, as described in, *e.g.*, US5534254; bifunctional antibodies, *e.g.*, Fab fragments with different binding specificities dimerized through leucine zippers (*e.g.*, c-fos and c-jun) that have replaced the constant domain, as described in, *e.g.*, US5582996; bispecific
15 and oligospecific mono-and oligovalent receptors, *e.g.*, VH-CH1 regions of two antibodies (two Fab fragments) linked through a polypeptide spacer between the CH1 region of one antibody and the VH region of the other antibody typically with associated light chains, as described in, *e.g.*, US5591828; bispecific DNA-antibody conjugates, *e.g.*, crosslinking of antibodies or Fab fragments through a double stranded piece of DNA, as described in, *e.g.*,
20 US5635602; bispecific fusion proteins, *e.g.*, an expression construct containing two scFvs with a hydrophilic helical peptide linker between them and a full constant region, as described in, *e.g.*, US5637481; multivalent and multispecific binding proteins, *e.g.*, dimer of polypeptides having first domain with binding region of Ig heavy chain variable region, and second domain with binding region of Ig light chain variable region, generally termed diabodies (higher order
25 structures are also encompassed creating for bispecific, trispecific, or tetraspecific molecules, as described in, *e.g.*, US5837242; minibody constructs with linked VL and VH chains further connected with peptide spacers to an antibody hinge region and CH3 region, which can be dimerized to form bispecific/multivalent molecules, as described in, *e.g.*, US5837821; VH and VL domains linked with a short peptide linker (*e.g.*, 5 or 10 amino acids) or no linker at all in
30 either orientation, which can form dimers to form bispecific diabodies; trimers and tetramers, as described in, *e.g.*, US5844094; String of VH domains (or VL domains in family members) connected by peptide linkages with crosslinkable groups at the C-terminus further associated with VL domains to form a series of FVs (or scFvs), as described in, *e.g.*, US5864019; and single chain binding polypeptides with both a VH and a VL domain linked through a peptide
35 linker are combined into multivalent structures through non-covalent or chemical crosslinking to form, *e.g.*, homobivalent, heterobivalent, trivalent, and tetravalent structures using both scFV

5 or diabody type format, as described in, *e.g.*, US5869620. Additional exemplary multispecific and bispecific molecules and methods of making the same are found, for example, in US5910573, US5932448, US5959083, US5989830, US6005079, US6239259, US6294353, US6333396, US6476198, US6511663, US6670453, US6743896, US6809185, US6833441, US7129330, US7183076, US7521056, US7527787, US7534866, US7612181,
10 US2002004587A1, US2002076406A1, US2002103345A1, US2003207346A1, US2003211078A1, US2004219643A1, US2004220388A1, US2004242847A1, US2005003403A1, US2005004352A1, US2005069552A1, US2005079170A1, US2005100543A1, US2005136049A1, US2005136051A1, US2005163782A1, US2005266425A1, US2006083747A1, US2006120960A1, US2006204493A1,
15 US2006263367A1, US2007004909A1, US2007087381A1, US2007128150A1, US2007141049A1, US2007154901A1, US2007274985A1, US2008050370A1, US2008069820A1, US2008152645A1, US2008171855A1, US2008241884A1, US2008254512A1, US2008260738A1, US2009130106A1, US2009148905A1, US2009155275A1, US2009162359A1, US2009162360A1, US2009175851A1,
20 US2009175867A1, US2009232811A1, US2009234105A1, US2009263392A1, US2009274649A1, EP346087A2, WO0006605A2, WO02072635A2, WO04081051A1, WO06020258A2, WO2007044887A2, WO2007095338A2, WO2007137760A2, WO2008119353A1, WO2009021754A2, WO2009068630A1, WO9103493A1, WO9323537A1, WO9409131A1, WO9412625A2, WO9509917A1, WO9637621A2,
25 WO9964460A1. The contents of the above-referenced applications are incorporated herein by reference in their entireties.

Within each antibody or antibody fragment (*e.g.*, scFv) of a bispecific antibody molecule, the VH can be upstream or downstream of the VL. In some embodiments, the upstream antibody or antibody fragment (*e.g.*, scFv) is arranged with its VH (VH₁) upstream of
30 its VL (VL₁) and the downstream antibody or antibody fragment (*e.g.*, scFv) is arranged with its VL (VL₂) upstream of its VH (VH₂), such that the overall bispecific antibody molecule has the arrangement VH₁-VL₁-VL₂-VH₂. In other embodiments, the upstream antibody or antibody fragment (*e.g.*, scFv) is arranged with its VL (VL₁) upstream of its VH (VH₁) and the downstream antibody or antibody fragment (*e.g.*, scFv) is arranged with its VH (VH₂) upstream
35 of its VL (VL₂), such that the overall bispecific antibody molecule has the arrangement VL₁-

VH₁-VH₂-VL₂. Optionally, a linker is disposed between the two antibodies or antibody fragments (e.g., scFvs), e.g., between VL₁ and VL₂ if the construct is arranged as VH₁-VL₁-VL₂-VH₂, or between VH₁ and VH₂ if the construct is arranged as VL₁-VH₁-VH₂-VL₂. The linker may be a linker as described herein, e.g., a (Gly₄-Ser)_n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 4 (SEQ ID NO: 26). In general, the linker between the two scFvs should be long enough to avoid mispairing between the domains of the two scFvs. Optionally, a linker is disposed between the VL and VH of the first scFv. Optionally, a linker is disposed between the VL and VH of the second scFv. In constructs that have multiple linkers, any two or more of the linkers can be the same or different. Accordingly, in some embodiments, a bispecific CAR comprises VLs, VHs, and optionally one or more linkers in an arrangement as described herein.

In one aspect, the bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence, e.g., a scFv, which has binding specificity for BCMA, e.g., comprises a scFv as described herein, e.g., as described in Table 1 or Table 16, or comprises the light chain CDRs and/or heavy chain CDRs from a BCMA scFv described herein, and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope on a different antigen. In some aspects the second immunoglobulin variable domain sequence has binding specificity for an antigen expressed on AML cells, e.g., an antigen other than BCMA. For example, the second immunoglobulin variable domain sequence has binding specificity for CD123. As another example, the second immunoglobulin variable domain sequence has binding specificity for CLL-1. As another example, the second immunoglobulin variable domain sequence has binding specificity for CD34. As another example, the second immunoglobulin variable domain sequence has binding specificity for FLT3. For example, the second immunoglobulin variable domain sequence has binding specificity for folate receptor beta. In some aspects, the second immunoglobulin variable domain sequence has binding specificity for an antigen expressed on B-cells, for example, CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a.

Chimeric TCR

In one aspect, the anti-BCMA antibodies and antibody fragments of the present invention (for example, those disclosed in Tables 1 and 16) can be grafted to one or more constant domain of a T cell receptor ("TCR") chain, for example, a TCR alpha or TCR beta chain, to create an chimeric TCR that binds specificity to BCMA. Without being bound by

theory, it is believed that chimeric TCRs will signal through the TCR complex upon antigen binding. For example, a BCMA scFv as disclosed herein, can be grafted to the constant domain, e.g., at least a portion of the extracellular constant domain, the transmembrane domain and the cytoplasmic domain, of a TCR chain, for example, the TCR alpha chain and/or the TCR beta chain. As another example, a BCMA antibody fragment, for example a VL domain as described herein, can be grafted to the constant domain of a TCR alpha chain, and a BCMA antibody fragment, for example a VH domain as described herein, can be grafted to the constant domain of a TCR beta chain (or alternatively, a VL domain may be grafted to the constant domain of the TCR beta chain and a VH domain may be grafted to a TCR alpha chain). As another example, the CDRs of an anti-BCMA antibody or antibody fragment, e.g., the CDRs of an anti-BCMA antibody or antibody fragment as described in Tables 20, 21, 22, 23, 24, or 25 may be grafted into a TCR alpha and/or beta chain to create a chimeric TCR that binds specifically to BCMA. For example, the LCDRs disclosed herein may be grafted into the variable domain of a TCR alpha chain and the HCDRs disclosed herein may be grafted to the variable domain of a TCR beta chain, or vice versa. Such chimeric TCRs may be produced by methods known in the art (For example, Willemsen RA et al, Gene Therapy 2000; 7: 1369–1377; Zhang T et al, Cancer Gene Ther 2004; 11: 487–496; Aggen et al, Gene Ther. 2012 Apr;19(4):365-74).

Transmembrane domain

With respect to the transmembrane domain, in various embodiments, a CAR can be designed to comprise a transmembrane domain that is attached to the extracellular domain of the CAR. A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is one that is associated with one of the other domains of the CAR is used. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the

5 same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. In one aspect, the transmembrane domain is capable of homodimerization with another CAR on the CAR-expressing cell, e.g., CART cell, surface. In a different aspect the amino acid sequence of the transmembrane domain may be modified or substituted so as to minimize interactions with the binding domains of the native binding
 10 partner present in the same CAR-expressing cell, e.g., CART.

The transmembrane domain may be derived either from a natural or from a recombinant source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one aspect the transmembrane domain is capable of signaling to the intracellular domain(s) whenever the CAR has bound to a target. A transmembrane domain of
 15 particular use in this invention may include at least the transmembrane region(s) of e.g., the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8 (e.g., CD8 alpha, CD8 beta), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In some embodiments, a transmembrane domain may include at least the transmembrane region(s) of a costimulatory molecule, e.g., MHC class I molecule, TNF
 20 receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD80, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CD27, CD28, CD30, CD40, CD80, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46,
 25 CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55),
 30 PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

In some instances, the transmembrane domain can be attached to the extracellular
 35 region of the CAR, e.g., the antigen binding domain of the CAR, via a hinge, e.g., a hinge from

5 a human protein. For example, in one embodiment, the hinge can be a human Ig (immunoglobulin) hinge, e.g., an IgG4 hinge, or a CD8a hinge. In one embodiment, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO:2. In one aspect, the transmembrane domain comprises (e.g., consists of) a transmembrane domain of SEQ ID NO: 6.

10 In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence
 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNW
 YVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK
 TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
 15 TTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLGKM
 (SEQ ID NO:3). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide sequence of
 GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCTGGGCGG
 ACCCAGCGTGTTCTGTTCCTGTTCCCCCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGA
 20 CCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGGAGGACCCCGAGGTCCA
 GTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAACGCCAAGACCAAGCCCCGG
 GAGGAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCA
 GGACTGGCTGAACGGCAAGGAATACAAGTGTAAGGTGTCCAACAAGGGCCTGCCC
 AGCAGCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGG
 25 TGTACACCCTGCCCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGAC
 CTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAC
 GGCCAGCCCGAGAACAACACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCA
 GCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAGGAGGGCAA
 CGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGA
 30 GCCTGAGCCTGTCCCTGGGCAAGATG (SEQ ID NO:14).

In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence
 RWPESPKAQASSVPTAQPPAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERET
 KTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTG
 35 GVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQA

5 PVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPG
STTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLNASRSLEVSIVTDH (SEQ ID
NO:4). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide
sequence of
AGGTGGCCCGAAAGTCCCAAGGCCAGGCATCTAGTGTTCTACTGCACAGCCCCA
10 GGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTACGCGCAATACT
GGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAAGAAGAACAGGAAGA
GAGGGAGACCAAGACCCCTGAATGTCCATCCCATAACCAGCCGCTGGGCGTCTATC
TCTTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAAGGCCACCTTTACATGT
TTCGTCGTGGGCTCTGACCTGAAGGATGCCCATTTGACTTGGGAGGTTGCCGGAAA
15 GGTACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCT
CAGAGCCAGCACTCAAGACTCACCTTCCGAGATCCCTGTGGAACGCCGGGACCTC
TGTCACATGTACTCTAAATCATCCTAGCCTGCCCCACAGCGTCTGATGGCCCTTAG
AGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTG
ATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGCTTTAGCCCGCCC
20 AACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGTGAACACCAGCGGCTTCG
CTCCAGCCCGGGCCCCACCCAGCCGGGTTCTACCACATTCTGGGCCTGGAGTGTC
TTAAGGGTCCCAGCACCACTAGCCCCAGCCAGCCACATACACCTGTGTTGTGTC
CCATGAAGATAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACG
TGACTGACCATT (SEQ ID NO:15).

25 In one aspect, the transmembrane domain may be recombinant, in which case it will
comprise predominantly hydrophobic residues such as leucine and valine. In one aspect a triplet
of phenylalanine, tryptophan and valine can be found at each end of a recombinant
transmembrane domain.

Optionally, a short oligo- or polypeptide linker, between 2 and 10 amino acids in length
30 may form the linkage between the transmembrane domain and the cytoplasmic region of the
CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one
aspect, the linker comprises the amino acid sequence of GGGSGGGGS (SEQ ID NO:5). In
some embodiments, the linker is encoded by a nucleotide sequence of
GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC (SEQ ID NO:16).

35 In one aspect, the hinge or spacer comprises a KIR2DS2 hinge.

5 **Cytoplasmic domain**

The cytoplasmic domain or region of a CAR of the present invention includes an intracellular signaling domain. An intracellular signaling domain is generally responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR has been introduced.

10 Examples of intracellular signaling domains for use in the CAR of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability.

15 It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary and/or costimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide
20 a secondary or costimulatory signal (secondary cytoplasmic domain, e.g., a costimulatory domain).

A primary signaling domain regulates primary activation of the TCR complex either in a stimulatory way, or in an inhibitory way. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor
25 tyrosine-based activation motifs or ITAMs.

Examples of ITAM containing primary intracellular signaling domains that are of particular use in the invention include those of TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also known as "ICOS"), FcεRI, DAP10, DAP12, and CD66d. In one embodiment, a CAR of the invention comprises an
30 intracellular signaling domain, e.g., a primary signaling domain of CD3-zeta.

In one embodiment, a primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain which has altered (e.g., increased or decreased) activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an

- 5 optimized and/or truncated ITAM-containing primary intracellular signaling domain. In an embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs.

Further examples of molecules containing a primary intracellular signaling domain that are of particular use in the invention include those of DAP10, DAP12, and CD32.

- 10 The intracellular signalling domain of the CAR can comprise the primary signalling domain, e.g., CD3-zeta signaling domain, by itself or it can be combined with any other desired intracellular signaling domain(s) useful in the context of a CAR of the invention. For example, the intracellular signaling domain of the CAR can comprise a primary signalling domain, e.g., CD3 zeta chain portion, and a costimulatory signaling domain. The costimulatory signaling
- 15 domain refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM
- 20 proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6,
- 25 CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG
- 30 (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83, and the like. For example, CD27 costimulation has been demonstrated to enhance expansion, effector function, and survival of human CART cells in vitro and augments human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706). The intracellular signaling sequences within the cytoplasmic portion of the CAR of the
- 35 invention may be linked to each other in a random or specified order. Optionally, a short oligo-

5 or polypeptide linker, for example, between 2 and 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length may form the linkage between intracellular signaling sequence. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., an alanine, a glycine, can be used as a suitable linker.

10 In one aspect, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In an embodiment, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains, are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue.

15 In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD28. In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of 4-1BB. In one aspect, the signaling domain of 4-1BB is a signaling domain of SEQ ID NO: 7. In one aspect, the signaling domain of CD3-zeta is a signaling domain of SEQ ID NO: 9 (mutant CD3zeta) or SEQ ID NO: 10 (wild type human CD3zeta).

In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD27. In one aspect, the signaling domain of CD27 comprises an amino acid sequence of QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP (SEQ ID NO:8). In one aspect, the signalling domain of CD27 is encoded by a nucleic acid sequence of AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCC GCCCCGGGCCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCA GCCTATCGCTCC (SEQ ID NO:19).

30 In one aspect, the intracellular is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD28. In one aspect, the signaling domain of CD28 comprises an amino acid sequence of SEQ ID NO: 1104. In one aspect, the signaling domain of CD28 is encoded by a nucleic acid sequence of SEQ ID NO: 1105.

In one aspect, the intracellular is designed to comprise the signaling domain of CD3-zeta and the signaling domain of ICOS. In one aspect, the signaling domain of ICOS

- 5 comprises an amino acid sequence of SEQ ID NO: 1106. In one aspect, the signaling domain of ICOS is encoded by a nucleic acid sequence of SEQ ID NO: 1107.

In one aspect, the CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR that includes a different antigen binding domain, e.g., to the same
10 target (BCMA) or a different target (e.g., CD19, CD20, or CS-1, or other multiple myeloma targets, e.g., kappa light chain, CD138, Lewis Y antigen, or CD38 (Garfall et al., *Discovery Medicine*, 2014, 17(91):37-46)). In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and includes an intracellular signaling domain having a costimulatory signaling domain but not a primary signaling domain, and a second CAR that
15 targets a second, different, antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. While not wishing to be bound by theory, placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27 ICOS, or OX-40, onto the first CAR, and the primary signaling domain, e.g., CD3 zeta, on the second CAR can limit the CAR activity to cells where both targets are expressed. In one
20 embodiment, the CAR expressing cell comprises a first BCMA CAR that includes a BCMA binding domain, a transmembrane domain and a costimulatory domain and a second CAR that targets an antigen other than BCMA (e.g., an antigen expressed on leukemia or lymphoma cells, e.g., CD19, CD20, CS-1, kappa light chain, CD139, Lewis Y antigen, or CD38) and includes an antigen binding domain, a transmembrane domain and a primary signaling domain.
25 In another embodiment, the CAR expressing cell comprises a first BCMA CAR that includes a BCMA binding domain, a transmembrane domain and a primary signaling domain and a second CAR that targets an antigen other than BCMA (e.g., an antigen expressed on leukemia or lymphoma cells, e.g., CD19, CD20, CS-1, kappa light chain, CD139, Lewis Y antigen, or CD38) and includes an antigen binding domain to the antigen, a transmembrane domain and a
30 costimulatory signaling domain. In one embodiment, the CAR-expressing cell comprises a BCMA CAR described herein and a CAR that targets CD19 (CD19 CAR).

In one embodiment, the CAR-expressing cell comprises a BCMA CAR described herein and an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen binding domain that binds an antigen found on normal cells but not cancer cells, e.g., normal
35 cells that also express mesothelin. In one embodiment, the inhibitory CAR comprises the

- 5 antigen binding domain, a transmembrane domain and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be an intracellular domain of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I,
10 MHC class II, GAL9, adenosine, and TGFR beta.

In one embodiment, when the CAR-expressing cell comprises two or more different CARs, the antigen binding domains of the different CARs can be such that the antigen binding domains do not interact with one another. For example, a cell expressing a first and second CAR can have an antigen binding domain of the first CAR, e.g., as a fragment, e.g., an scFv,
15 that does not form an association with the antigen binding domain of the second CAR, e.g., the antigen binding domain of the second CAR is a VHH.

In some embodiments, the antigen binding domain comprises a single domain antigen binding (SDAB) molecules include molecules whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain
20 variable domains, binding molecules naturally devoid of light chains, single domains derived from conventional 4-chain antibodies, engineered domains and single domain scaffolds other than those derived from antibodies. SDAB molecules may be any of the art, or any future single domain molecules. SDAB molecules may be derived from any species including, but not limited to mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and bovine. This term
25 also includes naturally occurring single domain antibody molecules from species other than Camelidae and sharks.

In one aspect, an SDAB molecule can be derived from a variable region of the immunoglobulin found in fish, such as, for example, that which is derived from the immunoglobulin isotype known as Novel Antigen Receptor (NAR) found in the serum of
30 shark. Methods of producing single domain molecules derived from a variable region of NAR ("IgNARs") are described in WO 03/014161 and Streltsov (2005) Protein Sci. 14:2901-2909.

According to another aspect, an SDAB molecule is a naturally occurring single domain antigen binding molecule known as heavy chain devoid of light chains. Such single domain molecules are disclosed in WO 9404678 and Hamers-Casterman, C. et al. (1993) Nature

5 363:446-448, for example. For clarity reasons, this variable domain derived from a heavy chain molecule naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain molecules naturally devoid of light
10 chain; such VHHs are within the scope of the invention.

The SDAB molecules can be recombinant, CDR-grafted, humanized, camelized, de-immunized and/or in vitro generated (e.g., selected by phage display).

It has also been discovered, that cells having a plurality of chimeric membrane embedded receptors comprising an antigen binding domain that interactions between the
15 antigen binding domain of the receptors can be undesirable, e.g., because it inhibits the ability of one or more of the antigen binding domains to bind its cognate antigen. Accordingly, disclosed herein are cells having a first and a second non-naturally occurring chimeric membrane embedded receptor comprising antigen binding domains that minimize such interactions. Also disclosed herein are nucleic acids encoding a first and a second non-naturally
20 occurring chimeric membrane embedded receptor comprising a antigen binding domains that minimize such interactions, as well as methods of making and using such cells and nucleic acids. In an embodiment the antigen binding domain of one of said first said second non-naturally occurring chimeric membrane embedded receptor, comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a
25 single VH domain derived from a human or mouse sequence.

In some embodiments, the claimed invention comprises a first and second CAR, wherein the antigen binding domain of one of said first CAR said second CAR does not comprise a variable light domain and a variable heavy domain. In some embodiments, the antigen binding domain of one of said first CAR said second CAR is an scFv, and the other is
30 not an scFv. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises a nanobody. In some embodiments, the antigen binding domain of one of said first CAR said
35 second CAR comprises a camelid VHH domain.

5 In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises an scFv, and the other comprises a nanobody. In some embodiments, the antigen
10 binding domain of one of said first CAR said second CAR comprises comprises an scFv, and the other comprises a camelid VHH domain.

In some embodiments, when present on the surface of a cell, binding of the antigen binding domain of said first CAR to its cognate antigen is not substantially reduced by the presence of said second CAR. In some embodiments, binding of the antigen binding domain of
15 said first CAR to its cognate antigen in the presence of said second CAR is 85%, 90%, 95%, 96%, 97%, 98% or 99% of binding of the antigen binding domain of said first CAR to its cognate antigen in the absence of said second CAR.

In some embodiments, when present on the surface of a cell, the antigen binding domains of said first CAR said second CAR, associate with one another less than if both were
20 scFv antigen binding domains. In some embodiments, the antigen binding domains of said first CAR said second CAR, associate with one another 85%, 90%, 95%, 96%, 97%, 98% or 99% less than if both were scFv antigen binding domains.

In another aspect, the CAR-expressing cell described herein can further express another agent, e.g., an agent which enhances the activity of a CAR-expressing cell. For example, in
25 one embodiment, the agent can be an agent which inhibits an inhibitory molecule, e.g., an agent described herein. Inhibitory molecules, e.g., PD1, can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4,
30 CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta. In one embodiment, the agent which inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a
35 first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, PD-L2, CTLA4, TIM3,

- 5 CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta, or a fragment of any of these (e.g., at least a portion of an extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein
- 10 (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 ICOS, or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of an extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described
- 15 herein and/or a CD3 zeta signaling domain described herein). In embodiments, the CAR-expressing cell described herein comprises a switch costimulatory receptor, e.g., as described in WO 2013/019615, which is incorporated herein by reference in its entirety. PD1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996
- 20 Int. Immunol 8:765-75). Two ligands for PD1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD1 (Freeman et al. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094).
- 25 Immune suppression can be reversed by inhibiting the local interaction of PD1 with PD-L1.

In one embodiment, the agent comprises the extracellular domain (ECD) of an inhibitory molecule, e.g., Programmed Death 1 (PD1), can be fused to a transmembrane domain and intracellular signaling domains such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In one embodiment, the PD1 CAR, when used in combinations with a BCMA

30 CAR described herein, improves the persistence of the CAR-expressing cell, e.g., T cell or NK cell. In one embodiment, the CAR is a PD1 CAR comprising the extracellular domain of PD1 indicated as underlined in SEQ ID NO: 24. In one embodiment, the PD1 CAR comprises the amino acid sequence of SEQ ID NO:24.

Malpvtalllplalllhaarppgwflspdrpwnpptfspallvvtgednatftcsfsntsesfvlnwyrmspsnqtdklaaf

35 pedrsqpgqdcfrfvrtqlpngrdfhmsvvrarndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqlvttt

5 paprpptpaptiasqplslrpeacrpaaggavhtrglfacdiyiwaplagtcgvllslvitlyckrgrkkllyifkqpfmrpvqttee
dgcscrpfeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprknqpqeglynelqkdkma
eayseigmkgerrrgkghdglyqglstatkdydalhmqlppr (SEQ ID NO:24).

In one embodiment, the PD1 CAR comprises the amino acid sequence provided below
(SEQ ID NO:22).

10 pgwfldspdrpwnpptsfpallvvtgednatftcsfsntsesfvlnwyrmspsnqtdklaafpedrsqpgqdcfrvtqlp
ngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqlvtttpaprpptpaptiasqplslr
peacrpaaggavhtrglfacdiyiwaplagtcgvllslvitlyckrgrkkllyifkqpfmrpvqtteedgcscrpfeeeeggcelrv
kfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprknqpqeglynelqkdkmaeayseigmkgerrrgkgh
dglyqglstatkdydalhmqlppr (SEQ ID NO:22).

15 In one embodiment, the agent comprises a nucleic acid sequence encoding the PD1
CAR, e.g., the PD1 CAR described herein. In one embodiment, the nucleic acid sequence for
the PD1 CAR is shown below, with the PD1 ECD underlined below in SEQ ID NO: 23

atggccctccctgtcaactgccctgcttctccccctgcactcctgtccacgccgctagaccacccggatggtttctggactctc
cggatcgcccgtggaatcccccaacctctcaccggcactcttggttgactgagggcgataatgcgaccttcacgtgctcgttctccaa
20 cacctccgaatcattcgtgctgaactgtaccgcatgagcccgtaaacagaccgacaagctcgccgcgtttccggaagatcggtcgc
aaccgggacaggattgtcgttccgcgtgactcaactgccgaatggcagagacttcacatgagcgtggtccgcgctaggcgaaacga
ctccgggacctacgtgctggagccatctcgtgctggcctaaggcccaaatcaagagagccttgagggccgaactgagagtaccga
gcgcagagctgaggtgccaaactgcacatccatccccatcgctcgccctgcggggcagtttcagacctggtcacgaccactccggcg
ccgcgcccaccgactccggccccaaactatcgcgagccagccctgtcgtgaggccggaagcatgccgcctgccgcggaggtgc
25 tgtgcataccggggattggacttgcacatctacatttggctcctctcgcggaaactgtggcgtgctccttctgtccctggtcat
cacctgtactgcaagcggggtcggaataagcttctgtacatttcaagcagccctcatgagggccgtgcaaacaccaggaggagg
acggttgcctcctgccggttccccgaagaggaagaaggaggtgcgagctgcgcgtgaagtctccggagcgccgacgccccgcct
ataagcagggccagaaccagctgtacaacgaactgaacctgggacggcggaagagtacgatgtgtgacaagcggcgcgccg
ggacccccgaaatggcggggaagcctagaagaaagaaccctcaggaaggcctgtataacgagctgcagaaggacaagatggccgag
30 gcctactccgaaattgggatgaaggagagcggcgagggggaaaggggcacgacggcctgtaccaaggactgtccaccgccacca
aggacacatacatgacctgcacatgcaggccctccccctcgc (SEQ ID NO: 23).

In another aspect, the present invention provides a population of CAR-expressing cells,
e.g., CART cells or CAR-expressing NK cells. In some embodiments, the population of CAR-
expressing cells comprises a mixture of cells expressing different CARs. For example, in one

embodiment, the population of CAR-expressing cells (e.g., CART cells or CAR-expressing NK cells) can include a first cell expressing a CAR having an anti-BCMA binding domain described herein, and a second cell expressing a CAR having a different anti-BCMA binding domain, e.g., an anti-BCMA binding domain described herein that differs from the anti-BCMA binding domain in the CAR expressed by the first cell. As another example, the population of CAR-expressing cells can include a first cell expressing a CAR that includes an anti-BCMA binding domain, e.g., as described herein, and a second cell expressing a CAR that includes an antigen binding domain to a target other than BCMA (e.g., CD19, CD20, CS-1, kappa light chain, CD139, Lewis Y antigen, or CD38). In one embodiment, the population of CAR-expressing cells includes a first cell expressing a CAR comprising an anti-BCMA binding domain, e.g., as described herein, and a second cell expressing a CAR comprising an antigen binding domain that targets CD19 (CD19 CAR). In one embodiment, the population of CAR-expressing cells includes, e.g., a first cell expressing a CAR that includes a primary intracellular signaling domain, and a second cell expressing a CAR that includes a secondary signaling domain.

In another aspect, the present invention provides a population of cells wherein at least one cell in the population expresses a CAR having an anti-BCMA domain described herein, and a second cell expressing another agent, e.g., an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta. In one embodiment, the agent which inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4

5 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta, or a fragment of any of these (e.g., at least a portion of an extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27, ICOS, or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a
 10 CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and/or a CD3 zeta signaling domain described herein).

15 In one aspect, the present invention provides methods comprising administering a population of CAR-expressing cells (e.g., CART cells or CAR-expressing NK cells), e.g., a mixture of cells expressing different CARs, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein. In another aspect, the present invention provides methods comprising administering a population of cells wherein at least one cell in the
 20 population expresses a CAR having an anti- cancer associated antigen binding domain as described herein, and a second cell expressing another agent, e.g., an agent which enhances the activity of a CAR-expressing cell, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein.

Natural Killer Cell Receptor (NKR) CARs

25 In an embodiment, the CAR molecule described herein comprises one or more components of a natural killer cell receptor (NKR), thereby forming an NKR-CAR. The NKR component can be a transmembrane domain, a hinge domain, or a cytoplasmic domain from any of the following natural killer cell receptors: killer cell immunoglobulin-like receptor (KIR), e.g., KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1,
 30 KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3, KIR2DP1, and KIR3DP1; natural cytotoxicity receptor (NCR), e.g., NKp30, NKp44, NKp46; signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, e.g., CD48, CD229, 2B4, CD84, NTB-A, CRACC, BLAME, and CD2F-10; Fc receptor (FcR), e.g., CD16, and CD64; and Ly49 receptors, e.g., LY49A, LY49C. The NKR-CAR molecules described herein
 35 may interact with an adaptor molecule or intracellular signaling domain, e.g., DAP12.

- 5 Exemplary configurations and sequences of CAR molecules comprising NKR components are described in International Publication No. WO2014/145252, the contents of which are hereby incorporated by reference.

Strategies for Regulating Chimeric Antigen Receptors

- 10 There are many ways CAR activities can be regulated. In some embodiments, a regulatable CAR (RCAR) where the CAR activity can be controlled is desirable to optimize the safety and efficacy of a CAR therapy. For example, inducing apoptosis using, e.g., a caspase fused to a dimerization domain (see, e.g., Di et al., N Engl. J. Med. 2011 Nov. 3; 365(18):1673-1683), can be used as a safety switch in the CAR therapy of the instant invention. In another
- 15 example, CAR-expressing cells can also express an inducible Caspase-9 (iCaspase-9) molecule that, upon administration of a dimerizer drug (e.g., rimiducid (also called AP1903 (Bellicum Pharmaceuticals) or AP20187 (Ariad)) leads to activation of the Caspase-9 and apoptosis of the cells. The iCaspase-9 molecule contains a chemical inducer of dimerization (CID) binding domain that mediates dimerization in the presence of a CID. This results in inducible and
- 20 selective depletion of CAR-expressing cells. In some cases, the iCaspase-9 molecule is encoded by a nucleic acid molecule separate from the CAR-encoding vector(s). In some cases, the iCaspase-9 molecule is encoded by the same nucleic acid molecule as the CAR-encoding vector. The iCaspase-9 can provide a safety switch to avoid any toxicity of CAR-expressing cells. See, e.g., Song et al. Cancer Gene Ther. 2008; 15(10):667-75; Clinical Trial Id. No.
- 25 NCT02107963; and Di Stasi et al. N. Engl. J. Med. 2011; 365:1673-83.

- Alternative strategies for regulating the CAR therapy of the instant invention include utilizing small molecules or antibodies that deactivate or turn off CAR activity, e.g., by deleting CAR-expressing cells, e.g., by inducing antibody dependent cell-mediated cytotoxicity (ADCC). For example, CAR-expressing cells described herein may also express an antigen that
- 30 is recognized by molecules capable of inducing cell death, e.g., ADCC or complement-induced cell death. For example, CAR expressing cells described herein may also express a receptor capable of being targeted by an antibody or antibody fragment. Examples of such receptors include EpCAM, VEGFR, integrins (e.g., integrins $\alpha\beta3$, $\alpha4$, $\alpha1\beta3$, $\alpha4\beta7$, $\alpha5\beta1$, $\alpha\beta3$, $\alpha\gamma$), members of the TNF receptor superfamily (e.g., TRAIL-R1, TRAIL-R2), PDGF Receptor,

5 interferon receptor, folate receptor, GPNMB, ICAM-1, HLA-DR, CEA, CA-125, MUC1, TAG-72, IL-6 receptor, 5T4, GD2, GD3, CD2, CD3, CD4, CD5, CD11, CD11a/LFA-1, CD15, CD18/ITGB2, CD19, CD20, CD22, CD23/IgE Receptor, CD25, CD28, CD30, CD33, CD38, CD40, CD41, CD44, CD51, CD52, CD62L, CD74, CD80, CD125, CD147/basigin, CD152/CTLA-4, CD154/CD40L, CD195/CCR5, CD319/SLAMF7, and EGFR, and truncated
 10 versions thereof (e.g., versions preserving one or more extracellular epitopes but lacking one or more regions within the cytoplasmic domain). For example, CAR-expressing cells described herein may also express a truncated epidermal growth factor receptor (EGFR) which lacks signaling capacity but retains the epitope that is recognized by molecules capable of inducing ADCC, e.g., cetuximab (ERBITUX®), such that administration of cetuximab induces ADCC
 15 and subsequent depletion of the CAR-expressing cells (see, e.g., WO2011/056894, and Jonnalagadda et al., *Gene Ther.* 2013; 20(8)853-860). Another strategy includes expressing a highly compact marker/suicide gene that combines target epitopes from both CD32 and CD20 antigens in the CAR-expressing cells described herein, which binds rituximab, resulting in selective depletion of the CAR-expressing cells, e.g., by ADCC (see, e.g., Philip et al., *Blood.*
 20 2014; 124(8)1277-1287). Other methods for depleting CAR-expressing cells described herein include administration of CAMPATH®, a monoclonal anti-CD52 antibody that selectively binds and targets mature lymphocytes, e.g., CAR-expressing cells, for destruction, e.g., by inducing ADCC. In other embodiments, CAR-expressing cells can be selectively targeted using a CAR ligand, e.g., an anti-idiotypic antibody. In some embodiments, the anti-idiotypic
 25 antibody can cause effector cell activity, e.g., ADCC or ADC activities, thereby reducing the number of CAR-expressing cells. In other embodiments, the CAR ligand, e.g., the anti-idiotypic antibody, can be coupled to an agent that induces cell killing, e.g., a toxin, thereby reducing the number of CAR-expressing cells. Alternatively, the CAR molecules themselves can be configured such that the activity can be regulated, e.g., turned on and off, as described
 30 below.

In some embodiments, a RCAR comprises a set of polypeptides, typically two in the simplest embodiments, in which the components of a standard CAR described herein, e.g., an antigen binding domain and an intracellular signaling domain, are partitioned on separate polypeptides or members. In some embodiments, the set of polypeptides include a dimerization
 35 switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one

5 another, e.g., can couple an antigen binding domain to an intracellular signaling domain. Additional description and exemplary configurations of such regulatable CARs are provided herein and in International Publication No. WO 2015/090229, hereby incorporated by reference in its entirety.

10 In an embodiment, an RCAR comprises two polypeptides or members: 1) an intracellular signaling member comprising an intracellular signaling domain, e.g., a primary intracellular signaling domain described herein, and a first switch domain; 2) an antigen binding member comprising an antigen binding domain, e.g., that targets a tumor antigen described herein, as described herein and a second switch domain. Optionally, the RCAR comprises a transmembrane domain described herein. In an embodiment, a transmembrane domain can be disposed on the intracellular signaling member, on the antigen binding member, or on both. (Unless otherwise indicated, when members or elements of an RCAR are described herein, the order can be as provided, but other orders are included as well. In other words, in an embodiment, the order is as set out in the text, but in other embodiments, the order can be different. E.g., the order of elements on one side of a transmembrane region can be different from the example, e.g., the placement of a switch domain relative to a intracellular signaling domain can be different, e.g., reversed).

25 In an embodiment, the first and second switch domains can form an intracellular or an extracellular dimerization switch. In an embodiment, the dimerization switch can be a homodimerization switch, e.g., where the first and second switch domain are the same, or a heterodimerization switch, e.g., where the first and second switch domain are different from one another.

30 In embodiments, an RCAR can comprise a “multi switch.” A multi switch can comprise heterodimerization switch domains or homodimerization switch domains. A multi switch comprises a plurality of, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10, switch domains, independently, on a first member, e.g., an antigen binding member, and a second member, e.g., an intracellular signaling member. In an embodiment, the first member can comprise a plurality of first switch domains, e.g., FKBP-based switch domains, and the second member can comprise a plurality of second switch domains, e.g., FRB-based switch domains. In an embodiment, the first member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a

- 5 FRB-based switch domain, and the second member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a FRB-based switch domain.

In an embodiment, the intracellular signaling member comprises one or more intracellular signaling domains, e.g., a primary intracellular signaling domain and one or more costimulatory signaling domains.

- 10 In an embodiment, the antigen binding member may comprise one or more intracellular signaling domains, e.g., one or more costimulatory signaling domains. In an embodiment, the antigen binding member comprises a plurality, e.g., 2 or 3 costimulatory signaling domains described herein, e.g., selected from 4-1BB, CD28, CD27, ICOS, and OX40, and in
15 embodiments, no primary intracellular signaling domain. In an embodiment, the antigen binding member comprises the following costimulatory signaling domains, from the extracellular to intracellular direction: 4-1BB-CD27; 4-1BB-CD27; CD27-4-1BB; 4-1BB-CD28; CD28-4-1BB; OX40-CD28; CD28-OX40; CD28-4-1BB; or 4-1BB-CD28. In such
20 embodiments, the intracellular binding member comprises a CD3zeta domain. In one such embodiment the RCAR comprises (1) an antigen binding member comprising, an antigen binding domain, a transmembrane domain, and two costimulatory domains and a first switch domain; and (2) an intracellular signaling domain comprising a transmembrane domain or membrane tethering domain and at least one primary intracellular signaling domain, and a second switch domain.

- An embodiment provides RCARs wherein the antigen binding member is not tethered
25 to the surface of the CAR cell. This allows a cell having an intracellular signaling member to be conveniently paired with one or more antigen binding domains, without transforming the cell with a sequence that encodes the antigen binding member. In such embodiments, the RCAR comprises: 1) an intracellular signaling member comprising: a first switch domain, a transmembrane domain, an intracellular signaling domain, e.g., a primary intracellular
30 signaling domain, and a first switch domain; and 2) an antigen binding member comprising: an antigen binding domain, and a second switch domain, wherein the antigen binding member does not comprise a transmembrane domain or membrane tethering domain, and, optionally, does not comprise an intracellular signaling domain. In some embodiments, the RCAR may further comprise 3) a second antigen binding member comprising: a second antigen binding

5 domain, e.g., a second antigen binding domain that binds a different antigen than is bound by the antigen binding domain; and a second switch domain.

Also provided herein are RCARs wherein the antigen binding member comprises bispecific activation and targeting capacity. In this embodiment, the antigen binding member can comprise a plurality, e.g., 2, 3, 4, or 5 antigen binding domains, e.g., scFvs, wherein each
10 antigen binding domain binds to a target antigen, e.g. different antigens or the same antigen, e.g., the same or different epitopes on the same antigen. In an embodiment, the plurality of antigen binding domains are in tandem, and optionally, a linker or hinge region is disposed between each of the antigen binding domains. Suitable linkers and hinge regions are described herein.

15 An embodiment provides RCARs having a configuration that allows switching of proliferation. In this embodiment, the RCAR comprises: 1) an intracellular signaling member comprising: optionally, a transmembrane domain or membrane tethering domain; one or more co-stimulatory signaling domain, e.g., selected from 4-1BB, CD28, CD27, ICOS, and OX40, and a switch domain; and 2) an antigen binding member comprising: an antigen binding
20 domain, a transmembrane domain, and a primary intracellular signaling domain, e.g., a CD3zeta domain, wherein the antigen binding member does not comprise a switch domain, or does not comprise a switch domain that dimerizes with a switch domain on the intracellular signaling member. In an embodiment, the antigen binding member does not comprise a co-stimulatory signaling domain. In an embodiment, the intracellular signaling member comprises
25 a switch domain from a homodimerization switch. In an embodiment, the intracellular signaling member comprises a first switch domain of a heterodimerization switch and the RCAR comprises a second intracellular signaling member which comprises a second switch domain of the heterodimerization switch. In such embodiments, the second intracellular signaling member comprises the same intracellular signaling domains as the intracellular signaling
30 member. In an embodiment, the dimerization switch is intracellular. In an embodiment, the dimerization switch is extracellular.

In any of the RCAR configurations described here, the first and second switch domains comprise a FKBP-FRB based switch as described herein.

5 Also provided herein are cells comprising an RCAR described herein. Any cell that is engineered to express a RCAR can be used as a RCARX cell. In an embodiment the RCARX cell is a T cell, and is referred to as a RCART cell. In an embodiment the RCARX cell is an NK cell, and is referred to as a RCARN cell.

Also provided herein are nucleic acids and vectors comprising RCAR encoding
10 sequences. Sequence encoding various elements of an RCAR can be disposed on the same nucleic acid molecule, e.g., the same plasmid or vector, e.g., viral vector, e.g., lentiviral vector. In an embodiment, (i) sequence encoding an antigen binding member and (ii) sequence encoding an intracellular signaling member, can be present on the same nucleic acid, e.g., vector. Production of the corresponding proteins can be achieved, e.g., by the use of separate
15 promoters, or by the use of a bicistronic transcription product (which can result in the production of two proteins by cleavage of a single translation product or by the translation of two separate protein products). In an embodiment, a sequence encoding a cleavable peptide, e.g., a P2A or F2A sequence, is disposed between (i) and (ii). In an embodiment, a sequence encoding an IRES, e.g., an EMCV or EV71 IRES, is disposed between (i) and (ii). In these
20 embodiments, (i) and (ii) are transcribed as a single RNA. In an embodiment, a first promoter is operably linked to (i) and a second promoter is operably linked to (ii), such that (i) and (ii) are transcribed as separate mRNAs.

Alternatively, the sequence encoding various elements of an RCAR can be disposed on the different nucleic acid molecules, e.g., different plasmids or vectors, e.g., viral vector, e.g.,
25 lentiviral vector. E.g., the (i) sequence encoding an antigen binding member can be present on a first nucleic acid, e.g., a first vector, and the (ii) sequence encoding an intracellular signaling member can be present on the second nucleic acid, e.g., the second vector.

Dimerization switches

30 Dimerization switches can be non-covalent or covalent. In a non-covalent dimerization switch, the dimerization molecule promotes a non-covalent interaction between the switch domains. In a covalent dimerization switch, the dimerization molecule promotes a covalent interaction between the switch domains.

5 In an embodiment, the RCAR comprises a FKBP/FRAP, or FKBP/FRB,-based dimerization switch. FKBP12 (FKBP, or FK506 binding protein) is an abundant cytoplasmic protein that serves as the initial intracellular target for the natural product immunosuppressive drug, rapamycin. Rapamycin binds to FKBP and to the large PI3K homolog FRAP (RAFT, mTOR). FRB is a 93 amino acid portion of FRAP, that is sufficient for binding the FKBP-
 10 rapamycin complex (Chen, J., Zheng, X. F., Brown, E. J. & Schreiber, S. L. (1995) *Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue*. Proc Natl Acad Sci U S A 92: 4947-51.)

In embodiments, an FKBP/FRAP, e.g., an FKBP/FRB, based switch can use a
 15 dimerization molecule, e.g., rapamycin or a rapamycin analog.

The amino acid sequence of FKBP is as follows:

DVPDYASLGGPSSPKKKRKVSRGVQVETISPGDGRTFPK
 RGQTCVVHYTGMLLEDGKKFDSSRDRNKPFFKFMLGKQEVIRG
 WEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFD
 20 VELLKLETSY (SEQ ID NO: 275)

In embodiments, an FKBP switch domain can comprise a fragment of FKBP having the ability to bind with FRB, or a fragment or analog thereof, in the presence of rapamycin or a rapalog, e.g., the underlined portion of SEQ ID NO: 275, which is:

VQVETISPGDGRTFPKRGQTCVVHYTGMLLEDGKKFDSSR
 25 DRNKPFFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLETS (SEQ ID NO:276)

The amino acid sequence of FRB is as follows:

ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER GPQTLKETSF
 NQAYGRDLME AQEWCRKYMK SGNVKDLTQA WDLYYHVFRF ISK (SEQ ID NO:
 30 277)

“FKBP/FRAP, e.g., an FKBP/FRB, based switch” as that term is used herein, refers to a dimerization switch comprising: a first switch domain, which comprises an FKBP fragment or analog thereof having the ability to bind with FRB, or a fragment or analog thereof, in the

5 presence of rapamycin or a rapalog, e.g., RAD001, and has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from, the FKBP sequence of SEQ ID NO: 275 or 276; and a second switch domain, which comprises an FRB fragment or analog thereof having the ability to bind with FRB, or a fragment or analog thereof, in the presence of rapamycin or a rapalog, and has at
10 least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from, the FRB sequence of SEQ ID NO: 277. In an embodiment, a RCAR described herein comprises one switch domain comprises amino acid residues disclosed in SEQ ID NO: 275 (or SEQ ID NO: 276), and one switch domain comprises amino acid residues disclosed in SEQ ID NO: 277.

15 In embodiments, the FKBP/FRB dimerization switch comprises a modified FRB switch domain that exhibits altered, e.g., enhanced, complex formation between an FRB-based switch domain, e.g., the modified FRB switch domain, a FKBP-based switch domain, and the dimerization molecule, e.g., rapamycin or a rapalogue, e.g., RAD001. In an embodiment, the modified FRB switch domain comprises one or more mutations, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or
20 more, selected from mutations at amino acid position(s) L2031, E2032, S2035, R2036, F2039, G2040, T2098, W2101, D2102, Y2105, and F2108, where the wild-type amino acid is mutated to any other naturally-occurring amino acid. In an embodiment, a mutant FRB comprises a mutation at E2032, where E2032 is mutated to phenylalanine (E2032F), methionine (E2032M), arginine (E2032R), valine (E2032V), tyrosine (E2032Y), isoleucine (E2032I), e.g., SEQ ID
25 NO: 278, or leucine (E2032L), e.g., SEQ ID NO: 279. In an embodiment, a mutant FRB comprises a mutation at T2098, where T2098 is mutated to phenylalanine (T2098F) or leucine (T2098L), e.g., SEQ ID NO: 280. In an embodiment, a mutant FRB comprises a mutation at E2032 and at T2098, where E2032 is mutated to any amino acid, and where T2098 is mutated to any amino acid, e.g., SEQ ID NO: 281. In an embodiment, a mutant FRB comprises an
30 E2032I and a T2098L mutation, e.g., SEQ ID NO: 282. In an embodiment, a mutant FRB comprises an E2032L and a T2098L mutation, e.g., SEQ ID NO: 283.

Table 17. Exemplary mutant FRB having increased affinity for a dimerization molecule.

FRB mutant	Amino Acid Sequence	EQ ID
------------	---------------------	-------

		NO:
E2032I mutant	ILWHEMWHEGLIEASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFERRISKTS	78
E2032L mutant	ILWHEMWHEGLLEASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFERRISKTS	79
T2098L mutant	ILWHEMWHEGLEEASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLLQAWDLYYHVFERRISKTS	80
E2032, T2098 mutant	ILWHEMWHEGLX E ASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLX Q AWDLYYHVFERRISKTS	81
E2032I, T2098L mutant	ILWHEMWHEGLIEASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLLQAWDLYYHVFERRISKTS	82
E2032L, T2098L mutant	ILWHEMWHEGLLEASRLYFGERNVKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLLQAWDLYYHVFERRISKTS	83

5

Other suitable dimerization switches include a GyrB-GyrB based dimerization switch, a Gibberellin-based dimerization switch, a tag/binder dimerization switch, and a halo-tag/snap-tag dimerization switch. Following the guidance provided herein, such switches and relevant dimerization molecules will be apparent to one of ordinary skill.

10

Dimerization molecule

Association between the switch domains is promoted by the dimerization molecule. In the presence of dimerization molecule interaction or association between switch domains allows for signal transduction between a polypeptide associated with, e.g., fused to, a first switch domain, and a polypeptide associated with, e.g., fused to, a second switch domain. In the presence of non-limiting levels of dimerization molecule signal transduction is increased by 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 5, 10, 50, 100 fold, e.g., as measured in a system described herein.

15

Rapamycin and rapamycin analogs (sometimes referred to as rapalogues), e.g., RAD001, can be used as dimerization molecules in a FKBP/FRB-based dimerization switch described herein. In an embodiment the dimerization molecule can be selected from rapamycin (sirolimus), RAD001 (everolimus), zotarolimus, temsirolimus, AP-23573 (ridaforolimus), biolimus and AP21967. Additional rapamycin analogs suitable for use with FKBP/FRB-based dimerization switches are further described in the section entitled "Combination Therapies", or in the subsection entitled "Combination with a Low, Immune Enhancing, Dose of an mTOR inhibitor".

25

Split CAR

5 In some embodiments, the CAR-expressing cell uses a split CAR. The split CAR approach is described in more detail in publications WO2014/055442 and WO2014/055657, incorporated herein by reference. Briefly, a split CAR system comprises a cell expressing a first CAR having a first antigen binding domain and a costimulatory domain (e.g., 41BB), and the cell also expresses a second CAR having a second antigen binding domain and an
10 intracellular signaling domain (e.g., CD3 zeta). When the cell encounters the first antigen, the costimulatory domain is activated, and the cell proliferates. When the cell encounters the second antigen, the intracellular signaling domain is activated and cell-killing activity begins. Thus, the CAR-expressing cell is only fully activated in the presence of both antigens. In embodiments the first antigen binding domain recognizes BCMA, e.g., comprises an antigen
15 binding domain described herein, and the second antigen binding domain recognizes an antigen expressed on acute myeloid leukemia cells, e.g., CD123, CLL-1, CD34, FLT3, or folate receptor beta. In embodiments the first antigen binding domain recognizes BCMA, e.g., comprises an antigen binding domain described herein, and the second antigen binding domain recognizes an antigen expressed on B-cells, e.g., CD10, CD19, CD20, CD22, CD34, CD123,
20 FLT-3, ROR1, CD79b, CD179b, or CD79a.

Stability and Mutations

The stability of an anti-BCMA binding domain, e.g., scFv molecules (e.g., soluble scFv) can be evaluated in reference to the biophysical properties (e.g., thermal stability) of a
25 conventional control scFv molecule or a full length antibody. In one embodiment, the humanized scFv has a thermal stability that is greater than about 0.1, about 0.25, about 0.5, about 0.75, about 1, about 1.25, about 1.5, about 1.75, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10 degrees, about 11 degrees, about 12 degrees, about 13 degrees,
30 about 14 degrees, or about 15 degrees Celsius than a control binding molecule (e.g. a conventional scFv molecule) in the described assays.

The improved thermal stability of the anti-BCMA binding domain, e.g., scFv is subsequently conferred to the entire CART-BCMA construct, leading to improved therapeutic properties of the CART-BCMA construct. The thermal stability of the anti-BCMA binding
35 domain, e.g., scFv can be improved by at least about 2°C or 3°C as compared to a conventional

antibody. In one embodiment, the anti-BCMA binding domain, e.g., scFv has a 1°C improved thermal stability as compared to a conventional antibody. In another embodiment, the anti-BCMA binding domain, e.g., scFv has a 2°C improved thermal stability as compared to a conventional antibody. In another embodiment, the scFv has a 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15°C improved thermal stability as compared to a conventional antibody. Comparisons can be made, for example, between the scFv molecules disclosed herein and scFv molecules or Fab fragments of an antibody from which the scFv VH and VL were derived. Thermal stability can be measured using methods known in the art. For example, in one embodiment, T_m can be measured. Methods for measuring T_m and other methods of determining protein stability are described in more detail below.

Mutations in scFv (arising through humanization or direct mutagenesis of the soluble scFv) alter the stability of the scFv and improve the overall stability of the scFv and the CART33 construct. Stability of the human scFv can be compared against the murine scFv using measurements such as T_m, temperature denaturation and temperature aggregation.

The binding capacity of the mutant scFvs can be determined using assays described in the Examples.

In one embodiment, the anti-BCMA binding domain, e.g., scFv comprises at least one mutation arising from the humanization process such that the mutated scFv confers improved stability to the CART-BCMA construct. In another embodiment, the anti-BCMA binding domain, e.g., scFv comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutations arising from the humanization process such that the mutated scFv confers improved stability to the CART-BCMA construct.

Methods of Evaluating Protein Stability

The stability of an antigen binding domain may be assessed using, e.g., the methods described below. Such methods allow for the determination of multiple thermal unfolding transitions where the least stable domain either unfolds first or limits the overall stability threshold of a multidomain unit that unfolds cooperatively (e.g., a multidomain protein which exhibits a single unfolding transition). The least stable domain can be identified in a number of additional ways. Mutagenesis can be performed to probe which domain limits the overall stability. Additionally, protease resistance of a multidomain protein can be performed under conditions where the least stable domain is known to be intrinsically unfolded via DSC or other

5 spectroscopic methods (Fontana, *et al.*, (1997) Fold. Des., 2: R17-26; Dimasi *et al.* (2009) J. Mol. Biol. 393: 672-692). Once the least stable domain is identified, the sequence encoding this domain (or a portion thereof) may be employed as a test sequence in the methods.

a) Thermal Stability

10 The thermal stability of the compositions may be analyzed using a number of non-limiting biophysical or biochemical techniques known in the art. In certain embodiments, thermal stability is evaluated by analytical spectroscopy.

An exemplary analytical spectroscopy method is Differential Scanning Calorimetry (DSC). DSC employs a calorimeter which is sensitive to the heat absorbances that accompany the unfolding of most proteins or protein domains (see, e.g. Sanchez-Ruiz, *et al.*, Biochemistry, 15 27: 1648-52, 1988). To determine the thermal stability of a protein, a sample of the protein is inserted into the calorimeter and the temperature is raised until the Fab or scFv unfolds. The temperature at which the protein unfolds is indicative of overall protein stability.

Another exemplary analytical spectroscopy method is Circular Dichroism (CD) spectroscopy. CD spectrometry measures the optical activity of a composition as a function of 20 increasing temperature. Circular dichroism (CD) spectroscopy measures differences in the absorption of left-handed polarized light versus right-handed polarized light which arise due to structural asymmetry. A disordered or unfolded structure results in a CD spectrum very different from that of an ordered or folded structure. The CD spectrum reflects the sensitivity of the proteins to the denaturing effects of increasing temperature and is therefore indicative of a 25 protein's thermal stability (see van Mierlo and Steemsma, J. Biotechnol., 79(3):281-98, 2000).

Another exemplary analytical spectroscopy method for measuring thermal stability is Fluorescence Emission Spectroscopy (see van Mierlo and Steemsma, *supra*). Yet another exemplary analytical spectroscopy method for measuring thermal stability is Nuclear Magnetic Resonance (NMR) spectroscopy (see, e.g. van Mierlo and Steemsma, *supra*).

30 The thermal stability of a composition can be measured biochemically. An exemplary biochemical method for assessing thermal stability is a thermal challenge assay. In a "thermal challenge assay", a composition is subjected to a range of elevated temperatures for a set period of time. For example, in one embodiment, test scFv molecules or molecules comprising scFv molecules are subject to a range of increasing temperatures, e.g., for 1-1.5 hours. The activity

5 of the protein is then assayed by a relevant biochemical assay. For example, if the protein is a binding protein (e.g. an scFv or scFv-containing polypeptide) the binding activity of the binding protein may be determined by a functional or quantitative ELISA.

Such an assay may be done in a high-throughput format and those disclosed in the Examples using *E. coli* and high throughput screening. A library of anti-BCMA binding
 10 domain, e.g., scFv variants may be created using methods known in the art. Anti-BCMA binding domain, e.g., scFv expression may be induced and the anti-BCMA binding domain, e.g., scFv may be subjected to thermal challenge. The challenged test samples may be assayed for binding and those anti-BCMA binding domain, e.g., scFvs which are stable may be scaled up and further characterized.

15 Thermal stability is evaluated by measuring the melting temperature (T_m) of a composition using any of the above techniques (e.g. analytical spectroscopy techniques). The melting temperature is the temperature at the midpoint of a thermal transition curve wherein 50% of molecules of a composition are in a folded state (See e.g., Dimasi *et al.* (2009) J. Mol Biol. 393: 672-692). In one embodiment, T_m values for an anti-BCMA binding domain, e.g.,
 20 scFv are about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C. In one embodiment, T_m values for an IgG is about 40°C, 41°C,
 25 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C. In one embodiment, T_m values for an multivalent antibody is about 40°C, 41°C, 42°C, 43°C,
 30 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C.

Thermal stability is also evaluated by measuring the specific heat or heat capacity (C_p)
 35 of a composition using an analytical calorimetric technique (e.g. DSC). The specific heat of a

composition is the energy (e.g. in kcal/mol) is required to rise by 1°C, the temperature of 1 mol of water. As large C_p is a hallmark of a denatured or inactive protein composition. The change in heat capacity (ΔC_p) of a composition is measured by determining the specific heat of a composition before and after its thermal transition. Thermal stability may also be evaluated by measuring or determining other parameters of thermodynamic stability including Gibbs free energy of unfolding (ΔG), enthalpy of unfolding (ΔH), or entropy of unfolding (ΔS). One or more of the above biochemical assays (e.g. a thermal challenge assay) are used to determine the temperature (i.e. the T_C value) at which 50% of the composition retains its activity (e.g. binding activity).

In addition, mutations to the anti-BCMA binding domain, e.g., scFv alter the thermal stability of the anti-BCMA binding domain, e.g., scFv compared with the unmutated anti-BCMA binding domain, e.g., scFv. When the human or humanized anti-BCMA binding domain, e.g., scFv is incorporated into a BCMA construct, the anti-BCMA binding domain, e.g., humanized scFv confers thermal stability to the overall anti-BCMA CART construct. In one embodiment, the anti-BCMA binding domain, e.g., scFv comprises a single mutation that confers thermal stability to the anti-BCMA binding domain, e.g., scFv. In another embodiment, the anti-BCMA binding domain, e.g., scFv comprises multiple mutations that confer thermal stability to the anti-BCMA binding domain, e.g., scFv. In one embodiment, the multiple mutations in the anti-BCMA binding domain, e.g., scFv have an additive effect on thermal stability of the anti-BCMA binding domain, e.g., scFv.

b) % Aggregation

The stability of a composition can be determined by measuring its propensity to aggregate. Aggregation can be measured by a number of non-limiting biochemical or biophysical techniques. For example, the aggregation of a composition may be evaluated using chromatography, e.g. Size-Exclusion Chromatography (SEC). SEC separates molecules on the basis of size. A column is filled with semi-solid beads of a polymeric gel that will admit ions and small molecules into their interior but not large ones. When a protein composition is applied to the top of the column, the compact folded proteins (i.e. non-aggregated proteins) are distributed through a larger volume of solvent than is available to the large protein aggregates. Consequently, the large aggregates move more rapidly through the column, and in this way the mixture can be separated or fractionated into its components. Each fraction can be separately

5 quantified (e.g. by light scattering) as it elutes from the gel. Accordingly, the % aggregation of a composition can be determined by comparing the concentration of a fraction with the total concentration of protein applied to the gel. Stable compositions elute from the column as essentially a single fraction and appear as essentially a single peak in the elution profile or chromatogram.

10 *c) Binding Affinity*

The stability of a composition can be assessed by determining its target binding affinity. A wide variety of methods for determining binding affinity are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for the analysis of real-time biospecific
15 interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Jonsson, U., et al. (1993) *Ann. Biol. Clin.* 51:19-26; Jonsson, U., i (1991) *Biotechniques* 11:620-627; Johnsson, B., *et al.* (1995) *J. Mol. Recognit.* 8:125-131; and Johnsson, B., *et al.* (1991) *Anal. Biochem.* 198:268-277.

20 In one aspect, the antigen binding domain of the CAR comprises an amino acid sequence that is homologous to an antigen binding domain amino acid sequence described herein, and the antigen binding domain retains the desired functional properties of the anti-BCMA antibody fragments described herein. In one specific aspect, the CAR composition of the invention comprises an antibody fragment. In a further aspect, that antibody fragment
25 comprises an scFv.

In various aspects, the antigen binding domain of the CAR is engineered by modifying one or more amino acids within one or both variable regions (e.g., VH and/or VL), for example within one or more CDR regions and/or within one or more framework regions. In one specific aspect, the CAR composition of the invention comprises an antibody fragment. In a further
30 aspect, that antibody fragment comprises a scFv.

It will be understood by one of ordinary skill in the art that the antibody or antibody fragment of the invention may further be modified such that they vary in amino acid sequence (e.g., from wild-type), but not in desired activity. For example, additional nucleotide substitutions, e.g., conservative substitutions leading to amino acid substitutions, e.g.,
35 conservative substitutions at "non-essential" amino acid residues may be made to the protein

5 For example, a nonessential amino acid residue in a molecule may be replaced with another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced with a structurally similar string that differs in order and/or composition of side chain family members, e.g., a conservative substitution, in which an amino acid residue is replaced with an amino acid residue having a similar side chain, may be made.

10 Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, 15 valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

Percent identity in the context of two or more nucleic acids or polypeptide sequences, refers to two or more sequences that are the same. Two sequences are "substantially identical" if two sequences have a specified percentage of amino acid residues or nucleotides that are the 20 same (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison 25 algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which 30 test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference 35 sequence, based on the program parameters. Methods of alignment of sequences for

5 comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP,
10 BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).

Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in
15 Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.

The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4:11-17) which has
20 been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or
25 a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

In one aspect, the present invention contemplates modifications of the starting antibody or fragment (e.g., scFv) amino acid sequence that generate functionally equivalent molecules. For example, the VH or VL of an anti-BCMA binding domain, e.g., scFv, comprised in the
30 CAR can be modified to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting VH or VL framework region of the anti-BCMA binding domain, e.g., scFv. The present invention contemplates modifications of the entire CAR construct, e.g., modifications in one or more amino acid sequences of the
35 various domains of the CAR construct in order to generate functionally equivalent molecules.

- 5 The CAR construct can be modified to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting CAR construct.

RNA Transfection

- 10 Disclosed herein are methods for producing an in vitro transcribed RNA CAR. The present invention also includes a CAR encoding RNA construct that can be directly transfected into a cell. A method for generating mRNA for use in transfection can involve in vitro transcription (IVT) of a template with specially designed primers, followed by polyA addition, to produce a construct containing 3' and 5' untranslated sequence ("UTR"), a 5' cap and/or
- 15 Internal Ribosome Entry Site (IRES), the nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO:35). RNA so produced can efficiently transfect different kinds of cells. In one aspect, the template includes sequences for the CAR.

- In one aspect the anti-BCMA CAR is encoded by a messenger RNA (mRNA). In one aspect the mRNA encoding the anti-BCMA CAR is introduced into an immune effector cell,
- 20 e.g., a T cell or a NK cell, for production of a CAR-expressing cell (e.g., CART cell or CAR-expressing NK cell).

- In one embodiment, the in vitro transcribed RNA CAR can be introduced to a cell as a form of transient transfection. The RNA is produced by in vitro transcription using a polymerase chain reaction (PCR)-generated template. DNA of interest from any source can be
- 25 directly converted by PCR into a template for in vitro mRNA synthesis using appropriate primers and RNA polymerase. The source of the DNA can be, for example, genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or any other appropriate source of DNA. The desired template for in vitro transcription is a CAR of the present invention. For example, the template for the RNA CAR comprises an extracellular region comprising a single
- 30 chain variable domain of an anti-tumor antibody; a hinge region, a transmembrane domain (e.g., a transmembrane domain of CD8a); and a cytoplasmic region that includes an intracellular signaling domain, e.g., comprising the signaling domain of CD3-zeta and the signaling domain of 4-1BB.

5 In one embodiment, the DNA to be used for PCR contains an open reading frame. The DNA can be from a naturally occurring DNA sequence from the genome of an organism. In one embodiment, the nucleic acid can include some or all of the 5' and/or 3' untranslated regions (UTRs). The nucleic acid can include exons and introns. In one embodiment, the DNA to be used for PCR is a human nucleic acid sequence. In another embodiment, the DNA to be
10 used for PCR is a human nucleic acid sequence including the 5' and 3' UTRs. The DNA can alternatively be an artificial DNA sequence that is not normally expressed in a naturally occurring organism. An exemplary artificial DNA sequence is one that contains portions of genes that are ligated together to form an open reading frame that encodes a fusion protein. The portions of DNA that are ligated together can be from a single organism or from more than one
15 organism.

PCR is used to generate a template for in vitro transcription of mRNA which is used for transfection. Methods for performing PCR are well known in the art. Primers for use in PCR are designed to have regions that are substantially complementary to regions of the DNA to be used as a template for the PCR. "Substantially complementary," as used herein, refers to
20 sequences of nucleotides where a majority or all of the bases in the primer sequence are complementary, or one or more bases are non-complementary, or mismatched. Substantially complementary sequences are able to anneal or hybridize with the intended DNA target under annealing conditions used for PCR. The primers can be designed to be substantially complementary to any portion of the DNA template. For example, the primers can be designed
25 to amplify the portion of a nucleic acid that is normally transcribed in cells (the open reading frame), including 5' and 3' UTRs. The primers can also be designed to amplify a portion of a nucleic acid that encodes a particular domain of interest. In one embodiment, the primers are designed to amplify the coding region of a human cDNA, including all or portions of the 5' and 3' UTRs. Primers useful for PCR can be generated by synthetic methods that are well known in
30 the art. "Forward primers" are primers that contain a region of nucleotides that are substantially complementary to nucleotides on the DNA template that are upstream of the DNA sequence that is to be amplified. "Upstream" is used herein to refer to a location 5' to the DNA sequence to be amplified relative to the coding strand. "Reverse primers" are primers that contain a region of nucleotides that are substantially complementary to a double-stranded DNA template

5 that are downstream of the DNA sequence that is to be amplified. "Downstream" is used herein to refer to a location 3' to the DNA sequence to be amplified relative to the coding strand.

Any DNA polymerase useful for PCR can be used in the methods disclosed herein. The reagents and polymerase are commercially available from a number of sources.

10 Chemical structures with the ability to promote stability and/or translation efficiency may also be used. The RNA preferably has 5' and 3' UTRs. In one embodiment, the 5' UTR is between one and 3000 nucleotides in length. The length of 5' and 3' UTR sequences to be added to the coding region can be altered by different methods, including, but not limited to, designing primers for PCR that anneal to different regions of the UTRs. Using this approach, one of ordinary skill in the art can modify the 5' and 3' UTR lengths required to achieve optimal
15 translation efficiency following transfection of the transcribed RNA.

The 5' and 3' UTRs can be the naturally occurring, endogenous 5' and 3' UTRs for the nucleic acid of interest. Alternatively, UTR sequences that are not endogenous to the nucleic acid of interest can be added by incorporating the UTR sequences into the forward and reverse primers or by any other modifications of the template. The use of UTR sequences that are not
20 endogenous to the nucleic acid of interest can be useful for modifying the stability and/or translation efficiency of the RNA. For example, it is known that AU-rich elements in 3' UTR sequences can decrease the stability of mRNA. Therefore, 3' UTRs can be selected or designed to increase the stability of the transcribed RNA based on properties of UTRs that are well known in the art.

25 In one embodiment, the 5' UTR can contain the Kozak sequence of the endogenous nucleic acid. Alternatively, when a 5' UTR that is not endogenous to the nucleic acid of interest is being added by PCR as described above, a consensus Kozak sequence can be redesigned by adding the 5' UTR sequence. Kozak sequences can increase the efficiency of translation of some RNA transcripts, but does not appear to be required for all RNAs to enable efficient
30 translation. The requirement for Kozak sequences for many mRNAs is known in the art. In other embodiments the 5' UTR can be 5'UTR of an RNA virus whose RNA genome is stable in cells. In other embodiments various nucleotide analogues can be used in the 3' or 5' UTR to impede exonuclease degradation of the mRNA.

5 To enable synthesis of RNA from a DNA template without the need for gene cloning, a promoter of transcription should be attached to the DNA template upstream of the sequence to be transcribed. When a sequence that functions as a promoter for an RNA polymerase is added to the 5' end of the forward primer, the RNA polymerase promoter becomes incorporated into the PCR product upstream of the open reading frame that is to be transcribed. In one preferred
10 embodiment, the promoter is a T7 polymerase promoter, as described elsewhere herein. Other useful promoters include, but are not limited to, T3 and SP6 RNA polymerase promoters. Consensus nucleotide sequences for T7, T3 and SP6 promoters are known in the art.

In a preferred embodiment, the mRNA has both a cap on the 5' end and a 3' poly(A) tail which determine ribosome binding, initiation of translation and stability mRNA in the cell. On
15 a circular DNA template, for instance, plasmid DNA, RNA polymerase produces a long concatameric product which is not suitable for expression in eukaryotic cells. The transcription of plasmid DNA linearized at the end of the 3' UTR results in normal sized mRNA which is not effective in eukaryotic transfection even if it is polyadenylated after transcription.

On a linear DNA template, phage T7 RNA polymerase can extend the 3' end of the
20 transcript beyond the last base of the template (Schenborn and Mierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva and Berzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003).

The conventional method of integration of polyA/T stretches into a DNA template is molecular cloning. However polyA/T sequence integrated into plasmid DNA can cause plasmid instability, which is why plasmid DNA templates obtained from bacterial cells are often highly
25 contaminated with deletions and other aberrations. This makes cloning procedures not only laborious and time consuming but often not reliable. That is why a method which allows construction of DNA templates with polyA/T 3' stretch without cloning highly desirable.

The polyA/T segment of the transcriptional DNA template can be produced during PCR by using a reverse primer containing a polyT tail, such as 100T tail (SEQ ID NO: 31) (size can
30 be 50-5000 T (SEQ ID NO: 32)), or after PCR by any other method, including, but not limited to, DNA ligation or in vitro recombination. Poly(A) tails also provide stability to RNAs and reduce their degradation. Generally, the length of a poly(A) tail positively correlates with the stability of the transcribed RNA. In one embodiment, the poly(A) tail is between 100 and 5000 adenosines (SEQ ID NO: 33).

5 Poly(A) tails of RNAs can be further extended following in vitro transcription with the use of a poly(A) polymerase, such as E. coli polyA polymerase (E-PAP). In one embodiment, increasing the length of a poly(A) tail from 100 nucleotides to between 300 and 400 nucleotides (SEQ ID NO: 34) results in about a two-fold increase in the translation efficiency of the RNA. Additionally, the attachment of different chemical groups to the 3' end can
10 increase mRNA stability. Such attachment can contain modified/artificial nucleotides, aptamers and other compounds. For example, ATP analogs can be incorporated into the poly(A) tail using poly(A) polymerase. ATP analogs can further increase the stability of the RNA.

5' caps on also provide stability to RNA molecules. In a preferred embodiment, RNAs produced by the methods disclosed herein include a 5' cap. The 5' cap is provided using
15 techniques known in the art and described herein (Cougot, et al., Trends in Biochem. Sci., 29:436-444 (2001); Stepinski, et al., RNA, 7:1468-95 (2001); Elango, et al., Biochim. Biophys. Res. Commun., 330:958-966 (2005)).

The RNAs produced by the methods disclosed herein can also contain an internal ribosome entry site (IRES) sequence. The IRES sequence may be any viral, chromosomal or
20 artificially designed sequence which initiates cap-independent ribosome binding to mRNA and facilitates the initiation of translation. Any solutes suitable for cell electroporation, which can contain factors facilitating cellular permeability and viability such as sugars, peptides, lipids, proteins, antioxidants, and surfactants can be included.

RNA can be introduced into target cells using any of a number of different methods, for
25 instance, commercially available methods which include, but are not limited to, electroporation (Amaza Nucleofector-II (Amaza Biosystems, Cologne, Germany)), (ECM 830 (BTX) (Harvard Instruments, Boston, Mass.) or the Gene Pulser II (BioRad, Denver, Colo.), Multiporator (Eppendorf, Hamburg Germany), cationic liposome mediated transfection using lipofection, polymer encapsulation, peptide mediated transfection, or biolistic particle delivery systems
30 such as "gene guns" (see, for example, Nishikawa, et al. Hum Gene Ther., 12(8):861-70 (2001).

Non-viral delivery methods

In some aspects, non-viral methods can be used to deliver a nucleic acid encoding a CAR described herein into a cell or tissue or a subject.

5 In some embodiments, the non-viral method includes the use of a transposon (also called a transposable element). In some embodiments, a transposon is a piece of DNA that can insert itself at a location in a genome, for example, a piece of DNA that is capable of self-replicating and inserting its copy into a genome, or a piece of DNA that can be spliced out of a longer nucleic acid and inserted into another place in a genome. For example, a transposon
10 comprises a DNA sequence made up of inverted repeats flanking genes for transposition.

Exemplary methods of nucleic acid delivery using a transposon include a Sleeping Beauty transposon system (SBTS) and a piggyBac (PB) transposon system. See, e.g., Aronovich et al. Hum. Mol. Genet. 20.R1(2011):R14-20; Singh et al. Cancer Res. 15(2008):2961–2971; Huang et al. Mol. Ther. 16(2008):580–589; Grabundzija et al. Mol. Ther. 18(2010):1200–1209; Kebriaei et al. Blood. 122.21(2013):166; Williams. Molecular Therapy 16.9(2008):1515–16; Bell et al. Nat. Protoc. 2.12(2007):3153-65; and Ding et al. Cell. 122.3(2005):473-83, all of which are incorporated herein by reference.

The SBTS includes two components: 1) a transposon containing a transgene and 2) a source of transposase enzyme. The transposase can transpose the transposon from a carrier
20 plasmid (or other donor DNA) to a target DNA, such as a host cell chromosome/genome. For example, the transposase binds to the carrier plasmid/donor DNA, cuts the transposon (including transgene(s)) out of the plasmid, and inserts it into the genome of the host cell. See, e.g., Aronovich et al. *supra*.

Exemplary transposons include a pT2-based transposon. See, e.g., Grabundzija et al. Nucleic Acids Res. 41.3(2013):1829-47; and Singh et al. Cancer Res. 68.8(2008): 2961–2971,
25 all of which are incorporated herein by reference. Exemplary transposases include a Tc1/mariner-type transposase, e.g., the SB10 transposase or the SB11 transposase (a hyperactive transposase which can be expressed, e.g., from a cytomegalovirus promoter). See, e.g., Aronovich et al.; Kebriaei et al.; and Grabundzija et al., all of which are incorporated
30 herein by reference.

Use of the SBTS permits efficient integration and expression of a transgene, e.g., a nucleic acid encoding a CAR described herein. Provided herein are methods of generating a cell, e.g., T cell or NK cell, that stably expresses a CAR described herein, e.g., using a transposon system such as SBTS.

5 In accordance with methods described herein, in some embodiments, one or more nucleic acids, e.g., plasmids, containing the SBTS components are delivered to a cell (e.g., T or NK cell). For example, the nucleic acid(s) are delivered by standard methods of nucleic acid (e.g., plasmid DNA) delivery, e.g., methods described herein, e.g., electroporation, transfection, or lipofection. In some embodiments, the nucleic acid contains a transposon comprising a
10 transgene, e.g., a nucleic acid encoding a CAR described herein. In some embodiments, the nucleic acid contains a transposon comprising a transgene (e.g., a nucleic acid encoding a CAR described herein) as well as a nucleic acid sequence encoding a transposase enzyme. In other embodiments, a system with two nucleic acids is provided, e.g., a dual-plasmid system, e.g., where a first plasmid contains a transposon comprising a transgene, and a second plasmid
15 contains a nucleic acid sequence encoding a transposase enzyme. For example, the first and the second nucleic acids are co-delivered into a host cell.

In some embodiments, cells, e.g., T or NK cells, are generated that express a CAR described herein by using a combination of gene insertion using the SBTS and genetic editing using a nuclease (e.g., Zinc finger nucleases (ZFNs), Transcription Activator-Like Effector
20 Nucleases (TALENs), the CRISPR/Cas system, or engineered meganuclease re-engineered homing endonucleases).

In some embodiments, use of a non-viral method of delivery permits reprogramming of cells, e.g., T or NK cells, and direct infusion of the cells into a subject. Advantages of non-viral vectors include but are not limited to the ease and relatively low cost of producing
25 sufficient amounts required to meet a patient population, stability during storage, and lack of immunogenicity.

Nucleic Acid Constructs Encoding a CAR

The present invention also provides nucleic acid molecules encoding one or more CAR
30 constructs described herein. In one aspect, the nucleic acid molecule is provided as a messenger RNA transcript. In one aspect, the nucleic acid molecule is provided as a DNA construct.

Accordingly, in one aspect, the invention pertains to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a anti-BCMA

5 binding domain (e.g., a human anti-BCMA binding domain), a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain, e.g., a costimulatory signaling domain and/or a primary signaling domain, e.g., zeta chain. In one embodiment, the anti-BCMA binding domain is an anti-BCMA binding domain described herein, e.g., an anti-BCMA binding domain which comprises a sequence selected from a group consisting of SEQ

10 ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO:

15 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148 or SEQ ID NO: 149, or a sequence with 95-99% identity thereof. In one embodiment, the transmembrane domain is transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37,

20 CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain comprises a sequence of SEQ ID NO: 6, or a sequence with 95-99% identity thereof. In one embodiment, the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region, e.g., a hinge described herein. In one embodiment, the hinge region comprises SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5, or a sequence

25 with 95-99% identity thereof. In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein selected from the group consisting of MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating

30 NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD5, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CD28, ICAM-1, ICOS (CD278), GITR, BAFTR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d,

35 ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1

5 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9
 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108),
 SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT,
 GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83. In one
 10 embodiment, the costimulatory domain comprises a sequence of SEQ ID NO:7, or a sequence
 with 95-99% identity thereof or a CD27 costimulatory domain having a sequence of SEQ ID
 NO:8 (or a sequence with 95-99% identity thereof) or a CD28 costimulatory domain having a
 sequence of SEQ ID NO:379 (or a sequence with 95-99% identity thereof) or a ICOS
 costimulatory domain having a sequence of SEQ ID NO: 381 (or a sequence with 95-99%
 15 identity thereof). In one embodiment, the intracellular signaling domain comprises a functional
 signaling domain of 4-1BB and a functional signaling domain of CD3 zeta. In one embodiment,
 the intracellular signaling domain comprises the sequence of SEQ ID NO: 7 or SEQ ID NO: 8,
 or a sequence with 95-99% identity thereof, and the sequence of SEQ ID NO: 9 or SEQ ID
 NO:10, or a sequence with 95-99% identity thereof, wherein the sequences comprising the
 intracellular signaling domain are expressed in the same frame and as a single polypeptide
 20 chain.

In another aspect, the invention pertains to an isolated nucleic acid molecule encoding
 a CAR construct comprising a leader sequence of SEQ ID NO: 1, a scFv domain having a
 sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO:
 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ
 25 ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO:
 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132,
 SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137,
 SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142,
 SEQ ID NO: 143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ
 30 ID NO:148 or SEQ ID NO:149 (or a sequence with 95-99% identify thereof), a hinge region of
 SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 (or a sequence with 95-99%
 identity thereof), a transmembrane domain having a sequence of SEQ ID NO: 6 (or a sequence
 with 95-99% identity thereof), a 4-1BB costimulatory domain having a sequence of SEQ ID
 NO:7 or a CD27 costimulatory domain having a sequence of SEQ ID NO:8 (or a sequence with
 35 95-99% identity thereof) or a CD28 costimulatory domain having a sequence of SEQ ID

5 NO:1104 (or a sequence with 95-99% identity thereof) or a ICOS costimulatory domain having a sequence of SEQ ID NO: 1106 (or a sequence with 95-99% identity thereof), and a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:9 or SEQ ID NO:10 (or a sequence with 95-99% identity thereof).

In another aspect, the invention pertains to an isolated polypeptide molecule encoded by
 10 the nucleic acid molecule. In one embodiment, the isolated polypeptide molecule comprises a sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132,
 15 SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148 and SEQ ID NO:149, or a sequence with 95-99% identify thereof.

In another aspect, the invention pertains to a nucleic acid molecule encoding a chimeric
 20 antigen receptor (CAR) molecule that comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain, and wherein said anti-BCMA binding domain comprises a sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO:
 25 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, SEQ ID NO:148 and SEQ ID
 30 NO:149, or a sequence with 95-99% identify thereof.

In one embodiment, the encoded CAR molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein, e.g., described herein, e.g., selected from the group consisting of MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine
 35 receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating

5 NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRP1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, 10 ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, 15 GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83. In one embodiment, the costimulatory domain comprises a sequence of SEQ ID NO:7. In one embodiment, the transmembrane domain is a transmembrane domain of a protein, e.g., described herein, e.g., selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, 20 CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain comprises a sequence of SEQ ID NO:6. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and a functional signaling domain of zeta. In one embodiment, the intracellular signaling domain comprises the sequence of SEQ ID NO: 7 and the sequence of SEQ ID NO: 9, wherein the 25 sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region. In one embodiment, the hinge region comprises SEQ ID NO:2. In one embodiment, the hinge region comprises SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5.

30 In another aspect, the invention pertains to an encoded CAR molecule comprising a leader sequence of SEQ ID NO: 1, a scFv domain having a sequence selected from the group consisting of SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 35 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO:

5 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148 and SEQ ID NO: 149, or a sequence with 95-99% identity thereof, a hinge region of SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5, a transmembrane domain having a sequence of
 10 SEQ ID NO: 6, a 4-1BB costimulatory domain having a sequence of SEQ ID NO: 7, or a CD27 costimulatory domain having a sequence of SEQ ID NO: 8, or a CD28 costimulatory domain having a sequence of SEQ ID NO: 1104 (or a sequence with 95-99% identity thereof) or a ICOS costimulatory domain having a sequence of SEQ ID NO: 1106 (or a sequence with 95-99% identity thereof), and a CD3 zeta stimulatory domain having a sequence of SEQ ID NO: 9 or
 15 SEQ ID NO: 10. In one embodiment, the encoded CAR molecule comprises a sequence selected from a group consisting of SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, and SEQ ID NO: 233 or a sequence with 95-99% identity thereof.

The nucleic acid sequences coding for the desired molecules can be obtained using
 25 recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the gene of interest can be produced synthetically, rather than cloned.

The present invention also provides vectors in which a DNA of the present invention is
 30 inserted. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low
 35 immunogenicity. A retroviral vector may also be, e.g., a gammaretroviral vector. A

5 gammaretroviral vector may include, e.g., a promoter, a packaging signal (ψ), a primer binding site (PBS), one or more (e.g., two) long terminal repeats (LTR), and a transgene of interest, e.g., a gene encoding a CAR. A gammaretroviral vector may lack viral structural genes such as gag, pol, and env. Exemplary gammaretroviral vectors include Murine Leukemia Virus (MLV), Spleen-Focus Forming Virus (SFFV), and Myeloproliferative Sarcoma Virus (MPSV),
10 and vectors derived therefrom. Other gammaretroviral vectors are described, e.g., in Tobias Maetzig et al., "Gammaretroviral Vectors: Biology, Technology and Application" *Viruses*. 2011 Jun; 3(6): 677–713.

 In another embodiment, the vector comprising the nucleic acid encoding the desired CAR of the invention is an adenoviral vector (A5/35). In another embodiment, the expression
15 of nucleic acids encoding CARs can be accomplished using of transposons such as sleeping beauty, CRISPR, CAS9, and zinc finger nucleases. See below June et al. 2009 *Nature Reviews Immunology* 9.10: 704-716, is incorporated herein by reference.

 In brief summary, the expression of natural or synthetic nucleic acids encoding CARs is typically achieved by operably linking a nucleic acid encoding the CAR polypeptide or
20 portions thereof to a promoter, and incorporating the construct into an expression vector. The vectors can be suitable for replication and integration in eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.

 The expression constructs of the present invention may also be used for nucleic acid
25 immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties. In another embodiment, the invention provides a gene therapy vector.

 The nucleic acid can be cloned into a number of types of vectors. For example, the
30 nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

 Further, the expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et

5 al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1 -4, Cold Spring Harbor Press, NY), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient
10 restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193).

A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged in retroviral particles using
15 techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems are known in the art. In some embodiments, adenovirus vectors are used. A number of adenovirus vectors are known in the art. In one embodiment, lentivirus vectors are used.

Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional
20 initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to
25 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.

An example of a promoter that is capable of expressing a CAR transgene in a mammalian T cell is the EF1a promoter. The native EF1a promoter drives expression of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic
30 delivery of aminoacyl tRNAs to the ribosome. The EF1a promoter has been extensively used in mammalian expression plasmids and has been shown to be effective in driving CAR expression from transgenes cloned into a lentiviral vector. See, e.g., Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). In one aspect, the EF1a promoter comprises the sequence provided as SEQ ID NO:11.

Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the elongation factor-1 α promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the invention should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the invention. The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

Another example of a promoter is the phosphoglycerate kinase (PGK) promoter. In embodiments, a truncated PGK promoter (e.g., a PGK promoter with one or more, e.g., 1, 2, 5, 10, 100, 200, 300, or 400, nucleotide deletions when compared to the wild-type PGK promoter sequence) may be desired. The nucleotide sequences of exemplary PGK promoters are provided below.

WT PGK Promoter

ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTAC
GCCTTGTGGCGCGCCCGTCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGC
CGGCGACGAGAGCCGCGCGGGACGACTCGTCCGCGATAACCGGTGTCTGGGTAGCGCCAGCCGCGACGGTAA
CGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGC
GCTTGGCGTTCTTGGGAAGGGCTGAATCCCCGCCCTCGTCTTTCGCAGCGGCCCGGGTGTTCCTCATCGCCG
CTTCTAGGCCCACTGCGACGCTTGCTGCACTTCTTACACGCTCTGGGTCCCAGCCGCGCGACGCAAAGGGC
CTTGGTGCGGGTCTCGTCCGCGCAGGGACGCGTTTGGGTCCCCGACGGAACCTTTTCCGCGTTGGGGTTGGGGC
ACCATAAGCT
(SEQ ID NO: 1109)

Exemplary truncated PGK Promoters:

PGK100:

5 ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTAC
GCCTTGTGGCGCGCCCGTCTTGTCCCGGGTGTGATGGCGGGGTG
(SEQ ID NO: 1110)

PGK200:

10 ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTAC
GCCTTGTGGCGCGCCCGTCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGC
CGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCTGGGTAGCGCCAGCCGCGCGACGGTAA
CG
(SEQ ID NO: 1111)

PGK300:

15 ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTAC
GCCTTGTGGCGCGCCCGTCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGC
CGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCTGGGTAGCGCCAGCCGCGCGACGGTAA
20 CGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGC
GCTTGGCGTTCTTGGAAAGGGCTGAATCCCCG
(SEQ ID NO: 1112)

PGK400:

25 ACCCCTCTCTCCAGCCACTAAGCCAGTTGCTCCCTCGGCTGACGGCTGCACGCGAGGCCTCCGAACGTCTTAC
GCCTTGTGGCGCGCCCGTCTTGTCCCGGGTGTGATGGCGGGGTGTGGGGCGGAGGGCGTGGCGGGGAAGGGC
CGGCGACGAGAGCCGCGCGGGACGACTCGTCGGCGATAACCGGTGTCTGGGTAGCGCCAGCCGCGCGACGGTAA
CGAGGGACCGCGACAGGCAGACGCTCCCATGATCACTCTGCACGCCGAAGGCAAATAGTGCAGGCCGTGCGGC
30 GCTTGGCGTTCTTGGAAAGGGCTGAATCCCCGCTCTGCTTTCGCAGCGGCCCCCGGGTGTTCCTCATCGCCG
CTTCTAGGCCCCACTGCGACGCTTGCTGCACTTCTTACACGCTCTGGGTCCCAGCCG
(SEQ ID NO: 1113)

A vector may also include, e.g., a signal sequence to facilitate secretion, a polyadenylation signal and transcription terminator (e.g., from Bovine Growth Hormone (BGH) gene), an element allowing episomal replication and replication in prokaryotes (e.g. SV40 origin and ColE1 or others known in the art) and/or elements to allow selection (e.g., ampicillin resistance gene and/or zeocin marker).

In order to assess the expression of a CAR polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co- transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like.

5 Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced
10 into the recipient cells. Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82). Suitable expression systems are well known and may be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5' flanking region showing the highest
15 level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription.

In one embodiment, the vector can further comprise a nucleic acid encoding a second CAR. In one embodiment, the second CAR includes an antigen binding domain to a target
20 expressed on acute myeloid leukemia cells, such as, e.g., CD123, CD34, CLL-1, folate receptor beta, or FLT3; or a target expressed on a B cell, e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. In one embodiment, the vector comprises a nucleic acid sequence encoding a first CAR that specifically binds a first antigen and includes an intracellular signaling domain having a costimulatory signaling domain but not a primary
25 signaling domain, and a nucleic acid encoding a second CAR that specifically binds a second, different, antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. In one embodiment, the vector comprises a nucleic acid encoding a first BCMA CAR that includes a BCMA binding domain, a transmembrane domain and a costimulatory domain and a nucleic acid encoding a second CAR
30 that targets an antigen other than BCMA (e.g., an antigen expressed on AML cells, e.g., CD123, CD34, CLL-1, folate receptor beta, or FLT3; or an antigen expressed on a B cell, e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a) and includes an antigen binding domain, a transmembrane domain and a primary signaling domain. In another embodiment, the vector comprises a nucleic acid encoding a first BCMA CAR that
35 includes a BCMA binding domain, a transmembrane domain and a primary signaling domain

5 and a nucleic acid encoding a second CAR that specifically binds an antigen other than BCMA (e.g., an antigen expressed on AML cells, e.g., CD123, CD34, CLL-1, folate receptor beta, or FLT3; or an antigen expressed on a B cell, e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a) and includes an antigen binding domain to the antigen, a transmembrane domain and a costimulatory signaling domain.

10 In one embodiment, the vector comprises a nucleic acid encoding a BCMA CAR described herein and a nucleic acid encoding an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen binding domain that binds an antigen found on normal cells but not cancer cells, e.g., normal cells that also express BCMA. In one embodiment, the inhibitory CAR comprises the antigen binding domain, a transmembrane domain and an intracellular domain of an inhibitory
 15 molecule. For example, the intracellular domain of the inhibitory CAR can be an intracellular domain of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta.

20 In embodiments, the vector may comprise two or more nucleic acid sequences encoding a CAR, e.g., a BCMA CAR described herein and a second CAR, e.g., an inhibitory CAR or a CAR that specifically binds to an antigen other than BCMA (e.g., an antigen expressed on AML cells, e.g., CD123, CLL-1, CD34, FLT3, or folate receptor beta; or antigen expression B cells, e.g., CD10, CD19, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or
 25 CD79a). In such embodiments, the two or more nucleic acid sequences encoding the CAR are encoded by a single nucleic molecule in the same frame and as a single polypeptide chain. In this aspect, the two or more CARs, can, e.g., be separated by one or more peptide cleavage sites. (e.g., an auto-cleavage site or a substrate for an intracellular protease). Examples of peptide cleavage sites include the following, wherein the GSG residues are optional:

30 T2A: (GSG) E G R G S L L T C G D V E E N P G P (SEQ ID NO: 1114)
 P2A: (GSG) A T N F S L L K Q A G D V E E N P G P (SEQ ID NO: 1115)
 E2A: (GSG) Q C T N Y A L L K L A G D V E S N P G P (SEQ ID NO: 1116)
 F2A: (GSG) V K Q T L N F D L L K L A G D V E S N P G P (SEQ ID NO:
 1117)

5 Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means.

10 Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1 -4, Cold Spring Harbor Press, NY). A preferred method for the introduction of a polynucleotide into a host cell is calcium phosphate
15 transfection

 Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and
20 adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362.

 Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
25 An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). Other methods of state-of-the-art targeted delivery of nucleic acids are available, such as delivery of polynucleotides with targeted nanoparticles or other suitable sub-micron sized delivery system.

 In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle
30 is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo). In another aspect, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the

5 oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or
10 with a "collapsed" structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino
15 alcohols, and aldehydes.

Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be obtained from Sigma, St. Louis, MO; dicetyl phosphate ("DCP") can be obtained from K & K Laboratories (Plainview, NY); cholesterol ("Choi") can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol
20 ("DMPG") and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. "Liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be
25 characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., 1991
30 Glycobiology 5: 505-10). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids may assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.

Regardless of the method used to introduce exogenous nucleic acids into a host cell or
35 otherwise expose a cell to the inhibitor of the present invention, in order to confirm the

- 5 presence of the recombinant DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, “molecular biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify
10 agents falling within the scope of the invention.

The present invention further provides a vector comprising a CAR encoding nucleic acid molecule. In one aspect, a CAR vector can be directly transduced into a cell, e.g., a T cell or NK cell. In one aspect, the vector is a cloning or expression vector, e.g., a vector including, but not limited to, one or more plasmids (e.g., expression plasmids, cloning vectors,
15 minicircles, minivectors, double minute chromosomes), retroviral and lentiviral vector constructs. In one aspect, the vector is capable of expressing the CAR construct in mammalian T cells or NK cells. In one aspect, the mammalian T cell is a human T cell. In one aspect, the mammalian NK cell is a human NK cell.

20 Sources of cells

Prior to expansion and genetic modification, a source of cells, e.g., immune effector cells (e.g., T cells or NK cells), is obtained from a subject. The term “subject” is intended to include living organisms in which an immune response can be elicited (e.g., mammals). Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T
25 cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors.

In certain aspects of the present invention, any number of immune effector cell (e.g., T cell or NK cell) lines available in the art, may be used. In certain aspects of the present
30 invention, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll™ separation. In one preferred aspect, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one aspect, the cells

5 collected by apheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one aspect of the invention, the cells are washed with phosphate buffered saline (PBS). In an alternative aspect, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations.

Initial activation steps in the absence of calcium can lead to magnified activation. As
10 those of ordinary skill in the art would readily appreciate a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated "flow-through" centrifuge (for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer's instructions. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free,
15 Mg-free PBS, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media.

It is recognized that the methods of the application can utilize culture media conditions comprising 5% or less, for example 2%, human AB serum, and employ known culture media
20 conditions and compositions, for example those described in Smith *et al.*, "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement" *Clinical & Translational Immunology* (2015) 4, e31; doi:10.1038/cti.2014.31.

In one aspect, T cells are isolated from peripheral blood lymphocytes by lysing the red
25 blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLLTM gradient or by counterflow centrifugal elutriation. A specific subpopulation of T cells, such as CD3+, CD28+, CD4+, CD8+, CD45RA+, and CD45RO+T cells, can be further isolated by positive or negative selection techniques. For example, in one aspect, T cells are isolated by incubation with anti-CD3/anti-CD28 (e.g., 3x28)-conjugated beads, such as
30 DYNABEADS[®] M-450 CD3/CD28 T, for a time period sufficient for positive selection of the desired T cells. In one aspect, the time period is about 30 minutes. In a further aspect, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further aspect, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another preferred aspect, the time period is 10 to 24 hours. In one aspect, the incubation time period is 24 hours. Longer
35 incubation times may be used to isolate T cells in any situation where there are few T cells as

5 compared to other cell types, such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immunocompromised individuals. Further, use of longer incubation times can increase the efficiency of capture of CD8+ T cells. Thus, by simply shortening or lengthening the time T cells are allowed to bind to the CD3/CD28 beads and/or by increasing or decreasing the ratio of beads to T cells (as described further herein), subpopulations of T cells can be
10 preferentially selected for or against at culture initiation or at other time points during the process. Additionally, by increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for or against at culture initiation or at other desired time points. The skilled artisan would recognize that multiple rounds of selection can also be used in the context of this
15 invention. In certain aspects, it may be desirable to perform the selection procedure and use the “unselected” cells in the activation and expansion process. “Unselected” cells can also be subjected to further rounds of selection.

Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells.
20 One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain aspects, it may be desirable to enrich for or positively select for
25 regulatory T cells which typically express CD4+, CD25+, CD62Lhi, GITR+, and FoxP3+. Alternatively, in certain aspects, T regulatory cells are depleted by anti-CD25 conjugated beads or other similar method of selection.

The methods described herein can include, e.g., selection of a specific subpopulation of immune effector cells, e.g., T cells, that are a T regulatory cell-depleted population, CD25+
30 depleted cells, using, e.g., a negative selection technique, e.g., described herein. Preferably, the population of T regulatory depleted cells contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells.

In one embodiment, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, IL-2.

35 In one embodiment, the anti-CD25 antibody, or fragment thereof, or CD25-binding ligand is

5 conjugated to a substrate, e.g., a bead, or is otherwise coated on a substrate, e.g., a bead. In one embodiment, the anti-CD25 antibody, or fragment thereof, is conjugated to a substrate as described herein.

In one embodiment, the T regulatory cells, e.g., CD25+ T cells, are removed from the population using CD25 depletion reagent from MiltenyiTM. In one embodiment, the ratio of
10 cells to CD25 depletion reagent is 1×10^7 cells to 20 uL, or 1×10^7 cells to 15 uL, or 1×10^7 cells to 10 uL, or 1×10^7 cells to 5 uL, or 1×10^7 cells to 2.5 uL, or 1×10^7 cells to 1.25 uL. In one embodiment, e.g., for T regulatory cells, e.g., CD25+ depletion, greater than 500 million cells/ml is used. In a further aspect, a concentration of cells of 600, 700, 800, or 900 million cells/ml is used.

In one embodiment, the population of immune effector cells to be depleted includes
15 about 6×10^9 CD25+ T cells. In other aspects, the population of immune effector cells to be depleted include about 1×10^9 to 1×10^{10} CD25+ T cell, and any integer value in between. In one embodiment, the resulting population T regulatory depleted cells has 2×10^9 T regulatory cells, e.g., CD25+ cells, or less (e.g., 1×10^9 , 5×10^8 , 1×10^8 , 5×10^7 , 1×10^7 , or less CD25+ cells).

20 In one embodiment, the T regulatory cells, e.g., CD25+ cells, are removed from the population using the CliniMAC system with a depletion tubing set, such as, e.g., tubing 162-01. In one embodiment, the CliniMAC system is run on a depletion setting such as, e.g., DEPLETION2.1.

Without wishing to be bound by a particular theory, decreasing the level of negative
25 regulators of immune cells (e.g., decreasing the number of unwanted immune cells, e.g., T_{REG} cells), in a subject prior to apheresis or during manufacturing of a CAR-expressing cell product can reduce the risk of subject relapse. For example, methods of depleting T_{REG} cells are known in the art. Methods of decreasing T_{REG} cells include, but are not limited to, cyclophosphamide, anti-GITR antibody (an anti-GITR antibody described herein), CD25-depletion, and
30 combinations thereof.

In some embodiments, the manufacturing methods comprise reducing the number of (e.g., depleting) T_{REG} cells prior to manufacturing of the CAR-expressing cell. For example, manufacturing methods comprise contacting the sample, e.g., the apheresis sample, with an anti-GITR antibody and/or an anti-CD25 antibody (or fragment thereof, or a CD25-binding

- 5 ligand), e.g., to deplete T_{REG} cells prior to manufacturing of the CAR-expressing cell (e.g., T cell, NK cell) product.

In an embodiment, a subject is pre-treated with one or more therapies that reduce T_{REG} cells prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment. In an embodiment,
10 methods of decreasing T_{REG} cells include, but are not limited to, administration to the subject of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof, can occur before, during or after an infusion of the CAR-expressing cell product.

15 In an embodiment, a subject is pre-treated with cyclophosphamide prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment. In an embodiment, a subject is pre-treated with an anti-GITR antibody prior to collection of cells for CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment.

20 In one embodiment, the population of cells to be removed are neither the regulatory T cells or tumor cells, but cells that otherwise negatively affect the expansion and/or function of CART cells, e.g. cells expressing CD14, CD11b, CD33, CD15, or other markers expressed by potentially immune suppressive cells. In one embodiment, such cells are envisioned to be removed concurrently with regulatory T cells and/or tumor cells, or following said depletion, or
25 in another order.

The methods described herein can include more than one selection step, e.g., more than one depletion step. Enrichment of a T cell population by negative selection can be accomplished, e.g., with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic
30 immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail can include antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8.

5 The methods described herein can further include removing cells from the population which express a tumor antigen, e.g., a tumor antigen that does not comprise CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted, and tumor antigen depleted cells that are suitable for expression of a CAR, e.g., a CAR described herein. In one embodiment, tumor antigen
10 expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-tumor antigen antibody, or fragment thereof, can be attached to the same substrate, e.g., bead, which can be used to remove the cells or an anti-CD25 antibody, or fragment thereof, or the anti-tumor antigen antibody, or fragment thereof, can be attached to separate beads, a mixture of which can be
15 used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the tumor antigen expressing cells is sequential, and can occur, e.g., in either order.

 Also provided are methods that include removing cells from the population which express a check point inhibitor, e.g., a check point inhibitor described herein, e.g., one or more
20 of PD1+ cells, LAG3+ cells, and TIM3+ cells, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted cells, and check point inhibitor depleted cells, e.g., PD1+, LAG3+ and/or TIM3+ depleted cells. Exemplary check point inhibitors include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4
25 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta. In embodiments, the checkpoint inhibitor is PD1 or PD-L1. In one embodiment, check point inhibitor expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-check point inhibitor antibody, or fragment thereof, can be attached to the same bead
30 which can be used to remove the cells, or an anti-CD25 antibody, or fragment thereof, and the anti-check point inhibitor antibody, or fragment there, can be attached to separate beads, a mixture of which can be used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the check point inhibitor expressing cells is sequential, and can occur, e.g., in either order.

5 In one embodiment, a T cell population can be selected that expresses one or more of IFN- γ , TNF α , IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10, IL-13, granzyme B, and perforin, or other appropriate molecules, e.g., other cytokines. Methods for screening for cell expression can be determined, e.g., by the methods described in PCT Publication No.: WO 2013/126712.

For isolation of a desired population of cells by positive or negative selection, the
10 concentration of cells and surface (e.g., particles such as beads) can be varied. In certain aspects, it may be desirable to significantly decrease the volume in which beads and cells are mixed together (e.g., increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one aspect, a concentration of 2 billion cells/ml is used. In one aspect, a concentration of 1 billion cells/ml is used. In a further aspect, greater than 100 million
15 cells/ml is used. In a further aspect, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells
20 that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples where there are many tumor cells present (e.g., leukemic blood, tumor tissue, etc.). Such populations of cells may have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression.

25 In a related aspect, it may be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells in dilute
30 concentrations. In one aspect, the concentration of cells used is 5×10^6 /ml. In other aspects, the concentration used can be from about 1×10^5 /ml to 1×10^6 /ml, and any integer value in between.

In other aspects, the cells may be incubated on a rotator for varying lengths of time at varying speeds at either 2-10°C or at room temperature.

5 T cells for stimulation can also be frozen after a washing step. Wishing not to be bound by theory, the freeze and subsequent thaw step provides a more uniform product by removing granulocytes and to some extent monocytes in the cell population. After the washing step that removes plasma and platelets, the cells may be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one
10 method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture media containing 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable cell freezing media containing for example, Hespan and PlasmaLyte A, the cells then are frozen to -80°C at a rate
15 of 1° per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used as well as uncontrolled freezing immediately at -20° C or in liquid nitrogen.

In certain aspects, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation using the methods of the
20 present invention.

Also contemplated in the context of the invention is the collection of blood samples or apheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as immune effector cells, e.g., T cells or NK cells,
25 isolated and frozen for later use in cell therapy, e.g., T cell therapy, for any number of diseases or conditions that would benefit from cell therapy, e.g., T cell therapy, such as those described herein. In one aspect a blood sample or an apheresis is taken from a generally healthy subject. In certain aspects, a blood sample or an apheresis is taken from a generally healthy subject who is at risk of developing a disease, but who has not yet developed a disease, and the cells of
30 interest are isolated and frozen for later use. In certain aspects, the immune effector cells (e.g., T cells or NK cells) may be expanded, frozen, and used at a later time. In certain aspects, samples are collected from a patient shortly after diagnosis of a particular disease as described herein but prior to any treatments. In a further aspect, the cells are isolated from a blood sample or an apheresis from a subject prior to any number of relevant treatment modalities, including
35 but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents,

5 chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation.

10 In a further aspect of the present invention, T cells are obtained from a patient directly following treatment that leaves the subject with functional T cells. In this regard, it has been observed that following certain cancer treatments, in particular treatments with drugs that damage the immune system, shortly after treatment during the period when patients would normally be recovering from the treatment, the quality of T cells obtained may be optimal or improved for their ability to expand ex vivo. Likewise, following ex vivo manipulation using
15 the methods described herein, these cells may be in a preferred state for enhanced engraftment and in vivo expansion. Thus, it is contemplated within the context of the present invention to collect blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. Further, in certain aspects, mobilization (for example, mobilization with GM-CSF) and conditioning regimens can be used to create a condition in a subject
20 wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system.

In one embodiment, the immune effector cells expressing a CAR molecule, e.g., a CAR molecule described herein, are obtained from a subject that has received a low, immune
25 enhancing dose of an mTOR inhibitor. In an embodiment, the population of immune effector cells, e.g., T cells, to be engineered to express a CAR, are harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive immune effector cells, e.g., T cells, in the subject or
30 harvested from the subject has been, at least transiently, increased.

In other embodiments, population of immune effector cells, e.g., T cells, which have, or will be engineered to express a CAR, can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells or increases the ratio of PD1 negative immune effector cells, e.g., T cells/ PD1 positive
35 immune effector cells, e.g., T cells.

5 In one embodiment, a T cell population is diacylglycerol kinase (DGK)-deficient. DGK-deficient cells include cells that do not express DGK RNA or protein, or have reduced or inhibited DGK activity. DGK-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent DGK expression. Alternatively, DGK-deficient cells can be generated by treatment with DGK inhibitors described herein.

In one embodiment, a T cell population is Ikaros-deficient. Ikaros-deficient cells include cells that do not express Ikaros RNA or protein, or have reduced or inhibited Ikaros activity, Ikaros-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent Ikaros expression. Alternatively, Ikaros-deficient cells can be generated by treatment with Ikaros inhibitors, e.g., lenalidomide.

In embodiments, a T cell population is DGK-deficient and Ikaros-deficient, e.g., does not express DGK and Ikaros, or has reduced or inhibited DGK and Ikaros activity. Such DGK and Ikaros-deficient cells can be generated by any of the methods described herein.

20 In an embodiment, the NK cells are obtained from the subject. In another embodiment, the NK cells are an NK cell line, e.g., NK-92 cell line (Conkwest).

Allogeneic CAR

In embodiments described herein, the immune effector cell can be an allogeneic immune effector cell, e.g., T cell or NK cell. For example, the cell can be an allogeneic T cell, e.g., an allogeneic T cell lacking expression of a functional T cell receptor (TCR) and/or human leukocyte antigen (HLA), e.g., HLA class I and/or HLA class II.

A T cell lacking a functional TCR can be, e.g., engineered such that it does not express any functional TCR on its surface, engineered such that it does not express one or more subunits that comprise a functional TCR (e.g., engineered such that it does not express (or exhibits reduced expression) of TCR alpha, TCR beta, TCR gamma, TCR delta, TCR epsilon, and/or TCR zeta) or engineered such that it produces very little functional TCR on its surface. Alternatively, the T cell can express a substantially impaired TCR, e.g., by expression of mutated or truncated forms of one or more of the subunits of the TCR. The term "substantially impaired TCR" means that this TCR will not elicit an adverse immune reaction in a host.

5 A T cell described herein can be, e.g., engineered such that it does not express a functional HLA on its surface. For example, a T cell described herein, can be engineered such that cell surface expression HLA, e.g., HLA class I and/or HLA class II, is downregulated. In some aspects, downregulation of HLA may be accomplished by reducing or eliminating expression of beta-2 microglobulin (B2M). In some embodiments, the T cell can lack a functional TCR and a
10 functional HLA, e.g., HLA class I and/or HLA class II.

Modified T cells that lack expression of a functional TCR and/or HLA can be obtained by any suitable means, including a knock out or knock down of one or more subunit of TCR or HLA. For example, the T cell can include a knock down of TCR and/or HLA using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR) transcription-
15 activator like effector nuclease (TALEN), or zinc finger endonuclease (ZFN).

In some embodiments, the allogeneic cell can be a cell which does not express or expresses at low levels an inhibitory molecule, e.g. a cell engineered by any method described herein. For example, the cell can be a cell that does not express or expresses at low levels an inhibitory molecule, e.g., that can decrease the ability of a CAR-expressing cell to mount an
20 immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta. Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can
25 optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used.

30 ***siRNA and shRNA to inhibit TCR or HLA***

In some embodiments, TCR expression and/or HLA expression can be inhibited using siRNA or shRNA that targets a nucleic acid encoding a TCR, and/or HLA, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86,
35 B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta), in a cell, e.g., T cell.

5 Expression of siRNA and shRNAs in T cells can be achieved using any conventional expression system, e.g., such as a lentiviral expression system.

Exemplary shRNAs that downregulate expression of components of the TCR are described, e.g., in US Publication No.: 2012/0321667. Exemplary siRNA and shRNA that downregulate expression of HLA class I and/or HLA class II genes are described, e.g., in U.S.
 10 publication No.: US 2007/0036773.

CRISPR to inhibit TCR or HLA

“CRISPR” or “CRISPR to TCR and/or HLA” or “CRISPR to inhibit TCR and/or HLA” as used herein refers to a set of clustered regularly interspaced short palindromic repeats, or a system comprising such a set of repeats. “Cas”, as used herein, refers to a CRISPR-associated protein. A “CRISPR/Cas” system refers to a system derived from CRISPR and Cas
 15 which can be used to silence or mutate a TCR and/or HLA gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC
 20 class I, MHC class II, GAL9, adenosine, and TIGR beta).

Naturally-occurring CRISPR/Cas systems are found in approximately 40% of sequenced eubacteria genomes and 90% of sequenced archaea. Grissa *et al.* (2007) *BMC Bioinformatics* 8: 172. This system is a type of prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of
 25 acquired immunity. Barrangou *et al.* (2007) *Science* 315: 1709-1712; Marragini *et al.* (2008) *Science* 322: 1843-1845.

The CRISPR/Cas system has been modified for use in gene editing (silencing, enhancing or changing specific genes) in eukaryotes such as mice or primates. Wiedenheft *et al.* (2012) *Nature* 482: 331-8. This is accomplished by introducing into the eukaryotic cell a
 30 plasmid containing a specifically designed CRISPR and one or more appropriate Cas.

The CRISPR sequence, sometimes called a CRISPR locus, comprises alternating repeats and spacers. In a naturally-occurring CRISPR, the spacers usually comprise sequences foreign to the bacterium such as a plasmid or phage sequence; in the TCR and/or HLA CRISPR/Cas system, the spacers are derived from the TCR or HLA gene sequence.

35 RNA from the CRISPR locus is constitutively expressed and processed by Cas proteins into small RNAs. These comprise a spacer flanked by a repeat sequence. The RNAs guide

5 other Cas proteins to silence exogenous genetic elements at the RNA or DNA level. Horvath *et al.* (2010) *Science* 327: 167-170; Makarova *et al.* (2006) *Biology Direct* 1: 7. The spacers thus serve as templates for RNA molecules, analogously to siRNAs. Pennisi (2013) *Science* 341: 833-836.

10 As these naturally occur in many different types of bacteria, the exact arrangements of the CRISPR and structure, function and number of Cas genes and their product differ somewhat from species to species. Haft *et al.* (2005) *PLoS Comput. Biol.* 1: e60; Kunin *et al.* (2007) *Genome Biol.* 8: R61; Mojica *et al.* (2005) *J. Mol. Evol.* 60: 174-182; Bolotin *et al.* (2005) *Microbiol.* 151: 2551-2561; Pourcel *et al.* (2005) *Microbiol.* 151: 653-663; and Stern *et al.* (2010) *Trends. Genet.* 28: 335-340. For example, the Cse (Cas subtype, *E. coli*) proteins
15 (e.g., CasA) form a functional complex, Cascade, that processes CRISPR RNA transcripts into spacer-repeat units that Cascade retains. Brouns *et al.* (2008) *Science* 321: 960-964. In other prokaryotes, Cas6 processes the CRISPR transcript. The CRISPR-based phage inactivation in *E. coli* requires Cascade and Cas3, but not Cas1 or Cas2. The Cmr (Cas RAMP module) proteins in *Pyrococcus furiosus* and other prokaryotes form a functional complex with small
20 CRISPR RNAs that recognizes and cleaves complementary target RNAs. A simpler CRISPR system relies on the protein Cas9, which is a nuclease with two active cutting sites, one for each strand of the double helix. Combining Cas9 and modified CRISPR locus RNA can be used in a system for gene editing. Pennisi (2013) *Science* 341: 833-836.

The CRISPR/Cas system can thus be used to edit a TCR and/or HLA gene (adding or
25 deleting a basepair), or introducing a premature stop which thus decreases expression of a TCR and/or HLA. The CRISPR/Cas system can alternatively be used like RNA interference, turning off TCR and/or HLA gene in a reversible fashion. In a mammalian cell, for example, the RNA can guide the Cas protein to a TCR and/or HLA promoter, sterically blocking RNA polymerases.

30 Artificial CRISPR/Cas systems can be generated which inhibit TCR and/or HLA, using technology known in the art, e.g., that described in U.S. Publication No.20140068797, and Cong (2013) *Science* 339: 819-823. Other artificial CRISPR/Cas systems that are known in the art may also be generated which inhibit TCR and/or HLA, e.g., that described in Tsai (2014) *Nature Biotechnol.*, 32:6 569-576, U.S. Patent No.: 8,871,445; 8,865,406; 8,795,965;
35 8,771,945; and 8,697,359.

TALEN to inhibit TCR and/or HLA

“TALEN” or “TALEN to HLA and/or TCR” or “TALEN to inhibit HLA and/or TCR” refers to a transcription activator-like effector nuclease, an artificial nuclease which can be used to edit the HLA, and/or TCR gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta).

TALENs are produced artificially by fusing a TAL effector DNA binding domain to a DNA cleavage domain. Transcription activator-like effects (TALEs) can be engineered to bind any desired DNA sequence, including a portion of the HLA or TCR gene. By combining an engineered TALE with a DNA cleavage domain, a restriction enzyme can be produced which is specific to any desired DNA sequence, including a HLA or TCR sequence. These can then be introduced into a cell, wherein they can be used for genome editing. Boch (2011) *Nature Biotech.* 29: 135-6; and Boch et al. (2009) *Science* 326: 1509-12; Moscou et al. (2009) *Science* 326: 3501.

TALEs are proteins secreted by *Xanthomonas* bacteria. The DNA binding domain contains a repeated, highly conserved 33-34 amino acid sequence, with the exception of the 12th and 13th amino acids. These two positions are highly variable, showing a strong correlation with specific nucleotide recognition. They can thus be engineered to bind to a desired DNA sequence.

To produce a TALEN, a TALE protein is fused to a nuclease (N), which is a wild-type or mutated FokI endonuclease. Several mutations to FokI have been made for its use in TALENs; these, for example, improve cleavage specificity or activity. Cermak et al. (2011) *Nucl. Acids Res.* 39: e82; Miller et al. (2011) *Nature Biotech.* 29: 143-8; Hockemeyer et al. (2011) *Nature Biotech.* 29: 731-734; Wood et al. (2011) *Science* 333: 307; Doyon et al. (2010) *Nature Methods* 8: 74-79; Szczepek et al. (2007) *Nature Biotech.* 25: 786-793; and Guo et al. (2010) *J. Mol. Biol.* 200: 96.

The FokI domain functions as a dimer, requiring two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing. Both the number of amino acid residues between the TALE DNA binding domain and the FokI cleavage domain and the number of bases between the two individual TALEN binding sites appear to be

5 important parameters for achieving high levels of activity. Miller et al. (2011) *Nature Biotech.* 29: 143-8.

A HLA or TCR TALEN can be used inside a cell to produce a double-stranded break (DSB). A mutation can be introduced at the break site if the repair mechanisms improperly repair the break via non-homologous end joining. For example, improper repair may introduce
 10 a frame shift mutation. Alternatively, foreign DNA can be introduced into the cell along with the TALEN; depending on the sequences of the foreign DNA and chromosomal sequence, this process can be used to correct a defect in the HLA or TCR gene or introduce such a defect into a wt HLA or TCR gene, thus decreasing expression of HLA or TCR.

TALENs specific to sequences in HLA or TCR can be constructed using any method
 15 known in the art, including various schemes using modular components. Zhang et al. (2011) *Nature Biotech.* 29: 149-53; Geibler et al. (2011) *PLoS ONE* 6: e19509.

Zinc finger nuclease to inhibit HLA and/or TCR

“ZFN” or “Zinc Finger Nuclease” or “ZFN to HLA and/or TCR” or “ZFN to inhibit HLA and/or TCR” refer to a zinc finger nuclease, an artificial nuclease which can be used to
 20 edit the HLA, and/or TCR gene, and/or an inhibitory molecule described herein (e.g., PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GAL9, adenosine, and TGFR beta).

25 Like a TALEN, a ZFN comprises a FokI nuclease domain (or derivative thereof) fused to a DNA-binding domain. In the case of a ZFN, the DNA-binding domain comprises one or more zinc fingers. Carroll et al. (2011) *Genetics Society of America* 188: 773-782; and Kim et al. (1996) *Proc. Natl. Acad. Sci. USA* 93: 1156-1160.

A zinc finger is a small protein structural motif stabilized by one or more zinc ions. A
 30 zinc finger can comprise, for example, Cys2His2, and can recognize an approximately 3-bp sequence. Various zinc fingers of known specificity can be combined to produce multi-finger polypeptides which recognize about 6, 9, 12, 15 or 18-bp sequences. Various selection and modular assembly techniques are available to generate zinc fingers (and combinations thereof) recognizing specific sequences, including phage display, yeast one-hybrid systems, bacterial
 35 one-hybrid and two-hybrid systems, and mammalian cells.

5 Like a TALEN, a ZFN must dimerize to cleave DNA. Thus, a pair of ZFNs are required to target non-palindromic DNA sites. The two individual ZFNs must bind opposite strands of the DNA with their nucleases properly spaced apart. Bitinaite et al. (1998) *Proc. Natl. Acad. Sci. USA* 95: 10570-5.

10 Also like a TALEN, a ZFN can create a double-stranded break in the DNA, which can create a frame-shift mutation if improperly repaired, leading to a decrease in the expression and amount of HLA and/or TCR in a cell. ZFNs can also be used with homologous recombination to mutate in the HLA or TCR gene.

 ZFNs specific to sequences in HLA AND/OR TCR can be constructed using any method known in the art. See, e.g., Provasi (2011) *Nature Med.* 18: 807-815; Torikai (2013) *Blood* 122: 1341-1349; Cathomen et al. (2008) *Mol. Ther.* 16: 1200-7; Guo et al. (2010) *J. Mol. Biol.* 400: 96; U.S. Patent Publication 2011/0158957; and U.S. Patent Publication 2012/0060230.

Telomerase expression

20 While not wishing to be bound by any particular theory, in some embodiments, a therapeutic T cell has short term persistence in a patient, due to shortened telomeres in the T cell; accordingly, transfection with a telomerase gene can lengthen the telomeres of the T cell and improve persistence of the T cell in the patient. See Carl June, "Adoptive T cell therapy for cancer in the clinic", *Journal of Clinical Investigation*, 117:1466-1476 (2007). Thus, in an embodiment, an immune effector cell, e.g., a T cell, ectopically expresses a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. In some aspects, this disclosure provides a method of producing a CAR-expressing cell, comprising contacting a cell with a nucleic acid encoding a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. The cell may be contacted with the nucleic acid before, simultaneous with, or after being contacted with a construct encoding a CAR.

 In one aspect, the disclosure features a method of making a population of immune effector cells (e.g., T cells, NK cells). In an embodiment, the method comprises: providing a population of immune effector cells (e.g., T cells or NK cells), contacting the population of immune effector cells with a nucleic acid encoding a CAR; and contacting the population of

- 5 immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, under conditions that allow for CAR and telomerase expression.

In an embodiment, the nucleic acid encoding the telomerase subunit is DNA. In an embodiment, the nucleic acid encoding the telomerase subunit comprises a promoter capable of driving expression of the telomerase subunit.

- 10 In an embodiment, hTERT has the amino acid sequence of GenBank Protein ID AAC51724.1 (Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization" Cell Volume 90, Issue 4, 22 August 1997, Pages 785–795) as follows:

MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVA
15 QCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARG
GPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCA
YQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRR
GGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEA
TSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQL
20 RPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTTPRRLPRLPQRYWQMRPLFLELLGNH
AQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSP
WQVYGFVRACLRRRLVPPGLWGSRHNERFLRNTKKFISLGKHAKLSLQELTWKMSVR
GCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRL
FFYRKS VWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPI
25 VNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRW
RTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQK
AAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFD
VFLRFMCHHAVRIRGKSYVQCQGIQGSILSTLLCSLCYGD MENKLFAGIRRDGLLLRL
VDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFVPEDEALGGTAFVQMP
30 AHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLR LK
CHSLFLDLQVNSLQTVCTNIYKILLQAYRFHACVLQLPFHQVWKNPTFFLRVISDTA
SLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLCLKLTRHRVTYVPLLGLSLR
TAQTQLSRKLP GTTLTALEAAANPALPSDFKTILD (SEQ ID NO: 284)

5 In an embodiment, the hTERT has a sequence at least 80%, 85%, 90%, 95%, 96[^], 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 284. In an embodiment, the hTERT has a sequence of SEQ ID NO: 284. In an embodiment, the hTERT comprises a deletion (e.g., of no more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both. In an
 10 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both.

In an embodiment, the hTERT is encoded by the nucleic acid sequence of GenBank Accession No. AF018167 (Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization" Cell Volume 90, Issue 4, 22 August 1997, Pages 785–795):

15 1 caggcagcgt ggtcctgctg cgcacgtggg aagccctggc cccggccacc cccgcgatgc
 61 cgcgcgctcc ccgctgccga gccgtgcgct cctgctgcg cagccactac cgcgaggtgc
 121 tgccgctggc cagttcgtg cggcgccctgg gggcccaggg ctggcggctg gtgcagcgcg
 181 gggaccgcggc ggctttccgc gcgctggctg cccagtgcct ggtgtgcgtg cctggggacg
 241 cacggccgcc ccccgccgcc cctccttcc gccaggtgtc ctgcctgaag gagctggtgg
 20 301 cccgagtgtc gcagaggctg tgcgagcgcg gcgcgaagaa cgtgctggcc ttcggcttcg
 361 cgtgctgga cggggcccg cggggccccc ccgaggcctt caccaccagc gtgcgcagct
 421 acctgcccac cacggtgacc gacgcactgc gggggagcgg ggcggtgggg ctgctgttgc
 481 gccgcgtggg cgacgacgtg ctggttcacc tgctggcacg ctgcgcgtc tttgtgctgg
 541 tggtccccag ctgcgcctac caggtgtgcg ggccgccgct gtaccagctc ggcgctgcc
 25 601 ctcaggcccc gccccgccac cacgctagtg gaccccgaa ggcgtctggga tgcgaacggg
 661 cctggaacca tagcgtcagg gaggcggggg tccccctggg cctgccagcc ccgggtgcga
 721 ggaggcgcgg gggcagtgcc agccgaagtc tgccgttgcc caagaggccc aggcgtggcg
 781 ctgcccctga gccggagcgg acgcccgttg ggcagggggtc ctgggcccac ccgggcagga
 841 cgcgtggacc gactgaccgt ggtttctgtg tgggtgcacc tgccagacc gccgaagaag
 30 901 ccacctcttt ggagggtgcg ctctctggca cgcgccactc ccacccatcc gtgggccgcc
 961 agcaccacgc gggcccccca tccacatgc gccaccacg tcctgggac acgccttgc
 1021 cccgggtgta cgcgagacc aagcacttcc ttactctc aggcgacaag gagcagctgc
 1081 ggccctcctt cctactcagc tctctagggc ccagcctgac tggcgctcgg aggcctgtgg
 1141 agaccatctt tctgggttcc aggccttga tgccaggac tccccgagg ttccccgcc
 35 1201 tgccccagcg ctactggcaa atggggccc tgtttctgga gctgcttggg aaccacgcgc
 1261 agtggcccta cggggtgctc ctcaagacgc actggccgct gcgagctgcg gtcacccag

5 1321 cagccgggtgt ctgtccccgg gagaagcccc agggctctgt ggcggccccc gagggaggagg
 1381 acacagaccc ccgtcgctg gtgcagctgc tccgccagca cagcagcccc tggcagggtgt
 1441 acggcttcgt gcgggcctgc ctgcgcgggc tgggtccccc aggcctctgg ggtccaggc
 1501 acaacgaacg ccgttcctc aggaacacca agaagttcat ctccctgggg aagcatgcca
 1561 agctctcgt gcaggagctg acgtggaaga tgagcgtgcg gggctgcgt tggctgcga
 10 1621 ggagcccagg ggttggtgt gtccggccg cagagcaccg tctgcgtgag gagatcctgg
 1681 ccaagttcct gactggctg atgagtgtgt acgtcgtcga gctgctcagg tctttcttt
 1741 atgtcacgga gaccacgttt caaaagaaca ggtcttttt ctaccggaag agtgtctgga
 1801 gcaagttgca aagcattgga atcagacagc acttgaagag ggtgcagctg cgggagctgt
 1861 cgggaagcaga ggtcaggcag catcggaag ccaggccgc cctgctgacg tccagactcc
 15 1921 gttcatccc caagcctgac gggctgcggc cgattgtgaa catggactac gtcgtgggag
 1981 ccagaacgtt ccgagagaa aagagggccg agcgtctac ctgaggggtg aaggcactgt
 2041 tcagcgtgt caactacgag cgggcgcggc gccccggcct cctgggcgc tctgtctgg
 2101 gcttgacga tatccacagg gcctggcgca cctcgtgt gctgtgcgg gccagggacc
 2161 cgcgcctga gctgtacttt gtcaaggtgg atgtgacggg cgcgtacgac accatcccc
 20 2221 aggacaggct caggagggtc atgccagca tcatcaaac ccagaacag tactgcgtgc
 2281 gtcgggtatgc cgtggtcag aaggccgcc atgggcacgt ccgaaggcc ttaagagcc
 2341 acgtctctac ctgacagac ctccagcgt acatgcgaca gtctgtggt cacctgcagg
 2401 agaccagccc gctgagggat gccgtcgtc tgagcagag ctctccctg aatgaggcca
 2461 gcagtggcct ctgcagtc ttctacgt tcatgtgcca ccacgccgtg cgcacaggg
 25 2521 gcaagtccta cgtccagtgc caggggatcc cgcagggtc catctctcc acgtctct
 2581 gcagcctgtg ctacggcgac atggagaaca agctgttgc ggggattcgg cgggacgggc
 2641 tgctctcgc tttggtggat gatttctgt tggtagacc tcacctacc cagcgaaaa
 2701 ccttctcag gacctggtc cgagggttc ctgagtatgg ctgcgtggtg aacttgcgga
 2761 agacagtgt gaacttcct gtagaagac aggcctggg tggcacggct tttgtcaga
 30 2821 tgccggccca cggcctatc cctggtgcg gcctgctgt ggataccgg acctggagg
 2881 tgcagagcga ctactccag tatgccgga ctccatcag agccagtct acctcaacc
 2941 gcggttcaa ggtgggagg aacatgcgt gcaaactct tgggtcttg cggctgaagt
 3001 gtcacagcct gttctggat ttgcaggta acagcctca gacggtgtg accaacatc
 3061 acaagatct cctgctgag gctacaggt ttacgcattg tgtgctgag ctccatttc
 35 3121 atcagcaagt ttggaagaac cccacattt tctgcgct catctctgac acggcctccc
 3181 tctgtactc catctgaaa gccagaacg cagggatgt gctgggggcc aagggcgccg

5 3241 cccgccctct gccctccgag gccgtgcagt ggctgtgcca ccaagcattc ctgetcaage
 3301 tgactegaca ccgtgtcacc tacgtgccac tcctggggtc actcaggaca gcccagacgc
 3361 agctgagtcg gaagctcccg gggacgacgc tgactgccct ggaggccgca gccaaacccg
 3421 cactgccctc agacttcaag accatcctgg actgatggcc acccgcccac agccaggccg
 3481 agagcagaca ccagcagccc tgtcacgccg ggctctacgt cccagggagg gaggggaggc
 10 3541 ccacaccag gcccgacccg ctgggagtct gaggcctgag tgagtgttg gccgaggcct
 3601 gcatgtccgg ctgaaggctg agtgtccggc tgaggcctga gcgagtgtcc agccaagggc
 3661 tgagtgtcca gcacacctgc cgtcttcaact tccccacagg ctggcgctcg gctccacccc
 3721 agggccagct ttctctacc aggagcccgg ctccactcc ccacatagga atagtccatc
 3781 cccagattcg ccattgttca cccctgccc tgccctcctt tgcctccac cccaccatc
 15 3841 cagggtggaga ccttgagaag gaccctggga gctctgggaa ttggagtga ccaaagggtg
 3901 gccctgtaca caggcgagga cctgcacct ggatgggggt cctgtgggt caaattgggg
 3961 ggaggtgctg tgggagtaaa atactgaata tatgagttt tcagtttga aaaaaaaaaa
 4021 aaaaaaa (SEQ ID NO: 285)

In an embodiment, the hTERT is encoded by a nucleic acid having a sequence at
 20 least 80%, 85%, 90%, 95%, 96, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:
 285. In an embodiment, the hTERT is encoded by a nucleic acid of SEQ ID NO: 285.

Activation and Expansion of T Cells

T cells may be activated and expanded generally using methods as described, for
 25 example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466;
 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874;
 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.

Generally, the T cells of the invention may be expanded by contact with a surface
 having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a
 30 ligand that stimulates a costimulatory molecule on the surface of the T cells. In particular, T
 cell populations may be stimulated as described herein, such as by contact with an anti-CD3
 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a
 surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a
 calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a
 35 ligand that binds the accessory molecule is used. For example, a population of T cells can be

5 contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody can be used. Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diacclone, Besançon, France) can be used as can other methods commonly known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, 10 1998; Haanen et al., J. Exp. Med. 190(9):1319-1328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999).

In certain aspects, the primary stimulatory signal and the costimulatory signal for the T cell may be provided by different protocols. For example, the agents providing each signal may be in solution or coupled to a surface. When coupled to a surface, the agents may be coupled to 15 the same surface (i.e., in "cis" formation) or to separate surfaces (i.e., in "trans" formation). Alternatively, one agent may be coupled to a surface and the other agent in solution. In one aspect, the agent providing the costimulatory signal is bound to a cell surface and the agent providing the primary activation signal is in solution or coupled to a surface. In certain aspects, both agents can be in solution. In one aspect, the agents may be in soluble form, and then cross- 20 linked to a surface, such as a cell expressing Fc receptors or an antibody or other binding agent which will bind to the agents. In this regard, see for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs) that are contemplated for use in activating and expanding T cells in the present invention.

In one aspect, the two agents are immobilized on beads, either on the same bead, i.e., 25 "cis," or to separate beads, i.e., "trans." By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the agent providing the costimulatory signal is an anti-CD28 antibody or antigen-binding fragment thereof; and both agents are co-immobilized to the same bead in equivalent molecular amounts. In one aspect, a 1:1 ratio of each antibody bound to the beads for CD4+ T cell expansion and T 30 cell growth is used. In certain aspects of the present invention, a ratio of anti CD3:CD28 antibodies bound to the beads is used such that an increase in T cell expansion is observed as compared to the expansion observed using a ratio of 1:1. In one particular aspect an increase of from about 1 to about 3 fold is observed as compared to the expansion observed using a ratio of 1:1. In one aspect, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 35 1:100 and all integer values there between. In one aspect of the present invention, more anti-

CD28 antibody is bound to the particles than anti-CD3 antibody, i.e., the ratio of CD3:CD28 is less than one. In certain aspects of the invention, the ratio of anti CD28 antibody to anti CD3 antibody bound to the beads is greater than 2:1. In one particular aspect, a 1:100 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a further aspect, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In one preferred aspect, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. In yet one aspect, a 3:1 CD3:CD28 ratio of antibody bound to the beads is used.

Ratios of particles to cells from 1:500 to 500:1 and any integer values in between may be used to stimulate T cells or other target cells. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells may depend on particle size relative to the target cell. For example, small sized beads could only bind a few cells, while larger beads could bind many. In certain aspects the ratio of cells to particles ranges from 1:100 to 100:1 and any integer values in-between and in further aspects the ratio comprises 1:9 to 9:1 and any integer values in between, can also be used to stimulate T cells. The ratio of anti-CD3- and anti-CD28-coupled particles to T cells that result in T cell stimulation can vary as noted above, however certain preferred values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1 with one preferred ratio being at least 1:1 particles per T cell. In one aspect, a ratio of particles to cells of 1:1 or less is used. In one particular aspect, a preferred particle: cell ratio is 1:5. In further aspects, the ratio of particles to cells can be varied depending on the day of stimulation. For example, in one aspect, the ratio of particles to cells is from 1:1 to 10:1 on the first day and additional particles are added to the cells every day or every other day thereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (based on cell counts on the day of addition). In one particular aspect, the ratio of particles to cells is 1:1 on the first day of stimulation and adjusted to 1:5 on the third and fifth days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:5 on the third and fifth days of stimulation. In one aspect, the ratio of particles to cells is 2:1 on the first day of stimulation and adjusted to 1:10 on the third and fifth days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:10 on the third and fifth days of

5 stimulation. One of skill in the art will appreciate that a variety of other ratios may be suitable for use in the present invention. In particular, ratios will vary depending on particle size and on cell size and type. In one aspect, the most typical ratios for use are in the neighborhood of 1:1, 2:1 and 3:1 on the first day.

10 In further aspects of the present invention, the cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative aspect, prior to culture, the agent-coated beads and cells are not separated but are cultured together. In a further aspect, the beads and cells are first concentrated by application of a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing cell stimulation.

15 By way of example, cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3x28 beads) to contact the T cells. In one aspect the cells (for example, 10^4 to 10^9 T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1) are combined in a buffer, for example PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill
20 in the art can readily appreciate any cell concentration may be used. For example, the target cell may be very rare in the sample and comprise only 0.01% of the sample or the entire sample (i.e., 100%) may comprise the target cell of interest. Accordingly, any cell number is within the context of the present invention. In certain aspects, it may be desirable to significantly decrease the volume in which particles and cells are mixed together (i.e., increase the concentration of
25 cells), to ensure maximum contact of cells and particles. For example, in one aspect, a concentration of about 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, 5 billion/ml, or 2 billion cells/ml is used. In one aspect, greater than 100 million cells/ml is used. In a further aspect, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100
30 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells. Such populations of cells may have therapeutic value and would be desirable to obtain in certain

5 aspects. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression.

In one embodiment, cells transduced with a nucleic acid encoding a CAR, e.g., a CAR described herein, are expanded, e.g., by a method described herein. In one embodiment, the cells are expanded in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 10 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days). In one embodiment, the cells are expanded for a period of 4 to 9 days. In one embodiment, the cells are expanded for a period of 8 days or less, e.g., 7, 6 or 5 days. In one embodiment, the cells, e.g., a BCMA CAR cell described herein, are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the 15 same culture conditions. Potency can be defined, e.g., by various T cell functions, e.g. proliferation, target cell killing, cytokine production, activation, migration, or combinations thereof. In one embodiment, the cells, e.g., a BCMA CAR cell described herein, expanded for 5 days show at least a one, two, three or four fold increase in cells doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture 20 conditions. In one embodiment, the cells, e.g., the cells expressing a BCMA CAR described herein, are expanded in culture for 5 days, and the resulting cells exhibit higher proinflammatory cytokine production, e.g., IFN- γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, the cells, e.g., a BCMA CAR cell described herein, expanded for 5 days show at 25 least a one, two, three, four, five, ten fold or more increase in pg/ml of proinflammatory cytokine production, e.g., IFN- γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions.

In one aspect of the present invention, the mixture may be cultured for several hours (about 3 hours) to about 14 days or any hourly integer value in between. In one aspect, the 30 mixture may be cultured for 21 days. In one aspect of the invention the beads and the T cells are cultured together for about eight days. In one aspect, the beads and T cells are cultured together for 2-3 days. Several cycles of stimulation may also be desired such that culture time of T cells can be 60 days or more. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) 35 that may contain factors necessary for proliferation and viability, including serum (e.g., fetal

- 5 bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGF β , and TNF- α or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM, α -MEM, F-12, X-Vivo 15, and X-Vivo 20,
- 10 Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions
- 15 necessary to support growth, for example, an appropriate temperature (e.g., 37° C) and atmosphere (e.g., air plus 5% CO₂).

In one embodiment, the cells are expanded in an appropriate media (e.g., media described herein) that includes one or more interleukin that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14 day expansion period, e.g., as

20 measured by a method described herein such as flow cytometry. In one embodiment, the cells are expanded in the presence of IL-15 and/or IL-7 (e.g., IL-15 and IL-7).

In embodiments, methods described herein, e.g., CAR-expressing cell manufacturing methods, comprise removing T regulatory cells, e.g., CD25+ T cells, from a cell population, e.g., using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, IL-2.

25 Methods of removing T regulatory cells, e.g., CD25+ T cells, from a cell population are described herein. In embodiments, the methods, e.g., manufacturing methods, further comprise contacting a cell population (e.g., a cell population in which T regulatory cells, such as CD25+ T cells, have been depleted; or a cell population that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) with IL-15 and/or IL-7. For example, the

30 cell population (e.g., that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) is expanded in the presence of IL-15 and/or IL-7.

In some embodiments a CAR-expressing cell described herein is contacted with a composition comprising a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra

35 polypeptide e.g., hetIL-15, during the manufacturing of the CAR-expressing cell, e.g., ex vivo.

5 In embodiments, a CAR-expressing cell described herein is contacted with a composition comprising a IL-15 polypeptide during the manufacturing of the CAR-expressing cell, e.g., ex vivo. In embodiments, a CAR-expressing cell described herein is contacted with a composition comprising a combination of both a IL-15 polypeptide and a IL-15 Ra polypeptide during the manufacturing of the CAR-expressing cell, e.g., ex vivo. In embodiments, a CAR-expressing
10 cell described herein is contacted with a composition comprising hetIL-15 during the manufacturing of the CAR-expressing cell, e.g., ex vivo.

In one embodiment the CAR-expressing cell described herein is contacted with a composition comprising hetIL-15 during ex vivo expansion. In an embodiment, the CAR-expressing cell described herein is contacted with a composition comprising an IL-15
15 polypeptide during ex vivo expansion. In an embodiment, the CAR-expressing cell described herein is contacted with a composition comprising both an IL-15 polypeptide and an IL-15Ra polypeptide during ex vivo expansion. In one embodiment the contacting results in the survival and proliferation of a lymphocyte subpopulation, e.g., CD8+ T cells.

T cells that have been exposed to varied stimulation times may exhibit different
20 characteristics. For example, typical blood or apheresed peripheral blood mononuclear cell products have a helper T cell population (TH, CD4+) that is greater than the cytotoxic or suppressor T cell population (TC, CD8+). Ex vivo expansion of T cells by stimulating CD3 and CD28 receptors produces a population of T cells that prior to about days 8-9 consists predominately of TH cells, while after about days 8-9, the population of T cells comprises an
25 increasingly greater population of TC cells. Accordingly, depending on the purpose of treatment, infusing a subject with a T cell population comprising predominately of TH cells may be advantageous. Similarly, if an antigen-specific subset of TC cells has been isolated it may be beneficial to expand this subset to a greater degree.

Further, in addition to CD4 and CD8 markers, other phenotypic markers vary
30 significantly, but in large part, reproducibly during the course of the cell expansion process. Thus, such reproducibility enables the ability to tailor an activated T cell product for specific purposes.

Once a BCMA CAR is constructed, various assays can be used to evaluate the activity of the molecule, such as but not limited to, the ability to expand T cells following antigen

5 stimulation, sustain T cell expansion in the absence of re-stimulation, and anti-cancer activities in appropriate in vitro and animal models. Assays to evaluate the effects of a BCMA CAR are described in further detail below

Western blot analysis of CAR expression in primary T cells can be used to detect the presence of monomers and dimers. See, *e.g.*, Milone *et al.*, Molecular Therapy 17(8): 1453-1464 (2009). Very briefly, T cells (1:1 mixture of CD4⁺ and CD8⁺ T cells) expressing the CARs are expanded *in vitro* for more than 10 days followed by lysis and SDS-PAGE under reducing conditions. CARs containing the full length TCR- ζ cytoplasmic domain and the endogenous TCR- ζ chain are detected by western blotting using an antibody to the TCR- ζ chain. The same T cell subsets are used for SDS-PAGE analysis under non-reducing conditions to permit evaluation of covalent dimer formation.

In vitro expansion of CAR⁺ T cells following antigen stimulation can be measured by flow cytometry. For example, a mixture of CD4⁺ and CD8⁺ T cells are stimulated with α CD3/ α CD28 aAPCs followed by transduction with lentiviral vectors expressing GFP under the control of the promoters to be analyzed. Exemplary promoters include the CMV IE gene, EF-1 α , ubiquitin C, or phosphoglycerokinase (PGK) promoters. GFP fluorescence is evaluated on day 6 of culture in the CD4⁺ and/or CD8⁺ T cell subsets by flow cytometry. See, *e.g.*, Milone *et al.*, Molecular Therapy 17(8): 1453-1464 (2009). Alternatively, a mixture of CD4⁺ and CD8⁺ T cells are stimulated with α CD3/ α CD28 coated magnetic beads on day 0, and transduced with CAR on day 1 using a bicistronic lentiviral vector expressing CAR along with eGFP using a 2A ribosomal skipping sequence. Cultures are re-stimulated with BCMA-expressing cells, such as multiple myeloma cell lines or K562-BCMA, following washing. Exogenous IL-2 is added to the cultures every other day at 100 IU/ml. GFP⁺ T cells are enumerated by flow cytometry using bead-based counting. See, *e.g.*, Milone *et al.*, Molecular Therapy 17(8): 1453-1464 (2009).

30 Sustained CAR⁺ T cell expansion in the absence of re-stimulation can also be measured. See, *e.g.*, Milone *et al.*, Molecular Therapy 17(8): 1453-1464 (2009). Briefly, mean T cell volume (fl) is measured on day 8 of culture using a Coulter Multisizer III particle counter, a Nexcelom Cellometer Vision or Millipore Scepter, following stimulation with α CD3/ α CD28 coated magnetic beads on day 0, and transduction with the indicated CAR on day 1.

5 Animal models can also be used to measure a CART activity. For example, xenograft model using human BCMA-specific CAR⁺ T cells to treat a primary human multiple myeloma in immunodeficient mice can be used. See, *e.g.*, Milone *et al.*, *Molecular Therapy* 17(8): 1453-1464 (2009). Very briefly, after establishment of MM, mice are randomized as to treatment groups. Different numbers of BCMA CART cells can be injected into immunodeficient mice
10 bearing MM. Animals are assessed for disease progression and tumor burden at weekly intervals. Survival curves for the groups are compared using the log-rank test. In addition, absolute peripheral blood CD4⁺ and CD8⁺ T cell counts 4 weeks following T cell injection in the immunodeficient mice can also be analyzed. Mice are injected with multiple myeloma cells and 3 weeks later are injected with T cells engineered to express BCMA CAR, *e.g.*, by a
15 bicistronic lentiviral vector that encodes the CAR linked to eGFP. T cells are normalized to 45–50% input GFP⁺ T cells by mixing with mock-transduced cells prior to injection, and confirmed by flow cytometry. Animals are assessed for leukemia at 1-week intervals. Survival curves for the CAR⁺ T cell groups are compared using the log-rank test.

 Assessment of cell proliferation and cytokine production has been previously described, *e.g.*, at Milone *et al.*, *Molecular Therapy* 17(8): 1453-1464 (2009). Briefly, assessment of
20 CAR-mediated proliferation is performed in microtiter plates by mixing washed T cells with K562 cells expressing BCMA or other BCMA-expressing myeloma cells are irradiated with gamma-radiation prior to use. Anti-CD3 (clone OKT3) and anti- CD28 (clone 9.3) monoclonal antibodies are added to cultures with KT32-BBL cells to serve as a positive control for
25 stimulating T-cell proliferation since these signals support long-term CD8⁺ T cell expansion *ex vivo*. T cells are enumerated in cultures using CountBright™ fluorescent beads (Invitrogen, Carlsbad, CA) and flow cytometry as described by the manufacturer. CAR⁺ T cells are identified by GFP expression using T cells that are engineered with eGFP-2A linked CAR-expressing lentiviral vectors. For CAR⁺ T cells not expressing GFP, the CAR⁺ T cells are
30 detected with biotinylated recombinant BCMA protein and a secondary avidin-PE conjugate. CD4⁺ and CD8⁺ expression on T cells are also simultaneously detected with specific monoclonal antibodies (BD Biosciences). Cytokine measurements are performed on supernatants collected 24 hours following re-stimulation using the human TH1/TH2 cytokine cytometric bead array kit (BD Biosciences, San Diego, CA) according the manufacturer's

5 instructions. Fluorescence is assessed using a FACScalibur flow cytometer, and data is analyzed according to the manufacturer's instructions.

Cytotoxicity can be assessed by a standard ⁵¹Cr-release assay. See, e.g., Milone *et al.*, Molecular Therapy 17(8): 1453-1464 (2009). Briefly, target cells (e.g., K562 lines expressing BCMA and primary multiple myeloma cells) are loaded with ⁵¹Cr (as NaCrO₄, New England
10 Nuclear, Boston, MA) at 37°C for 2 hours with frequent agitation, washed twice in complete RPMI and plated into microtiter plates. Effector T cells are mixed with target cells in the wells in complete RPMI at varying ratios of effector cell:target cell (E:T). Additional wells containing media only (spontaneous release, SR) or a 1% solution of triton-X 100 detergent (total release, TR) are also prepared. After 4 hours of incubation at 37°C, supernatant from each
15 well is harvested. Released ⁵¹Cr is then measured using a gamma particle counter (Packard Instrument Co., Waltham, MA). Each condition is performed in at least triplicate, and the percentage of lysis is calculated using the formula: % Lysis = (ER – SR) / (TR – SR), where ER represents the average ⁵¹Cr released for each experimental condition.

Imaging technologies can be used to evaluate specific trafficking and proliferation of
20 CARs in tumor-bearing animal models. Such assays have been described, for example, in Barrett *et al.*, Human Gene Therapy 22:1575-1586 (2011). Briefly, NOD/SCID/ $\gamma c^{-/-}$ (NSG) mice or other immunodeficient are injected IV with multiple myeloma cells followed 7 days later with BCMA CART cells 4 hour after electroporation with the CAR constructs. The T cells are stably transfected with a lentiviral construct to express firefly luciferase, and mice are
25 imaged for bioluminescence. Alternatively, therapeutic efficacy and specificity of a single injection of CAR⁺ T cells in a multiple myeloma xenograft model can be measured as the following: NSG mice are injected with multiple myeloma cells transduced to stably express firefly luciferase, followed by a single tail-vein injection of T cells electroporated with BCMA CAR construct days later. Animals are imaged at various time points post injection. For
30 example, photon-density heat maps of firefly luciferasepositive tumors in representative mice at day 5 (2 days before treatment) and day 8 (24 hr post CAR⁺ PBLs) can be generated.

Alternatively, or in combination to the methods disclosed herein, methods and compositions for one or more of: detection and/or quantification of CAR-expressing cells (e.g.,
in vitro or *in vivo* (e.g., clinical monitoring)); immune cell expansion and/or activation; and/or
35 CAR-specific selection, that involve the use of a CAR ligand, are disclosed. In one exemplary

5 embodiment, the CAR ligand is an antibody that binds to the CAR molecule, e.g., binds to the extracellular antigen binding domain of CAR (e.g., an antibody that binds to the antigen binding domain, e.g., an anti-idiotypic antibody; or an antibody that binds to a constant region of the extracellular binding domain). In other embodiments, the CAR ligand is a CAR antigen molecule (e.g., a CAR antigen molecule as described herein).

10 In one aspect, a method for detecting and/or quantifying CAR-expressing cells is disclosed. For example, the CAR ligand can be used to detect and/or quantify CAR-expressing cells *in vitro* or *in vivo* (e.g., clinical monitoring of CAR-expressing cells in a patient, or dosing a patient). The method includes:

15 providing the CAR ligand (optionally, a labelled CAR ligand, e.g., a CAR ligand that includes a tag, a bead, a radioactive or fluorescent label);

 acquiring the CAR-expressing cell (e.g., acquiring a sample containing CAR-expressing cells, such as a manufacturing sample or a clinical sample);

 contacting the CAR-expressing cell with the CAR ligand under conditions where binding occurs, thereby detecting the level (e.g., amount) of the CAR-expressing cells present.

20 Binding of the CAR-expressing cell with the CAR ligand can be detected using standard techniques such as FACS, ELISA and the like.

 In another aspect, a method of expanding and/or activating cells (e.g., immune effector cells) is disclosed. The method includes:

25 providing a CAR-expressing cell (e.g., a first CAR-expressing cell or a transiently expressing CAR cell);

 contacting said CAR-expressing cell with a CAR ligand, e.g., a CAR ligand as described herein), under conditions where immune cell expansion and/or proliferation occurs, thereby producing the activated and/or expanded cell population.

30 In certain embodiments, the CAR ligand is present on (e.g., is immobilized or attached to a substrate, e.g., a non-naturally occurring substrate). In some embodiments, the substrate is a non-cellular substrate. The non-cellular substrate can be a solid support chosen from, e.g., a plate (e.g., a microtiter plate), a membrane (e.g., a nitrocellulose membrane), a

5 matrix, a chip or a bead. In embodiments, the CAR ligand is present in the substrate (e.g., on the substrate surface). The CAR ligand can be immobilized, attached, or associated covalently or non-covalently (e.g., cross-linked) to the substrate. In one embodiment, the CAR ligand is attached (e.g., covalently attached) to a bead. In the aforesaid embodiments, the immune cell population can be expanded *in vitro* or *ex vivo*. The method can further include culturing the
10 population of immune cells in the presence of the ligand of the CAR molecule, e.g., using any of the methods described herein.

In other embodiments, the method of expanding and/or activating the cells further comprises addition of a second stimulatory molecule, e.g., CD28. For example, the CAR ligand and the second stimulatory molecule can be immobilized to a substrate, e.g., one or more
15 beads, thereby providing increased cell expansion and/or activation.

In yet another aspect, a method for selecting or enriching for a CAR expressing cell is provided. The method includes contacting the CAR expressing cell with a CAR ligand as described herein; and selecting the cell on the basis of binding of the CAR ligand.

In yet other embodiments, a method for depleting, reducing and/or killing a CAR
20 expressing cell is provided. The method includes contacting the CAR expressing cell with a CAR ligand as described herein; and targeting the cell on the basis of binding of the CAR ligand, thereby reducing the number, and/or killing, the CAR-expressing cell. In one embodiment, the CAR ligand is coupled to a toxic agent (e.g., a toxin or a cell ablative drug). In another embodiment, the anti-idiotypic antibody can cause effector cell activity, e.g.,
25 ADCC or ADC activities.

Exemplary anti-CAR antibodies that can be used in the methods disclosed herein are described, e.g., in WO 2014/190273 and by Jena et al., "Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T cells in Clinical Trials", PLOS
March 2013 8:3 e57838, the contents of which are incorporated by reference. In one
30 embodiment, the anti-idiotypic antibody molecule recognizes an anti-CD19 antibody molecule, e.g., an anti-CD19 scFv. For instance, the anti-idiotypic antibody molecule can compete for binding with the CD19-specific CAR mAb clone no. 136.20.1 described in Jena et al., PLOS March 2013 8:3 e57838; may have the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3, using the Kabat

5 definition, the Chothia definition, or a combination of the Kabat and Chothia definitions) as the CD19-specific CAR mAb clone no. 136.20.1; may have one or more (e.g., 2) variable regions as the CD19-specific CAR mAb clone no. 136.20.1, or may comprise the CD19-specific CAR mAb clone no. 136.20.1. In some embodiments, the anti-idiotypic antibody was made according to a method described in Jena et al. In another embodiment, the anti-idiotypic antibody molecule is an anti-idiotypic antibody molecule described in WO 10 2014/190273. In some embodiments, the anti-idiotypic antibody molecule has the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3) as an antibody molecule of WO 2014/190273 such as 136.20.1; may have one or more (e.g., 2) variable regions of an antibody molecule of WO 2014/190273, or 15 may comprise an antibody molecule of WO 2014/190273 such as 136.20.1. In other embodiments, the anti-CAR antibody binds to a constant region of the extracellular binding domain of the CAR molecule, e.g., as described in WO 2014/190273. In some embodiments, the anti-CAR antibody binds to a constant region of the extracellular binding domain of the CAR molecule, e.g., a heavy chain constant region (e.g., a CH2-CH3 hinge region) or light chain constant region. For instance, in some embodiments the anti-CAR antibody competes for binding with the 2D3 monoclonal antibody described in WO 2014/190273, has the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3) as 2D3, or has one or more (e.g., 2) variable regions of 2D3, or 20 comprises 2D3 as described in WO 2014/190273.

25 In some aspects and embodiments, the compositions and methods herein are optimized for a specific subset of T cells, e.g., as described in US Serial No. 62/031,699 filed July 31, 2014, the contents of which are incorporated herein by reference in their entirety. In some embodiments, the optimized subsets of T cells display an enhanced persistence compared to a control T cell, e.g., a T cell of a different type (e.g., CD8⁺ or CD4⁺) expressing the same construct.

In some embodiments, a CD4⁺ T cell comprises a CAR described herein, which CAR comprises an intracellular signaling domain suitable for (e.g., optimized for, e.g., leading to enhanced persistence in) a CD4⁺ T cell, e.g., an ICOS domain. In some embodiments, a CD8⁺ T cell comprises a CAR described herein, which CAR comprises an intracellular 35

5 signaling domain suitable for (e.g., optimized for, e.g., leading to enhanced persistence of) a CD8⁺ T cell, e.g., a 4-1BB domain, a CD28 domain, or another costimulatory domain other than an ICOS domain. In some embodiments, the CAR described herein comprises an antigen binding domain described herein, e.g., a CAR comprising an antigen binding domain that targets BCMA, e.g., a CAR of Table 1 or 16).

10 In an aspect, described herein is a method of treating a subject, e.g., a subject having cancer. The method includes administering to said subject, an effective amount of:

1) a CD4⁺ T cell comprising a CAR (the CAR^{CD4+}) comprising:

15 an antigen binding domain, e.g., an antigen binding domain described herein, e.g., an antigen binding domain that targets BCMA, e.g., an antigen-binding domain of Table 1 or 16; a transmembrane domain; and an intracellular signaling domain, e.g., a first costimulatory domain, e.g., an ICOS domain; and

2) a CD8⁺ T cell comprising a CAR (the CAR^{CD8+}) comprising:

20 an antigen binding domain, e.g., an antigen binding domain described herein, e.g., an antigen binding domain that targets BCMA, e.g., an antigen-binding domain of Table 1 or 16; a transmembrane domain; and an intracellular signaling domain, e.g., a second costimulatory domain, e.g., a 4-1BB domain, a CD28 domain, or another costimulatory domain other than an ICOS domain;

25 wherein the CAR^{CD4+} and the CAR^{CD8+} differ from one another.

Optionally, the method further includes administering:

3) a second CD8⁺ T cell comprising a CAR (the second CAR^{CD8+}) comprising:

30 an antigen binding domain, e.g., an antigen binding domain described herein, e.g., an antigen binding domain that specifically binds BCMA, e.g., an antigen-binding domain of Table 1 or 16;

a transmembrane domain; and

an intracellular signaling domain, wherein the second CAR^{CD8+} comprises an intracellular signaling domain, e.g., a costimulatory signaling domain, not present on the CAR^{CD8+}, and, optionally, does not comprise an ICOS signaling domain.

5 Other assays, including those described in the Example section herein as well as those that are known in the art can also be used to evaluate the BCMA CAR constructs of the invention.

Therapeutic Application

10 *BCMA Associated Diseases and/or Disorders*

 In one aspect, the invention provides methods for treating a disease associated with BCMA expression. In one aspect, the invention provides methods for treating a disease wherein part of the tumor is negative for BCMA and part of the tumor is positive for BCMA. For example, the CAR of the invention is useful for treating subjects that have undergone treatment
15 for a disease associated with elevated expression of BCMA, wherein the subject that has undergone treatment for elevated levels of BCMA exhibits a disease associated with elevated levels of BCMA. In embodiments, the CAR of the invention is useful for treating subjects that have undergone treatment for a disease associated with expression of BCMA, wherein the subject that has undergone treatment related to expression of BCMA exhibits a disease
20 associated with expression of BCMA.

 In one embodiment, the invention provides methods for treating a disease wherein BCMA is expressed on both normal cells and cancer cells, but is expressed at lower levels on normal cells. In one embodiment, the method further comprises selecting a CAR that binds of the invention with an affinity that allows the BCMA CAR to bind and kill the cancer cells
25 expressing BCMA but less than 30%, 25%, 20%, 15%, 10%, 5% or less of the normal cells expressing BCMA are killed, e.g., as determined by an assay described herein. For example, a killing assay such as flow cytometry based on Cr51 CTL can be used. In one embodiment, the BCMA CAR has an antigen binding domain that has a binding affinity K_D of 10^{-4} M to 10^{-8} M, e.g., 10^{-5} M to 10^{-7} M, e.g., 10^{-6} M or 10^{-7} M, for the target antigen. In one embodiment, the
30 BCMA antigen binding domain has a binding affinity that is at least five-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold or 1,000-fold less than a reference antibody, e.g., an antibody described herein.

 In one aspect, the invention pertains to a vector comprising BCMA CAR operably linked to promoter for expression in mammalian immune effector cells, e.g., T cells or NK

5 cells. In one aspect, the invention provides a recombinant immune effector cell, e.g., T cell or NK cell, expressing the BCMA CAR for use in treating BCMA-expressing tumors, wherein the recombinant immune effector cell (e.g., T cell or NK cell) expressing the BCMA CAR is termed a BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell). In one aspect, the BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) of the invention is capable of contacting a tumor cell with at least one BCMA CAR of the invention expressed on its surface such that the BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) targets the tumor cell and growth of the tumor is inhibited.

15 In one aspect, the invention pertains to a method of inhibiting growth of a BCMA-expressing tumor cell, comprising contacting the tumor cell with a BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) of the present invention such that the BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) is activated in response to the antigen and targets the cancer cell, wherein the growth of the tumor is inhibited.

20 In one aspect, the invention pertains to a method of treating cancer in a subject. The method comprises administering to the subject a BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) of the present invention such that the cancer is treated in the subject. An example of a cancer that is treatable by the BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) of the invention is a cancer associated with expression of BCMA.

The invention includes a type of cellular therapy where immune effector cells (e.g., T cells or NK cells) are genetically modified to express a chimeric antigen receptor (CAR) and the BCMA CAR-expressing cell (e.g., BCMA CART or BCMA CAR-expressing NK cell) is infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. Unlike antibody therapies, CAR-modified cells, e.g., T cells or NK cells, are able to replicate in vivo resulting in long-term persistence that can lead to sustained tumor control. In various aspects, the cells (e.g., T cells or NK cells) administered to the patient, or their progeny, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty

5 months, twenty-one months, twenty-two months, twenty-three months, two years, three years, four years, or five years after administration of the cell (e.g., T cell or NK cell) to the patient.

The invention also includes a type of cellular therapy where immune effector cells (e.g., T cells or NK cells) are modified, e.g., by in vitro transcribed RNA, to transiently express a chimeric antigen receptor (CAR) and the immune effector cell (e.g., T cell or NK cell) is
10 infused to a recipient in need thereof. The infused cell is able to kill tumor cells in the recipient. Thus, in various aspects, the immune effector cells (e.g., T cells or NK cells) administered to the patient, is present for less than one month, e.g., three weeks, two weeks, one week, after administration of the immune effector cell (e.g., T cell or NK cell) to the patient.

Without wishing to be bound by any particular theory, the anti-tumor immunity
15 response elicited by the CAR-modified immune effector cells (e.g., T cells or NK cells) may be an active or a passive immune response, or alternatively may be due to a direct vs indirect immune response. In one aspect, the CAR transduced immune effector cells (e.g., T cells or NK cells) exhibit specific proinflammatory cytokine secretion and potent cytolytic activity in response to human cancer cells expressing the BCMA, resist soluble BCMA inhibition, mediate
20 bystander killing and mediate regression of an established human tumor. For example, antigen-less tumor cells within a heterogeneous field of BCMA-expressing tumor may be susceptible to indirect destruction by BCMA-redirected immune effector cells (e.g., T cells or NK cells) that has previously reacted against adjacent antigen-positive cancer cells.

In one aspect, the fully-human CAR-modified immune effector cells (e.g., T cells or
25 NK cells) of the invention may be a type of vaccine for ex vivo immunization and/or in vivo therapy in a mammal. In one aspect, the mammal is a human.

With respect to ex vivo immunization, at least one of the following occurs in vitro prior to administering the cell into a mammal: i) expansion of the cells, ii) introducing a nucleic acid encoding a CAR to the cells or iii) cryopreservation of the cells.

30 Ex vivo procedures are well known in the art and are discussed more fully below. Briefly, cells are isolated from a mammal (e.g., a human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing a CAR disclosed herein. The CAR-modified cell can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian recipient may be a human and the CAR-modified cell can be autologous with

5 respect to the recipient. Alternatively, the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient.

The procedure for ex vivo expansion of hematopoietic stem and progenitor cells is described in U.S. Pat. No. 5,199,942, incorporated herein by reference, can be applied to the cells of the present invention. Other suitable methods are known in the art, therefore the present
10 invention is not limited to any particular method of ex vivo expansion of the cells. Briefly, ex vivo culture and expansion of T cells comprises: (1) collecting CD34+ hematopoietic stem and progenitor cells from a mammal from peripheral blood harvest or bone marrow explants; and (2) expanding such cells ex vivo. In addition to the cellular growth factors described in U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 and c-kit ligand, can be used for
15 culturing and expansion of the cells.

In addition to using a cell-based vaccine in terms of ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient.

Generally, the cells activated and expanded as described herein may be utilized in the
20 treatment and prevention of diseases that arise in individuals who are immunocompromised. In particular, the CAR-modified immune effector cells (e.g., T cells or NK cells) of the invention are used in the treatment of diseases, disorders and conditions associated with expression of BCMA. In certain aspects, the cells of the invention are used in the treatment of patients at risk for developing diseases, disorders and conditions associated with expression of BCMA. Thus,
25 the present invention provides methods for the treatment or prevention of diseases, disorders and conditions associated with expression of BCMA comprising administering to a subject in need thereof, a therapeutically effective amount of the CAR-modified immune effector cells (e.g., T cells or NK cells) of the invention.

In one aspect the CAR-expressing cells (e.g., CART cells or CAR-expressing NK cells)
30 of the inventions may be used to treat a proliferative disease such as a cancer or malignancy or is a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia. In one aspect, the cancer is a hematological cancer. Hematological cancer conditions are the types of cancer such as leukemia and malignant lymphoproliferative conditions that affect blood, bone marrow and the lymphatic system. In one aspect, the

5 hematological cancer is a leukemia or a hematological. An example of a disease or disorder associated with BCMA is multiple myeloma (also known as MM) (See Claudio et al., *Blood*. 2002, 100(6):2175-86; and Novak et al., *Blood*. 2004, 103(2):689-94). Multiple myeloma, also known as plasma cell myeloma or Kahler's disease, is a cancer characterized by an accumulation of abnormal or malignant plasma B-cells in the bone marrow. Frequently, the cancer cells invade adjacent bone, destroying skeletal structures and resulting in bone pain and fractures. Most cases of myeloma also features the production of a paraprotein (also known as M proteins or myeloma proteins), which is an abnormal immunoglobulin produced in excess by the clonal proliferation of the malignant plasma cells. Blood serum paraprotein levels of more than 30g/L is diagnostic of multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group (IMWG) (See Kyle et al. (2009), *Leukemia*. 23:3-9). Other symptoms or signs of multiple myeloma include reduced kidney function or renal failure, bone lesions, anemia, hypercalcemia, and neurological symptoms.

Criteria for distinguishing multiple myeloma from other plasma cell proliferative disorders have been established by the International Myeloma Working Group (See Kyle et al. (2009), *Leukemia*. 23:3-9). All three of the following criteria must be met:

- Clonal bone marrow plasma cells $\geq 10\%$
- Present of serum and/or urinary monoclonal protein (except in patients with true non-secretory multiple myeloma)
- Evidence of end-organ damage attributable to the underlying plasma cell proliferative disorder, specifically:
 - o Hypercalcemia: serum calcium ≥ 11.5 mg/100 ml
 - o Renal insufficiency: serum creatinine > 1.73 mmol/l
 - o Anemia: normochromic, normocytic with a hemoglobin value of > 2 g/100 ml below the lower limit of normal, or a hemoglobin value < 10 g/100ml
 - o Bone lesions: lytic lesions, severe osteopenia, or pathologic fractures.

Other plasma cell proliferative disorders that can be treated by the compositions and methods described herein include, but are not limited to, asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell

- 5 dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome).

Two staging systems are used in the staging of multiple myeloma: the International Staging System (ISS) (*See Greipp et al. (2005), J. Clin. Oncol. 23 (15):3412-3420*) and the
 10 Durie-Salmon Staging system (DSS) (*See Durie et al. (1975), Cancer 36 (3): 842-854*). The two staging systems are summarized in the table below:

Table 18

Stage	International Staging System		Durie-Salmon Staging System	
	Criteria	Median survival	Criteria	Median survival*
I	$\beta_2M < 3.5$ mg/l and serum albumin ≥ 3.5 g/dL	62 months	All of the following: Hemoglobin level > 10 g/dL Serum calcium, normal or < 12 mg/dL Bone x-ray, normal or 1 plasmacytoma only Low monoclonal protein production (IgG < 5 g/dL, IgA < 3 g/dL, Bence Jones protein < 4 g/dL per 24 hours)	IA: 62 months IB: 22 months
II	Neither stage I or stage III	44 months	Neither stage I or stage III	IIA: 58 months IIB: 354 months
III	$\beta_2M \geq 5.5$ mg/l	29 months	One or more of the following: Hemoglobin level < 8.5 g/dL Serum calcium, normal or > 12 mg/dL Advanced osteolytic lesions High monoclonal protein production (IgG > 7 g/dL,	IIIA: 45 months IIIB: 24 months

			IgA>5g/dL, Bence Jones protein >12g/dL per 24 hours	
--	--	--	--	--

- 5 *The Durie-Salmon Staging system also includes a subclassification that designates the status of renal function. The designation of “A” or “B” is added after the stage number, wherein “A” indicates relatively normal renal function (serum creatinine value <2.0 mg/dL), and B indicates abnormal renal function (serum creatinine value >2.0 mg/dL).

Standard treatment for multiple myeloma and associated diseases includes

10 chemotherapy, stem cell transplant (autologous or allogeneic), radiation therapy, and other drug therapies. Frequently used anti-myeloma drugs include alkylating agents (e.g., bendamustine, cyclophosphamide and melphalan), proteasome inhibitors (e.g., bortezomib), corticosteroids (e.g., dexamethasone and prednisone), and immunomodulators (e.g., thalidomide and lenalidomide or Revlimid®), or any combination thereof. Biphosphonate drugs are also

15 frequently administered in combination with the standard anti-MM treatments to prevent bone loss. Patients older than 65-70 years of age are unlikely candidates for stem cell transplant. In some cases, double-autologous stem cell transplants are options for patients less than 60 years of age with suboptimal response to the first transplant. The compositions and methods of the present invention may be administered in combination with any of the currently prescribed

20 treatments for multiple myeloma.

Another example of a disease or disorder associated with BCMA is Hodgkin's lymphoma and non-Hodgkin's lymphoma (*See Chiu et al., Blood.* 2007, 109(2):729-39; He et al., *J Immunol.* 2004, 172(5):3268-79).

Hodgkin's lymphoma (HL), also known as Hodgkin's disease, is a cancer of the

25 lymphatic system that originates from white blood cells, or lymphocytes. The abnormal cells that comprise the lymphoma are called Reed-Sternberg cells. In Hodgkin's lymphoma, the cancer spreads from one lymph node group to another. Hodgkin's lymphoma can be subclassified into four pathologic subtypes based upon Reed-Sternberg cell morphology and the cell composition around the Reed-Sternberg cells (as determined through lymph node

30 biopsy): nodular sclerosing HL, mixed-cellularity subtype, lymphocyte-rich or lymphocytic predominance, lymphocyte depleted. Some Hodgkin's lymphoma can also be nodular lymphocyte predominant Hodgkin's lymphoma, or can be unspecified. Symptoms and signs of

- 5 Hodgkin's lymphoma include painless swelling in the lymph nodes in the neck, armpits, or groin, fever, night sweats, weight loss, fatigue, itching, or abdominal pain.

Non-Hodgkin's lymphoma (NHL) comprises a diverse group of blood cancers that include any kind of lymphoma other than Hodgkin's lymphoma. Subtypes of non-Hodgkin's lymphoma are classified primarily by cell morphology, chromosomal aberrations, and surface
 10 markers. NHL subtypes (or NHL-associated cancers) include B cell lymphomas such as, but not limited to, Burkitt's lymphoma, B-cell chronic lymphocytic leukemia (B-CLL), B-cell prolymphocytic leukemia (B-PLL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) (e.g., intravascular large B-cell lymphoma and primary mediastinal B-cell lymphoma), follicular lymphoma (e.g., follicle center lymphoma, follicular small cleaved cell),
 15 hair cell leukemia, high grade B-cell lymphoma (Burkitt's like), lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia), mantle cell lymphoma, marginal zone B-cell lymphomas (e.g., extranodal marginal zone B-cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, and splenic marginal zone B-cell lymphoma), plasmacytoma/myeloma, precursor B-lymphoblastic leukemia/lymphoma (PB-
 20 LBL/L), primary central nervous system (CNS) lymphoma, primary intraocular lymphoma, small lymphocytic lymphoma (SLL); and T cell lymphomas, such as, but not limited to, anaplastic large cell lymphoma (ALCL), adult T-cell lymphoma/leukemia (e.g., smoldering, chronic, acute and lymphomatous), angiocentric lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphomas (e.g., mycosis fungoides, Sezary syndrome, etc.),
 25 extranodal natural killer/T-cell lymphoma (nasal-type), enteropathy type intestinal T-cell lymphoma, large granular lymphocyte leukemia, precursor T-lymphoblastic lymphoma/leukemia (T-LBL/L), T-cell chronic lymphocytic leukemia/prolymphocytic leukemia (T-CLL/PLL), and unspecified peripheral T-cell lymphoma. Symptoms and signs of Hodgkin's lymphoma include painless swelling in the lymph nodes in the neck, armpits, or
 30 groin, fever, night sweats, weight loss, fatigue, itching, abdominal pain, coughing, or chest pain.

The staging is the same for both Hodgkin's and non-Hodgkin's lymphoma, and refers to the extent of spread of the cancer cells within the body. In stage I, the lymphoma cells are in one lymph node group. In stage II, lymphoma cells are present in at least two lymph node
 35 groups, but both groups are on the same side of the diaphragm, or in one part of a tissue or

5 organ and the lymph nodes near that organ on the same side of the diaphragm. In stage III, lymphoma cells are in lymph nodes on both sides of the diaphragm, or in one part of a tissue or organ near these lymph node groups or in the spleen. In stage IV, lymphoma cells are found in several parts of at least one organ or tissue, or lymphoma cells are in an organ and in lymph nodes on the other side of the diaphragm. In addition to the Roman numeral staging
10 designation, the stages of can also be described by letters A, B, E, and S, wherein A refers to patients without symptoms, B refers to patients with symptoms, E refers to patients in which lymphoma is found in tissues outside the lymph system, and S refers to patients in which lymphoma is found in the spleen.

Hodgkin's lymphoma is commonly treated with radiation therapy, chemotherapy, or
15 hematopoietic stem cell transplantation. The most common therapy for non-Hodgkin's lymphoma is R-CHOP, which consists of four different chemotherapies (cyclophosphamide, doxorubicin, vincristine, and prednisolone) and rituximab (Rituxan®). Other therapies commonly used to treat NHL include other chemotherapeutic agents, radiation therapy, stem cell transplantation (autologous or allogeneic bone marrow transplantation), or biological
20 therapy, such as immunotherapy. Other examples of biological therapeutic agents include, but are not limited to, rituximab (Rituxan®), tositumomab (Bexxar®), epratuzumab (LymphoCide®), and alemtuzumab (MabCampath®). The compositions and methods of the present invention may be administered in combination with any of the currently prescribed treatments for Hodgkin's lymphoma or non-Hodgkin's lymphoma.

25 BCMA expression has also been associated Waldenstrom's macroglobulinemia (WM), also known as lymphoplasmacytic lymphoma (LPL). (See Elsawa et al., *Blood*. 2006, 107(7):2882-8). Waldenstrom's macroglobulinemia was previously considered to be related to multiple myeloma, but has more recently been classified as a subtype of non-Hodgkin's lymphoma. WM is characterized by uncontrolled B-cell lymphocyte proliferation, resulting in
30 anemia and production of excess amounts of paraprotein, or immunoglobulin M (IgM), which thickens the blood and results in hyperviscosity syndrome. Other symptoms or signs of WM include fever, night sweats, fatigue, anemia, weight loss, lymphadenopathy or splenomegaly, blurred vision, dizziness, nose bleeds, bleeding gums, unusual bruises, renal impairment or failure, amyloidosis, or peripheral neuropathy.

5 Standard treatment for WM consists of chemotherapy, specifically with rituximab (Rituxan®). Other chemotherapeutic drugs can be used in combination, such as chlorambucil (Leukeran®), cyclophosphamide (Neosar®), fludarabine (Fludara®), cladribine (Leustatin®), vincristine, and/or thalidomide. Corticosteroids, such as prednisone, can also be administered in combination with the chemotherapy. Plasmapheresis, or plasma exchange, is commonly used
10 throughout treatment of the patient to alleviate some symptoms by removing the paraprotein from the blood. In some cases, stem cell transplantation is an option for some patients.

Another example of a disease or disorder associated with BCMA is brain cancer. Specifically, expression of BCMA has been associated with astrocytoma or glioblastoma (See Deshayes et al, *Oncogene*. 2004, 23(17):3005-12, Pelekanou et al., *PLoS One*. 2013,
15 8(12):e83250). Astrocytomas are tumors that arise from astrocytes, which are a type of glial cell in the brain. Glioblastoma (also known as glioblastoma multiforme or GBM) is the most malignant form of astrocytoma, and is considered the most advanced stage of brain cancer (stage IV). There are two variants of glioblastoma: giant cell glioblastoma and gliosarcoma. Other astrocytomas include juvenile pilocytic astrocytoma (JPA), fibrillary astrocytoma,
20 pleomorphic xanthoastrocytoma (PXA), desmoplastic neuroepithelial tumor (DNET), and anaplastic astrocytoma (AA).

Symptoms or signs associated with glioblastoma or astrocytoma include increased pressure in the brain, headaches, seizures, memory loss, changes in behavior, loss in movement or sensation on one side of the body, language dysfunction, cognitive impairments, visual
25 impairment, nausea, vomiting, and weakness in the arms or legs.

Surgical removal of the tumor (or resection) is the standard treatment for removal of as much of the glioma as possible without damaging or with minimal damage to the normal, surrounding brain. Radiation therapy and/or chemotherapy are often used after surgery to suppress and slow recurrent disease from any remaining cancer cells or satellite lesions.
30 Radiation therapy includes whole brain radiotherapy (conventional external beam radiation), targeted three-dimensional conformal radiotherapy, and targeted radionuclides. Chemotherapeutic agents commonly used to treat glioblastoma include temozolomide, gefitinib or erlotinib, and cisplatin. Angiogenesis inhibitors, such as Bevacizumab (Avastin®), are also commonly used in combination with chemotherapy and/or radiotherapy.

5 Supportive treatment is also frequently used to relieve neurological symptoms and improve neurologic function, and is administered in combination any of the cancer therapies described herein. The primary supportive agents include anticonvulsants and corticosteroids. Thus, the compositions and methods of the present invention may be used in combination with any of the standard or supportive treatments to treat a glioblastoma or astrocytoma.

10 Non-cancer related diseases and disorders associated with BCMA expression can also be treated by the compositions and methods disclosed herein. Examples of non-cancer related diseases and disorders associated with BCMA expression include, but are not limited to: viral infections; e.g., HIV, fungal infections, e.g., *C. neoformans*; irritable bowel disease; ulcerative colitis, and disorders related to mucosal immunity.

15 The CAR-modified immune effector cells (e.g., T cells or NK cells) of the present invention may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2 or other cytokines or cell populations.

The present invention provides for compositions and methods for treating cancer. In one aspect, the cancer is a hematologic cancer including but is not limited to hematological cancer is a leukemia or a lymphoma. In one aspect, the CAR-expressing cells (e.g., CART cells or CAR-expressing NK cells) of the invention may be used to treat cancers and malignancies such as, but not limited to, e.g., acute leukemias including but not limited to, e.g., B-cell acute lymphoid leukemia ("BALL"), T-cell acute lymphoid leukemia ("TALL"), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic cancers or hematologic conditions including, but not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and "preleukemia" which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further a disease associated with BCMA expression includes, but not

- 5 limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing BCMA.

In embodiments, a composition described herein can be used to treat a disease including but not limited to a plasma cell proliferative disorder, e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined
10 significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome).

In embodiments, a composition described herein can be used to treat a disease including
15 but not limited to a cancer, e.g., a cancer described herein, e.g., a prostate cancer (e.g., castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), pancreatic cancer, or lung cancer.

The present invention also provides methods for inhibiting the proliferation or reducing a BCMA-expressing cell population, the methods comprising contacting a population of cells
20 comprising a BMCA-expressing cell with an anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention that binds to the BCMA-expressing cell. In a specific aspect, the present invention provides methods for inhibiting the proliferation or reducing the population of cancer cells expressing BCMA, the methods comprising contacting the BCMA-expressing cancer cell population with an anti-BCMA CAR-
25 expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention that binds to the BCMA-expressing cell. In one aspect, the present invention provides methods for inhibiting the proliferation or reducing the population of cancer cells expressing BCMA, the methods comprising contacting the BMCA-expressing cancer cell population with an anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of
30 the invention that binds to the BCMA-expressing cell. In certain aspects, the anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention reduces the quantity, number, amount or percentage of cells and/or cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject with or animal model for myeloid leukemia or another cancer

5 associated with BCMA-expressing cells relative to a negative control. In one aspect, the subject is a human.

The present invention also provides methods for preventing, treating and/or managing a disease associated with BCMA-expressing cells (e.g., a hematologic cancer or atypical cancer expressing BCMA), the methods comprising administering to a subject in need an anti-BCMA
10 CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention that binds to the BCMA-expressing cell. In one aspect, the subject is a human. Non-limiting examples of disorders associated with BCMA-expressing cells include viral or fungal infections, and disorders related to mucosal immunity.

The present invention also provides methods for preventing, treating and/or managing a
15 disease associated with BCMA-expressing cells, the methods comprising administering to a subject in need an anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention that binds to the BCMA-expressing cell. In one aspect, the subject is a human.

The present invention provides methods for preventing relapse of cancer associated
20 with BCMA-expressing cells, the methods comprising administering to a subject in need thereof an anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK cell) of the invention that binds to the BCMA-expressing cell. In one aspect, the methods comprise administering to the subject in need thereof an effective amount of an anti-BCMA CAR-expressing cell (e.g., BCMA CART cell or BCMA CAR-expressing NK
25 cell) described herein that binds to the BCMA-expressing cell in combination with an effective amount of another therapy.

Combination Therapies

A CAR-expressing cell described herein may be used in combination with other known
30 agents and therapies. Administered “in combination”, as used herein, means that two (or more) different treatments are delivered to the subject during the course of the subject's affliction with the disorder, e.g., the two or more treatments are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the delivery of one treatment is still occurring when

5 the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery”. In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an
10 equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment, or the analogous situation is seen with the first treatment. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the
15 absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered.

A CAR-expressing cell described herein and the at least one additional therapeutic agent can be administered simultaneously, in the same or in separate compositions, or
20 sequentially. For sequential administration, the CAR-expressing cell described herein can be administered first, and the additional agent can be administered second, or the order of administration can be reversed.

The CAR therapy and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active
25 disease. The CAR therapy can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder.

When administered in combination, the CAR therapy and the additional agent (e.g., second or third agent), or all, can be administered in an amount or dose that is higher, lower or the same than the amount or dosage of each agent used individually, e.g., as a monotherapy. In
30 certain embodiments, the administered amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50%) than the amount or dosage of each agent used individually, e.g., as a monotherapy. In other embodiments, the amount or dosage of the CAR therapy, the additional agent (e.g., second or third agent), or all, that results in a desired effect (e.g., treatment of
35 cancer) is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the

5 amount or dosage of each agent used individually, e.g., as a monotherapy, required to achieve the same therapeutic effect.

In further aspects, a CAR-expressing cell described herein may be used in a treatment regimen in combination with surgery, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or
10 other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation. peptide vaccine, such as that described in Izumoto et al. 2008 J Neurosurg 108:963-971.

In certain instances, compounds of the present invention are combined with other
15 therapeutic agents, such as other anti-cancer agents, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof.

In one embodiment, a first CAR-expressing cell described herein, e.g., a BCMA CAR-expressing cell described herein, may be used in combination with a second CAR-expressing cell. In one embodiment, the second CAR-expressing cell expresses a CAR comprising a
20 different anti-BCMA binding domain, e.g., an anti-BCMA binding domain described herein that differs from the anti-BCMA binding domain in the CAR expressed by the first CAR-expressing cell. In one embodiment, the second CAR-expressing cell expresses a CAR comprising an antigen-binding domain that targets an antigen other than BCMA (e.g., CD19, CD20, CS-1, kappa light chain, CD139, Lewis Y antigen, or CD38). In one embodiment, a
25 first CAR-expressing cell described herein, e.g., a BCMA CAR-expressing cell described herein, is used in combination with a second CAR-expressing cell comprising a CD19 CAR. In one embodiment, a BCMA CAR-expressing cell described herein is used in combination with a CD19 CAR-expressing cell to treat a BCMA-associated cancer described herein, e.g., multiple myeloma. In some embodiments, the multiple myeloma is CD19-negative, e.g., having a vast
30 majority (e.g., at least 98%, 99%, 99.5%, 99.9%, or 99.95%) of the neoplastic plasma cells with a CD19-negative phenotype, e.g., as detected flow cytometry, RT-PCR, or both flow cytometry and RT-PCR. As shown in Example 17 herein, a CD19 CAR can be effective even against a CD19-negative multiple myeloma. While not wishing to be bound by theory, the CD19 CAR may act on a small but important CD19-positive population of neoplastic cells, by targeting a
35 cell that expresses levels of CD19 that fall below the detection threshold of the assays

5 described herein, or by targeting a non-neoplastic cell that supports the neoplastic cells. In embodiments, a CD19 CAR can remove B cells, e.g., B regulatory B cells.

For example, in one embodiment, the first CAR-expressing cell described herein, e.g., a BCMA CAR-expressing cell, and the second CAR-expressing cell described herein, e.g., a CD19 CAR-expressing cell, are prepared in the same composition and are administered
10 simultaneously. In another embodiment, the first CAR-expressing cell described herein, e.g., a BCMA CAR-expressing cell, and the second CAR-expressing cell described herein, e.g., a CD19 CAR-expressing cell, are prepared in separate compositions, and the separate compositions are administered simultaneously or sequentially. When the BCMA CAR-expressing cell and the second CAR-expressing cell are prepared in separate compositions, the
15 BCMA CAR-expressing cell can be administered first, and the second CAR-expressing cell can be administered second, or the order of administration can be reversed.

In one embodiment, a CD19 CAR is a CD19 CAR, e.g., a humanized CD19 CAR, described in WO2014/153270, filed March 15, 2014 (which is incorporated by reference herein in its entirety) or a sequence at least 95%, e.g., 95-99%, identical thereto. In some
20 embodiments, the CD19 CAR construct is a CAR19 construct provided in PCT publication WO2012/079000 (which is incorporated by reference herein in its entirety) or a sequence at least 95%, e.g., 95-99%, identical thereto. In one embodiment, the anti-CD19 binding domain is a scFv described in WO2012/079000, or a sequence at least 95%, e.g., 95-99%, identical thereto.

25 In embodiments, a first CAR-expressing cell is administered to a subject, and a second CAR-expressing cell is administered to the subject. In embodiments, the first CAR-expressing cell comprises a CAR (e.g., BCMA or CD19 CAR) comprising a CD27 costimulatory domain and a CD3zeta (mutant or wild type) primary signaling domain. In embodiments, the second CAR-expressing cell comprises a CAR (e.g., BCMA CAR) comprising a 4-1BB costimulatory
30 domain and a CD3zeta (mutant or wild type) primary signaling domain. Without wishing to be bound by theory, in embodiments, the first CAR-expressing cell can be less toxic than the second CAR-expressing cell and be used to debulk a tumor.

In one embodiment, a CAR-expressing cell described herein can be used in combination with a chemotherapeutic agent. Exemplary chemotherapeutic agents include an anthracycline

- 5 (e.g., doxorubicin (e.g., liposomal doxorubicin)), a vinca alkaloid (e.g., vinblastine, vincristine, vindesine, vinorelbine), an alkylating agent (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), an immune cell antibody (e.g., alemtuzumab, gemtuzumab, rituximab, tositumomab), an antimetabolite (including, e.g., folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors (e.g., fludarabine)), an mTOR
 10 inhibitor, a TNFR glucocorticoid induced TNFR related protein (GITR) agonist, a proteasome inhibitor (e.g., aclacinomycin A, gliotoxin or bortezomib), an immunomodulator such as thalidomide or a thalidomide derivative (e.g., lenalidomide).

- General Chemotherapeutic agents considered for use in combination therapies include anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), busulfan
 15 (Myleran®), busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), cladribine (Leustatin®), cyclophosphamide (Cytosan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposome injection (DepoCyt®), dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin D, Cosmegen),
 20 daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection (DaunoXome®), dexamethasone, docetaxel (Taxotere®), doxorubicin hydrochloride (Adriamycin®, Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-fluorouracil (Adrucil®, Efudex®), flutamide (Eulexin®), tezacitibine, Gemcitabine (difluorodeoxycytidine), hydroxyurea (Hydrea®), Idarubicin (Idamycin®), ifosfamide
 25 (IFEX®), irinotecan (Camptosar®), L-asparaginase (ELSPAR®), leucovorin calcium, melphalan (Alkeran®), 6-mercaptopurine (Purinethol®), methotrexate (Folex®), mitoxantrone (Novantrone®), mylotarg, paclitaxel (Taxol®), phoenix (Yttrium90/MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazone®), topotecan hydrochloride for
 30 injection (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®), and vinorelbine (Navelbine®).

- Anti-cancer agents of particular interest for combinations with the compounds of the present invention include: anthracyclines; alkylating agents; antimetabolites; drugs that inhibit either the calcium dependent phosphatase calcineurin or the p70S6 kinase FK506) or inhibit the
 35 p70S6 kinase; mTOR inhibitors; immunomodulators; anthracyclines; vinca alkaloids;

- 5 proteasome inhibitors; G1TR agonists; protein tyrosine phosphatase inhibitors; a CDK4 kinase inhibitor; a BTK inhibitor; a MKN kinase inhibitor; a DGK kinase inhibitor; or an oncolytic virus.

Exemplary alkylating agents include, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes): uracil mustard
 10 (Aminouracil Mustard®, Chlorethaminacil®, Demethyldopan®, Desmethyldopan®, Haemanthamine®, Nordopan®, Uracil nitrogen mustard®, Uracillost®, Uracilmustaza®, Uramustin®, Uramustine®), chlormethine (Mustargen®), cyclophosphamide (Cytosan®, Neosar®, Clafen®, Endoxan®, Procytox®, Revimmune™), ifosfamide (Mitoxana®), melphalan (Alkeran®), Chlorambucil (Leukeran®), pipobroman (Amedel®, Vercyte®),
 15 triethylenemelamine (Hemel®, Hexalen®, Hexastat®), triethylenethiophosphoramine, Temozolomide (Temodar®), thiotepa (Thioplex®), busulfan (Busilvex®, Myleran®), carmustine (BiCNU®), lomustine (CeeNU®), streptozocin (Zanosar®), and Dacarbazine (DTIC-Dome®). Additional exemplary alkylating agents include, without limitation, Oxaliplatin (Eloxatin®); Temozolomide (Temodar® and Temodal®); Dactinomycin (also
 20 known as actinomycin-D, Cosmegen®); Melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, Alkeran®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Carmustine (BiCNU®); Bendamustine (Treanda®); Busulfan (Busulfex® and Myleran®); Carboplatin (Paraplatin®); Lomustine (also known as CCNU, CeeNU®); Cisplatin (also known as CDDP, Platinol® and Platinol®-AQ); Chlorambucil (Leukeran®);
 25 Cyclophosphamide (Cytosan® and Neosar®); Dacarbazine (also known as DTIC, DIC and imidazole carboxamide, DTIC-Dome®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Ifosfamide (Ifex®); Prednumustine; Procarbazine (Matulane®); Mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, Mustargen®); Streptozocin (Zanosar®); Thiotepa (also known as
 30 thiophosphoamide, TSPA and TSPA, Thioplex®); Cyclophosphamide (Endoxan®, Cytosan®, Neosar®, Procytox®, Revimmune®); and Bendamustine HCl (Treanda®).

Exemplary mTOR inhibitors include, e.g., temsirolimus; ridaforolimus (formally known as deferolimus, (1*R*,2*R*,4*S*)-4-[(2*R*)-2 [(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,
 23*S*,24*E*,26*E*,28*Z*,30*S*,32*S*,35*R*)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-
 35 hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}] hexatriaconta-

5 16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03/064383); everolimus (Afinitor® or RAD001); rapamycin (AY22989, Sirolimus®); simapimod (CAS 164301-51-3); emsirolimus, (5-{2,4-Bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-Amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-
 10 (6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one (PF04691502, CAS 1013101-36-4); and *N*²-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4*H*-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartyl-L-serine- (SEQ ID NO: 383), inner salt (SF1126, CAS 936487-67-1), and XL765.

Exemplary immunomodulators include, e.g., afutuzumab (available from Roche®);
 15 pegfilgrastim (Neulasta®); lenalidomide (CC-5013, Revlimid®); thalidomide (Thalomid®), actimid (CC4047); and IRX-2 (mixture of human cytokines including interleukin 1, interleukin 2, and interferon γ, CAS 951209-71-5, available from IRX Therapeutics).

Exemplary anthracyclines include, e.g., doxorubicin (Adriamycin® and Rubex®); bleomycin (lenoxane®); daunorubicin (daunorubicin hydrochloride, daunomycin, and
 20 rubidomycin hydrochloride, Cerubidine®); daunorubicin liposomal (daunorubicin citrate liposome, DaunoXome®); mitoxantrone (DHAD, Novantrone®); epirubicin (Ellence™); idarubicin (Idamycin®, Idamycin PFS®); mitomycin C (Mutamycin®); geldanamycin; herbimycin; ravidomycin; and desacetylavidomycin.

Exemplary vinca alkaloids include, e.g., vinorelbine tartrate (Navelbine®), Vincristine
 25 (Oncovin®), and Vindesine (Eldisine®)); vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, Alkaban-AQ® and Velban®); and vinorelbine (Navelbine®).

Exemplary proteasome inhibitors include bortezomib (Velcade®); carfilzomib (PX-171-007, (*S*)-4-Methyl-*N*-((*S*)-1-(((*S*)-4-methyl-1-((*R*)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((*S*)-2-(2-morpholinoacetamido)-4-
 30 phenylbutanamido)-pentanamide); marizomib (NPI-0052); ixazomib citrate (MLN-9708); delanzomib (CEP-18770); and *O*-Methyl-*N*-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-*O*-methyl-*N*-[(1*S*)-2-[(2*R*)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide (ONX-0912).

5 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with fludarabine, cyclophosphamide, and/or rituximab. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with fludarabine, cyclophosphamide, and rituximab (FCR). In embodiments, the subject has CLL. For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic
10 cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV_H) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV_H) gene. In embodiments, the fludarabine is administered at a dosage of about 10-50 mg/m² (e.g., about 10-
15 15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, or 45-50 mg/m²), e.g., intravenously. In embodiments, the cyclophosphamide is administered at a dosage of about 200-300 mg/m² (e.g., about 200-225, 225-250, 250-275, or 275-300 mg/m²), e.g., intravenously. In embodiments, the rituximab is administered at a dosage of about 400-600 mg/m² (e.g., 400-450, 450-500, 500-550, or 550-600 mg/m²), e.g., intravenously.

20 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with bendamustine and rituximab. In embodiments, the subject has CLL. For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain
25 variable-region (IgV_H) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV_H) gene. In embodiments, the bendamustine is administered at a dosage of about 70-110 mg/m² (e.g., 70-80, 80-90, 90-100, or 100-110 mg/m²), e.g., intravenously. In embodiments, the rituximab is administered at a dosage of about 400-600 mg/m² (e.g., 400-450, 450-500, 500-550, or 550-
30 600 mg/m²), e.g., intravenously.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicine, vincristine, and/or a corticosteroid (e.g., prednisone). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicine,
35 vincristine, and prednisone (R-CHOP). In embodiments, the subject has diffuse large B-cell

5 lymphoma (DLBCL). In embodiments, the subject has nonbulky limited-stage DLBCL (e.g., comprises a tumor having a size/diameter of less than 7 cm). In embodiments, the subject is treated with radiation in combination with the R-CHOP. For example, the subject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4, 5, or 6 cycles of R-CHOP), followed by radiation. In some cases, the subject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4,
10 5, or 6 cycles of R-CHOP) following radiation.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and/or rituximab. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide,
15 doxorubicin, and rituximab (EPOCH-R). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with dose-adjusted EPOCH-R (DA-EPOCH-R). In embodiments, the subject has a B cell lymphoma, e.g., a Myc-rearranged aggressive B cell lymphoma.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab and/or lenalidomide. Lenalidomide ((*RS*)-3-(4-Amino-1-oxo 1,3-dihydro-2*H*-isoindol-2-yl)piperidine-2,6-dione) is an immunomodulator. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab and lenalidomide. In embodiments, the subject has follicular lymphoma (FL) or mantle cell lymphoma (MCL). In embodiments, the subject has FL and has not previously
25 been treated with a cancer therapy. In embodiments, lenalidomide is administered at a dosage of about 10-20 mg (e.g., 10-15 or 15-20 mg), e.g., daily. In embodiments, rituximab is administered at a dosage of about 350-550 mg/m² (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m²), e.g., intravenously.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with brentuximab. Brentuximab is an antibody-drug conjugate of anti-CD30 antibody and monomethyl auristatin E. In embodiments, the subject has Hodgkin's lymphoma (HL), e.g., relapsed or refractory HL. In embodiments, the subject comprises CD30+ HL. In
30 embodiments, the subject has undergone an autologous stem cell transplant (ASCT). In embodiments, the subject has not undergone an ASCT. In embodiments, brentuximab is

5 administered at a dosage of about 1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg), e.g., intravenously, e.g., every 3 weeks.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with brentuximab and dacarbazine or in combination with brentuximab and bendamustine. Dacarbazine is an alkylating agent with a chemical name of 5-(3,3-Dimethyl-1-
10 triazenyl)imidazole-4-carboxamide. Bendamustine is an alkylating agent with a chemical name of 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid. In embodiments, the subject has Hodgkin's lymphoma (HL). In embodiments, the subject has not previously been treated with a cancer therapy. In embodiments, the subject is at least 60 years of age, e.g., 60, 65, 70, 75, 80, 85, or older. In embodiments, dacarbazine is administered at a dosage of
15 about 300-450 mg/m² (e.g., about 300-325, 325-350, 350-375, 375-400, 400-425, or 425-450 mg/m²), e.g., intravenously. In embodiments, bendamustine is administered at a dosage of about 75-125 mg/m² (e.g., 75-100 or 100-125 mg/m², e.g., about 90 mg/m²), e.g., intravenously. In embodiments, brentuximab is administered at a dosage of about 1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg), e.g., intravenously, e.g., every 3 weeks.

20 In some embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a CD20 inhibitor, e.g., an anti-CD20 antibody (e.g., an anti-CD20 mono- or bispecific antibody) or a fragment thereof. Exemplary anti-CD20 antibodies include but are not limited to rituximab, ofatumumab, ocrelizumab, veltuzumab, obinutuzumab, TRU-015 (Trubion Pharmaceuticals), ocaratuzumab, and Pro131921 (Genentech). See, e.g., Lim et
25 al. *Haematologica*. 95.1(2010):135-43.

In some embodiments, the anti-CD20 antibody comprises rituximab. Rituximab is a chimeric mouse/human monoclonal antibody IgG1 kappa that binds to CD20 and causes cytolysis of a CD20 expressing cell, e.g., as described in www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. In embodiments, a
30 CAR-expressing cell described herein is administered to a subject in combination with rituximab. In embodiments, the subject has CLL or SLL.

In some embodiments, rituximab is administered intravenously, e.g., as an intravenous infusion. For example, each infusion provides about 500-2000 mg (e.g., about 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1100,

5 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, or 1900-2000 mg) of rituximab. In some embodiments, rituximab is administered at a dose of 150 mg/m² to 750 mg/m², e.g., about 150-175 mg/m², 175-200 mg/m², 200-225 mg/m², 225-250 mg/m², 250-300 mg/m², 300-325 mg/m², 325-350 mg/m², 350-375 mg/m², 375-400 mg/m², 400-425 mg/m², 425-450 mg/m², 450-475 mg/m², 475-500 mg/m², 500-525 mg/m²,
10 525-550 mg/m², 550-575 mg/m², 575-600 mg/m², 600-625 mg/m², 625-650 mg/m², 650-675 mg/m², or 675-700 mg/m², where m² indicates the body surface area of the subject. In some embodiments, rituximab is administered at a dosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example, rituximab is administered at a dosing interval of at least 0.5 weeks, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8 weeks, or more. In some embodiments, rituximab is
15 administered at a dose and dosing interval described herein for a period of time, e.g., at least 2 weeks, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks, or greater. For example, rituximab is administered at a dose and dosing interval described herein for a total of at least 4 doses per treatment cycle (e.g., at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more doses per treatment cycle).

20 In some embodiments, the anti-CD20 antibody comprises ofatumumab. Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody with a molecular weight of approximately 149 kDa. For example, ofatumumab is generated using transgenic mouse and hybridoma technology and is expressed and purified from a recombinant murine cell line (NS0). See, e.g., www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf; and Clinical Trial
25 Identifier number NCT01363128, NCT01515176, NCT01626352, and NCT01397591. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with ofatumumab. In embodiments, the subject has CLL or SLL.

In some embodiments, ofatumumab is administered as an intravenous infusion. For example, each infusion provides about 150-3000 mg (e.g., about 150-200, 200-250, 250-300,
30 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, 1800-2000, 2000-2200, 2200-2400, 2400-2600, 2600-2800, or 2800-3000 mg) of ofatumumab. In embodiments, ofatumumab is administered at a starting dosage of about 300 mg, followed by 2000 mg, e.g., for about 11 doses, e.g., for 24 weeks. In some embodiments, ofatumumab is
35 administered at a dosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For

5 example, ofatumumab is administered at a dosing interval of at least 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26, 28, 30 weeks, or more. In some embodiments, ofatumumab is administered at a dose and dosing interval described herein for a period of time, e.g., at least 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or
10 greater, or 1, 2, 3, 4, 5 years or greater. For example, ofatumumab is administered at a dose and dosing interval described herein for a total of at least 2 doses per treatment cycle (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, or more doses per treatment cycle).

In some cases, the anti-CD20 antibody comprises ocrelizumab. Ocrelizumab is a humanized anti-CD20 monoclonal antibody, e.g., as described in Clinical Trials Identifier Nos.
15 NCT00077870, NCT01412333, NCT00779220, NCT00673920, NCT01194570, and Kappos et al. *Lancet*. 19.378(2011):1779-87.

In some cases, the anti-CD20 antibody comprises veltuzumab. Veltuzumab is a humanized monoclonal antibody against CD20. See, e.g., Clinical Trial Identifier No. NCT00547066, NCT00546793, NCT01101581, and Goldenberg et al. *Leuk Lymphoma*.
20 51(5)(2010):747-55.

In some cases, the anti-CD20 antibody comprises GA101. GA101 (also called obinutuzumab or RO5072759) is a humanized and glyco-engineered anti-CD20 monoclonal antibody. See, e.g., Robak. *Curr. Opin. Investig. Drugs*. 10.6(2009):588-96; Clinical Trial Identifier Numbers: NCT01995669, NCT01889797, NCT02229422, and NCT01414205; and
25 www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s000lbl.pdf.

In some cases, the anti-CD20 antibody comprises AME-133v. AME-133v (also called LY2469298 or ocaratuzumab) is a humanized IgG1 monoclonal antibody against CD20 with increased affinity for the FcγRIIIa receptor and an enhanced antibody dependent cellular cytotoxicity (ADCC) activity compared with rituximab. See, e.g., Robak et al. *BioDrugs*
30 25.1(2011):13-25; and Forero-Torres et al. *Clin Cancer Res*. 18.5(2012):1395-403.


In some cases, the anti-CD20 antibody comprises PRO131921. PRO131921 is a humanized anti-CD20 monoclonal antibody engineered to have better binding to FcγRIIIa and enhanced ADCC compared with rituximab. See, e.g., Robak et al. *BioDrugs* 25.1(2011):13-25;

- 5 and Casulo et al. Clin Immunol. 154.1(2014):37-46; and Clinical Trial Identifier No. NCT00452127.

In some cases, the anti-CD20 antibody comprises TRU-015. TRU-015 is an anti-CD20 fusion protein derived from domains of an antibody against CD20. TRU-015 is smaller than monoclonal antibodies, but retains Fc-mediated effector functions. See, e.g., Robak et al.
 10 BioDrugs 25.1(2011):13-25. TRU-015 contains an anti-CD20 single-chain variable fragment (scFv) linked to human IgG1 hinge, CH2, and CH3 domains but lacks CH1 and CL domains.

In some embodiments, an anti-CD20 antibody described herein is conjugated or otherwise bound to a therapeutic agent, e.g., a chemotherapeutic agent (e.g., cytoxan, fludarabine, histone deacetylase inhibitor, demethylating agent, peptide vaccine, anti-tumor
 15 antibiotic, tyrosine kinase inhibitor, alkylating agent, anti-microtubule or anti-mitotic agent), anti-allergic agent, anti-nausea agent (or anti-emetic), pain reliever, or cytoprotective agent described herein.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a B-cell lymphoma 2 (BCL-2) inhibitor (e.g., venetoclax, also called ABT-
 20 199 or GDC-0199;) and/or rituximab. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with venetoclax and rituximab. Venetoclax is a small molecule that inhibits the anti-apoptotic protein, BCL-2. The structure of venetoclax (4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-(1H-pyrrolo[2,3-
 25 b]pyridin-5-yloxy)benzamide) is shown below.



In embodiments, the subject has CLL. In embodiments, the subject has relapsed CLL, e.g., the subject has previously been administered a cancer therapy. In embodiments,
 30 venetoclax is administered at a dosage of about 15-600 mg (e.g., 15-20, 20-50, 50-75, 75-100,

5 100-200, 200-300, 300-400, 400-500, or 500-600 mg), e.g., daily. In embodiments, rituximab is administered at a dosage of about 350-550 mg/m² (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m²), e.g., intravenously, e.g., monthly.

Without being bound by theory, it is believed that in some cancers, B cells (e.g., B regulatory cells) can suppress T cells. Further, it is believed that a combination of oxiplatin and
10 the B cell depleting agent may reduce tumor size and/or eliminate tumors in a subject. In some embodiments, a CAR-expressing cell described herein (e.g., BCMA CAR) is administered in combination with a B cell depleting agent (e.g., a CD19 CAR-expressing cell, a CD20 CAR-expressing cell, rituximab, ocrelizumab, epratuzumab, or belimumab) and oxiplatin. In
15 embodiments, the cancer cell can be CD19 negative or CD19 positive; or BCMA negative or BMCA positive. In embodiments, a CAR-expressing cell described herein (e.g., BCMA CAR) is administered in combination with a B cell depleting agent and oxiplatin to treat a cancer, e.g., a cancer described herein, e.g., solid cancer, e.g., prostate cancer, pancreatic cancer, or lung cancer.

In embodiments, a CAR-expressing cell described herein (e.g., BCMA CAR) may
20 deplete B cells (e.g., B cells having a plasma cell-like phenotype, e.g., that express BCMA, CD19, and/or CD20) in a subject. In embodiments, the B cell can be CD19 negative or CD19 positive; or BCMA negative or BMCA positive. In some embodiments, a CAR-expressing cell described herein (e.g., BCMA CAR) is administered in combination with oxiplatin. In
25 embodiments, a CAR-expressing cell described herein is administered in combination with oxiplatin is used to treat a cancer, e.g., solid cancer, e.g., prostate cancer, pancreatic cancer, or lung cancer. In some embodiments, a CAR-expressing cell described herein is administered in combination with an oncolytic virus. In embodiments, oncolytic viruses are capable of selectively replicating in and triggering the death of or slowing the growth of a cancer cell. In
30 some cases, oncolytic viruses have no effect or a minimal effect on non-cancer cells. An oncolytic virus includes but is not limited to an oncolytic adenovirus, oncolytic Herpes Simplex Viruses, oncolytic retrovirus, oncolytic parvovirus, oncolytic vaccinia virus, oncolytic Sinbis virus, oncolytic influenza virus, or oncolytic RNA virus (e.g., oncolytic reovirus, oncolytic Newcastle Disease Virus (NDV), oncolytic measles virus, or oncolytic vesicular stomatitis virus (VSV)).

5 In some embodiments, the oncolytic virus is a virus, e.g., recombinant oncolytic virus, described in US2010/0178684 A1, which is incorporated herein by reference in its entirety. In some embodiments, a recombinant oncolytic virus comprises a nucleic acid sequence (e.g., heterologous nucleic acid sequence) encoding an inhibitor of an immune or inflammatory response, e.g., as described in US2010/0178684 A1, incorporated herein by reference in its
10 entirety. In embodiments, the recombinant oncolytic virus, e.g., oncolytic NDV, comprises a pro-apoptotic protein (e.g., apoptin), a cytokine (e.g., GM-CSF, interferon-gamma, interleukin-2 (IL-2), tumor necrosis factor-alpha), an immunoglobulin (e.g., an antibody against ED-B fibronectin), tumor associated antigen, a bispecific adapter protein (e.g., bispecific antibody or antibody fragment directed against NDV HN protein and a T cell co-stimulatory receptor, such
15 as CD3 or CD28; or fusion protein between human IL-2 and single chain antibody directed against NDV HN protein). See, e.g., Zamarin et al. Future Microbiol. 7.3(2012):347-67, incorporated herein by reference in its entirety. In some embodiments, the oncolytic virus is a chimeric oncolytic NDV described in US 8591881 B2, US 2012/0122185 A1, or US 2014/0271677 A1, each of which is incorporated herein by reference in their entireties.

20 In some embodiments, the oncolytic virus comprises a conditionally replicative adenovirus (CRAd), which is designed to replicate exclusively in cancer cells. See, e.g., Alemany et al. Nature Biotechnol. 18(2000):723-27. In some embodiments, an oncolytic adenovirus comprises one described in Table 1 on page 725 of Alemany et al., incorporated herein by reference in its entirety.

25 Exemplary oncolytic viruses include but are not limited to the following:

Group B Oncolytic Adenovirus (ColoAd1) (PsiOxus Therapeutics Ltd.) (see, e.g., Clinical Trial Identifier: NCT02053220);

30 ONCOS-102 (previously called CGTG-102), which is an adenovirus comprising granulocyte-macrophage colony stimulating factor (GM-CSF) (Oncos Therapeutics) (see, e.g., Clinical Trial Identifier: NCT01598129);

VCN-01, which is a genetically modified oncolytic human adenovirus encoding human PH20 hyaluronidase (VCN Biosciences, S.L.) (see, e.g., Clinical Trial Identifiers: NCT02045602 and NCT02045589);

35 Conditionally Replicative Adenovirus ICOVIR-5, which is a virus derived from wild-type human adenovirus serotype 5 (Had5) that has been modified to selectively replicate in

5 cancer cells with a deregulated retinoblastoma/E2F pathway (Institut Català d'Oncologia) (see, e.g., Clinical Trial Identifier: NCT01864759);

Celyvir, which comprises bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with ICOVIR5, an oncolytic adenovirus (Hospital Infantil Universitario Niño Jesús, Madrid, Spain/ Ramon Alemany) (see, e.g., Clinical Trial Identifier: NCT01844661);

10 CG0070, which is a conditionally replicating oncolytic serotype 5 adenovirus (Ad5) in which human E2F-1 promoter drives expression of the essential E1a viral genes, thereby restricting viral replication and cytotoxicity to Rb pathway-defective tumor cells (Cold Genesys, Inc.) (see, e.g., Clinical Trial Identifier: NCT02143804); or

DNX-2401 (formerly named Delta-24-RGD), which is an adenovirus that has been
15 engineered to replicate selectively in retinoblastoma (Rb)-pathway deficient cells and to infect cells that express certain RGD-binding integrins more efficiently (Clinica Universidad de Navarra, Universidad de Navarra/ DNATRIX, Inc.) (see, e.g., Clinical Trial Identifier: NCT01956734).

In some embodiments, an oncolytic virus described herein is administering by injection,
20 e.g., subcutaneous, intra-arterial, intravenous, intramuscular, intrathecal, or intraperitoneal injection. In embodiments, an oncolytic virus described herein is administered intratumorally, transdermally, transmucosally, orally, intranasally, or via pulmonary administration.

In an embodiment, cells expressing a CAR described herein are administered to a subject in combination with a molecule that decreases the Treg cell population. Methods that
25 decrease the number of (e.g., deplete) Treg cells are known in the art and include, e.g., CD25 depletion, cyclophosphamide administration, modulating GITR function. Without wishing to be bound by theory, it is believed that reducing the number of Treg cells in a subject prior to apheresis or prior to administration of a CAR-expressing cell described herein reduces the number of unwanted immune cells (e.g., Tregs) in the tumor microenvironment and reduces the
30 subject's risk of relapse. In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a molecule targeting GITR and/or modulating GITR functions, such as a GITR agonist and/or a GITR antibody that depletes regulatory T cells (Tregs). In embodiments, cells expressing a CAR described herein are administered to a subject in combination with cyclophosphamide. In one embodiment, the GITR binding
35 molecules and/or molecules modulating GITR functions (e.g., GITR agonist and/or Treg

5 depleting GITR antibodies) are administered prior to administration of the CAR-expressing cell. For example, in one embodiment, the GITR agonist can be administered prior to apheresis of the cells. In embodiments, cyclophosphamide is administered to the subject prior to administration (e.g., infusion or re-infusion) of the CAR-expressing cell or prior to apheresis of the cells. In embodiments, cyclophosphamide and an anti-GITR antibody are administered to
 10 the subject prior to administration (e.g., infusion or re-infusion) of the CAR-expressing cell or prior to apheresis of the cells. In one embodiment, the subject has cancer (e.g., a solid cancer or a hematological cancer such as multiple myeloma, ALL or CLL). In an embodiment, the subject has CLL. In embodiments, the subject has multiple myeloma. In embodiments, the subject has a solid cancer, e.g., a solid cancer described herein. Exemplary GITR agonists
 15 include, e.g., GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies) such as, e.g., a GITR fusion protein described in U.S. Patent No.: 6,111,090, European Patent No.: 090505B1, U.S. Patent No.: 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, e.g., in U.S. Patent No.: 7,025,962, European Patent No.: 1947183B1, U.S. Patent No.: 7,812,135, U.S. Patent No.:
 20 8,388,967, U.S. Patent No.: 8,591,886, European Patent No.: EP 1866339, PCT Publication No.: WO 2011/028683, PCT Publication No.: WO 2013/039954, PCT Publication No.: WO2005/007190, PCT Publication No.: WO 2007/133822, PCT Publication No.: WO2005/055808, PCT Publication No.: WO 99/40196, PCT Publication No.: WO 2001/03720, PCT Publication No.: WO99/20758, PCT Publication No.: WO2006/083289, PCT
 25 Publication No.: WO 2005/115451, U.S. Patent No.: 7,618,632, and PCT Publication No.: WO 2011/051726.

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with an mTOR inhibitor, e.g., an mTOR inhibitor described herein, e.g., a rapalog such as everolimus. In one embodiment, the mTOR inhibitor is administered prior to
 30 the CAR-expressing cell. For example, in one embodiment, the mTOR inhibitor can be administered prior to apheresis of the cells.

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a GITR agonist, e.g., a GITR agonist described herein. In one embodiment, the GITR agonist is administered prior to the CAR-expressing cell. For example,
 35 in one embodiment, the GITR agonist can be administered prior to apheresis of the cells.

5 In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a protein tyrosine phosphatase inhibitor, e.g., a protein tyrosine phosphatase inhibitor described herein. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-1 inhibitor, e.g., an SHP-1 inhibitor described herein, such as, e.g., sodium stibogluconate. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-2
10 inhibitor.


In one embodiment, a CAR-expressing cell described herein can be used in combination with a kinase inhibitor. In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CDK4/6 inhibitor, such as, e.g., 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8*H*-pyrido[2,3-*d*]pyrimidin-7-one, hydrochloride (also referred to as palbociclib or PD0332991). In one embodiment, the
15 kinase inhibitor is a BTK inhibitor, e.g., a BTK inhibitor described herein, such as, e.g., ibrutinib. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitor described herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2 inhibitor, e.g., an mTORC1
20 inhibitor and/or mTORC2 inhibitor described herein. In one embodiment, the kinase inhibitor is a MNK inhibitor, e.g., a MNK inhibitor described herein, such as, e.g., 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-*d*] pyrimidine. The MNK inhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor. In one embodiment, the kinase inhibitor is a dual PI3K/mTOR inhibitor described herein, such as, e.g., PF-04695102. In one embodiment, the
25 kinase inhibitor is a DGK inhibitor, e.g., a DGK inhibitor described herein, such as, e.g., DGKinh1 (D5919) or DGKinh2 (D5794).

In one embodiment, the kinase inhibitor is a CDK4 inhibitor selected from aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3*S*,4*R*)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-Chlorophenyl)-5,7-dihydroxy-8-
30 [(2*R*,3*S*)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]- 4*H*-1-benzopyran-4-one, hydrochloride (P276-00); 1-methyl-5-[[2-[5-(trifluoromethyl)-1*H*-imidazol-2-yl]-4-pyridinyl]oxy]-*N*-[4-(trifluoromethyl)phenyl]-1*H*-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); *N*-[5-[[5-*tert*-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5*H*-pyrimido[5,4-*d*][2]benzazepin-2-yl]amino]-benzoic acid
35

5 (MLN8054); 5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-pyridinemethanamine (AG-024322); 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662).

10 In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125 mg) daily for a period of time, e.g., daily for 14-21 days of a 28 day cycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered.


15 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a cyclin-dependent kinase (CDK) 4 or 6 inhibitor, e.g., a CDK4 inhibitor or a CDK6 inhibitor described herein. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a CDK4/6 inhibitor (e.g., an inhibitor that targets both CDK4 and CDK6), e.g., a CDK4/6 inhibitor described herein. In an embodiment, the
 20 subject has MCL. MCL is an aggressive cancer that is poorly responsive to currently available therapies, i.e., essentially incurable. In many cases of MCL, cyclin D1 (a regulator of CDK4/6) is expressed (e.g., due to chromosomal translocation involving immunoglobulin and Cyclin D1 genes) in MCL cells. Thus, without being bound by theory, it is thought that MCL cells are highly sensitive to CDK4/6 inhibition with high specificity (i.e., minimal effect on normal
 25 immune cells). CDK4/6 inhibitors alone have had some efficacy in treating MCL, but have only achieved partial remission with a high relapse rate. An exemplary CDK4/6 inhibitor is LEE011 (also called ribociclib), the structure of which is shown below.



30 Without being bound by theory, it is believed that administration of a CAR-expressing cell described herein with a CDK4/6 inhibitor (e.g., LEE011 or other CDK4/6 inhibitor described herein) can achieve higher responsiveness, e.g., with higher remission rates and/or lower relapse rates, e.g., compared to a CDK4/6 inhibitor alone.

In one embodiment, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In a preferred embodiment, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK), and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13.

In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a BTK inhibitor (e.g., ibrutinib). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with ibrutinib (also called PCI-32765). The structure of ibrutinib (1-[(3*R*)-3-[4-Amino-3-(4-phenoxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one) is shown below.



In embodiments, the subject has CLL, mantle cell lymphoma (MCL), or small lymphocytic lymphoma (SLL). For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject has relapsed CLL or SLL, e.g., the subject has previously been administered a cancer therapy (e.g., previously been administered one, two, three, or four prior cancer therapies). In embodiments, the subject has refractory CLL or SLL. In other embodiments, the subject has follicular lymphoma, e.g., relapse or refractory follicular lymphoma. In some embodiments, ibrutinib is administered at a dosage of about 300-600 mg/day (e.g., about 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mg/day, e.g., about 420 mg/day or about 560 mg/day), e.g., orally. In embodiments, the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered. In


5 some embodiments, ibrutinib is administered in combination with rituximab. See, e.g., Burger et al. (2013) Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients, Abstract 675 presented at 55th ASH Annual Meeting and Exposition, New Orleans, LA 7-10 Dec. Without being bound by

10 theory, it is thought that the addition of ibrutinib enhances the T cell proliferative response and may shift T cells from a T-helper-2 (Th2) to T-helper-1 (Th1) phenotype. Th1 and Th2 are phenotypes of helper T cells, with Th1 versus Th2 directing different immune response pathways. A Th1 phenotype is associated with proinflammatory responses, e.g., for killing cells, such as intracellular pathogens/viruses or cancerous cells, or perpetuating autoimmune

15 responses. A Th2 phenotype is associated with eosinophil accumulation and anti-inflammatory responses.

In some embodiments of the methods, uses, and compositions herein, the BTK inhibitor is a BTK inhibitor described in International Application WO/2015/079417, which is herein incorporated by reference in its entirety. For instance, in some embodiments, the BTK

20 inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof;



wherein,

R1 is hydrogen, C1-C6 alkyl optionally substituted by hydroxy;

R2 is hydrogen or halogen;

25 R3 is hydrogen or halogen;

R4 is hydrogen;

R5 is hydrogen or halogen;

5 or R4 and R5 are attached to each other and stand for a bond, -CH₂-, -CH₂-CH₂-, -CH=CH-, -CH=CH-CH₂-, -CH₂-CH=CH-, or -CH₂-CH₂-CH₂-;

R6 and R7 stand independently from each other for H, C1-C6 alkyl optionally substituted by hydroxyl, C3-C6 cycloalkyl optionally substituted by halogen or hydroxy, or halogen;

10 R8, R9, R, R', R10 and R11 independently from each other stand for H, or C1-C6 alkyl optionally substituted by C1-C6 alkoxy; or any two of R8, R9, R, R', R10 and R11 together with the carbon atom to which they are bound may form a 3 – 6 membered saturated carbocyclic ring;

R12 is hydrogen or C1-C6 alkyl optionally substituted by halogen or C1-C6 alkoxy;

15 or R12 and any one of R8, R9, R, R', R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

n is 0 or 1; and

R13 is C2-C6 alkenyl optionally substituted by C1-C6 alkyl, C1-C6 alkoxy or N,N-di-
20 C1-C6 alkyl amino; C2-C6 alkynyl optionally substituted by C1-C6 alkyl or C1-C6 alkoxy; or C2-C6 alkylenyl oxide optionally substituted by C1-C6 alkyl.

In some embodiments, the BTK inhibitor of Formula I is chosen from: N-(3-(5-((1-Acryloylazetidin-3-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (E)-N-(3-(6-Amino-5-((1-(but-2-enoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-((1-propioloylazetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-((1-(but-2-ynoyl)azetidin-3-yl)oxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(5-((1-Acryloylpiperidin-4-yl)oxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (E)-N-(3-(6-Amino-5-(2-(N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(2-(N-methylpropiolamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (E)-N-(3-(6-Amino-5-(2-(4-methoxy-N-methylbut-2-enamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)ethoxy)pyrimidin-4-yl)-5-

- 5 fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(2-((4-Amino-6-(3-(4-cyclopropyl-2-fluorobenzamido)-5-fluoro-2-methylphenyl)pyrimidin-5-yl)oxy)ethyl)-N-methyloxirane-2-carboxamide; N-(2-((4-Amino-6-(3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1H)-yl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide; N-(3-(5-(2-Acrylamidoethoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-
- 10 fluorobenzamide; N-(3-(6-Amino-5-(2-(N-ethylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(2-(N-(2-fluoroethyl)acrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(5-((1-Acrylamidocyclopropyl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(5-(2-
- 15 Acrylamidopropoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(6-Amino-5-(2-(but-2-ynamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(6-Amino-5-(2-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(6-Amino-5-(2-(N-methylbut-2-ynamido)propoxy)pyrimidin-4-yl)-
- 20 5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(3-(N-methylacrylamido)propoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(6-Amino-5-((1-(but-2-ynoyl)pyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-
- 25 fluorobenzamide; (S)-2-(3-(5-((1-Acryloylpyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one; N-(2-((4-Amino-6-(3-(6-cyclopropyl-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)-5-fluoro-2-(hydroxymethyl)phenyl)pyrimidin-5-yl)oxy)ethyl)-N-methylacrylamide; N-(3-(5-(((2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-
- 30 methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; 2-(3-(5-(((2S,4R)-1-Acryloyl-4-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one; N-(3-(5-(((2S,4S)-1-Acryloyl-4-methoxypyrrolidin-2-
- 35 yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(((2S,4S)-1-(but-2-ynoyl)-4-methoxypyrrolidin-2-

- 5 yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(5-(((2S,4R)-1-Acryloyl-4-fluoropyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(6-Amino-5-(((2S,4R)-1-(but-2-ynoyl)-4-fluoropyrrolidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-N-(3-(6-Amino-5-((1-propiolylazetidin-2-yl)methoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (S)-2-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2H)-one; (R)-N-(3-(5-((1-Acryloylazetidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; (R)-N-(3-(5-((1-Acryloylpiperidin-3-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(5-(((2R,3S)-1-Acryloyl-3-methoxypyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; N-(3-(5-(((2S,4R)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide; or N-(3-(5-(((2S,4S)-1-Acryloyl-4-cyanopyrrolidin-2-yl)methoxy)-6-aminopyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide.

Unless otherwise provided, the chemical terms used above in describing the BTK inhibitor of Formula I are used according to their meanings as set out in International Application WO/2015/079417, which is herein incorporated by reference in its entirety.


In one embodiment, the kinase inhibitor is an mTOR inhibitor selected from temsirolimus; ridaforolimus (1*R*,2*R*,4*S*)-4-[(2*R*)-2 [(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*Z*,30*S*,32*S*,35*R*)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxo-4-azatricyclo[30.3.1.0^{4,9}] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimod; (5-{2,4-bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one (PF04691502); and *N*²-[1,4-dioxo-4-[[4-(4-oxo-8-

- 5 phenyl-4*H*-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L- α -aspartyl-L-serine- (SEQ ID NO: 383), inner salt (SF1126); and XL765.

In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a period of time, e.g., daily for 21 day cycle cycle, or daily for 28 day
 10 cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for a period of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more
 15 cycles of everolimus are administered.


In one embodiment, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo [3,4-*d*] pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-*d*] pyrimidine.

20 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a phosphoinositide 3-kinase (PI3K) inhibitor (e.g., a PI3K inhibitor described herein, e.g., idelalisib or duvelisib) and/or rituximab. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with idelalisib and rituximab. In
 25 embodiments, a CAR-expressing cell described herein is administered to a subject in combination with duvelisib and rituximab. Idelalisib (also called GS-1101 or CAL-101; Gilead) is a small molecule that blocks the delta isoform of PI3K. The structure of idelalisib (5-Fluoro-3-phenyl-2-[(1*S*)-1-(7*H*-purin-6-ylamino)propyl]-4(3*H*)-quinazolinone) is shown below.



5

Duvelisib (also called IPI-145; Infinity Pharmaceuticals and Abbvie) is a small molecule that blocks PI3K- δ,γ . The structure of duvelisib (8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone) is shown below.



10

In embodiments, the subject has CLL. In embodiments, the subject has relapsed CLL, e.g., the subject has previously been administered a cancer therapy (e.g., previously been administered an anti-CD20 antibody or previously been administered ibrutinib). For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV_H) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV_H) gene. In embodiments, the subject has a deletion in the long arm of chromosome 11 (del(11q)). In other embodiments, the subject does not have a del(11q). In embodiments, idelalisib is administered at a dosage of about 100-400 mg (e.g., 100-125, 125-150, 150-175, 175-200, 200-225, 225-250, 250-275, 275-300, 325-350, 350-375, or 375-400 mg), e.g., BID. In embodiments, duvelisib is administered at a dosage of about 15-100 mg (e.g., about 15-25, 25-50, 50-75, or 75-100 mg), e.g., twice a day. In embodiments, rituximab is administered at a dosage of about 350-550

20

5 mg/m² (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m²), e.g., intravenously.

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with an anaplastic lymphoma kinase (ALK) inhibitor. Exemplary ALK kinases include but are not limited to crizotinib (Pfizer), ceritinib (Novartis), alectinib (Chugai),
 10 brigatinib (also called AP26113; Ariad), entrectinib (Ignyta), PF-06463922 (Pfizer), TSR-011 (Tesar) (see, e.g., Clinical Trial Identifier No. NCT02048488), CEP-37440 (Teva), and X-396 (Xcovery). In some embodiments, the subject has a solid cancer, e.g., a solid cancer described herein, e.g., lung cancer.

The chemical name of crizotinib is 3-[(1*R*)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-
 15 (1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine. The chemical name of ceritinib is 5-Chloro-*N*²-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-*N*⁴-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine. The chemical name of alectinib is 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5*H*-benzo[*b*]carbazole-3-carbonitrile. The chemical name of brigatinib is 5-Chloro-*N*²-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-*N*⁴-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine. The chemical
 20 name of entrectinib is *N*-(5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2*H*-pyran-4-yl)amino)benzamide. The chemical name of PF-06463922 is (10*R*)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2*H*-8,4-(metheno)pyrazolo[4,3-*h*][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile. The chemical
 25 structure of CEP-37440 is (S)-2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5*H*-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-*N*-methylbenzamide. The chemical name of X-396 is (R)-6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-*N*-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide.

In one embodiment, the kinase inhibitor is a dual phosphatidylinositol 3-kinase (PI3K)
 30 and mTOR inhibitor selected from 2-Amino-8-[*trans*-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-*d*]pyrimidin-7(8*H*)-one (PF-04691502); *N*-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-*N*'-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea (PF-05212384, PKI-587); 2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1*H*-imidazo[4,5-*c*]quinolin-1-yl]phenyl}propanenitrile (BEZ-235); apitolisib
 35 (GDC-0980, RG7422); 2,4-Difluoro-*N*-[2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-

pyridinyl]benzenesulfonamide (GSK2126458); 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one Maleic acid (NVP-BGT226); 3-[4-(4-Morpholinylpyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)]phenol (PI-103); 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (VS-5584, SB2343); and N-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide (XL765).

Drugs that inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin). (Liu *et al.*, Cell 66:807-815, 1991; Henderson *et al.*, Immun. 73:316-321, 1991; Bierer *et al.*, Curr. Opin. Immun. 5:763-773, 1993) can also be used. In a further aspect, the cell compositions of the present invention may be administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, and/or antibodies such as OKT3 or CAMPATH. In one aspect, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a biphosphonate, e.g., Pamidronate (Aredia®); Zoledronic acid or Zoledronate (Zometa®, Zomera®, Aclasta®, or Reclast®); Alendronate (Fosamax®); Risedronate (Actonel®); Ibandronate (Boniva®); Clondronate (Bonefos®); Etidronate (Didronel®); Tiludronate (Skelid®); Pamidronate (Aredia®); Neridronate (Nerixia®); Strontium ranelate (Protelos®, or Protos®); and Teriparatide (Forteo®).

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a corticosteroid, e.g., dexamethasone (e.g., Decadron®), beclomethasone (e.g., Beclovent®), hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, hydrocortisone phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), prednisolone (sold under the

5 tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid Red®, Meticorten® and Orasone®), methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, sold under the tradenames Duralone®, Medralone®, Medrol®, M-Prednisol® and Solu-Medrol®); antihistamines, such as diphenhydramine (e.g., Benadryl®), hydroxyzine, and
 10 cyproheptadine; and bronchodilators, such as the beta-adrenergic receptor agonists, albuterol (e.g., Proventil®), and terbutaline (Brethine®).

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with an immunomodulator, e.g., Afutuzumab (available from Roche®); Pegfilgrastim (Neulasta®); Lenalidomide (CC-5013, Revlimid®); Thalidomide (Thalomid®),
 15 Actimid (CC4047); and IRX-2 (mixture of human cytokines including interleukin 1, interleukin 2, and interferon γ , CAS 951209-71-5, available from IRX Therapeutics).

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a proteasome inhibitor, e.g., Bortezomib (Velcade®); Ixazomib citrate (MLN9708, CAS 1201902-80-8); Danoprevir (RG7227, CAS 850876-88-9); Ixazomib
 20 (MLN2238, CAS 1072833-77-2); and (S)-N-[(phenylmethoxy)carbonyl]-L-leucyl-N-(1-formyl-3-methylbutyl)- L-Leucinamide (MG-132, CAS 133407-82-6).

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a vascular endothelial growth factor (VEGF) receptor, e.g., Bevacizumab (Avastin®), axitinib (Inlyta®); Brivanib alaninate (BMS-582664, (S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate); Sorafenib (Nexavar®); Pazopanib (Votrient®); Sunitinib malate (Sutent®); Cediranib (AZD2171, CAS 288383-20-1); Vargatef (BIBF1120, CAS 928326-83-4); Foretinib (GSK1363089); Telatinib (BAY57-9352, CAS 332012-40-5); Apatinib (YN968D1, CAS 811803-05-1); Imatinib (Gleevec®); Ponatinib (AP24534, CAS 943319-70-8); Tivozanib (AV951, CAS 475108-18-0); Regorafenib (BAY73-4506, CAS 755037-03-7); Vatalanib dihydrochloride (PTK787, CAS 212141-51-0); Brivanib (BMS-540215, CAS 649735-46-6); Vandetanib (Caprelsa® or AZD6474); Motesanib diphosphate (AMG706, CAS 857876-30-3, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, described in PCT Publication No. WO 02/066470); Dovitinib dilactic acid (TKI258, CAS 852433-84-2); Linfanib (ABT869, CAS 796967-16-3); Cabozantinib
 35

- 5 (XL184, CAS 849217-68-1); Lestaurtinib (CAS 111358-88-4); N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS38703, CAS 345627-80-7); (3R,4R)-4-Amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)methyl)piperidin-3-ol (BMS690514); *N*-(3,4-Dichloro-2-fluorophenyl)-6-methoxy-7-[[3 α ,5 β ,6 α]-octahydro-2-methylcyclopenta[*c*]pyrrol-5-yl]methoxy]-4-quinazolinamine (XL647, CAS 781613-23-8); 4-Methyl-3-[[1-methyl-6-(3-pyridinyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]amino]-*N*-(3-(trifluoromethyl)phenyl)-benzamide (BHG712, CAS 940310-85-0); . and Aflibercept (Eylea®).


In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with a CD20 antibody or a conjugate thereof, e.g.,: Rituximab (Riuxan® and
15 MabThera®); and Tositumomab (Bexxar®); and Ofatumumab (Arzerra®), Ibritumomab tiuxetan (Zevalin®); and Tositumomab,

In one embodiment, a CAR expressing cell described herein is administered to a subject in combination with an anticonvulsant, e.g., Anticonvulsants (antiepileptic or antiseizure drugs): aldehydes, e.g., paraldehyde; aromatic allylic alcohols, e.g., stiripentol (Diacomit®);
20 barbiturates, e.g., phenobarbital (Luminal®), methylphenobarbital (Mebaral®), barbexaclone (Maliasin®), benzodiazepines, e.g., clobazam (Onfi®), clonazepam (Klonopin®), clorazepate (Tranxene® and Novo-Clopate®), diazepam (Valium®, Lembrol®, Diastat®), midazolam (Versed®), lorazepam (Ativan® and Orfidal®), nitrazepam (Alodorm®, Arem®, Insoma®), temazepam (restoril®, Normison®), nimetazepam (Erimin®), bromides, e.g., potassium
25 bromide; carbamates, e.g., felbamate (Felbatol®); carboxamides, e.g., carbamazepine (Tegretol®, Equetro®), oxcarbazepine (Trileptal®, Oxcarb®), eslicarbazepine acetate (Aptiom®); fatty acids, e.g., valproates (valproic acid, sodium valproate, divalproex sodium), vigabatrin (Sabril®), progabide (Gabren®), tiagabine (Gabitril®); fructose derivatives, e.g., topiramate (Topamax®); GABA analogs, e.g., gabapentin (Neurontin®), pregabalin (Lyrica®);
30 hydantoins, e.g., ethotoin (Peganone®), phenytoin (Dilantin®), mephentyoin (Mesantoin®), fosphenytoin (Cerebyx®, Prodilantin®); oxazolidinediones, e.g., paramethadione (Paradione®), trimethadione (Tridione®); propionates, e.g., beclamide (Choracon®, Hibicon®, Posedrine®); pyrimidinediones, e.g., primidone (Mysoline®); pyrrolidines, e.g., brivaracetam, levetiracetam, seletracetam (Keppra®); succinimides, e.g., ethosuximide (Zarontin®),
35 phensuximide (Milontin®), mesuximide (Celontin®, Petinutin®); sulfonamides, e.g.,

5 acetazolamide (Diamox®), sultiame (Ospolot®), methazolamide (Neptazane®), zonisamide (Zonegran®); triazines, e.g., lamotrigine (Lamictal®); ureas, e.g., pheneturide, phenacemide (Phenurone®); valproylamides (amide derivatives of valproate), e.g., valpromide (Depamide®), valnoctamide; AMPA receptor antagonist, e.g., perampanel (Fycompa®).

10 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with an indoleamine 2,3-dioxygenase (IDO) inhibitor. IDO is an enzyme that catalyzes the degradation of the amino acid, L-tryptophan, to kynurenine. Many cancers overexpress IDO, e.g., prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head, and lung cancer. pDCs, macrophages, and dendritic cells (DCs) can express IDO. Without being bound by theory, it is thought that a decrease in L-tryptophan (e.g., catalyzed by IDO) results in
15 an immunosuppressive milieu by inducing T-cell anergy and apoptosis. Thus, without being bound by theory, it is thought that an IDO inhibitor can enhance the efficacy of a CAR-expressing cell described herein, e.g., by decreasing the suppression or death of a CAR-expressing immune cell. In embodiments, the subject has a solid tumor, e.g., a solid tumor described herein, e.g., prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head, or lung
20 cancer. Exemplary inhibitors of IDO include but are not limited to 1-methyl-tryptophan, indoximod (NewLink Genetics) (see, e.g., Clinical Trial Identifier Nos. NCT01191216; NCT01792050), and INCB024360 (Incyte Corp.) (see, e.g., Clinical Trial Identifier Nos. NCT01604889; NCT01685255)

25 In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a modulator of myeloid-derived suppressor cells (MDSCs). MDSCs accumulate in the periphery and at the tumor site of many solid tumors. These cells suppress T cell responses, thereby hindering the efficacy of CAR-expressing cell therapy. Without being bound by theory, it is thought that administration of a MDSC modulator enhances the efficacy of a CAR-expressing cell described herein. In an embodiment, the subject has a solid tumor, e.g., a solid tumor described herein, e.g., glioblastoma. Exemplary modulators of MDSCs
30 include but are not limited to MCS110 and BLZ945. MCS110 is a monoclonal antibody (mAb) against macrophage colony-stimulating factor (M-CSF). See, e.g., Clinical Trial Identifier No. NCT00757757. BLZ945 is a small molecule inhibitor of colony stimulating factor 1 receptor (CSF1R). See, e.g., Pyonteck et al. Nat. Med. 19(2013):1264-72. The structure of BLZ945 is
35 shown below.



5

In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a CD19 CART cell (e.g., CTL019, e.g., as described in WO2012/079000, incorporated herein by reference). In embodiments, the subject has acute myeloid leukemia (AML), e.g., a CD19 positive AML or a CD19 negative AML. In embodiments, the subject

10 has a CD19+ lymphoma, e.g., a CD19+ Non-Hodgkin's Lymphoma (NHL), a CD19+ FL, or a CD19+ DLBCL. In embodiments, the subject has a relapsed or refractory CD19+ lymphoma. In embodiments, a lymphodepleting chemotherapy is administered to the subject prior to, concurrently with, or after administration (e.g., infusion) of CD19 CART cells. In an example, the lymphodepleting chemotherapy is administered to the subject prior to administration of

15 CD19 CART cells. For example, the lymphodepleting chemotherapy ends 1-4 days (e.g., 1, 2, 3, or 4 days) prior to CD19 CART cell infusion. In embodiments, multiple doses of CD19 CART cells are administered, e.g., as described herein. For example, a single dose comprises about 5×10^8 CD19 CART cells. In embodiments, a lymphodepleting chemotherapy is administered to the subject prior to, concurrently with, or after administration (e.g., infusion) of

20 a CAR-expressing cell described herein, e.g., a non-CD19 CAR-expressing cell. In embodiments, a CD19 CART is administered to the subject prior to, concurrently with, or after administration (e.g., infusion) of a non-CD19 CAR-expressing cell, e.g., a non-CD19 CAR-expressing cell described herein.

In some embodiments, a CAR-expressing cell described herein is administered to a

25 subject in combination with a CD19 CAR-expressing cell, e.g., CTL019, e.g., as described in WO2012/079000, incorporated herein by reference, for treatment of a disease associated with the expression of BCMA, e.g., a cancer described herein. Without being bound by theory, it is believed that administering a CD19 CAR-expressing cell in combination with a CAR-expressing cell improves the efficacy of a CAR-expressing cell described herein by targeting

30 early lineage cancer cells, e.g., cancer stem cells, modulating the immune response, depleting

5 regulatory B cells, and/or improving the tumor microenvironment. For example, a CD19 CAR-expressing cell targets cancer cells that express early lineage markers, e.g., cancer stem cells and CD19-expressing cells, while the CAR-expressing cell described herein targets cancer cells that express later lineage markers, e.g., BCMA. This preconditioning approach can improve the efficacy of the CAR-expressing cell described herein. In such embodiments, the CD19 CAR-
10 expressing cell is administered prior to, concurrently with, or after administration (e.g., infusion) of a CAR-expressing cell described herein.

In embodiments, a CAR-expressing cell described herein also expresses a CAR targeting CD19, e.g., a CD19 CAR. In an embodiment, the cell expressing a CAR described herein and a CD19 CAR is administered to a subject for treatment of a cancer described herein,
15 e.g., AML. In an embodiment, the configurations of one or both of the CAR molecules comprise a primary intracellular signaling domain and a costimulatory signaling domain. In another embodiment, the configurations of one or both of the CAR molecules comprise a primary intracellular signaling domain and two or more, e.g., 2, 3, 4, or 5 or more, costimulatory signaling domains. In such embodiments, the CAR molecule described herein
20 and the CD19 CAR may have the same or a different primary intracellular signaling domain, the same or different costimulatory signaling domains, or the same number or a different number of costimulatory signaling domains. Alternatively, the CAR described herein and the CD19 CAR are configured as a split CAR, in which one of the CAR molecules comprises an antigen binding domain and a costimulatory domain (e.g., 4-1BB), while the other CAR
25 molecule comprises an antigen binding domain and a primary intracellular signaling domain (e.g., CD3 zeta).

In some embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra
30 polypeptide e.g., hetIL-15 (Admune Therapeutics, LLC). hetIL-15 is a heterodimeric non-covalent complex of IL-15 and IL-15Ra. hetIL-15 is described in, e.g., U.S. 8,124,084, U.S. 2012/0177598, U.S. 2009/0082299, U.S. 2012/0141413, and U.S. 2011/0081311, incorporated herein by reference. In embodiments, het-IL-15 is administered subcutaneously. In
embodiments, the subject has a cancer, e.g., solid cancer, e.g., melanoma or colon cancer. In
35 embodiments, the subject has a metastatic cancer.

5 In one embodiment, the subject can be administered an agent which reduces or ameliorates a side effect associated with the administration of a CAR-expressing cell. Side effects associated with the administration of a CAR-expressing cell include, but are not limited to CRS, and hemophagocytic lymphohistiocytosis (HLH), also termed Macrophage Activation Syndrome (MAS). Symptoms of CRS include high fevers, nausea, transient hypotension,
10 hypoxia, and the like. CRS may include clinical constitutional signs and symptoms such as fever, fatigue, anorexia, myalgias, arthalgias, nausea, vomiting, and headache. CRS may include clinical skin signs and symptoms such as rash. CRS may include clinical gastrointestinal signs and symptoms such as nausea, vomiting and diarrhea. CRS may include clinical respiratory signs and symptoms such as tachypnea and hypoxemia. CRS may include
15 clinical cardiovascular signs and symptoms such as tachycardia, widened pulse pressure, hypotension, increased cardiac output (early) and potentially diminished cardiac output (late). CRS may include clinical coagulation signs and symptoms such as elevated d-dimer, hypofibrinogenemia with or without bleeding. CRS may include clinical renal signs and symptoms such as azotemia. CRS may include clinical hepatic signs and symptoms such as
20 transaminitis and hyperbilirubinemia. CRS may include clinical neurologic signs and symptoms such as headache, mental status changes, confusion, delirium, word finding difficulty or frank aphasia, hallucinations, tremor, dymetria, altered gait, and seizures.

Accordingly, the methods described herein can comprise administering a CAR-expressing cell described herein to a subject and further administering one or more agents to
25 manage elevated levels of a soluble factor resulting from treatment with a CAR-expressing cell. In one embodiment, the soluble factor elevated in the subject is one or more of IFN- γ , TNF α , IL-2 and IL-6. In an embodiment, the factor elevated in the subject is one or more of IL-1, GM-CSF, IL-10, IL-8, IL-5 and fraktalkine. Therefore, an agent administered to treat this side effect can be an agent that neutralizes one or more of these soluble factors. In one
30 embodiment, the agent that neutralizes one or more of these soluble forms is an antibody or antibody fragment. Examples of such agents include, but are not limited to a steroid (e.g., corticosteroid), an inhibitor of TNF α , and an inhibitor of IL-6. An example of a TNF α inhibitor is an anti-TNF α antibody molecule such as, infliximab, adalimumab, certolizumab pegol, and golimumab. Another example of a TNF α inhibitor is a fusion protein such as entanercept.
35 Small molecule inhibitors of TNF α include, but are not limited to, xanthine derivatives (e.g.

5 pentoxifylline) and bupropion. An example of an IL-6 inhibitor is an anti-IL-6 antibody molecule such as tocilizumab (toc), sarilumab, elsilimomab, CNTO 328, ALD518/BMS-945429, CNTO 136, CPSI-2364, CDP6038, VX30, ARGX-109, FE301, and FM101. In one embodiment, the anti-IL-6 antibody molecule is tocilizumab. An example of an IL-1R based inhibitor is anakinra.

10 In some embodiment, the subject is administered a corticosteroid, such as, e.g., methylprednisolone, hydrocortisone, among others.

In some embodiments, the subject is administered a vasopressor, such as, e.g., norepinephrine, dopamine, phenylephrine, epinephrine, vasopressin, or a combination thereof.

In an embodiment, the subject can be administered an antipyretic agent. In an
15 embodiment, the subject can be administered an analgesic agent.

In one embodiment, the subject can be administered an agent that prevents trafficking of the BCMA CAR-expressing cell to the brain, e.g., natalizumab (TYSABRI®). BCMA expression, e.g., a splice variant thereof, has been detected in some parts of the brain, e.g., the cerebellum or medulla oblongata. Without being bound by any particular theory, prevention of
20 trafficking of the BCMA CAR-expressing cells to the brain is preferred to prevent any BCMA CAR-expressing cells from interacting with or acting on BCMA-expressing brain tissue.

In one embodiment, the subject can be administered an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule, e.g., the agent is a checkpoint inhibitor. Inhibitory
25 molecules, e.g., Programmed Death 1 (PD1), can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC
30 class I, MHC class II, GAL9, adenosine, and TGFR beta. Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger

5 endonuclease (ZFN), e.g., as described herein, can be used to inhibit expression of an inhibitory molecule in the CAR-expressing cell. In an embodiment the inhibitor is an shRNA. In an embodiment, the inhibitory molecule is inhibited within a CAR-expressing cell. In these embodiments, a dsRNA molecule that inhibits expression of the inhibitory molecule is linked to the nucleic acid that encodes a component, e.g., all of the components, of the CAR. In
10 embodiments, a CAR-expressing cell described herein is administered in combination with an inhibitor of an inhibitory molecule, e.g., in combination with a checkpoint inhibitor, e.g., in combination with an inhibitor of PD1 and/or PD-L1. In embodiments, a CAR- expressing cell described herein is administered in combination with an inhibitor of PD1. In embodiments, a CAR- expressing cell described herein is administered in combination with an inhibitor of PD-
15 L1.

In an embodiment, a nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is operably linked to a promoter, e.g., a H1- or a U6-derived promoter such that the dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is
20 expressed, e.g., is expressed within a CAR-expressing cell. See e.g., Tiscornia G., “Development of Lentiviral Vectors Expressing siRNA,” Chapter 3, in *Gene Transfer: Delivery and Expression of DNA and RNA* (eds. Friedmann and Rossi). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2007; Brummelkamp TR, *et al.* (2002) *Science* 296: 550–553; Miyagishi M, *et al.* (2002) *Nat. Biotechnol.* 19: 497–500. In an
25 embodiment the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is present on the same vector, e.g., a lentiviral vector, that comprises a nucleic acid molecule that encodes a component, e.g., all of the components, of the CAR. In such an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that
30 modulates or regulates, e.g., inhibits, T-cell function is located on the vector, e.g., the lentiviral vector, 5'- or 3'- to the nucleic acid that encodes a component, e.g., all of the components, of the CAR. The nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function can be transcribed in the same or different direction as the nucleic acid that encodes a component, e.g., all of the
35 components, of the CAR. In an embodiment the nucleic acid molecule that encodes a dsRNA

5 molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is present on a vector other than the vector that comprises a nucleic acid molecule that encodes a component, e.g., all of the components, of the CAR. In an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is transiently expressed within a CAR-expressing cell. In an embodiment, the nucleic acid molecule that encodes a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function is stably integrated into the genome of a CAR-expressing cell. Figures 41A-41E depicts examples of vectors for expressing a component, e.g., all of the components, of the CAR with a dsRNA molecule that inhibits expression of the molecule that modulates or regulates, e.g., inhibits, T-cell function.

Examples of dsRNA molecules useful for inhibiting expression of a molecule that modulates or regulates, e.g., inhibits, T-cell function, wherein the molecule that modulates or regulates, e.g., inhibits, T-cell function is PD-1 are provided below.

Provided in Table 18 below are the names of PDCD1 (PD1) RNAi agents (derived from their position in the mouse PDCD1 gene sequence NM_008798.2), along with the SEQ ID NOs: 286-333 representing the DNA sequence. Both sense (S) and antisense (AS) sequences are presented as 19mer and 21mer sequences are in this table. Also note that the position (PoS, e.g., 176) is derived from the position number in the mouse PDCD1 gene sequence NM_008798.2. SEQ ID NOs are indicated in groups of 12 that correspond with “sense 19” SEQ ID NOs: 286-297; “sense 21” SEQ ID NOs: 298-309; “asense 21” SEQ ID NOs: 310-321; “asense 19” SEQ ID NOs: 322-333.

Table 18. Mouse PDCD1 (PD1) shRNA sequences

Position on NM_008798.2	Target region	Sense19	Sense21	Asense21	Asense19
176	CDS	GGAGGTCCCT CACCTTCTA (SEQ ID NO: 286)	CTGGAGGTCC CTCACCTTCT A (SEQ ID NO: 298)	TAGAAGGTGA GGGACCTCCA G (SEQ ID NO: 310)	TAGAAGGTGA GGGACCTCC (SEQ ID NO: 322)

			298)	310)	
260	CDS	CGGAGGATCT TATGCTGAA (SEQ ID NO: 287)	GTCGGAGGAT CTTATGCTGA A (SEQ ID NO: 299)	TTCAGCATAA GATCCTCCGA C (SEQ ID NO: 311)	TTCAGCATAA GATCCTCCG (SEQ ID NO: 323)
359	CDS	CCCGCTTCCA GATCATACA (SEQ ID NO: 288)	TGCCCCGCTTC CAGATCATAC A (SEQ ID NO: 300)	TGTATGATCT GGAAGCGGGC A (SEQ ID NO: 312)	TGTATGATCT GGAAGCGGG (SEQ ID NO: 324)
528	CDS	GGAGACCTCA ACAAGATAT (SEQ ID NO: 289)	CTGGAGACCT CAACAAGATA T (SEQ ID NO: 301)	ATATCTTGTT GAGGTCTCCA G (SEQ ID NO: 313)	ATATCTTGTT GAGGTCTCC (SEQ ID NO: 325)
581	CDS	AAGGCATGGT CATTGGTAT (SEQ ID NO: 290)	TCAAGGCATG GTCATTGGTA T (SEQ ID NO: 302)	ATACCAATGA CCATGCCTTG A (SEQ ID NO: 314)	ATACCAATGA CCATGCCTT (SEQ ID NO: 326)
584	CDS	GCATGGTCAT TGGTATCAT (SEQ ID NO: 291)	AGGCATGGTC ATTGGTATCA T (SEQ ID NO: 303)	ATGATACCAA TGACCATGCC T (SEQ ID NO: 315)	ATGATACCAA TGACCATGC (SEQ ID NO: 327)
588	CDS	GGTCATTGGT ATCATGAGT (SEQ ID NO: 292)	ATGGTCATTG GTATCATGAG T (SEQ ID NO: 304)	ATGGTCATTG GTATCATGAG T (SEQ ID NO: 316)	ATGGTCATTG GTATCATGA (SEQ ID NO: 328)
609	CDS	CCTAGTGGGT ATCCCTGTA (SEQ ID NO: 293)	GCCCTAGTGG GTATCCCTGT A	GCCCTAGTGG GTATCCCTGT A	GCCCTAGTGG GTATCCCTG (SEQ ID NO: 329)

		293)	(SEQ ID NO: 305)	(SEQ ID NO: 317)	329)
919	CDS	GAGGATGGAC ATTGTTCTT (SEQ ID NO: 294)	ATGAGGATGG ACATTGTTCTT (SEQ ID NO: 306)	ATGAGGATGG ACATTGTTCTT (SEQ ID NO: 318)	ATGAGGATGG ACATTGTTC (SEQ ID NO: 330)
1021	3'UTR	GCATGCAGGC TACAGTTCA (SEQ ID NO: 295)	GAGCATGCAG GCTACAGTTC A (SEQ ID NO: 307)	GAGCATGCAG GCTACAGTTC A (SEQ ID NO: 319)	GAGCATGCAG GCTACAGTT (SEQ ID NO: 331)
1097	3'UTR	CCAGCACATG CACTGTTGA (SEQ ID NO: 296)	TTCCAGCACA TGCACTGTTG A (SEQ ID NO: 308)	TTCCAGCACA TGCACTGTTG A (SEQ ID NO: 320)	TTCCAGCACA TGCACTGTT (SEQ ID NO: 332)
1101	3'UTR	CACATGCACT GTTGAGTGA (SEQ ID NO: 297)	AGCACATGCA CTGTTGAGTG A (SEQ ID NO: 309)	AGCACATGCA CTGTTGAGTG A (SEQ ID NO: 321)	AGCACATGCA CTGTTGAGT (SEQ ID NO: 333)

5

Provided in Table 19 below are the names of PDCD1 (PD1) RNAi agents (derived from their position in the human PDCD1 gene sequence, along with the SEQ ID NOs. 334-381 representing the DNA sequence. Both sense (S) and antisense (AS) sequences are presented as 19mer and 21mer sequences. SEQ ID NOs are indicated in groups of 12 that correspond with

10 “sense 19” SEQ ID NOs: 334-345; “sense 21” SEQ ID NOs: 346-357; “asense 21” SEQ ID NOs: 358-369; “asense 19” SEQ ID NOs: 370-381.

Table 19. Human PDCD1 (PD1) shRNA sequences

Position on NM_005018.2	Target region	Sense19	Asense19	Sense21	Asense21
145	CDS	GGCCAGGATG	TCTAAGAACC	GCGGCCAGGA	TCTAAGAACC

		GTTCTTAGA (SEQ ID NO: 334)	ATCCTGGCC (SEQ ID NO: 346)	TGGTTCTTAG A (SEQ ID NO: 358)	ATCCTGGCCG C (SEQ ID NO: 370)
271	CDS	GCTTCGTGCT AAACTGGTA (SEQ ID NO: 335)	TACCAGTTTA GCACGAAGC (SEQ ID NO: 347)	GAGCTTCGTG CTAAACTGGT A (SEQ ID NO: 359)	TACCAGTTTA GCACGAAGCT C (SEQ ID NO: 371)
393	CDS	GGGCGTGACT TCCACATGA (SEQ ID NO: 336)	TCATGTGGAA GTCACGCC (SEQ ID NO: 348)	ACGGGCGTGA CTTCCACATG A (SEQ ID NO: 360)	TCATGTGGAA GTCACGCCCG T (SEQ ID NO: 372)
1497	3'UTR	CAGGCCTAGA GAAGTTTCA (SEQ ID NO: 337)	TGAAACTTCT CTAGGCCTG (SEQ ID NO: 349)	TGCAGGCCTA GAGAAGTTTC A (SEQ ID NO: 361)	TGAAACTTCT CTAGGCCTGC A (SEQ ID NO: 373)
1863	3'UTR	CTTGGAACCC ATTCTGAA (SEQ ID NO: 338)	TTCAGGAATG GGTTCCAAG (SEQ ID NO: 350)	TCCTTGGAAC CCATTCTGA A (SEQ ID NO: 362)	TTCAGGAATG GGTTCCAAG A (SEQ ID NO: 374)
1866	3'UTR	GGAACCCATT CCTGAAATT (SEQ ID NO: 339)	AATTTTCAGGA ATGGGTTC (SEQ ID NO: 351)	TTGGAACCCA TTCCTGAAAT T (SEQ ID NO: 363)	AATTTTCAGGA ATGGGTTC A (SEQ ID NO: 375)
1867	3'UTR	GAACCCATTC CTGAAATTA (SEQ ID NO: 340)	TAATTTTCAGG AATGGGTTC (SEQ ID NO: 352)	TGGAACCCAT TCCTGAAATT A (SEQ ID NO: 364)	TAATTTTCAGG AATGGGTTC A (SEQ ID NO: 376)
1868	3'UTR	AACCCATTCC TGAAATTAT (SEQ ID NO: 341)	ATAATTTTCAG GAATGGGT (SEQ ID NO: 353)	GGAACCCATT CCTGAAATT T (SEQ ID NO: 365)	ATAATTTTCAG GAATGGGT C (SEQ ID NO:377)
1869	3'UTR	ACCCATTCTT GAAATTATT (SEQ ID NO: 342)	AATAATTTCA GGAATGGGT (SEQ ID NO: 354)	GAACCCATTC CTGAAATTAT T (SEQ ID NO: 366)	AATAATTTCA GGAATGGGT C (SEQ ID NO: 378)
1870	3'UTR	CCCATTCCTG AAATTATTT (SEQ ID NO: 343)	AAATAATTTTC AGGAATGGG (SEQ ID NO: 355)	AACCCATTCC TGAAATTATT T (SEQ ID NO: 367)	AAATAATTTTC AGGAATGGGT T (SEQ ID NO: 379)
2079	3'UTR	CTGTGGTTCT ATTATATTA	TAATATAATA GAACCACAG	CCCTGTGGTT CTATTATATT	TAATATAATA GAACCACAGG

		(SEQ ID NO: 344)	(SEQ ID NO: 356)	A (SEQ ID NO: 368)	G (SEQ ID NO: 380)
2109	3'UTR	AAATATGAGA GCATGCTAA (SEQ ID NO: 345)	TTAGCATGCT CTCATATTT (SEQ ID NO: 357)	TTAAATATGA GAGCATGCTA A (SEQ ID NO: 369)	TTAGCATGCT CTCATATTTA A (SEQ ID NO: 381)

5

In one embodiment, the inhibitor of an inhibitory signal can be, e.g., an antibody or antibody fragment that binds to an inhibitory molecule. For example, the agent can be an antibody or antibody fragment that binds to PD1, PD-L1, PD-L2 or CTLA4 (e.g., ipilimumab (also referred to as MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206).). In an embodiment, the agent is an antibody or antibody fragment that binds to TIM3. In an embodiment, the agent is an antibody or antibody fragment that binds to LAG3. In embodiments, the agent that enhances the activity of a CAR-expressing cell, e.g., inhibitor of an inhibitory molecule, is administered in combination with an allogeneic CAR, e.g., an allogeneic CAR described herein (e.g., described in the Allogeneic CAR section herein).

PD-1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 Int. Immunol 8:765-75). Two ligands for PD-1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094). Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1. Antibodies, antibody fragments, and other inhibitors of PD-1, PD-L1 and PD-L2 are available in the art and may be used combination with a cars of the present invention described herein. For example, nivolumab (also referred to as BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody which specifically blocks PD-1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are disclosed in US 8,008,449 and WO2006/121168. Pidilizumab (CT-011; Cure Tech)

- 5 is a humanized IgG1k monoclonal antibody that binds to PD-1. Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611. Pembrolizumab (formerly known as lambrolizumab, and also referred to as MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. Pembrolizumab and other humanized anti-PD-1 antibodies are disclosed in US 8,354,509 and WO2009/114335.
- 10 MEDI4736 (Medimmune) is a human monoclonal antibody that binds to PDL1, and inhibits interaction of the ligand with PD1. MDPL3280A (Genentech / Roche) is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Patent No.: 7,943,743 and U.S. Publication No.: 20120039906. Other anti-PD-L1 binding agents include YW243.55.S70
- 15 (heavy and light chain variable regions are shown in SEQ ID NOs 20 and 21 in WO2010/077634) and MDX-1 105 (also referred to as BMS-936559, and, e.g., anti-PD-L1 binding agents disclosed in WO2007/005874). AMP-224 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-H1. Other anti-PD-1 antibodies include AMP
- 20 514 (Amplimmune), among others, e.g., anti-PD-1 antibodies disclosed in US 8,609,089, US 2010028330, and/or US 20120114649.

TIM3 (T cell immunoglobulin-3) also negatively regulates T cell function, particularly in IFN- γ -secreting CD4⁺ T helper 1 and CD8⁺ T cytotoxic 1 cells, and plays a critical role in T cell exhaustion. Inhibition of the interaction between TIM3 and its ligands, e.g., galectin-9

25 (Gal9), phosphatidylserine (PS), and HMGB1, can increase immune response. Antibodies, antibody fragments, and other inhibitors of TIM3 and its ligands are available in the art and may be used combination with a CD19 or BCMA CAR described herein. For example, antibodies, antibody fragments, small molecules, or peptide inhibitors that target TIM3 binds to the IgV domain of TIM3 to inhibit interaction with its ligands. Antibodies and peptides that

30 inhibit TIM3 are disclosed in WO2013/006490 and US20100247521. Other anti-TIM3 antibodies include humanized versions of RMT3-23 (disclosed in Ngiow et al., 2011, Cancer Res, 71:3540-3551), and clone 8B.2C12 (disclosed in Monney et al., 2002, Nature, 415:536-541). Bi-specific antibodies that inhibit TIM3 and PD-1 are disclosed in US20130156774.

In other embodiments, the agent which enhances the activity of a CAR-expressing cell

35 is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor). In

one embodiment, the inhibitor of CEACAM is an anti-CEACAM antibody molecule. Exemplary anti-CEACAM-1 antibodies are described in WO 2010/125571, WO 2013/082366 WO 2014/059251 and WO 2014/022332, *e.g.*, a monoclonal antibody 34B1, 26H7, and 5F4; or a recombinant form thereof, as described in, *e.g.*, US 2004/0047858, US 7,132,255 and WO 99/052552. In other embodiments, the anti-CEACAM antibody binds to CEACAM-5 as described in, *e.g.*, Zheng et al. *PLoS One*. 2010 Sep 2;5(9). pii: e12529 (DOI:10.1371/journal.pone.0021146), or crossreacts with CEACAM-1 and CEACAM-5 as described in, *e.g.*, WO 2013/054331 and US 2014/0271618.

Without wishing to be bound by theory, carcinoembryonic antigen cell adhesion molecules (CEACAM), such as CEACAM-1 and CEACAM-5, are believed to mediate, at least in part, inhibition of an anti-tumor immune response (*see e.g.*, Markel et al. *J Immunol*. 2002 Mar 15;168(6):2803-10; Markel et al. *J Immunol*. 2006 Nov 1;177(9):6062-71; Markel et al. *Immunology*. 2009 Feb;126(2):186-200; Markel et al. *Cancer Immunol Immunother*. 2010 Feb;59(2):215-30; Ortenberg et al. *Mol Cancer Ther*. 2012 Jun;11(6):1300-10; Stern et al. *J Immunol*. 2005 Jun 1;174(11):6692-701; Zheng et al. *PLoS One*. 2010 Sep 2;5(9). pii: e12529). For example, CEACAM-1 has been described as a heterophilic ligand for TIM-3 and as playing a role in TIM-3-mediated T cell tolerance and exhaustion (*see e.g.*, WO 2014/022332; Huang, et al. (2014) *Nature* doi:10.1038/nature13848). In embodiments, co-blockade of CEACAM-1 and TIM-3 has been shown to enhance an anti-tumor immune response in xenograft colorectal cancer models (*see e.g.*, WO 2014/022332; Huang, et al. (2014), *supra*). In other embodiments, co-blockade of CEACAM-1 and PD-1 reduce T cell tolerance as described, *e.g.*, in WO 2014/059251. Thus, CEACAM inhibitors can be used with the other immunomodulators described herein (*e.g.*, anti-PD-1 and/or anti-TIM-3 inhibitors) to enhance an immune response against a cancer, *e.g.*, a melanoma, a lung cancer (*e.g.*, NSCLC), a bladder cancer, a colon cancer an ovarian cancer, and other cancers as described herein.

LAG3 (lymphocyte activation gene-3 or CD223) is a cell surface molecule expressed on activated T cells and B cells that has been shown to play a role in CD8+ T cell exhaustion. Antibodies, antibody fragments, and other inhibitors of LAG3 and its ligands are available in the art and may be used combination with a CD19 or BCMA CAR described herein. For example, BMS-986016 (Bristol-Myers Squib) is a monoclonal antibody that targets LAG3. IMP701 (Immutep) is an antagonist LAG3 antibody and IMP731 (Immutep and

5 GlaxoSmithKline) is a depleting LAG3 antibody. Other LAG3 inhibitors include IMP321 (Immutep), which is a recombinant fusion protein of a soluble portion of LAG3 and Ig that binds to MHC class II molecules and activates antigen presenting cells (APC). Other antibodies are disclosed, e.g., in WO2010/019570.

10 In some embodiments, the agent which enhances the activity of a CAR-expressing cell can be, e.g., a fusion protein comprising a first domain and a second domain, wherein the first domain is an inhibitory molecule, or fragment thereof, and the second domain is a polypeptide that is associated with a positive signal, e.g., a polypeptide comprising an intracellular signaling domain as described herein. In some embodiments, the polypeptide that is associated with a positive signal can include a costimulatory domain of CD28, CD27, ICOS, e.g., an
15 intracellular signaling domain of CD28, CD27 and/or ICOS, and/or a primary signaling domain, e.g., of CD3 zeta, e.g., described herein. In one embodiment, the fusion protein is expressed by the same cell that expressed the CAR. In another embodiment, the fusion protein is expressed by a cell, e.g., a T cell or NK cell that does not express an anti-BCMA CAR.

20 In one embodiment, the agent which enhances activity of a CAR-expressing cell described herein is miR-17-92.

In one embodiment, the agent which enhances activity of a CAR-described herein is a cytokine. Cytokines have important functions related to T cell expansion, differentiation, survival, and homeostasis. Cytokines that can be administered to the subject receiving a CAR-expressing cell described herein include: IL-2, IL-4, IL-7, IL-9, IL-15, IL-18, and IL-21, or a
25 combination thereof. In preferred embodiments, the cytokine administered is IL-7, IL-15, or IL-21, or a combination thereof. The cytokine can be administered once a day or more than once a day, e.g., twice a day, three times a day, or four times a day. The cytokine can be administered for more than one day, e.g. the cytokine is administered for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks. For example, the cytokine is
30 administered once a day for 7 days.

In embodiments, the cytokine is administered in combination with CAR-expressing T cells. The cytokine can be administered simultaneously or concurrently with the CAR-expressing T cells, e.g., administered on the same day. The cytokine may be prepared in the same pharmaceutical composition as the CAR-expressing T cells, or may be prepared in a

5 separate pharmaceutical composition. Alternatively, the cytokine can be administered shortly after administration of the CAR-expressing T cells, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration of the CAR-expressing T cells. In embodiments where the cytokine is administered in a dosing regimen that occurs over more than one day, the first day of the cytokine dosing regimen can be on the same day as administration with the CAR-
10 expressing T cells, or the first day of the cytokine dosing regimen can be 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration of the CAR-expressing T cells. In one embodiment, on the first day, the CAR-expressing T cells are administered to the subject, and on the second day, a cytokine is administered once a day for the next 7 days. In a preferred embodiment, the cytokine to be administered in combination with CAR-expressing T cells is
15 IL-7, IL-15, or IL-21.

In other embodiments, the cytokine is administered a period of time after administration of CAR-expressing cells, e.g., at least 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year or more after administration of CAR-expressing cells. In one embodiment,
20 the cytokine is administered after assessment of the subject's response to the CAR-expressing cells. For example, the subject is administered CAR-expressing cells according to the dosage and regimens described herein. The response of the subject to CAR-expressing cell therapy is assessed at 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year or more
25 after administration of CAR-expressing cells, using any of the methods described herein, including inhibition of tumor growth, reduction of circulating tumor cells, or tumor regression. Subjects that do not exhibit a sufficient response to CAR-expressing cell therapy can be administered a cytokine. Administration of the cytokine to the subject that has sub-optimal response to the CAR-expressing cell therapy improves CAR-expressing cell efficacy or anti-
30 cancer activity. In a preferred embodiment, the cytokine administered after administration of CAR-expressing cells is IL-7.

COMBINATION WITH A LOW, IMMUNE ENHANCING, DOSE OF AN mTOR INHIBITOR

Methods described herein use low, immune enhancing, doses of mTOR inhibitors, e.g.,
35 allosteric mTOR inhibitors, including rapalogs such as RAD001. Administration of a low,

5 immune enhancing, dose of an mTOR inhibitor (e.g., a dose that is insufficient to completely suppress the immune system, but sufficient to improve immune function) can optimize the performance of immune effector cells, e.g., T cells or CAR-expressing cells, in the subject. Methods for measuring mTOR inhibition, dosages, treatment regimens, and suitable pharmaceutical compositions are described in U.S. Patent Application No. 2015/01240036,
10 hereby incorporated by reference.

In an embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor results in one or more of the following:

- i) a decrease in the number of PD-1 positive immune effector cells;
- ii) an increase in the number of PD-1 negative immune effector cells;
- 15 iii) an increase in the ratio of PD-1 negative immune effector cells / PD-1 positive immune effector cells;
- iv) an increase in the number of naive T cells;
- v) an increase in the expression of one or more of the following markers: CD62L^{high}, CD127^{high}, CD27⁺, and BCL2, e.g., on memory T cells, e.g., memory T cell
20 precursors;
- vi) a decrease in the expression of KLRG1, e.g., on memory T cells, e.g., memory T cell precursors; or
- vii) an increase in the number of memory T cell precursors, e.g., cells with any one or combination of the following characteristics: increased CD62L^{high}, increased
25 CD127^{high}, increased CD27⁺, decreased KLRG1, and increased BCL2;

and wherein any of the foregoing, e.g., i), ii), iii), iv), v), vi), or vii), occurs e.g., at least transiently, e.g., as compared to a non-treated subject.

In another embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor results in increased or prolonged proliferation or persistence of CAR-expressing cells,
30 e.g., in culture or in a subject, e.g., as compared to non-treated CAR-expressing cells or a non-treated subject. In embodiments, increased proliferation or persistence is associated with an increase in the number of CAR-expressing cells. Methods for measuring increased or prolonged proliferation are described in Examples 15 and 16. In another embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor results in increased
35 killing of cancer cells by CAR-expressing cells, e.g., in culture or in a subject, e.g., as compared to non-treated CAR-expressing cells or a non-treated subject. In embodiments,

5 increased killing of cancer cells is associated with in a decrease in tumor volume. Methods for measuring increased killing of cancer cells are described herein, e.g., in Examples 2, 5-6, 8, and 13. In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with a low, immune enhancing dose of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001, or a catalytic mTOR inhibitor. For
10 example, administration of the low, immune enhancing, dose of the mTOR inhibitor can be initiated prior to administration of a CAR-expressing cell described herein; completed prior to administration of a CAR-expressing cell described herein; initiated at the same time as administration of a CAR-expressing cell described herein; overlapping with administration of a CAR-expressing cell described herein; or continuing after administration of a CAR-expressing
15 cell described herein.

Alternatively or in addition, administration of a low, immune enhancing, dose of an mTOR inhibitor can optimize immune effector cells to be engineered to express a CAR molecule described herein. In such embodiments, administration of a low, immune enhancing, dose of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalytic inhibitor,
20 is initiated or completed prior to harvest of immune effector cells, e.g., T cells or NK cells, to be engineered to express a CAR molecule described herein, from a subject.

In another embodiment, immune effector cells, e.g., T cells or NK cells, to be engineered to express a CAR molecule described herein, e.g., after harvest from a subject, or CAR-expressing immune effector cells, e.g., T cells or NK cells, e.g., prior to administration to
25 a subject, can be cultured in the presence of a low, immune enhancing, dose of an mTOR inhibitor.

In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in an immediate release dosage form, 0.1 to 20, 0.5 to 10, 2.5 to 7.5, 3 to 6, or about 5, mgs of RAD001, or a
30 bioequivalent dose thereof. In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in a sustained release dosage form, 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs of RAD001, or a bioequivalent dose thereof.

5 In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 90%, at least 10 but no more than 90%, at least 15, but no more than 90%, at least 20 but no more than 90%, at least 30 but no more than 90%, at least 40 but no more than 90%, at least 50 but no more than 90%, at least 60 but no more than 90%, at least 70 but no more than 90%, at least 5 but no more than 80%, at least 10 but no more than 80%, at least 15, but no more than 80%, at least 20 but no more than 80%, at least 30 but no more than 80%, at least 40 but no more than 80%, at least 50 but no more than 80%, at least 60 but no more than 80%, at least 5 but no more than 70%, at least 10 but no more than 70%, at least 15, but no more than 70%, at least 20 but no more than 70%, at least 30 but no more than 70%, at least 40 but no more than 70%, at least 50 but no more than 70%, at least 5 but no more than 60%, at least 10 but no more than 60%, at least 15, but no more than 60%, at least 20 but no more than 60%, at least 30 but no more than 60%, at least 40 but no more than 60%, at least 5 but no more than 50%, at least 10 but no more than 50%, at least 15, but no more than 50%, at least 20 but no more than 50%, at least 30 but no more than 50%, at least 40 but no more than 50%, at least 5 but no more than 40%, at least 10 but no more than 40%, at least 15, but no more than 40%, at least 20 but no more than 40%, at least 30 but no more than 40%, at least 35 but no more than 40%, at least 5 but no more than 30%, at least 10 but no more than 30%, at least 15, but no more than 30%, at least 20 but no more than 30%, or at least 25 but no more than 30%.


10 In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in an immediate release dosage form, 0.1 to 20, 0.5 to 10, 2.5 to 7.5, 3 to 6, or about 5, mgs of RAD001, or a bioequivalent dose thereof. In an embodiment, administering to the subject a low, immune enhancing, dose of an mTOR inhibitor comprises administering, e.g., once per week, e.g., in a sustained release dosage form, 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs of RAD001, or a bioequivalent dose thereof.

15 The extent of mTOR inhibition can be conveyed as, or corresponds to, the extent of P70 S6 kinase inhibition, e.g., the extent of mTOR inhibition can be determined by the level of decrease in P70 S6 kinase activity, e.g., by the decrease in phosphorylation of a P70 S6 kinase substrate. The level of mTOR inhibition can be evaluated by various methods, such as measuring P70 S6 kinase activity by the Boulay assay, as described in U.S. Patent Application

- 5 No. 2015/01240036, hereby incorporated by reference, or as described in U.S. Patent No. 7,727,950, hereby incorporated by reference; measuring the level of phosphorylated S6 by western blot; or evaluating a change in the ratio of PD1 negative immune effector cells to PD1 positive immune effector cells.

As used herein, the term “mTOR inhibitor” refers to a compound or ligand, or a
10 pharmaceutically acceptable salt thereof, which inhibits the mTOR kinase in a cell. In an embodiment, an mTOR inhibitor is an allosteric inhibitor. Allosteric mTOR inhibitors include the neutral tricyclic compound rapamycin (sirolimus), rapamycin-related compounds, that is compounds having structural and functional similarity to rapamycin including, e.g., rapamycin derivatives, rapamycin analogs (also referred to as rapalogs) and other macrolide compounds
15 that inhibit mTOR activity. In an embodiment, an mTOR inhibitor is a catalytic inhibitor.

Rapamycin is a known macrolide antibiotic produced by *Streptomyces hygroscopicus* having the structure shown in Formula A.



(A)

- See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L., et al., J.
20 Am. Chem. Soc. (1991) 113: 7433; U.S. Patent No. 3,929,992. There are various numbering schemes proposed for rapamycin. To avoid confusion, when specific rapamycin analogs are named herein, the names are given with reference to rapamycin using the numbering scheme of formula A.

Rapamycin analogs useful in the invention are, for example, O-substituted analogs in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by OR₁ in which R₁ is hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, or aminoalkyl; e.g. RAD001, also known as everolimus, as described in US 5,665,772 and WO94/09010, the contents of each are incorporated by reference.

Other suitable rapamycin analogs include those substituted at the 26- or 28-position. The rapamycin analog may be an epimer of an analog mentioned above, particularly an epimer of an analog substituted in position 40, 28 or 26, and may optionally be further hydrogenated, e.g. as described in US 6,015,815, WO95/14023 and WO99/15530 the contents of which are incorporated by reference, e.g. ABT578 also known as zotarolimus or a rapamycin analog described in US 7,091,213, WO98/02441 and WO01/14387 the contents of which are incorporated by reference, e.g. AP23573 also known as ridaforolimus.

Examples of rapamycin analogs suitable for use in the present invention from US 5,665,772 include, but are not limited to, 40-O-benzyl-rapamycin, 40-O-(4'-hydroxymethyl)benzyl-rapamycin, 40-O-[4'-(1,2-dihydroxyethyl)]benzyl-rapamycin, 40-O-allyl-rapamycin, 40-O-[3'-(2,2-dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin, (2'E,4'S)-40-O-(4',5'-dihydroxypent-2'-en-1'-yl)-rapamycin, 40-O-(2-hydroxy)ethoxycarbonylmethyl-rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-(6-hydroxy)hexyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-dihydroxyprop-1-yl]-rapamycin, 40-O-(2-acetoxy)ethyl-rapamycin, 40-O-(2-nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-methyl-N'-piperazinyloxy)acetoxy]ethyl-rapamycin, 39-O-desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(2-aminoethyl)-rapamycin, 40-O-(2-acetaminoethyl)-rapamycin, 40-O-(2-nicotinamidoethyl)-rapamycin, 40-O-(2-(N-methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-tolylsulfonamidoethyl)-rapamycin and 40-O-[2-(4',5'-dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin.

Other rapamycin analogs useful in the present invention are analogs where the hydroxyl group on the cyclohexyl ring of rapamycin and/or the hydroxy group at the 28 position is

5 replaced with an hydroxyester group are known, for example, rapamycin analogs found in US RE44,768, e.g. temsirolimus.

Other rapamycin analogs useful in the preset invention include those wherein the methoxy group at the 16 position is replaced with another substituent, preferably (optionally hydroxy-substituted) alkynyloxy, benzyl, orthomethoxybenzyl or chlorobenzyl and/or wherein
 10 the methoxy group at the 39 position is deleted together with the 39 carbon so that the cyclohexyl ring of rapamycin becomes a cyclopentyl ring lacking the 39 position methoxy group; e.g. as described in WO95/16691 and WO96/41807, the contents of which are incorporated by reference. The analogs can be further modified such that the hydroxy at the 40-position of rapamycin is alkylated and/or the 32-carbonyl is reduced.

15 Rapamycin analogs from WO95/16691 include, but are not limited to, 16-demthoxy-16-(pent-2-ynyl)oxy-rapamycin, 16-demthoxy-16-(but-2-ynyl)oxy-rapamycin, 16-demthoxy-16-(propargyl)oxy-rapamycin, 16-demethoxy-16-(4-hydroxy-but-2-ynyl)oxy-rapamycin, 16-demthoxy-16-benzyloxy-40-O-(2-hydroxyethyl)-rapamycin, 16-demthoxy-16-benzyloxy-rapamycin, 16-demethoxy-16-ortho-methoxybenzyl-rapamycin, 16-demethoxy-40-O-(2-methoxyethyl)-16-pent-2-ynyl)oxy-rapamycin, 39-demethoxy-40-desoxy-39-formyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-hydroxymethyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-carboxy-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(4-methyl-piperazin-1-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(morpholin-4-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-[N-methyl, N-(2-pyridin-2-yl-ethyl)]carbamoyl-42-nor-rapamycin and 39-demethoxy-40-desoxy-39-(p-toluenesulfonylhydrazonomethyl)-42-nor-rapamycin.
 25 rapamycin.

Rapamycin analogs from WO96/41807 include, but are not limited to, 32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-40-O-(2-hydroxy-ethyl)-rapamycin, 16-O-pent-2-ynyl-32-(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, 32(S)-dihydro-40-O-(2-methoxy)ethyl-rapamycin and 32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin.
 30 rapamycin.

Another suitable rapamycin analog is umirolimus as described in US2005/0101624 the contents of which are incorporated by reference.

RAD001, otherwise known as everolimus (Afinitor®), has the chemical name
 35 (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl]-19,30-dimethoxy-

5 15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone, as described in US 5,665,772 and WO94/09010, the contents of each are incorporated by reference.

Further examples of allosteric mTOR inhibitors include sirolimus (rapamycin, AY-22989), 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin (also called
10 temsirolimus or CCI-779) and ridaforolimus (AP-23573/MK-8669). Other examples of allosteric mTor inhibitors include zotarolimus (ABT578) and umirolimus.

Alternatively or additionally, catalytic, ATP-competitive mTOR inhibitors have been found to target the mTOR kinase domain directly and target both mTORC1 and mTORC2. These are also more effective inhibitors of mTORC1 than such allosteric mTOR inhibitors as
15 rapamycin, because they modulate rapamycin-resistant mTORC1 outputs such as 4EBP1-T37/46 phosphorylation and cap-dependent translation.

Catalytic inhibitors include: BEZ235 or 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, or the monotosylate salt form (the synthesis of BEZ235 is described in WO2006/122806); CCG168 (otherwise known
20 as AZD-8055, Chresta, C.M., et al., Cancer Res, 2010, 70(1), 288-298) which has the chemical name {5-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide (WO09104019); 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (WO10051043 and WO2013023184); A N-(3-(N-(3-((3,5-
25 dimethoxyphenyl)amino)quinoxaline-2-yl)sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide (WO07044729 and WO12006552); PKI-587 (Venkatesan, A.M., J. Med.Chem., 2010, 53, 2636-2645) which has the chemical name 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl]urea; GSK-2126458 (ACS Med. Chem. Lett., 2010, 1, 39-43) which has the chemical name 2,4-difluoro-N-{2-methoxy-5-
30 [4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (WO10114484); and (E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide (WO12007926).

Further examples of catalytic mTOR inhibitors include 8-(6-methoxy-pyridin-3-yl)-3-
35 methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (WO2006/122806) and Ku-0063794 (Garcia-Martinez JM, et al., Biochem J., 2009, 421(1),

- 5 29-42. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).) WYE-354 is another example of a catalytic mTOR inhibitor (Yu K, et al. (2009). Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Res. 69(15): 6232-6240).

10 mTOR inhibitors useful according to the present invention also include prodrugs, derivatives, pharmaceutically acceptable salts, or analogs thereof of any of the foregoing.

mTOR inhibitors, such as RAD001, may be formulated for delivery based on well-established methods in the art based on the particular dosages described herein. In particular, US Patent No. 6,004,973 (incorporated herein by reference) provides examples of formulations useable with the mTOR inhibitors described herein.

15

Methods and Biomarkers for Evaluating CAR-Effectiveness or Sample Suitability

In another aspect, the invention features a method of evaluating or monitoring the effectiveness of a CAR-expressing cell therapy (e.g., a BCMACAR therapy), in a subject (e.g., a subject having a cancer, e.g., a hematological cancer), or the suitability of a sample (e.g., an apheresis sample) for a CAR therapy (e.g., a BCMACAR therapy). The method includes
20 acquiring a value of effectiveness to the CAR therapy, or sample suitability, wherein said value is indicative of the effectiveness or suitability of the CAR-expressing cell therapy.

In embodiments, the value of effectiveness to the CAR therapy, or sample suitability, comprises a measure of one, two, three, four, five, six or more (all) of the following:

25 (i) the level or activity of one, two, three, or more (e.g., all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (e.g., younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

30 (ii) the level or activity of one, two, three, or more (e.g., all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (e.g., older CD4 or CD8 cells), or late memory T cells, or a combination thereof, in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample);

35 (iii) the level or activity of an immune cell exhaustion marker, e.g., one, two or more immune checkpoint inhibitors (e.g., PD-1, PD-L1, TIM-3 and/or LAG-3) in a sample (e.g., an apheresis sample or a manufactured CAR-expressing cell product sample). In one

5 embodiment, an immune cell has an exhausted phenotype, *e.g.*, co-expresses at least two exhaustion markers, *e.g.*, co-expresses PD-1 and TIM-3. In other embodiments, an immune cell has an exhausted phenotype, *e.g.*, co-expresses at least two exhaustion markers, *e.g.*, co-expresses PD-1 and LAG-3;

(iv) the level or activity of CD27 and/or CD45RO- (*e.g.*, CD27+ CD45RO-) immune
10 effector cells, *e.g.*, in a CD4+ or a CD8+ T cell population, in a sample (*e.g.*, an apheresis sample or a manufactured CAR-expressing cell product sample);

(v) the level or activity of one, two, three, four, five, ten, twenty or more of the biomarkers chosen from CCL20, IL-17a and/or IL-6, PD-1, PD-L1, LAG-3, TIM-3, CD57, CD27, CD122, CD62L, KLRG1;

15

(vi) a cytokine level or activity (*e.g.*, quality of cytokine repertoire) in a CAR-expressing cell product sample, *e.g.*, BCMA- expressing cell product sample; or

(vii) a transduction efficiency of a CAR-expressing cell in a manufactured CAR-expressing cell product sample.

20

In some embodiments of any of the methods disclosed herein, the CAR-expressing cell therapy comprises a plurality (*e.g.*, a population) of CAR-expressing immune effector cells, *e.g.*, a plurality (*e.g.*, a population) of T cells or NK cells, or a combination thereof. In one embodiment, the CAR-expressing cell therapy is a BCMA CAR therapy.

25

In some embodiments of any of the methods disclosed herein, the measure of one or more of (i)-(vii) is obtained from an apheresis sample acquired from the subject. The apheresis sample can be evaluated prior to infusion or re-infusion.

30

In some embodiments of any of the methods disclosed herein, the measure of one or more of (i)-(vii) is obtained from a manufactured CAR-expressing cell product sample, *e.g.*, BCMA CAR- expressing cell product sample. The manufactured CAR-expressing cell product can be evaluated prior to infusion or re-infusion.

In some embodiments of any of the methods disclosed herein, the subject is evaluated prior to receiving, during, or after receiving, the CAR-expressing cell therapy.

5 In some embodiments of any of the methods disclosed herein, the measure of one or more of (i)-(vii) evaluates a profile for one or more of gene expression, flow cytometry or protein expression.

 In some embodiments of any of the methods disclosed herein, the method further comprises identifying the subject as a responder, a non-responder, a relapser or a non-relapser,
10 based on a measure of one or more of (i)-(vii).

 In some embodiments of any of the methods disclosed herein, a responder (e.g., a complete responder) has, or is identified as having, a greater level or activity of one, two, or more (all) of GZMK, PPF1BP2, or naïve T cells as compared to a non-responder.

 In some embodiments of any of the methods disclosed herein, a non-responder has, or is
15 identified as having, a greater level or activity of one, two, three, four, five, six, seven, or more (e.g., all) of IL22, IL-2RA, IL-21, IRF8, IL8, CCL17, CCL22, effector T cells, or regulatory T cells, as compared to a responder.

 In an embodiment, a relapser is a patient having, or who is identified as having, an increased level of expression of one or more of (e.g., 2, 3, 4, or all of) the following genes,
20 compared to non relapsers: MIR199A1, MIR1203, uc021ovp, ITM2C, and HLA-DQB1 and/or a decreased levels of expression of one or more of (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of) the following genes, compared to non relapsers: PPIAL4D, TTTY10, TXLNG2P, MIR4650-1, KDM5D, USP9Y, PRKY, RPS4Y2, RPS4Y1, NCRNA00185, SULT1E1, and EIF1AY.

 In some embodiments of any of the methods disclosed herein, a complete responder
25 has, or is identified as having, a greater, e.g., a statistically significant greater, percentage of CD8+ T cells compared to a reference value, e.g., a non-responder percentage of CD8+ T cells.

 In some embodiments of any of the methods disclosed herein, a complete responder has, or is identified as having, a greater percentage of CD27+ CD45RO- immune effector cells, e.g., in the CD8+ population, compared to a reference value, e.g., a non-responder number of
30 CD27+ CD45RO- immune effector cells.

 In some embodiments of any of the methods disclosed herein, a complete responder or a partial responder has, or is identified as having, a greater, e.g., a statistically significant greater, percentage of CD4+ T cells compared to a reference value, e.g., a non-responder percentage of CD4+ T cells.

5 In some embodiments of any of the methods disclosed herein, a complete responder has, or is identified as having, a greater percentage of one, two, three, or more (*e.g.*, all) of resting T_{EFF} cells, resting T_{REG} cells, younger T cells (*e.g.*, younger CD4 or CD8 cells, or gamma/delta T cells), or early memory T cells, or a combination thereof, compared to a reference value, *e.g.*, a non-responder number of resting T_{EFF} cells, resting T_{REG} cells, younger
10 T cells (*e.g.*, younger CD4 or CD8 cells), or early memory T cells.

In some embodiments of any of the methods disclosed herein, a non-responder has, or is identified as having, a greater percentage of one, two, three, or more (*e.g.*, all) of activated T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells, or a combination thereof, compared to a reference value, *e.g.*, a responder number of activated
15 T_{EFF} cells, activated T_{REG} cells, older T cells (*e.g.*, older CD4 or CD8 cells), or late memory T cells.

In some embodiments of any of the methods disclosed herein, a non-responder has, or is identified as having, a greater percentage of an immune cell exhaustion marker, *e.g.*, one, two or more immune checkpoint inhibitors (*e.g.*, PD-1, PD-L1, TIM-3 and/or LAG-3). In one
20 embodiment, a non-responder has, or is identified as having, a greater percentage of PD-1, PD-L1, or LAG-3 expressing immune effector cells (*e.g.*, CD4+ T cells and/or CD8+ T cells) (*e.g.*, CAR-expressing CD4+ cells and/or CD8+ T cells) compared to the percentage of PD-1 or LAG-3 expressing immune effector cells from a responder.

In one embodiment, a non-responder has, or is identified as having, a greater percentage
25 of immune cells having an exhausted phenotype, *e.g.*, immune cells that co-express at least two exhaustion markers, *e.g.*, co-expresses PD-1, PD-L1 and/or TIM-3. In other embodiments, a non-responder has, or is identified as having, a greater percentage of immune cells having an exhausted phenotype, *e.g.*, immune cells that co-express at least two exhaustion markers, *e.g.*, co-expresses PD-1 and LAG-3.

30 In some embodiments of any of the methods disclosed herein, a non-responder has, or is identified as having, a greater percentage of PD-1/ PD-L1+/LAG-3+ cells in the CAR-expressing cell population (*e.g.*, a BCMACAR+ cell population) compared to a responder (*e.g.*, a complete responder) to the CAR-expressing cell therapy.

In some embodiments of any of the methods disclosed herein, a partial responder has, or
35 is identified as having, a higher percentages of PD-1/ PD-L1+/LAG-3+ cells, than a responder, in the CAR-expressing cell population (*e.g.*, a BCMACAR+ cell population).

5 In some embodiments of any of the methods disclosed herein, a non-responder has, or is identified as having, an exhausted phenotype of PD1/ PD-L1+ CAR+ and co-expression of LAG3 in the CAR-expressing cell population (e.g., a BCMACAR + cell population).

In some embodiments of any of the methods disclosed herein, a non-responder has, or is identified as having, a greater percentage of PD-1/ PD-L1+/TIM-3+ cells in the CAR-
10 expressing cell population (e.g., a BCMACAR + cell population) compared to the responder (e.g., a complete responder).

In some embodiments of any of the methods disclosed herein, a partial responders has, or is identified as having, a higher percentage of PD-1/ PD-L1+/TIM-3+ cells, than responders, in the CAR-expressing cell population (e.g., a BCMACAR + cell population).

15 In some embodiments of any of the methods disclosed herein, the presence of CD8+ CD27+ CD45RO- T cells in an apheresis sample is a positive predictor of the subject response to a CAR-expressing cell therapy (e.g., a BCMACAR therapy).

In some embodiments of any of the methods disclosed herein, a high percentage of PD1+ CAR+ and LAG3+ or TIM3+ T cells in an apheresis sample is a poor prognostic
20 predictor of the subject response to a CAR-expressing cell therapy (e.g., a BCMACAR therapy).

In some embodiments of any of the methods disclosed herein, the responder (e.g., the complete or partial responder) has one, two, three or more (or all) of the following profile:

(i) has a greater number of CD27+ immune effector cells compared to a reference value,
25 e.g., a non-responder number of CD27+ immune effector cells;

(ii) (i) has a greater number of CD8+ T cells compared to a reference value, e.g., a non-responder number of CD8+ T cells;

(iii) has a lower number of immune cells expressing one or more checkpoint inhibitors, e.g., a checkpoint inhibitor chosen from PD-1, PD-L1, LAG-3, TIM-3, or KLRG-1, or a
30 combination, compared to a reference value, e.g., a non-responder number of cells expressing one or more checkpoint inhibitors; or

(iv) has a greater number of one, two, three, four or more (all) of resting T_{EFF} cells, resting T_{REG} cells, naïve CD4 cells, unstimulated memory cells or early memory T cells, or a combination thereof, compared to a reference value, e.g., a non-responder number of resting
35 T_{EFF} cells, resting T_{REG} cells, naïve CD4 cells, unstimulated memory cells or early memory T cells.

5 In some embodiments of any of the methods disclosed herein, the cytokine level or activity of (vi) is chosen from one, two, three, four, five, six, seven, eight, or more (or all) of cytokine CCL20/MIP3a, IL17A, IL6, GM-CSF, IFN γ , IL10, IL13, IL2, IL21, IL4, IL5, IL9 or TNF α , or a combination thereof. The cytokine can be chosen from one, two, three, four or more (all) of IL-17a, CCL20, IL2, IL6, or TNF α . In one embodiment, an increased level or
10 activity of a cytokine is chosen from one or both of IL-17a and CCL20, is indicative of increased responsiveness or decreased relapse.

In some embodiments of any of the methods disclosed herein, a transduction efficiency of 15% or higher in (vii) is indicative of increased responsiveness or decreased relapse.

15 In some embodiments of any of the methods disclosed herein, a transduction efficiency of less than 15% in (vii) is indicative of decreased responsiveness or increased relapse.

In embodiments, the responder, a non-responder, a relapser or a non-relapser identified by the methods herein can be further evaluated according to clinical criteria. For example, a complete responder has, or is identified as, a subject having a disease, e.g., a cancer, who exhibits a complete response, e.g., a complete remission, to a treatment. A complete response
20 may be identified, e.g., using the NCCN Guidelines[®], or Cheson et al, J Clin Oncol 17:1244 (1999) and Cheson et al., "Revised Response Criteria for Malignant Lymphoma", J Clin Oncol 25:579-586 (2007) (both of which are incorporated by reference herein in their entireties), as described herein. A partial responder has, or is identified as, a subject having a disease, e.g., a cancer, who exhibits a partial response, e.g., a partial remission, to a treatment. A partial
25 response may be identified, e.g., using the NCCN Guidelines[®], or Cheson criteria as described herein. A non-responder has, or is identified as, a subject having a disease, e.g., a cancer, who does not exhibit a response to a treatment, e.g., the patient has stable disease or progressive disease. A non-responder may be identified, e.g., using the NCCN Guidelines[®], or Cheson criteria as described herein.

30 Alternatively, or in combination with the methods disclosed herein, responsive to said value, performing one, two, three four or more of:

- administering e.g., to a responder or a non-relapser, a CAR-expressing cell therapy;
- administered an altered dosing of a CAR-expressing cell therapy;
- 35 altering the schedule or time course of a CAR-expressing cell therapy;

5 administering, e.g., to a non-responder or a partial responder, an additional agent in combination with a CAR-expressing cell therapy, e.g., a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein;

administering to a non-responder or partial responder a therapy that increases the number of younger T cells in the subject prior to treatment with a CAR-expressing cell therapy;

10 modifying a manufacturing process of a CAR-expressing cell therapy, e.g., enriching for younger T cells prior to introducing a nucleic acid encoding a CAR, or increasing the transduction efficiency, e.g., for a subject identified as a non-responder or a partial responder;

administering an alternative therapy, e.g., for a non-responder or partial responder or relapser; or

15 if the subject is, or is identified as, a non-responder or a relapser, decreasing the T_{REG} cell population and/or T_{REG} gene signature, e.g., by one or more of CD25 depletion, administration of cyclophosphamide, anti-GITR antibody, or a combination thereof.

In certain embodiments, the subject is pre-treated with an anti-GITR antibody. In certain embodiment, the subject is treated with an anti-GITR antibody prior to infusion or re-
20 infusion.

Biopolymer delivery methods

In some embodiments, one or more CAR-expressing cells as disclosed herein can be
25 administered or delivered to the subject via a biopolymer scaffold, e.g., a biopolymer implant. Biopolymer scaffolds can support or enhance the delivery, expansion, and/or dispersion of the CAR-expressing cells described herein. A biopolymer scaffold comprises a biocompatible (e.g., does not substantially induce an inflammatory or immune response) and/or a biodegradable polymer that can be naturally occurring or synthetic.

30 Examples of suitable biopolymers include, but are not limited to, agar, agarose, alginate, alginate/calcium phosphate cement (CPC), beta-galactosidase (β -GAL), (1,2,3,4,6-pentaacetyl α -D-galactose), cellulose, chitin, chitosan, collagen, elastin, gelatin, hyaluronic acid collagen, hydroxyapatite, poly(3-hydroxybutyrate-co-3-hydroxy-hexanoate) (PHBHHx), poly(lactide), poly(caprolactone) (PCL), poly(lactide-co-glycolide) (PLG), polyethylene oxide

5 (PEO), poly(lactic-co-glycolic acid) (PLGA), polypropylene oxide (PPO), polyvinyl alcohol (PVA), silk, soy protein, and soy protein isolate, alone or in combination with any other polymer composition, in any concentration and in any ratio. The biopolymer can be augmented or modified with adhesion- or migration-promoting molecules, e.g., collagen-mimetic peptides that bind to the collagen receptor of lymphocytes, and/or stimulatory molecules to enhance the
10 delivery, expansion, or function, e.g., anti-cancer activity, of the cells to be delivered. The biopolymer scaffold can be an injectable, e.g., a gel or a semi-solid, or a solid composition.

In some embodiments, CAR-expressing cells described herein are seeded onto the biopolymer scaffold prior to delivery to the subject. In embodiments, the biopolymer scaffold further comprises one or more additional therapeutic agents described herein (e.g., another
15 CAR-expressing cell, an antibody, or a small molecule) or agents that enhance the activity of a CAR-expressing cell, e.g., incorporated or conjugated to the biopolymers of the scaffold. In embodiments, the biopolymer scaffold is injected, e.g., intratumorally, or surgically implanted at the tumor or within a proximity of the tumor sufficient to mediate an anti-tumor effect. Additional examples of biopolymer compositions and methods for their delivery are described
20 in Stephan et al., *Nature Biotechnology*, 2015, 33:97-101; and WO2014/110591.

Pharmaceutical compositions and treatments

Pharmaceutical compositions of the present invention may comprise a CAR-expressing cell, e.g., a plurality of CAR-expressing cells, as described herein, in combination with one or
25 more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the
30 present invention are in one aspect formulated for intravenous administration.

Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages may be determined by
35 clinical trials.

5 In one embodiment, the pharmaceutical composition is substantially free of, e.g., there are no detectable levels of a contaminant, e.g., selected from the group consisting of endotoxin, mycoplasma, replication competent lentivirus (RCL), p24, VSV-G nucleic acid, HIV gag, residual anti-CD3/anti-CD28 coated beads, mouse antibodies, pooled human serum, bovine serum albumin, bovine serum, culture media components, vector packaging cell or plasmid
10 components, a bacterium and a fungus. In one embodiment, the bacterium is at least one selected from the group consisting of *Alcaligenes faecalis*, *Candida albicans*, *Escherichia coli*, *Haemophilus influenza*, *Neisseria meningitidis*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Streptococcus pneumonia*, and *Streptococcus pyogenes* group A.

When “an immunologically effective amount,” “an anti-tumor effective amount,” “a
15 tumor-inhibiting effective amount,” or “therapeutic amount” is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the T cells described herein may be administered at a
20 dosage of 10^4 to 10^9 cells/kg body weight, in some instances 10^5 to 10^6 cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988)..

25 In certain aspects, it may be desired to administer activated T cells to a subject and then subsequently redraw blood (or have an apheresis performed), activate T cells therefrom according to the present invention, and reinfuse the patient with these activated and expanded T cells. This process can be carried out multiple times every few weeks. In certain aspects, T cells can be activated from blood draws of from 10cc to 400cc. In certain aspects, T cells are
30 activated from blood draws of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, or 100cc.

The administration of the subject compositions may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient trans
35 arterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one aspect, the T cell

5 compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In one aspect, the CAR-expressing cell (e.g., T cell or NK cell) compositions of the present invention are administered by i.v. injection. The compositions of CAR-expressing cells (e.g., T cells or NK cells) may be injected directly into a tumor, lymph node, or site of infection.

10 In a particular exemplary aspect, subjects may undergo leukapheresis, wherein leukocytes are collected, enriched, or depleted ex vivo to select and/or isolate the cells of interest, e.g., immune effector cells (e.g., T cells or NK cells). These immune effector cell (e.g., T cell or NK cell) isolates may be expanded by methods known in the art and treated such that one or more CAR constructs of the invention may be introduced, thereby creating a CAR-
15 expressing cell (e.g., CAR T cell or CAR-expressing NK cell) of the invention. Subjects in need thereof may subsequently undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain aspects, following or concurrent with the transplant, subjects receive an infusion of the expanded CAR-expressing cells (e.g., CAR T cells or NK cells) of the present invention. In an additional aspect, expanded
20 cells are administered before or following surgery.

In embodiments, lymphodepletion is performed on a subject, e.g., prior to administering one or more cells that express a CAR described herein, e.g., a BCMA-binding CAR described herein. In embodiments, the lymphodepletion comprises administering one or more of melphalan, cytoxan, cyclophosphamide, and fludarabine.

25 The dosage of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The scaling of dosages for human administration can be performed according to art-accepted practices. The dose for CAMPATH, for example, will generally be in the range 1 to about 100 mg for an adult patient, usually administered daily for a period between 1 and 30 days. The preferred daily dose
30 is 1 to 10 mg per day although in some instances larger doses of up to 40 mg per day may be used (described in U.S. Patent No. 6,120,766).

In one embodiment, the CAR is introduced into immune effector cells (e.g., T cells or NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of CAR immune effector cells (e.g., T cells or NK cells) of the invention, and

5 one or more subsequent administrations of the CAR immune effector cells (e.g., T cells or NK cells) of the invention, wherein the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration. In one embodiment, more than one administration of the CAR immune effector cells (e.g., T cells or NK cells) of the invention are administered to the subject (e.g., human)
10 per week, e.g., 2, 3, or 4 administrations of the CAR immune effector cells (e.g., T cells or NK cells) of the invention are administered per week. In one embodiment, the subject (e.g., human subject) receives more than one administration of the CAR immune effector cells (e.g., T cells or NK cells) per week (e.g., 2, 3 or 4 administrations per week) (also referred to herein as a cycle), followed by a week of no CAR immune effector cells (e.g., T cells or NK cells)
15 administrations, and then one or more additional administration of the CAR immune effector cells (e.g., T cells or NK cells) (e.g., more than one administration of the CAR immune effector cells (e.g., T cells or NK cells) per week) is administered to the subject. In another embodiment, the subject (e.g., human subject) receives more than one cycle of CAR immune effector cells (e.g., T cells or NK cells), and the time between each cycle is less than 10, 9, 8, 7,
20 6, 5, 4, or 3 days. In one embodiment, the CAR immune effector cells (e.g., T cells or NK cells) are administered every other day for 3 administrations per week. In one embodiment, the CAR immune effector cells (e.g., T cells or NK cells) of the invention are administered for at least two, three, four, five, six, seven, eight or more weeks.

In one aspect, BCMA CAR-expressing cells (e.g., BCMA CARTs or BCMA CAR-expressing NK cells) are generated using lentiviral viral vectors, such as lentivirus. CAR-expressing cells (e.g., CARTs or CAR-expressing NK cells) generated that way will have stable CAR expression.
25

In one aspect, CAR-expressing cells, e.g., CARTs, are generated using a viral vector such as a gammaretroviral vector, e.g., a gammaretroviral vector described herein. CARTs generated using these vectors can have stable CAR expression.
30

In one aspect, CAR-expressing cells (e.g., CARTs or CAR-expressing NK cells) transiently express CAR vectors for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days after transduction. Transient expression of CARs can be effected by RNA CAR vector delivery. In one aspect, the CAR RNA is transduced into the cell, e.g., T cell or NK cell, by electroporation.

5 A potential issue that can arise in patients being treated using transiently expressing CAR-expressing cells (e.g., CARTs or CAR-expressing NK cells) (particularly with murine scFv bearing CAR-expressing cells (e.g., CARTs or CAR-expressing NK cells)) is anaphylaxis after multiple treatments.

Without being bound by this theory, it is believed that such an anaphylactic response
10 might be caused by a patient developing humoral anti-CAR response, i.e., anti-CAR antibodies having an anti-IgE isotype. It is thought that a patient's antibody producing cells undergo a class switch from IgG isotype (that does not cause anaphylaxis) to IgE isotype when there is a ten to fourteen day break in exposure to antigen.

If a patient is at high risk of generating an anti-CAR antibody response during the
15 course of transient CAR therapy (such as those generated by RNA transductions), CAR-expressing cell (e.g., CART or CAR-expressing NK cell) infusion breaks should not last more than ten to fourteen days.

EXAMPLES

20 The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided
25 herein.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples specifically point out various aspects of the present invention, and are not to be construed as
30 limiting in any way the remainder of the disclosure.

Example 1: BCMA is expressed in Myeloma cell lines and primary samples

Analysis of BCMA expression in Myeloma cell lines by quantitative PCR

16 cell lines of human cancers were screened for BCMA RNA expression by
35 quantitative RT-PCR. RNA was extracted with RNAqueos-4PCR Kit (Ambion, AM-1914) and

5 cDNA was synthesized with iScript Reverse Transcription Supermix for RT-qPCR (BioRad, 170-8841). The relative BCMA cDNA copies were quantified by relative qPCR (qPCR) with ABI TaqMan BCMA-specific primers and probe set (ABI, Hs03045080, lot:1139777) ;TaqMan GUSB (ABI, Hs99999908_M1, lot: 1093869) primers and probe set for normalization.

10 Analysis of the qPCR showed that all MM cell lines (U266, NCI H929 and RPMI 8226) tested express BCMA. BCMA was also detected in BJAB and LCL cells (B-cell lymphoblastoid cell lines) and CEM cells (a T-lymphoblastoid cell line). None of the other non-MM cell lines exhibited detectable expression of BCMA. This RNA analysis compliments protein detection by flow cytometry for the selection of positive BCMA expressing cell lines used in evaluations. Detailed results are provided in Figure 1A.

15 Comparison by RNA analysis of BCMA expression in plasma cells and in the different multiple myeloma samples from patients is provided in Figure 1B.

Analysis of BCMA expression in multiple myeloma cells lines and primary samples by flow cytometry

20 Multiple Myeloma (MM) cell lines U266, NCI H929 or RPMI 8226 or primary samples from MM patients (PB or BM) were stained with Human BCMA/TNFRSF17 Phycoerythrin Affinity Purified PAb, Goat IgG (R&D, FAB193P). Primary samples from multiple myeloma patients were also stained with Live/dead dye (LifeTechnologies, L34960), CD45-BV421 (Biolegend, 304032), CD38-APCeF780 (eBioscience 47-0389-42), CD138-APC (eBioscience 17-1389-42), CD19-PECY7 (eBioscience, E10328-1632), lambda chain-PerCP-eF710 (eBioscience 46-9990-42) and Kappa light chain (eBioscience, 11-9970-42). Data from
25 stained samples were collected using a BD Fortessa cytometer. Flow cytometric analysis performed using Flowjo v10 (Tree Star Inc).

BCMA was detected on the surface of all the 3 MM cell lines as shown in Figure 2A, 2B, and 2C. Moreover, BCMA was homogenously expressed on majority of clonal (kappa or lambda restricted) plasma cells in most of the MM patients analyzed (9 of 10). (Fig. 2D and
30 2E). These results provide strong support for the relevance of BCMA as a target in MM.

Flow cytometric analysis of BCMA expression in normal peripheral blood cells, CD3/CD28 expanded T cells and bone marrow stem cells

In order to rule out possible off-target expression of BCMA in normal tissues and on T
35 cells, BCMA expression in two bone marrow (BM) and peripheral blood (PB) specimens from voluntary healthy donors, were evaluated by flow cytometry. Mononuclear cells were obtained

- 5 through Ficoll-Paque (GE healthcare) gradient separation. BM cells were marked with Live/dead dye (LifeTechnologies, L34960) then stained with monoclonal antibodies against, CD34-APC (eBioscience, 17-0349-42 , CD38-PECY7(eBioscience, 25-0389-42), human hemopoietic lineage markers mix-FITC (eBioscience, 22-7778-72), CD45RA-APC-eF780 (eBioscience, 47-0458-42, CD90-PerCPCy5.5 (eBioscience, 45-0909-41, CD10-BV421 (Biolegend, 312218) and BCMA-PE (R&D, FAB193P). Fresh PB cells were stained at baseline and following stimulation and expansion with CD3/CD28 beads. PB was stained with monoclonal antibodies against CD14-V500 (BD, 561391), CD45-BV421 (Biolegend, 304032), CD3-AF700 (56-0038-42), CD19-PECY7 (eBioscience, E10328-1632, and BCMA-PE (R&D, FAB193P). Cells were washed twice and staining data acquired in a BD Fortessa cytometer.
- 15 Flow cytometric analysis was carried out by using FlowJo v10 (Tree Star Inc).

No evidence of BCMA expression was observed on PBMC. Importantly, T cells remained negative for BCMA during expansion. (Fig. 3A) Analysis of different stem cells subsets in the BM revealed no expression of BCMA on immature, lineage negative CD34 positive stem cells. In particular, the Common Lymphocyte Progenitor and the Hemopoietic Stem Cells were negative. (Fig. 3B)

Analysis of BCMA expression in normal tissues by immunohistochemistry

- Three commercially available antibodies (Novus, Sigma) for immunohistochemistry were selected and titrated in paraffin-fixed normal splenic tissue. Tissue micro arrays (TMA) including 27 healthy human tissues were stained by immunohistochemistry.
- 25 All 3 antibodies showed positive staining on normal plasma cells in lymph nodes, spleen and tonsil, whereas normal lung, pancreas and thyroid tested negative. Staining, likely non-specific due to the polyclonal nature of the available antibodies, was observed in the following organs: stomach, salivary gland, kidney, adrenal gland, cerebellum, heart and appendix. Selected results are shown in Figures 4A-4E and summarized in Table 11.

30

Table 11. BCMA expression by immunohistochemistry staining in normal tissues

Site	n=	Staining
Placenta	2	neg
Adipose	2	neg
Urinary bladder	2	neg
Cerebral cortex	2	neg
Cerebellum	2	pos
breast	0	N/A
cervix	1	neg
colon	2	pos
diaphragm	2	neg
Duodenum	2	pos
Esophagus	2	pos
Gallbladder	2	neg
Heart	2	neg
Ileum	2	pos
Jejunum	2	pos
Kidney	2	neg
Liver	2	neg
Lung	2	neg
Ovary	2	neg
pancreas	2	neg
Thyroid	1	neg
Rectum	2	pos
Skin	2	neg
Skeletal muscle	2	neg
Spleen	2	pos
Stomach	2	pos
Testes	2	neg
Thymus	2	neg
Smooth muscle	2	neg
Tonsil	1	pos
Uterus	2	neg

These results led to further analysis of expression, in particular using RNAscope in situ hybridization to confirm the lack of BCMA expression in these tissues. Selected results are shown in Figure 4F.

Example 2: *In vitro* evaluation of CARs containing humanized anti-BCMA scFv

BCMA CAR constructs generated from humanized mouse anti-BCMA antibody

Four distinct anti-BCMA CARs constructs were designed using the VL and VH sequences disclosed in PCT Publication WO 2012/163805 (the contents of which are hereby incorporated by reference in its entirety). In order to create the anti-BCMA CARs, the VH and VL sequences were synthesized and joined with a [Gly-Gly-Gly-Gly-Ser] x 4 linker (SEQ ID NO: 27) creating two single-chain variable fragments (scFvs) in which the VH precedes the VL (H2L, SEQ ID NO: 255) or the VL precedes the VH (L2H, SEQ ID NO: 257). The CD8 leader was also synthesized and fused to the 5' end of each scFv with a BamHI site Restriction sites for XbaI and BspE1 were included at the 5' and 3' ends, respectively, at the time of synthesis to

5 facilitate cloning of the CD8 leader-scFvs into the pTRPE lentiviral vector containing the hinge and CD8TM regions with 4-1BB and CD3z cytoplasmic domains. Two separate CAR backbone constructs were used for the cloning, one containing a human CD8 hinge and the other containing a human IgG4 hinge to generate the 4 anti-BCMA CAR constructs shown schematically in Figure 5, designated pBCMA 1, pBCMA 2, pBCMA 3, and pBCMA 4. To
 10 produce infectious lentiviral vector supernatants, 293-T cells were transfected with the following plasmids: pTRP-VSV-G (encoding the vesicular stomatitis virus (VSV-G) envelope), pTRP gag/pol (encoding gag and pol) and pTRP-Rev with either of the four BCMA CAR constructs utilizing lipofectamine 2000 (Invitrogen).

The nucleic acid sequence of humanized anti-BCMA scFv in which VH precedes
 15 the VL (H2L, e.g., pBCMA 2 and pBCMA 4) is as follows:

CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAG
 GCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGACAGGGCCTGGAG
 TGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACC
 ATCACCGCCGACAAGAGCACCAGCACC GCCTACATGGAAGTGAAGCAGCCTCAGGAGCGAGGACACCGCT
 20 GTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAAGTGGGGCCAGGGCACA
 CTAGTGACCGTGTCCAGCGGTGGAGGAGGTAGCGGAGGAGGCGGGAGCGGTGGAGGTGGCTCTGGAGGT
 GGCGGAAGCGACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACC
 ATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCC
 CCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTTCAGCGGAAGCGGC
 25 AGCGGCACCGATTTCACCTGACCATCTCCAGCCTGCAGCCCCAGGACTTCGCCACCTACTACTGCCAG
 CAGTACAGGAAGCTCCCCTGGACTTTTCGGCCAGGGCACCAAAGTGGAGATCAAGCGT
 (SEQ ID NO: 272)

The corresponding amino acid sequence for the humanized anti-BCMA scFv in
 which Vh precedes the VL (H2L, e.g., pBCMA 2 and pBCMA 4) is as follows:

30 Q V Q L V Q S G A E V K K P G S S V K V S C K A S G G T F S N Y W M H W V R
 Q A P G Q G L E W M G A T Y R G H S D T Y Y N Q K F K G R V T I T A D K S T
 S T A Y M E L S S L R S E D T A V Y Y C A R G A I Y N G Y D V L D N W G Q G
 T L V T V S S G G G G S G G G G S G G G G S G G G G S D I Q M T Q S P S S L
 S A S V G D R V T I T C S A S Q D I S N Y L N W Y Q Q K P G K A P K L L I Y
 35 Y T S N L H S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y
 C Q Q Y R K L P W T F G Q G T K L E I K R (SEQ ID NO: 271)

The nucleic acid sequence of humanized anti-BCMA scFv in which VL precedes
 the VH (L2H, e.g., pBCMA1 and pBCMA3) is as follows:

40 GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGC
 TCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTG
 CTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTTCAGCGGAAGCGGCAGCGGCACC
 GATTTCACCTGACCATCTCCAGCCTGCAGCCCCAGGACTTCGCCACCTACTACTGCCAGCAGTACAGG
 AAGCTCCCCTGGACTTTTCGGCCAGGGCACCAAAGTGGAGATCAAGCGTGGTGGAGGAGGTAGCGGAGGA
 GGCGGGAGCGGTGGAGGTGGCTCTGGAGGTGGCGGAAGCCAGGTGCAGCTGGTCCAGAGCGGCGCCGAA

- 5 GTGAAGAAGCCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGG
 ATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGC
 GACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCC
 TACATGGAAGTGAAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTAC
 AACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGC
 10 (SEQ ID NO: 274) The corresponding amino acid sequence of humanized anti-BCMA scFv
 in which VL precedes the VH (L2H, e.g., pBCMA1 and pBCMA3) is as follows:
 DIQMTQSPSS LSASVGDRVITCSASQDIS NYLNWYQQKPKAPKLLIYY
 TSNLHSGVPSRFSGSGSGTD FTLTISSLQP EDFATYYCQQ YRKLPWTFGQ
 GTKLEIKRGG GSGGGGSGGGGSGGGGSQV QLVQSGAEVK KPGSSVKVSC
 15 KASGGTFSNY WMHWVRQAPG QGLEWMGATYRGHSPTYNQ KFKGRVTITA
 DKSTSTAYME LSSLRSEDTA VYYCARGAIYNGYDVLNWDWGQGLTVTVSS (SEQ ID
 NO: 273)

These pBCMA-CARs containing humanized anti-BCMA scFvs are utilized in the
 20 experiments detailed below and in Example 3.

Efficient expression of BCMA-CARs on T cells

Fresh isolated human T cells from healthy donors were transduced with lentiviral
 vector supernatants encoding the pBCMA 1 to 4 CARs, and anti-BCMA CAR expression was
 evaluated by flow cytometry. Briefly, T cells were cultured in RPMI 1640 medium with 10%
 25 FBS and stimulated with anti-CD3/anti-CD28 Dynabeads (Invitrogen). 24 hrs after stimulation,
 T cells were transduced with the four different pBCMA CAR lentiviral vector supernatants. T
 cells transduced with an anti-mesothelin CAR (SS1) vector were used as a positive control.
 Mock-transduced T cells (NTD) were used as a negative control. 4-6 days after lentiviral
 transduction T cells were stained with biotinylated Protein L antibody followed by streptavidin
 30 FITC (BD Biosciences) or Biotin Goat-anti mouse and CAR expression was evaluated by flow
 cytometry (FACS Calibur, BD). Flow cytometric analysis was carried out by using Flowjo
 (Tree Star Inc).

After transduction it was observed that pBCMA CARs were efficiently expressed
 on the cell surface of the transduced T cells as shown in Figure 6.

35 *Cytokine production from anti-BCMA CAR-expressing T cells (BCMA CARTs)*

K562 cells ectopically expressing human BCMA (K562-BCMA) were generated by
 lentiviral transduction using a vector supplied by GeneCopoeia followed by puromycin
 selection. K562-BCMA specific target cells were utilized *in vitro* to evaluate cytotoxic and
 cytokine production from pBCMA 1-4 CAR-transduced T cells. Anti-pBCMA CAR T cells or
 40 control T cells were expanded until the end of log-phase growth and subsequently co-cultured

for 16 hrs with either K562-BCMA specific target cells, K562-Mesothelin target cells as positive control or no target cells as negative control at a 3 to 1 ratio of effector cells to target cells. Culture supernatants were harvested and IFN-gamma and IL-2 concentration was measured by specific ELISA following manufacturer instructions (R&D).

T cells expressing all four anti-pBCMA CARs produced similar levels of IFN-gamma and IL-2 when co-cultured with BCMA-expressing target cells but not with BCMA-negative target cells as shown in Figure 7A and 7B.

Cytotoxic activity of BCMA CARTs on Myeloma cell lines

The ability of pBCMA CAR T cells to kill BCMA-expressing target cells was evaluated using a ^{51}Cr release-assay. Briefly, target MM cells were labeled with ^{51}Cr (Sodium Dichromate salt), washed and co-cultured with effector pBCMA CAR T cells at different effector/target ratios. Supernatants were collected at 4-hrs, and placed into 96 well Lumaplates (Perkin Elmer). The amount of ^{51}Cr released from the labeled target cells was measured on a liquid scintillation counter (MicroBeta trilux, Perkin Elmer). Target cells incubated in medium alone or with 1% SDS were used to determine spontaneous (S) or maximum (M) ^{51}Cr release. Percentage of specific lysis was calculated as follow: $100 \times (\text{cpm experimental release} - \text{cpm S release}) / (\text{cpm M release} - \text{cpm S release})$.

All four pBCMA-CAR-transduced T cells were able to induce lysis of K562-BCMA cells and BCMA-expressing multiple myeloma cells lines with little activity towards the BCMA negative cell lines as shown in Figures 8A, 8B, 8C, and 8D. pBCMA-CARs with a CD8 hinge (pBCMA 3 and 4) exhibited greater cytotoxicity compared with pBCMA CARs containing the IgG4 hinge, suggesting that the hinge is an important factor in the CAR design for optimal function.

Example 3: *In vivo* evaluation of pBCMA-CARTs for Multiple Myeloma

Based upon in vitro data supporting enhanced function of pBCMA 3 and pBCMA 4 CAR-modified T cells, the anti-tumor activity of these CARTs was evaluated in a preclinical animal model of multiple myeloma using the RPMI 8226 cell line. RPMI 8226 cells were engineered to express Click-beetle Green luciferase (CB-G Luc⁺) to track tumor progression by bioluminescent *in vivo* imaging (IVIS) and Living Image software (Perkin Elmer). 4 weeks after injection of CB-G Luc⁺ RPMI 8226 cells were IV injected in NSG recipients, T cells expressing pBCMA 3 CAR, pBCMA 4 CAR, CD19 CAR (FMC63 anti-CD19 scFv with

- 5 human CD8 hinge, 4-1BB and CD3z cytoplasmic domain) or SS1 CAR (SS1 anti-mesothelin scFv with human CD8 hinge, 4-1BB and CD3z cytoplasmic domain) were IV injected and the tumor burden was evaluated by optical imaging as well as by the appearance of clinical signs of disease (Table 12 below). Scoring was performed as follows: 1- no clinical signs; 2- minor gait change/minor tumor mass; 3- decreased mobility/tumor mass/still ambulatory; 4- hind limb
- 10 paralysis/big tumor mass/END POINT; and 5- complete limb paralysis.

Table 12. Treatment Groups and Clinical Scoring.

Groups	Scoring Day 50
BCMA3	2
BCMA4	2
SS1	3
CD19	4
CTL	4

- T cells expressing either the pBCMA-3 and pBCMA 4 CAR T cells induce a significant reduction in the tumor burden of mice bearing RPMI 8226 as well as improved clinical disease
- 15 activity compared with control T cells targeting mesothelin (designated SS1) or CD19 as shown in Figure 9A and 9B.

The experiments described in Examples 2 and 3 provided the rationale to identify human scFv binding domains for additional CAR constructs, which are described and assessed in Examples 4-7.

20

Example 4: Generating human anti-BCMA CAR constructs

- Human BCMA-specific scFvs for CAR constructs were identified by 3 rounds of bead-based Bio-BCMA panning. In Arm 1, SBAL-1Sk Phage Library (8.4E13) was used. In Arm 2, SBAL-3Sk(G1+G2+G4+G5) Phage Library (1E13) was used. The phage lysates were
- 25 screened for BCMA reactivity by ELISA. 319 positive hits were identified, representing 135 unique sequences. The phage sequences were converted to soluble scFv that can be expressed in *E. coli*. The *E. coli* lysates were next screened by ELISA, and the periplasm was screened by FACs. 15 hits were identified by the FACs analysis. Next, the scFvs were purified from the *E. coli* and the purified scFvs were tested by FACs. 15 scFvs were confirmed, and were
- 30 designated BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-

8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, and BCMA-15. The sequences of human anti-BCMA scFv fragments (SEQ ID NOS: 39-52), are provided in Table 1 (and the name designations are provided in Table 2). Full BCMA CAR constructs (SEQ ID NOS: 99-113) were generated using the human scFv fragments (SEQ ID NOS: 39-52) in combination with the additional sequences shown in the Detailed Description, e.g., leader, CD8 hinge, CD8 transmembrane, 4-1BB intracellular domain, CD27 intracellular domain, CD28 intracellular domain, ICOS domain, CD3zeta domain (mutant), human CD3zeta domain, IgG4 hinge, Gly/Ser sequences, and/or Poly(A) sequences.

The CAR scFv fragments were then cloned into lentiviral vectors to create a full length CAR construct in a single coding frame, and using the EF1 alpha promoter for expression (SEQ ID NO: 11).

The amino acid and nucleic acid sequences of the BCMA scFv domains and BCMA CAR molecules are provided in Table 1 in the Detailed Description. Table 2 in the Detailed Description designates the nicknames for the BCMA CAR constructs with respect to the DNA ID number, also listed in Table 1.

Additional tool BCMA CAR constructs were also generated using the VH and VL sequences from PCT Publication WO2012/0163805 (the contents of which are hereby incorporated by reference in its entirety), and are based upon the results from the pBCMA3 and pBCMA4 CARs described in Examples 2 and 3. A schematic of the tool BCMA constructs (BCMA-3NP and BCMA-4NP) is shown in Figure 10A. The two constructs differ in the orientation of the VH and VL chains (Fig. 10B). The tool BCMA CAR constructs and their corresponding DNA ID are shown below.

Table 3. Tool CAR construct IDs

Nickname	Novartis ID	DNA2.0 ID
BCMA-3NP		126022
BCMA-4NP		126021

Additional BCMA CAR constructs can also be generated using the VH and VL sequences found in Table 16 in the Detailed Description. The amino acid sequences of exemplary scFv domains comprising the VH and VL domains and a linker sequence, and full-length CARs are also found in Table 16.

5 *Production and calculation of viral titer for BCMA CAR constructs*

Lentiviral supernatants were generated from 15 BCMA-specific CAR constructs obtained from scFv phage screening (Table 2). Lentiviral supernatants for 2 BCMA tool CAR constructs, BCMA-3NP and BCMA-4NP, were also generated. The tool constructs described in this example are based on the pBCMA3 and pBCMA4 constructs previously described in
 10 Examples 2 and 3.

To generate lentiviral supernatants, LentiX-293T cells were seeded on Day 0 and transfected on Day 1 with Lipofectamine 2000 transfection reagent (Life Technologies). For each construct, the plasmid DNA used was: pRSV.REV (Rev expression plasmid), pMDLg/p.RRE (Gag/Pol expression plasmid), pVSV-G (VSV glycoprotein expression
 15 plasmid), and CAR transfer vector. The transfection mixture was replaced with fresh medium on Day 2, and viral supernatant were collected on Days 3 and 4.

Viral supernatants were concentrated using Lenti-X Concentrator reagent (Clontech), and the resulting pellets were resuspended in growth medium at 1/10 to 1/100 of the original volume. Concentrated viral supernatants were aliquoted and stored at -80°C.

20 Calculation of viral titer was determined by transducing SupT1 cells and assessing CAR expression. SupT1 cells were transduced on Day 1 with a 3-fold serial dilution series of viral supernatants with a starting concentration of 1:300. CAR expression was assessed on Day 5 with BCMA-Fc antigen (R&D Systems) and Biotin-Protein L reagent (GenScript). Viral titer was calculated according to the following formula:

$$25 \quad (\% \text{ CAR+}) \times (\# \text{ SupT1 cells}) / (\text{Amount of Virus (ml)}) \times (\text{Dilution})$$

Average viral titer was calculated from dilution points in the linear range between 1 and 20% CAR-positive. Titer calculations for BCMA CAR clones are shown in Table 4.

Table 4: Titer of lentiviral supernatants from LentiX-293T cells transduced with BCMA-targeting CARs as measured by either BCMA-Fc or Protein L.

Clone	BCMA-Fc titer (TU/ml)	Protein L titer (TU/ml)
BCMA-1	1.27E+08	7.54E+06
BCMA-2	1.02E+08	1.43E+08
BCMA-4	1.46E+08	1.58E+08

BCMA-5	9.98E+07	9.64E+07
BCMA-6	1.41E+08	4.82E+06
BCMA-7	6.41E+07	5.53E+07
BCMA-8	6.15E+07	6.98E+07
BCMA-9	8.57E+07	7.75E+07
BCMA-10	6.73E+07	8.77E+07
BCMA-11	4.60E+07	5.43E+06
BCMA-12	4.88E+07	5.97E+07
BCMA-13	9.96E+07	5.52E+07
BCMA-14	9.88E+07	1.20E+08
BCMA-15	7.39E+07	7.41E+07
BCMA-3NP	5.38E+07	6.11E+07
BCMA-4NP	5.35E+07	5.37E+07

- 5 All BCMA CAR clones were detected with BCMA-Fc antigen, but detection was weaker with Biotin-Protein L for a number of clones (BCMA-1, BCMA-6, BCMA-11). Titers based on BCMA-Fc detection were used to calculate MOI for transduction in primary T cells. The BCMA CAR constructs containing human anti-BCMA scFvs described in this example are used throughout the experiments in Examples 4 and 5. The tool BCMA CAR constructs
- 10 described in this example are also used in the experiments described in Examples 5, 6, and 7.

Example 5: *In vitro* characterization of tool BCMA CAR constructs

JNL reporter assay for tool BCMA CAR constructs

- Jurkat-NFAT-luciferase (JNL) cells transduced with the tool BCMA CAR
- 15 constructs were evaluated for activation in response to BCMA-expressing target cell lines. On Day 0, JNL cells were transduced with BCMA-3NP and BCMA-4NP. Virus concentrations were adjusted to a MOI of 3 and incubated overnight. On Day 6 following transduction, BCMA CAR-transduced JNL cells were incubated with target cells at effector-to-target (E:T) ratios ranging from 0 to 27. Target cell lines were: K562 (BCMA negative control), and BCMA
- 20 positive multiple myeloma cell lines, NCI-H929, KMS26, and RPMI 8226. JNL activation was measured using Bright-Glo substrate (Promega) on Day 7. CAR expression on transduced JNL was assessed on Day 6 with BCMA-Fc antigen (Table 5). This reporter assay demonstrates that the tool BCMA-targeting CAR clones are activated in a target-specific manner (Figure 11).

5 **Table 5: Percent CAR expression on JNL cells**

	BCMA-Fc detection
Clone	% CAR+
BCMA-3NP	31.2
BCMA-4NP	41.9

10 Schedule for isolation, transduction and activation of primary T cells with BCMA-targeting tool CARs is shown in Table 6. On Day 0, healthy human donor PBMCs (Novartis Employee Blood Donor program) were isolated from whole blood by Ficoll extraction, and T cells were isolated from PBMC by negative selection using the Pan T Cell Isolation Kit II (Miltenyi Biotec). Isolated T cells were stimulated overnight with Dynabeads Human T-Expander CD3/CD28 beads (Life Technologies) at a 3:1 ratio of beads-to-cells. T cells were also stained to assess relative amounts of CD4+ and CD8+ cells (Figure 12).

Table 6: Schedule for T cell expansion of BCMA CAR transduced clones

Day #	Activity
0	Isolate and activate T cells
1	Transduce T cells (MOI=5)
2	Add medium - 0.5 ml/well
3	
4	Split 1:2
5	
6	Split 1:2 (Split UTD control 1:2.5)
7	
8	
9	Split 1:2
10	
11	De-bead and freeze aliquots

15 On Day 1, T cells were transduced with BCMA-3NP and BCMA-4NP. Virus concentrations were adjusted to a MOI of 5 and incubated overnight. On Day 11, transduced CART cells were de-beaded and frozen in aliquots in 90% FBS, 10% DMSO. Following transduction and expansion, T cells were again stained to assess relative amounts of CD4+ and CD8+ cells. In addition, CAR expression was assessed with BCMA-Fc antigen (Figure 13).

20 *BCMA Proliferation Assay*

5 BCMA CART cell proliferation in response to BCMA-expressing target cells was evaluated. CART cells were thawed on Day 0 and incubated overnight to recover. On Day 1, CART cells were labeled with CellTrace CFSE (Life Technologies) and incubated with irradiated target cells at an E:T ratio of 1:1. Dynabeads Human T-Expander CD3/CD28 beads at a bead-to-cell ratio of 3:1 were included as a positive control. On Day 5, CFSE levels were
 10 measured in CART cells (Figure 14). In addition, CART cells were stained with CD3, CD4, CD8, and BCMA-Fc antigen and measured by flow cytometry relative to CountBright Absolute Counting Beads (Life Technologies) to determine relative cell counts (Figure 15). Specific proliferation in response to BCMA observed for both BCMA-3NP and BCMA-4NP.

BCMA CART luciferase cell killing assay

15 BCMA CART cell killing in response to BCMA-expressing target cells was evaluated. CART cells were thawed on Day 0 and incubated overnight to recover. On Day 1, CART cells were incubated with either BCMA expressing KMS11-luciferase or MM1-S-luciferase target cells at E:T ratios ranging from 0 to 20. Loss of luciferase signal resulting from cell killing was measured using Bright-Glo substrate on Day 2 and specific lysis was
 20 calculated according to the following formula:

$$\text{Specific lysis (\%)} = 100 - (\text{sample luminescence} / \text{average maximal luminescence}) * 100$$

Results of cell killing are showing in Figure 16 demonstrating tool CART clones have specific killing response.

BCMA CART CFSE cell killing assay

25 BCMA CART cell killing in response to BCMA-expressing target cells was evaluated. CART cells were thawed on Day 0 and incubated overnight to recover. On Day 1, target cells were labeled with CellTrace CFSE (Life Technologies) and incubated with BCMA CAR T cells at E:T ratios ranging from 0 to 10. Target cell lines were: K562-BCMA (engineered to stably express BCMA), K562 (parental line), and BCMA positive multiple
 30 myeloma cell lines, NCI-H929, KMS26, and RPMI 8226. Loss of CFSE-positive cells resulting from cell killing was measured on Day 2 by flow cytometry relative to CountBright Absolute Counting Beads (Life Technologies) to determine relative cell counts (Figure 17). Specific cell killing was observed for both BCMA-3NP and BCMA-4NP.

- 5 Based on in vitro characterization of BCMA tool CAR clones, BCMA-3NP and BCMA-4NP, were selected for in vivo evaluation in KMS11-luciferase disseminated tumor model. UTD (untransduced) T cells were selected as a negative control. The results from the *in vivo* characterization is further described in Example 5.

10 Example 6: *In vitro* characterization of BCMA CART

The experiments described in this example utilize CAR constructs containing human anti-BCMA scFvs from Table 1, and the tool BCMA CAR constructs.

JNL reporter assay for BCMA CAR constructs

- 15 Jurkat-NFAT-luciferase (JNL) cells transduced with BCMA CAR constructs were evaluated for activation in response to BCMA-expressing target cell lines. Small-scale viral supernatant samples were generated in HEK293T cells for transduction of JNL cells. On Day 3 following transduction, BCMA CAR-transduced JNL cells were incubated with target cells at an effector-to-target (E:T) ratio of 6:1. Target cell lines were: K562-BCMA (engineered to stably express BCMA), K562 (parental line), and BCMA positive multiple myeloma cell lines,
20 NCI-H929 and RPMI 8226. JNL activation was measured using Bright-Glo substrate (Promega) on Day 4. CAR expression on transduced JNL was assessed on Day 7 with BCMA-Fc antigen and Biotin-Protein L reagent (Table 7). This reporter assay demonstrates that several BCMA-targeting CAR clones are activated in a target-specific manner (Figure 18).

Table 7: Percent CAR expression on JNL cells

	BCMA-Fc detection
Clone	% CAR+
BCMA-1	72.1
BCMA-2	32.0
BCMA-3	0.0
BCMA-4	49.5
BCMA-5	28.9
BCMA-6	44.4
BCMA-7	30.4
BCMA-8	32.4
BCMA-9	54.7
BCMA-10	29.5
BCMA-11	42.7

BCMA-12	23.4
BCMA-13	32.7
BCMA-14	31.8
BCMA-15	36.9
BCMA-3NP	6.7
BCMA-4NP	28.3

- 5 JNL activity was not correlated with % CAR expression. Based on BCMA-specific activation, the following BCMA CAR clones were selected for characterization in primary T cells: BCMA-1, BCMA-4, BCMA-5, BCMA-7, BCMA-8, BCMA-10, BCMA-12, BCMA-13, BCMA-14, and BCMA-15. Based on the non-specific activation observed, BCMA-6 was selected as a negative control. Based on the absence of activity observed, BCMA-9 was also
10 selected as a negative control.

BCMA CAR transduction of primary human T cells

- Schedule for isolation, transduction and activation of primary T cells with BCMA-targeting CARs is shown in Table 8. On Day 0, healthy human donor PBMCs (Novartis Employee Blood Donor program) were isolated from whole blood by Ficoll extraction, and T
15 cells were isolated from PBMC by negative selection using the Pan T Cell Isolation Kit II (Miltenyi Biotec). Isolated T cells were stimulated overnight with Dynabeads Human T-Expander CD3/CD28 beads (Life Technologies) at a 3:1 ratio of beads-to-cells. T cells were also stained to assess relative amounts of CD4+ and CD8+ cells (Figure 19).

Table 8: Schedule for T cell expansion of BCMA CAR transduced clones

<i>Day #</i>	<i>Activity</i>
0	Isolate and activate T cells
1	Transduce T cells (MOI=5)
2	Add medium - 0.5 ml/well
3	
4	Split 1:3
5	
6	Split 1:2
7	
8	Split 1:2.25
9	
10	
11	De-bead and freeze aliquots

- 5 On Day 1, T cells were transduced with the following BCMA CAR clones: BCMA-1, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-12, BCMA-13, BCMA-14, BCMA-15, BCMA-3NP, and BCMA-4NP. Virus concentrations were adjusted to a MOI of 5 (Table 9) and incubated overnight.

Table 9: Calculation of T cells added per well for each clone to obtain an MOI of 5.

Clone	TU/ml	MOI:5 per well
BCMA-1	1.27E+08	39.4
BCMA-4	1.46E+08	34.3
BCMA-5	9.98E+07	50.1
BCMA-6	1.41E+08	35.5
BCMA-7	6.41E+07	78.0
BCMA-8	6.15E+07	81.4
BCMA-9	8.57E+07	58.3
BCMA-10	6.73E+07	74.3
BCMA-12	4.88E+07	102.5
BCMA-13	9.96E+07	50.2
BCMA-14	9.88E+07	50.6
BCMA-15	7.39E+07	67.6
BCMA-3NP	5.38E+07	92.9
BCMA-4NP	5.35E+07	93.5

- 10 On Day 11, transduced CART cells were de-beaded and frozen in aliquots in 90% FBS, 10% DMSO. Following transduction and expansion, T cells were again stained to assess relative amounts of CD4+ and CD8+ cells. In addition, CAR expression was assessed with BCMA-Fc antigen (Figure 20).

BCMA CART proliferation assay

- 15 BCMA CART cell proliferation in response to BCMA-expressing target cells was evaluated. CART cells were thawed on Day 0 and incubated overnight to recover. On Day 1, CART cells were labeled with CellTrace CFSE (Life Technologies) and incubated with irradiated target cells at an E:T ratio of 1:1. On Day 6, CFSE levels were measured in CART cells (Figure 21).

- 20 In addition, CART cells were stained with CD3, CD4, and CD8 and measured by flow cytometry relative to CountBright Absolute Counting Beads (Life Technologies) to

- 5 determine relative cell counts (Figure 22A, 22B, and 22C). Specific proliferation in response to BCMA observed for the following CART clones: BCMA-4, BCMA-10, BCMA-12, BCMA-13, BCMA-14, and BCMA-15.

BCMA CART killing assay

- 10 BCMA CART cell killing in response to BCMA-expressing target cells was evaluated. CART cells were thawed on Day 0 and incubated overnight to recover. On Day 1, CART cells were incubated with BCMA expressing KMS11-luciferase target cells at E:T ratios ranging from 0 to 10. Loss of luciferase signal resulting from cell killing was measured using Bright-Glo substrate on Day 2 and specific lysis was calculated according to the following formula:

- 15
$$\text{Specific lysis (\%)} = 100 - (\text{sample luminescence} / \text{average maximal luminescence}) * 100$$

- Results of the cell killing assay are shown in Figure 23A, comparing each BCMA CAR construct to BCMA-3NP and BCMA-4NP. These results demonstrate that several CART clones (expressing the human anti-BCMA scFvs) have a greater killing response than the control BCMA-3NP and BCMA-4NP constructs. The results from select candidate BCMA
20 CARs (BCMA-4, BCMA-9, BCMA-10, BCMA-13, and BCMA-15) are presented in graph in Figure 23B to compare the killing capacity between the candidate CARs. Untransduced T cells and T cells transduced with BCMA-4NP construct were used as negative and positive controls, respectively. The percentage of cell killing of the select BCMA CART clones (BCMA-4, BCMA-9, BCMA-10, BCMA-13, and BCMA-15) were normalized to the percent of CAR
25 expression for each CART and presented in Figure 23C. The results show that BCMA-4, BCMA-9, BCMA-10, BCMA-13, and BCMA-15 CART clones all had cell killing capacity similar to that of BCMA-4NP.

- A summary of the *in vitro* assays of BCMA CART clones described above is shown in Table 10. Based on the *in vitro* characterization of BCMA CART clones, BCMA-4, BCMA-
30 10, BCMA-13, and BCMA-15 were selected for *in vivo* evaluation in KMS11-luciferase disseminated tumor model, as described in Example 7. BCMA-4NP was selected a positive control. BCMA-9 and UTD (untransduced) were selected as negative controls.

5 **Table 10: Summary of *in vitro* characterization of BCMA CART clones**

	JNL binding assay				Cell Killing EC50	Proliferation				
	Ratio to K562					CD3 Ratio to no target				
	K562-BCMA	NCI-H829	RPMI 8226	KMS11-luc		K562	K562-BCMA	NCI-H829	KMS11-luc	
BCMA-3NP	1.22	1.0	1.22	0.18	1.77	1.22	1.0	2.22	2.22	BCMA-3NP
BCMA-4NP	3.15	2.37	3.64	0.72	1.36	3.33	3.33	3.41	3.63	BCMA-4NP
BCMA-1	3.08	4.89	0.84	0.73	1.18	1.19	4.87	1.15	2.98	BCMA-1
BCMA-4	4.87	0.81	0.85	0.83	1.44	1.25	0.85	1.15	1.97	BCMA-4
BCMA-5	2.94	2.84	3.40	0.21	3.31	3.58	1.72	3.81	3.78	BCMA-5
BCMA-6	1.74	1.27	1.75	0.23	2.04	2.14	3.38	2.85	2.17	BCMA-6
BCMA-7	2.48	2.38	2.77	0.18	1.34	1.74	1.80	1.71	1.62	BCMA-7
BCMA-8	3.17	2.67	2.87	0.14	1.13	2.86	2.77	2.48	2.65	BCMA-8
BCMA-9	3.29	1.89	1.51	0.25	1.11	1.51	4.83	1.88	2.80	BCMA-9
BCMA-10	3.23	2.70	3.28	0.38	1.21	2.84	4.57	4.25	2.88	BCMA-10
BCMA-12	3.17	2.78	3.08	0.22	1.11	2.80	2.18	2.78	3.27	BCMA-12
BCMA-13	3.74	2.68	3.66	0.71	1.11	3.47	3.46	3.20	3.48	BCMA-13
BCMA-14	2.81	2.65	3.91	0.15	1.04	4.12	3.88	3.40	3.38	BCMA-14
BCMA-15	2.91	2.79	3.48	0.71	1.13	3.94	4.88	3.81	3.73	BCMA-15

Proliferation										
CD8 Ratio to no target					CD4 Ratio to no target					
K562	K562- BCMA	NCI-H829	KMS11-luc	RPMI 8226	K562	K562- BCMA	NCI-H829	KMS11-luc	RPMI 8226	
1.54	6.78	7.08	8.21	6.80	1.78	1.42	10.47	4.48	11.57	BCMA-3NP
1.34	3.08	4.31	5.29	3.48	1.85	9.55	4.33	5.54	3.70	BCMA-4NP
1.13	1.81	4.34	1.66	3.58	1.71	1.67	5.57	1.24	2.49	BCMA-1
1.18	5.86	1.42	5.73	6.18	1.51	1.21	3.95	1.50	10.12	BCMA-4
6.69	6.68	1.11	1.27	1.45	3.57	2.49	2.69	3.12	4.15	BCMA-5
2.81	2.13	2.28	2.23	2.38	4.30	4.78	4.34	2.80	4.35	BCMA-6
6.77	1.48	1.12	1.28	1.15	3.78	2.87	2.28	1.98	1.81	BCMA-7
4.01	1.58	1.41	1.83	1.81	1.18	3.58	2.98	3.11	3.85	BCMA-8
1.75	1.43	4.78	1.33	2.78	1.91	1.31	4.45	1.82	2.74	BCMA-9
1.15	3.81	1.81	3.84	4.23	1.71	1.11	1.28	4.28	1.11	BCMA-10
3.12	1.55	1.78	2.11	2.12	3.16	3.42	3.41	2.98	3.85	BCMA-12
4.12	2.31	2.83	2.78	3.08	2.74	3.45	5.05	2.81	4.44	BCMA-13
1.14	3.85	2.73	2.83	3.08	1.41	5.73	5.87	3.87	4.54	BCMA-14
1.41	1.88	3.42	2.78	2.81	1.15	3.87	4.82	3.83	4.54	BCMA-15

Example 7: *In vivo* characterization of BCMA CART

- 10 KMS-11 is a human multiple myeloma cell line derived from an IgGκ pleural effusion, and can be grown as a xenograft in immune compromised mice. This xenograft will mimic disease in the bone marrow as seen in humans, establishing a model with which to test the efficacy of therapies on multiple myeloma in the bone. These mice can be used to test the efficacy of chimeric antigen receptor (CAR) T cells specific for cellular markers found on plasma cells and multiple myeloma cells, such as the B Cell Maturation Antigen (BCMA).
- 15 KMS-11 cells were tagged with a firefly luciferase reporter gene and used in an orthotopic model of multiple myeloma in NOD.Cg-*Prkdc*^{scid}*Il2rg*^{tm1Wjl}/SzJ (NSG) mice to test the efficacy of CAR T cells specific for BCMA.

5 BCMA expression was tested on KMS-11 cells and these cells were used in *in vitro* assays to look at the ability of BCMA-specific CAR T cells to recognize and respond to the target. *In vivo* KMS-11 cells grow when implanted intravenously via the tail vein and growth is limited primarily to the bone marrow. One week after the tumor cells are implanted, the disease shifts fully to the bones and begins to grow at an exponential rate. Left untreated, mice
10 will start to display clinical symptoms and hind limb paralysis 5-6 weeks after tumor implantation. Tool BCMA CAR T cells were first tested in this model in an efficacy study to determine if the model is an appropriate *in vivo* model to test the efficacy and anti-tumor activity of BCMA CAR T cells. Following this, lead BCMA scFvs from an *in vitro* screen have been tested in this *in vivo* model and are now being confirmed in a repeat efficacy study.

15 ***Materials and Methods:***

KMS-11 cell line: The KMS-11 human multiple myeloma cell line was developed from the pleural effusion of a patient with multiple myeloma. The cells were then tagged with firefly luciferase. These suspension cells grow in RPMI supplemented with 10% heat inactivated fetal bovine serum.

20 Mice: 6 week old NSG (NOD.Cg-*Prkdc*^{scid}*Il2rg*^{tm1Wjl}/SzJ) mice were received from the Jackson Laboratory (stock number 005557). Animals were allowed to acclimate to the Novartis NIBRI animal facility for at least 3 days prior to experimentation. Animals were handled in accordance with Novartis ACUC regulations and guidelines.

Tumor implantation: KMS-11-luc cells were grown and expanded *in vitro* in RPMI
25 supplemented with 10% heat inactivated fetal bovine serum. The cells were then transferred to a 15 ml conical tube and washed twice with cold sterile PBS. KMS-11-luc cells were then counted and resuspended at a concentration of 10×10^6 cells per milliliter of PBS. The cells were placed on ice and immediately (within one hour) implanted in the mice. KMS-11 cells were injected intravenously via the tail vein in a 100 μ l volume, for a total of 1×10^6 cells per
30 mouse.

CAR T cell dosing: Mice were administered 5×10^6 T cells 7-8 days after tumor implantation. Cells were partially thawed in a 37 degree Celsius water bath and then completely thawed by the addition of 1 ml of cold sterile PBS to the tube containing the cells. The thawed cells were transferred to a 15 ml falcon tube and adjusted to a final volume of 10 mls with PBS. The cells
35 were washed twice at 1000rpm for 10 minutes each time and then counted on a hemocytometer.

5 The CAR T cells were normalized for CAR transduction so that each group has the same percentage of CAR⁺ T cells. The total of the 5×10^6 cells were then resuspended at a concentration of 50×10^6 cells per ml of cold PBS and kept on ice until the mice were dosed. The mice were injected intravenously via the tail vein with 100 μ l of the CAR T cells for a dose of 5×10^6 T cells per mouse.

10 Five to seven mice per group were treated either with 100 μ l of PBS alone (PBS), untransduced T cells (Mock), tool BCMA CAR T cells (BCMA-3NP or BCMA-4NP), or novel BCMA CAR T cells (BCMA-4, BCMA-9, BCMA-10, BCMA-13, BCMA-15). The T cells were all prepared from the same human donor in parallel.

Animal monitoring: The health status of the mice was monitored daily, including twice weekly
15 body weight measurements. The percent change in body weight was calculated as $(BW_{\text{current}} - BW_{\text{initial}})/(BW_{\text{initial}}) \times 100\%$. Tumor burden was monitored twice weekly by bioluminescent imaging. Mice were intraperitoneally injected with D-luciferin 10 minutes prior to anesthetizing and imaging the mice with a Xenogen. Disease burden was calculated by calculating the bioluminescence of the tumor cells (photons/second).

20 Bioluminescence Analysis: Percent treatment/control (T/C) values were calculated using the following formula:

$$\% \text{ T/C} = 100 \times \Delta T / \Delta C \text{ if } \Delta T \geq 0 ;$$

$$\% \text{ Regression} = 100 \times \Delta T / T_{\text{initial}} \text{ if } \Delta T < 0 ;$$

where T = mean bioluminescence of the drug-treated group on the final day of the study; T_{initial}
25 = = mean bioluminescence of the drug-treated group on initial day of dosing; ΔT = = mean bioluminescence of the drug-treated group on the final day of the study – = mean bioluminescence of the drug treated group on the initial day of dosing; C = = mean bioluminescence of the control group on the final day of the study; and ΔC = = mean bioluminescence of the control group on the final day of the study – = mean bioluminescence
30 of the control group on the initial day of dosing.

T/C values in the range of 100% to 42% are interpreted to have no or minimal anti-tumor activity; T/C values that are $\leq 42\%$ and $> 10\%$ are interpreted to have anti-tumor activity or tumor growth inhibition. T/C values $\leq 10\%$ or regression values $\geq -10\%$ are interpreted to be tumor stasis. Regression values $< -10\%$ are reported as regression.

5 Peripheral blood FACS analysis: T cells in the peripheral blood of the mice were also monitored. Mice were bled weekly via the tail vein into EDTA coated tubes that were kept on ice. 10-20µl of blood was plated from the tubes into 96 well plates on ice. Red blood cells were lysed with ACK red blood cell lysis buffer (Life Technologies, catalog number A10492-01) and then washed twice with cold PBS. The cells were incubated with an Fc blocking mix
10 of human and mouse Fc block (Miltenyi Biotec, catalog numbers 130-059-901 and 130-092-575) for 30 minutes and then incubated with anti-mouse CD11b antibody (BD Biosciences, catalog number 557960), anti-human CD4 antibody (BD Biosciences catalog number 563550), anti-human CD8 antibody (BD Biosciences catalog number 560347), and BCMA-Fc antibody (R&D Systems, catalog number 193-BC-050) , followed by an Ig secondary (Jackson
15 ImmunoResearch). The cells were fixed with a 2% paraformaldehyde solution for 20 minutes, washed and stored in PBS + 2% FBS overnight prior to analysis on a BD Fortessa, followed by further analysis using the FlowJo FACS analysis software. The cells were analyzed to determine the number of CAR⁺ CD4⁺ and CD8⁺ T cells per milliliter of blood in the KMS-11-luc tumor-bearing NSG mice. T cell numbers in the blood are reported as the mean $\pm$ standard
20 error of the mean (SEM).

Results:

The anti-tumor activity of the tool BCMA CAR T cells (BCMA-3NP and BCMA 4-NP) were evaluated and directly compared in the KMS-11 model of human multiple myeloma. Following tumor implantation on day 0, mice were randomized into treatment groups and
25 treated with 5×10^6 T cells intravenously on day 7. Multiple myeloma disease burden and animal health were monitored until animals achieved endpoint. The mice in all the groups were euthanized on day 14 post-CAR T cell dosing (day 21 post-tumor implantation) when disease burden in the control groups nearing maximum luminescence via imaging.

A clear difference in disease burden can be seen between the control groups and the
30 groups treated with either of the tool CAR T cells with $P < 0.01$ on day 14 post-CAR T cell dosing. Both of the tool BCMA CAR T cells demonstrate a similar ability to control human multiple myeloma growth in NSG mice. The % T/C value for the mock transduced T cell group is 212.13%, demonstrating that the mock transduced T cells have no anti-tumor activity.

The percent delta T/C values for the BCMA-3NP and BCMA-4P groups are 1.10%
35 and 2.17% respectively, demonstrating tumor stasis after treatment with the tool BCMA CAR

5 T cells. The bioluminescence imaging results are shown in Figure 24. The PBS treatment group, which did not receive any T cells, demonstrates baseline KMS-11 tumor growth kinetics in intravenously implanted NSG mice. The Mock treatment group received untransduced T cells that underwent the same *in vitro* expansion process as the CAR T cells. These cells serve as a T cell control to show the non-specific response of the T cells in this tumor model. Both
10 the PBS and Mock transduced T cell treatment groups demonstrate continuous tumor progression throughout the experiment. Both the tool BCMA CAR T cells control the progression of disease after the 5×10^6 T cell injections.

Following confirmation that the KMS-11-luc model responds to targeting via BCMA CAR T cells, a study to evaluate novel scFv leads was initiated. Following tumor
15 implantation, mice were again randomized into treatment groups and treated with 5×10^6 T cells intravenously on day 7. Multiple myeloma disease burden and animal health were monitored until animals achieved endpoint. The mice in each of the groups were euthanized when disease burden in the group neared maximum luminescence via imaging.

A clear difference in disease burden can be seen between the control groups and
20 some of the groups treated with the BCMA CAR T cells. The tool BCMA CAR T cells (BMCA-4NP) did not control the KMS-11 tumor growth as they had been shown to do so previously. However, some of the novel BCMA CAR T cells did show varying levels of efficacy in this multiple myeloma model. The % T/C values calculated at the endpoint for each group show stasis in tumor growth for the BCMA-10 and BCMA-13 groups. The mock
25 transduced T cell group has a %T/C value of 61.56%, demonstrating that the mock transduced T cells have minimal to no anti-tumor activity. The percent delta T/C values for the BCMA-4P group is 32.03%, demonstrating some minimal anti-tumor efficacy after treatment with the tool BCMA CAR T cells. Both the BCMA-10 and BCMA-13 groups show stasis in tumor growth with T/C values of 0.07% and 6.04% respectively. The BCMA-4 shows an initial control in
30 tumor growth, but with only one T cell dose given to each group, the tumors in this group start to grow out. The bioluminescence imaging results from a first experiment are shown in Figures 25A. The PBS treatment group, which did not receive any T cells, demonstrates baseline KMS-11 tumor growth kinetics in intravenously implanted NSG mice. The Mock treatment group received untransduced T cells that underwent the same *in vitro* expansion process as the
35 CAR T cells. These cells serve as a T cell control to show the non-specific response of the T cells in this tumor model. Both the PBS and Mock transduced T cell treatment groups

5 demonstrate continuous tumor progression throughout the experiment. Among the BCMA CAR T cell groups, BCMA-4, BCMA-10, and BCMA-13 show anti-tumor activity, while the
10 tool BCMA CAR T cells (BCMA-4NP) and BCMA-9 and BCMA-15 show no anti-tumor efficacy. A second experiment was performed and the bioluminescence imaging results are provided in Figure 25B. Mice receiving untransduced T cells show the baseline KMS-11
15 tumor growth kinetics. BCMA-4NP* represents the results from the BCMA-4NP CART clones in the first experiment. In the second experiment, BCMA-10, BCMA-13, and BCMA-15 showed robust anti-tumor activity.

In addition to monitoring the disease burden via bioluminescence, the CAR⁺ T cell numbers in each group was also monitored via peripheral blood FACS analysis. The FACS
15 results of this study are shown in Figure 26. The groups that show anti-tumor effects on the KMS-11 tumors also show CD4⁺CAR⁺ and CD8⁺CAR⁺ T cells expanding in the peripheral blood. The BCMA-4, BCMA-10, and BCMA-13 groups show a peak of CD4⁺CAR⁺ proliferation between days 10 and 20 post T cell treatment. These same groups also show a prolonged CD8⁺CAR⁺ T cell expansion.

20 The anti-tumor activity of novel BCMA CAR transduced T cells was assessed in an efficacy study in NSG mice bearing a xenograft model of human multiple myeloma. These studies show that the KMS-11-luc model recapitulates human multiple myeloma in the NSG mouse and is capable of being targeted by BCMA CAR T cells (Figure 24). Following the confirmation that this model is suitable to test BCMA CAR T cells, novel human BCMA CARs
25 were tested in an efficacy study. This study demonstrated that several of the novel BCMA CARs (BCMA-4, BCMA-10, and BCMA-13) mounted an anti-tumor response in a xenograft model of multiple myeloma (Figures 25A). The tumor experiment was repeated, testing BCMA-4, BCMA-10, BCMA-13, and BCMA-15. BCMA-4, BCMA-10, BCMA-13, and BCMA-15 demonstrated anti-tumor efficacy by inhibiting or reducing tumor growth for at least
30 4 weeks (28 days) after implantation (Figure 25B).

In addition, the anti-tumor response correlates with the expansion of CD4⁺CAR⁺ and CD8⁺CAR⁺ T cells in the peripheral blood of these mice (Figures 26A, B, C, and D). No anti-tumor efficacy was observed for any of the BCMA CARs when this T cell expansion is not
35 observed. BCMA-10, which shows the greatest anti-tumor efficacy in this model, also shows the most sustained CD8⁺CAR⁺ T cell expansion. The BCMA-4, BCMA-10 and BCMA-13 groups all show a significant change in tumor growth as compared to the control groups. The

lack of efficacy seen with the tool BCMA CAR (BCMA-4NP) and BCMA-9 and BCMA-15 in the first tumor experiment (Figure 25A) correlates with a lack of T cell expansion in the peripheral blood in the mice in these groups. Similarly, the lack of efficacy seen with BCMA-4NP in the second tumor experiment (Figure 25B) correlates with the lack of T cell expansion in the peripheral blood in the mice.

Terminal bone marrow and spleen samples were also analyzed at the end of the *in vivo* tumor experiment to determine if the CART clones that demonstrated anti-tumor efficacy show a difference in being able to establish a bone marrow population compared to the groups that did not show anti-tumor efficacy. The number of CAR-expressing CD4+ and CD8+ T cells was determined in the bone marrow (Figures 27A and 27C) and the spleen (Figures 27B and 27D) of the mice from the first experiment. The results show that administration of BCMA-9 CART resulted in the highest number of CAR+ T cells (both CD4+ and CD8+ T cells) in the bone marrow and spleen, indicating that BCMA-9 CART cells undergo efficient expansion *in vivo*, but does not have killing capacity, or anti-tumor activity. BCMA-10 CART cells showed the next most consistent establishment of T cells in the bone marrow and spleen. BCMA-4 and BCMA-15 CART cells were also found in the spleen.

Example 8: Identifying lead BCMA CAR constructs for therapy

To identify the lead BCMA CAR constructs, the results of several *in vitro* and *in vivo* assays. The experimental assays, the Examples in which the details of the assays are described, and the number of lead BCMA CARs resulting after analysis of the assay are summarized in the following table (Table 13). The results of the assays were analyzed in the order as listed in Table 13 to select the candidate BCMA CARs that exhibited specificity, expression in immune effector cells, and *in vitro* and/or *in vivo* activity.

Table 13. Assays for selecting BCMA CARs

Assay	Example where assay is described	Criteria	BCMA CARs (out of 15)
CAR expression (Jurkat and/or primary T cells lentivirally transduced)	Examples 5 and 6	Yes	14
JNL NFAT reporter activation	Example 5	> 2-fold over negative control	10
T-cell expansion (Cell size, total cell count)	Examples 5 and 6	Size: 10 microns Cell count: > 20-fold over T =0	10

		cell number	
T-cell proliferation (CFSE stained cells FACS)		≥ 1 log shift relative to negative control	10
Target cell killing (CFSE or luciferase)	Examples 5 and 6	$> 90\%$ killing at E:T 3-fold $<$ negative control	7
Tumor regression (single dose administration; 1.5×10^6 CAR+ T cells)	Example 7	Sustained tumor regression > 2 weeks Evidence of CAR+ T cell expansion	4 or 2
Lentiviral titer	Example 8	Reproducibly high viral titers	4 or 2

Based on *in vitro* assays, e.g., lentivirally transduced CAR expression, JNL NFAT activation, T cell expansion, T cell proliferation, and target cell killing (as described in Examples 5, 6 and 7), 7 BCMA CARs were identified as lead CARs to be tested for therapeutic efficacy *in vivo*, and 5 BCMA CARs (BCMA-4, BCMA-9, BCMA-10, BCMA-13, and BCMA-15) were tested in Example 8. As described in Example 8, BCMA-4, BCMA-10, BCMA-13, and BCMA-15 all demonstrated anti-tumor efficacy, with BCMA-10 and BCMA-13 reproducibly demonstrating anti-tumor efficacy in two separate *in vivo* experiments.

Lentiviral titer was compared between the candidate BCMA CARs after automated viral production and automated transduction of SupT1 cells. Two independent lentiviral titer assays were run. The first titer test run analyzed two independent DNA preps (A and B) of BMCA-4, BCMA-10, BCMA-13, and BCMA-15 CARs. The second titer test run analyzed three independent DNA preps (A, B and C) of BMCA-4, BCMA-10, BCMA-13, and BCMA-15 CARs. Viral production was produced in an automated 96-well format. SupT1 cell transduction was also performed via an automated 96-well format. CAR expression was manually analyzed by FACs and the results are shown in Figures 28A and 28B. All tested BCMA CARs showed comparable levels and consistency of viral titer.

Thus, taking together the results from the *in vitro* and *in vivo* experiments as outlined in Table 13, BMCA-4, BCMA-10, BCMA-13, and BCMA-15 were identified as having met the criteria for each assay and are good prospects for further testing for therapeutic use. When more stringent criteria was used in the tumor regression analysis, in which only CAR constructs that reproducibly demonstrated anti-tumor efficacy in both experiments were analyzed further, then BCMA-10 and BCMA-13 were identified for further therapeutic testing.

Example 9: Characterization of lead BCMA CAR constructs

Additional assays were performed to characterize properties of the lead BCMA CAR constructs BMCA-4, BCMA-10, BCMA-13, and BCMA-15 CARs that have demonstrated *in vitro* and *in vivo* efficacy in various assays described in Examples 5-8. Sequence alignment of BCMA-10 and BCMA-13 showed that the two CARs have identical heavy chain CDRs and high homology in the light chain CDRs. A competition assay was performed between four lead candidates BMCA-4, BCMA-10, BCMA-13, and BCMA-15 CARs and BCMA-4NP (tool CAR) as the control. BCMA-4NP was incubated with BCMA substrate, and binds between 50 and 300 seconds after incubation, as shown in Figure 29. The four BCMA CAR constructs are added and binding to the substrate was monitored. As shown in Figure 29, all four BCMA CAR constructs were competitive with the BCMA-4NP control, indicating that all four candidate BCMA CARs bind to the same epitope as the BCMA-4NP tool CAR. At the given concentrations, if the candidate CARs were binding to a different epitope, the expected RU change would be about 70 RU. The small RU change observed during binding of the candidate BCMA CARs was due to the slight dissociation of the BCMA-4NP control sample from BCMA.

Antibody affinity was also assessed for the candidate BCMA CARs: BCMA-4, BCMA-10, BCMA-13, and BMCA-15. The results are shown in Figure 30, and summarized in the table below.

Table 14. BCMA CAR binding affinity

Sample	Fit	ka	kd	KD
BCMA-10	1:1 Binding	7.10E+04	2.39E-03	33.6
BCMA-13	1:1 Binding	6.56E+04	1.61E-03	24.5
BCMA-15	1:1 Binding	2.01E+05	1.87E-03	9.3
BCMA-4	1:1 Binding	6.17E+05	6.00E-04	1.0
BCMA-4NP	1:1 Binding	1.58E+06	1.72E-04	0.1

BCMA-10 and BCMA-13 have similar affinities and are the lowest affinities of the tested candidates.

Selective binding of the candidate BCMA CARs was also tested. BCMA is one receptor in the TNF receptor family, includes closely related family members BaffR and TACI. BCMA has about 41% homology to BaffR and about 22% homology to TACI. T cells expressing the candidate BCMA CARs BCMA-4, BCMA-10, BCMA-13, and BCMA-15 were

- 5 incubated with recombinant BCMA, BaffR, or TACI fused to Fc regions. Binding was assessed by staining CAR+ cells (Figure 31). The results indicate that specific binding was only observed between all of the BCMA-expressing T cells and recombinant BCMA-Fc, demonstrating that the BCMA CAR constructs selectively bind to BCMA.

Example 10: BCMA expression in the brain

- 10 The tissue microarray results shown in Table 11 indicated that by immunohistochemical analysis, BCMA expression was detected in the cerebellum. Human and non-human primate formalin fixed paraffin embedded (FFPE) brain tissues were stained with anti-BCMA antibodies, e.g., USBio rabbit polyclonal antibody (0807-50G) raised to a BCMA intracellular epitope, and J6MO rabbit chimera antibody recognizing a BCMA extracellular epitope.
- 15 Staining with the UsBio rabbit polyclonal antibody in non-primate human (cynomolgus macaque) brain tissue resulted in positive staining of the cerebellar climbing fibers (Figure 32A) and the cell bodies in the inferior olivary nucleus (Figure 32B) of the cerebellum. Staining of non-human primate brain tissue with J6MO resulted in BCMA positive staining only in the inferior olivary nucleus (Figure 32C; Ig control staining in Figure 32E). Similarly,
- 20 staining of human brain tissue with J6MO also resulted in BCMA positive staining only in the inferior olivary nucleus (Figure 32D; Ig control staining in Figure 32F).

- The immunohistochemistry results were confirmed by RNA analysis. In situ hybridization of non-human primate and human brain tissue was performed. Both the cerebellum and medulla oblongata was BCMA negative by mRNA detection by in situ
- 25 hybridization (Figures 33A and 33B). Quantitative PCR was also performed on cerebellum, medulla oblongata, stomach, and kidney tissues from non-human primate (cynomolgus macaque) and human. The qPCR results indicate that BCMA mRNA was not detected in the cerebellum and the medulla oblongata of human (Figure 33C) or non-human primate (Figure 33D). The potential discrepancy between the immunohistochemical and RNA analysis may be
- 30 due to the different BCMA splice variants known in the art (Smirnova et al., *Mol Immunol*, 2008, 45:1179-83).

RNAseq analysis, which would detect all BCMA isoforms and splice variants, was performed on normal tissues. The results show that little or no expression of BCMA was detected by RNAseq in normal tissue (Figure 33E).

Further analysis is performed to determine whether the BCMA detected protein would be accessible to BCMA CART cells, and the implications for BCMA CART therapy. PCR probes are redesigned and BCMA splice variant expression is re-assessed. Single cell RNAseq in cerebellum samples is performed. Confocal microscopy analysis is performed to visualize intracellular staining. Mice are also evaluated for effects on the brain in efficacious CARTs, e.g., BCMA-10 and BCMA-13. To prevent potential trafficking of BCMA CART cells to the brain, natalizumab can be administered to subjects.

Example 11: BCMA CART therapy in relapsed/refractory myeloma

This example provides a single cohort, open-label pilot study to assess the safety and feasibility of infusion of autologous T cells expressing BCMA-specific CARs in relapsed and/or refractory multiple myeloma. The BCMA-CARs comprise tandem TCR ζ and 4-1BB (TCR ζ /4-1BB) costimulatory domains, and the T cells expressing the BCMA-CARs are referred to as BCMA CAR T cells.

Study Objectives

The primary objective of the study is to determine the safety and tolerability of BCMA CAR T cells in MM patients. The secondary objectives include: describe outcomes, including response rates, minimal residual disease (MRD) rates, progression-free and overall survival; and assess the feasibility of manufacturing BCMA CAR T cells. The exploratory objectives include: characterize BCMA CAR T cells with respect to their expansion, persistence, homing, phenotype and function; evaluate for development of cellular and/or humoral immunity against BCMA CAR T cells; evaluate effect of BCMA CAR T cells on B cell and plasma cell compartments, including immunoglobulin levels; determine the impact of BCMA CAR T cells on systemic soluble immune factors in patients; assess BCMA expression on MM cells pre- and post-treatment; and evaluate safety and efficacy of re-treatment with BCMA CAR T cells in patients who progress after prior clinical benefit

Study Duration

The duration of active intervention and monitoring is approximately 2 years. After 2 years, monitoring for delayed adverse events will transition to a separate long term follow-up protocol in accordance with FDA guidelines. The protocol will require approximately 12-18 months to complete enrollment.

Diagnosis and Main Inclusion Criteria

5 Up to 12 evaluable subjects will be enrolled.

Inclusion criteria include adult patients aged >18 with relapsed and/or refractory multiple myeloma after at least 3 prior lines of therapy that must include a prior alkylator, a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) (or 2 priors if double-refractory to an IMiD (immunomodulatory drug, thalidomide and lenalidomide), and proteasome inhibitor). The patients have relapsed, defined as meeting IMWG (International Myeloma Working Group) criteria for PD) or are refractory, as defined as achieving <PR) after the most recent regimen. The patients have a limited prognosis (≤ 2 year expected survival) with currently available therapies.

Study product, Dose, Route, Regimen

15 Single infusion of BCMA CAR T cells administered by intravenous infusion. Cohort 1 will receive $1-5 \times 10^8$ BCMA CAR T cells alone, calculated as a range of 2-50% transduced cells in total cells (The cell dose in Cohort 1 may be decreased to $1-5 \times 10^7$ BCMA CAR T cells (Cohort -1) if there is unexpected severe toxicity). Cohort 2 will receive cyclophosphamide (cytoxan) 1.5 g/m^2 , administered by i.v. infusion, 1-3 days prior to infusion of $1-5 \times 10^7$ BCMA CAR T cells. Cohort 3 will receive cyclophosphamide 1.5 g/m^2 , administered by i.v. infusion, 1-3 days prior to infusion of $1-5 \times 10^8$ BCMA CAR T cells.

Based on the total volume to be infused and the recommended infusion rate of 10-20mL per minute. The dosage and regimens for each cohort is summarized in the table below and a schematic diagram is shown in Figure 34.

25 **Table 15. Summary of cohorts and dosages**

Cohort	Lymphodepleting chemo	BCMA-CAR T cell dose
-1	-	1 to 5×10^7
1 (n=3)	-	1 to 5×10^8
2 (n=3)	Cytosan 1.5 g/m^2	1 to 5×10^7
3 (n=6)	Cytosan 1.5 g/m^2	1 to 5×10^8

To prevent potential trafficking of T-cells to the brain, patients can be administered natalizumab (TYSABRI®).

Patient Monitoring

30 Tumor response will be measured by serum and urine protein electrophoresis and immunofixation; bone marrow biopsy; and imaging if skeletal lesions are present prior to

5 treatment. Neural exams will also be performed before and after therapy to ensure no neural changes.

Statistical Methodology

The statistical analysis will be primarily descriptive in keeping with the exploratory nature of the study. Descriptive statistics will be applied to determine the relative engraftment, persistence and trafficking of the study drug components to blood and bone marrow. All adverse events will be described and exact 95% confidence intervals will be produced for adverse event rates, both overall and within major categories. Analysis of other secondary endpoints such as anti-tumor activity will also be primarily descriptive and may include summary statistics such as means and standard deviations or Kaplan-Meier curves for survival information.

Example 12: Cytokine secretion from CART cells

The ability of CART cells to secrete cytokines in response to target was determined. CART cells containing BCMA-10 CAR or untransduced T-cells were co-cultured with BCMA-positive (KMS11-luc) or BCMA negative (U87-luc) target cells, and the secretion of IL-2, IFN γ , and TNF α into the media was measured. Specifically, thawed CAR T cells containing either BCMA-10 CAR or untransduced were co-cultured with target cells for 20 h at an effector:target ratio of 2.5:1. Target cells included BCMA positive luciferized KMS-11 (KMS11-luc) or BCMA negative luciferized U87 cells (U87-luc). Effector cells were cultured in 96-well U-bottom plates with 3×10^4 target cells in a total volume of 200 μ L/well in complete T cell media. After 20 h, supernatants were removed from the cultures, and IFN γ , IL-2, and TNF α secretion were quantified by cytometric bead array (BD Bioscience) on FACS according to manufacturer's instructions. Measurements were in duplicate. Error bars represent the standard deviation (Figures 35A-35B). The results show that the BCMA-10 CARTs but not untransduced T-cells were stimulated to produce cytokines by BCMA-expressing but not BCMA-negative target cells (Figures 35A-35B).

Example 13: Function of BCMA-CART in multiple myeloma

Multiple Myeloma (MM) is a malignancy of plasma cells in the bone marrow with clinical features that include anemia, skin lesions, bone tenderness or pain, tiredness, osteolytic lesions, hypercalcemia, kidney failure and recurrent bacterial infection as most

5 common. Despite the fact that recent treatments with drugs such as lenalidomide produce a significant increase in survival of relapsed MM, the disease is almost always incurable. The median 5-year survival rate is about 35%. Due to poor prognosis, an effective targeted therapy is needed.

Treatments using T-cells engineered to express chimeric antigen receptors (CAR) can
10 result in promising immunotherapies for hematologic malignancies such as ALL. CARs contain a fusion protein that recognizes a cell-surface target protein expressed on a tumor cell. Differential gene expression studies have identified B-cell maturation antigen (BCMA, CD269) as a highly specific target antigen for malignant plasma cells and normal plasma cells; thus, BCMA is a potentially useful target antigen for CAR T cell therapy. See, e.g., Carpenter et al.
15 Clin Cancer Res. 19.8(2013):2048-60.

BCMA is a member of the TNF-receptor superfamily. The protein is encoded by *TNFRSF17* gene. BCMA is expressed in mature B lymphocytes. It binds to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), APRIL and to various TRAF family members. Interaction with their ligands leads to NF-kappaB and MAPK8/JNK
20 signals that are linked to B cell development, long term plasma survival, and cell proliferation.

This example describes a preclinical study to evaluate the *in vitro* and *in vivo* function of huBCMA-BBz CAR-transduced T cells (CART-BCMA or BCMA-CART) that incorporates the BCMA10 scFv.

Materials

25 *T cells.* T cells from healthy donors were obtained from the University of Pennsylvania CFAR Human Immunology Core (Philadelphia, PA). Cells were prepared from the leukapheresis of healthy volunteer donors.

Medium. RPMI medium (Gibco) supplemented with 10% Fetal Bovine serum and filtered (Valley Biomedical), 2mM GlutaMax, (Invitrogen), 10mM HEPES (Invitrogen),
30 100U/ml Pencillin and 100 ug/ml Streptomycin (Gibco) was used.

CD3/28 beads. CD3/28 beads (GMP-grade) were manufactured by Clinical Cell and Vaccine Production Facility at University of Pennsylvania.

Plasmids. The huBCMA-BBz CAR construct cloned in the pELPS lentiviral vector NVP- MCM998 was generated by Novartis.

35 *Antibodies.* The antibodies, goat anti-human BCMA PE labeled (Biolegend cat# 357504), and streptavidin (BD Biosciences), were used to detect BCMA expression on

multiple myeloma cell lines. For CAR T cell expression, BCMA fc fusion protein (R&D Systems, cat#193-BC-050) was used followed by anti-human IgG fc-PE antibody (Biolengend, cat# 409304).

PBS. PBS was from Gibco.

Lentiviral package. PCL USUG, PRSV Rev, PGAG pol plasmids (Nature Technology corp, cat# NTC RP20) were used for huBCMA-BBz lentiviral preparation by transfecting with Lipofectamine 2000 (Invitrogen Cat# 11668027) on 293T cells.

Cell lines. Human embryonic kidney 293T cells (ATCC cat# CRL-3216) were used for lentiviral preparation. Multiple Myeloma cell lines RPMI 8226 (ATCC cat# CCL-155), MM1S (ATCC cat# CRL-2974), U266 (ATCC cat# CRL-3216), NCI H929 (ATCC cat# CRL-9068) and OPM2 (DSMZ cat# ACC-50); and K562 (ATCC cat# CCL-256), or K562- BCMA cells (BCMA Lentiviral vector from Genecopoeia cat# Lv105) were used for functional experiments on CART-BCMA cells.

Methods

Lentiviral production protocol and titer determination. 293T cells were seeded at 8.10^6 cells/per flask in a T150 flask (Corning Costar Cat. #430825) with RPMI1640 medium (Gibco Cat. #11875-080) supplemented with 10% FBS (ATCC cat # 30-2020) and strep/penicillin (Invitrogen cat # 10378-016) and transfected with packing plasmids mix (Nature Technology corp.) plus huBCMA-BBz encoding pELPS lentiviral vector for 24hrs. The resulting viral preparation was stored at -80°C . Recombinant lentivirus was titered on CD4 T.

Transduction protocol. T cells obtained from the Human Immunology Core were washed once in media, re-suspended at 10^6 cells/ml, and stimulated with CD3/28 beads at a cell:bead ratio of 1:3. Lentivirus transduction was performed on day 2 by mixing the lentivirus vector into the cell cultures at an MOI of 3.

T cell expansion. Stimulated T cells were fed and split every 2-3 days to 0.8×10^6 cells/ml for 7-9 days or until cells were rested as determined by decreased rate of cell division and a decrease in mean cellular volume to $< \sim 300\text{fl}$.

Cell cultures. Multiple Myeloma cell lines and K562, K562 BCMA cell lines were cultured in RPMI with 10% FBS and antibiotics.

Cell counting. Cells were counted every 3 days during the expansion by gently mixing cultures and collecting 40ul of cells from culture volume and placed into accuvettes (Beckman

5 Coulter) with 20ml Isoton II Diluent Buffer for counting using a Coulter Multisizer 3 (Beckman Coulter). The results of this test (absolute cell count and cell volume) were used to determine cell concentration, total cell numbers, growth rates, and dilution volumes.

⁵¹Cr release-assay. The ability of CART-BCMA cells to kill BCMA-expressing target cells was evaluated using a ⁵¹Cr release-assay. Briefly, target K562-BCMA cells (or control
10 K562 cells) and multiple myeloma cell lines were labeled with ⁵¹Cr (Sodium Dichromate salt), washed and co-cultured with effector CART-BCMA or control non-transduced T cells (NTD) at different effector/target ratios. Supernatants were collected a 4-hrs, and placed into 96 well Lumaplates (Perkin Elmer). The amount of ⁵¹Cr released from the labeled target cells was measured on a liquid scintillation counter (MicroBeta trilux, Perkin Elmer). Target cells
15 incubated in medium alone or with 1% SDS were used to determine spontaneous (S) or maximum (M) ⁵¹Cr release. Percentage of specific lysis was calculated as follow: 100x (cpm experimental release- cpm S release)/ (cpm M release- cpm S release).

CAR detection on transduced T cells. To evaluate transduction of CART-BCMA, T cells were stained with BCMA-Fc fusion protein (R&D Systems) followed by anti-human
20 IgG Fc-PE antibody (Biolengend).

Flow cytometry. For anti-BCMA staining, human myeloma cell lines were stained with goat anti-human-PE BCMA antibody (Biolegend) followed by streptavidin (BD Biosciences). Flow cytometry analysis for all experiments was carried out by using FlowJo (Tree Star, Inc.).

ELISA. Target K562-BCMA cells (or control K562 cells) or multiple myeloma cell
25 lines were combined with CAR-transduced T cells at a target:effector ratio 1:3 in duplicate wells of a 96 well flat bottom plate. ELISA assay was performed in a 1:10 dilution of supernatant collected after 16hr of incubation by using the human IFN γ or IL2 DuoSet ELISA kit (R&D) as recommended by the manufacturer.

Results

30 *huBCMA-BBz was highly expressed on transduced T cells.*

Freshly purified negatively selected normal human T cells were activated *in vitro* using CD3/28 beads (cell:bead ratio 1:3) and allowed to expand. On day 1 post-activation, cells were transduced with the preclinical lentiviral vector expressing huBMCA-BBz or mock transduced (NTD control). Figure 36A shows the increase of total T cells during culture. BCMA-CART
35 cells were counted every 3 days and adjusted for the ratio of split cells. T cells were enumerated using a Coulter Counter Multisizer III and fed every 2 days until the end of the

5 expansion cycle (Day 7-9). On day 6 of ex vivo expansion, 200ul of CART- BCMA or control NTD T cells were stained as described in the Methods section above. The live cell populations were gated using FCS vs. SSC. The flow acquisition was performed on a BC FACS Canto instrument and the flow analysis was performed using FlowJo software (TreeStar, Inc).

No differences in the proliferation rates of non transduced (NTD) and CART-BCMA
10 cells were observed, indicating that lentiviral expression did not affect the proliferative potential of T cells (Figure 36A). Transduction efficiency was evaluated at day 6 post-transduction as described in the methods section above. Figure 36B shows that huBCMA-BBz transduction efficiency was 49%. These results demonstrate that huBCMA-BBz CAR was efficiently expressed on the surface of human T cells.

15 *BCMA was expressed at different levels on multiple myeloma cell lines.*

BCMA surface expression on multiple myeloma cell lines was determined using flow cytometry staining. The live cell populations were gated by FCS/SCC parameters. The flow acquisition was done on a canto instrument and the flow analysis with FlowJo software. Most multiple myeloma cell lines tested showed strong BCMA expression, whereas RPMI 8226 and
20 control K562-BCMA cells expressed lower levels of surface BCMA (Figure 37). For all plots, the orange solid peak represents isotype control and the blue solid peak staining with BCMA antibody (Figure 37). Flow cytometry staining revealed BCMA expression on the surface of the multiple myeloma cell lines NCI H929, U266, RPMI 8226, OPM2 and MM1S, as well as by K562- BCMA cells. BCMA was not detected on the surface of K562 cell line (Figure 37).
25 These results demonstrate that BCMA was expressed by several multiple myeloma cell lines with expression levels varying by about 1 log.

CART-BCMA cells produced cytokines and showed cytotoxic properties specifically in response to different BCMA-expressing, multiple myeloma cell lines.

The ability of CART-BCMA cells to produce cytokines and kill BCMA+ target cells
30 was determined. CART-BCMA cells (huBCMA-BBz transduced T cells) or control non transduced T cells (NTD) were co-cultured in duplicates for 16hrs with K562, K562-BCMA or multiple myeloma cell lines (MM1S, OPM2, or U266). Cells were co-cultured at a 3:1 ratio of T cell to target cells. Cell-free supernatant was harvested and the production of IL2 or IFN γ was evaluated as described in the Methods section above.

35 CART-BCMA cells specifically produced IL2 or IFN γ in the presence of K562 engineered to express BCMA (K562-BCMA) compared to non-antigen-expressing, wildtype

5 K562 cells. CART-BCMA cells were also able to produce cytokines in the presence of U266, OPM2 and MM1S multiple myeloma cell lines (Figures 38A-38B). These results demonstrate that in the presence of BCMA+ target cell lines, CART-BCMA cells produced pro-inflammatory cytokines.

10 Another *in vitro* measure for the anti-tumor effectiveness of CART-BCMA cells is their ability to kill BCMA+ target cells. T cells were activated and transduced, as described above, e.g., in relation to Figures 36A-36B. BCMA10 CAR T cells were co-cultured with ⁵¹Cr-labeled K562-BCMA, RPMI 8226 or MM1S cell lines for 4 hrs at the effector to target ratios (E:T Ratio) indicated in Figures 39A-39C (E:T of 0, 10, 20, or 30) and percentage of lysis was calculated as described in the Methods section above. Figure 39A shows that CART-BCMA
15 cells specifically killed K562-BCMA cells. CART-BCMA cells also efficiently killed the BCMA^{high} multiple myeloma cell line MM1S and the BCMA^{low} RPMI 8226 cell line in a 4-hr cytotoxicity assay (Figures 39B, 39C). These results demonstrate that CART-BCMA displayed enhanced cytotoxic activity (⁵¹Cr assay) against multiple myeloma cell lines.

Antitumor activity of CART-BCMA cells in vivo

20 Using RPMI 8226 cells, which show lower levels of BCMA expression compared to many other myeloma cells lines, a mouse model was established to evaluate the capacity of CART-BCMA to recognize and eliminate tumors produced by the BCMA^{low} RPMI 8226 cell line engineered to express Click-beetle green luciferase (CBG) for bioluminescence imaging (BLI). NOD/SCID/ γ -chain^{-/-} (NSG) mice with established intravenous RPMI 8226 tumors
25 received intravenous injections of CART-BCMA cells (N=10) or non transduced control T cells (NTD) (N=10) on day 30 following tumor cell inoculation. NSG mice engrafted with RPMI-8226 cells were treated with 5x10⁶ CART-BCMA T cells at day 30 following tumor cell injection. Myeloma tumor progression was followed by *in vivo* BLI (BLI of ventral and dorsal mouse areas once per week) up to 9 weeks post-T cell infusion (14 weeks post-tumor
30 injection).

Non-transduced T cells failed to control the tumors, and all mice had to be euthanized due to disease progression 10-11 weeks after tumor injection (Figure 40A and 40C). In contrast, mice receiving CART-BCMA cells showed control of tumor growth in most mice resulting in 80% survival of CART-BCMA- treated mice at 10 weeks post-tumor cell
35 inoculation compared with 0% survival of the NTD control-treated mice (Figures 40B and

- 5 40C). These results demonstrate that intramedullary RPMI 8226 tumors were inhibited by CART-BCMA treatment.

Example 14: BCMA-CART dosing scheme

10 A BCMA CART cell therapy, e.g., a BCMA CART cell therapy described herein, can be administered to patients, e.g., multiple myeloma patients, according to a dosing regimen described herein, e.g., a dosing regimen described as follows.

Leukopheresis is performed on the patient prior to receiving a BCMA CART therapy to obtain autologous T cells. Manufacturing and/or cryopreservation of the BCMA lentiCAR T cells is performed. Patients may receive therapy during manufacturing to maintain disease
15 control. Some patients may receive a lympho-depleting therapy (e.g., cytoxan) before CART cell administration. For example, a lympho-depleting chemotherapy, e.g., cytoxan (e.g., at 1.5 g/m²) is administered to the patient. In other dosing regimens, a lympho-depleting chemotherapy is not administered to the patient. Patients are then treated with BCMA CART cells according to a dosing regimen described herein.

20 A dosing regimen involves dose fractionation, e.g., where a certain percentage of the total dose of cells is delivered on a first day of treatment, a different percentage of the total dose of cells is delivered on a subsequent day of treatment, and a different percentage of the total dose of cells is delivered on a yet subsequent day of treatment. For example, 10% of the total dose of cells is delivered on the first day, 30% of the total dose of cells is delivered on the
25 second day, and the remaining 60% of the total dose of cells is delivered on the third day of treatment. For example, a total cell dose includes 1 to 5 x 10⁷ or 1 to 5 x 10⁸ BCMA-CART cells.

In one dosing regimen, no lympho-depleting chemotherapy is administered, and a total BCMA-CART cell dose of 1 to 5 x 10⁷ is administered (e.g., by infusion) with 10% of the cell
30 dose on day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment. In another dosing regimen, no lympho-depleting chemotherapy is administered, and a total BCMA-CART cell dose of 1 to 5 x 10⁸ is administered (e.g., by infusion) with 10% of the cell dose on day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment. In another dosing regimen, a lympho-depleting chemotherapy (cytoxan at 1.5 g/m²) is
35 administered three days before BCMA-CART cell administration, and then a total BCMA-

5 CART cell dose of 1 to 5×10^7 is administered (e.g., by infusion) with 10% of the cell dose on day 1 of treatment, 30% on day 2 of treatment, and 60% on day 3 of treatment. In yet another dosing regimen, a lympho-depleting chemotherapy (cytoxan at 1.5 g/m^2) is administered three days before BCMA-CART cell administration, and then a total BCMA-CART cell dose of 1 to 5×10^8 is administered (e.g., by infusion) with 10% of the cell dose on day 1 of treatment, 30%
10 on day 2 of treatment, and 60% on day 3 of treatment.

Clinical lab assessments are performed on days 1, 2, 4, 7, 14, 21, 28, every 4 weeks, after CART cell administration (with day 0 being the first day of CART dosing). Multiple myeloma assessments are performed pre-CART dosing, on the first day of CART dosing (day 0), and days 14, 28, and every 4 weeks. Bone marrow aspirate/biopsy (bx) is performed pre-
15 CART dosing, and on days 28 and 90 after CART dosing. After the first 28 days of CART treatment, follow-up is performed every 4 weeks up to 6 months, then every 3 months, up to 2 years.

Example 15: Low dose RAD001 stimulates CART proliferation in a cell culture model

20 The effect of low doses of RAD001 on CAR T cell proliferation in vitro was evaluated by co-culturing CART-expressing cells with target cells in the presence of different concentrations of RAD001.

Materials and Methods

Generation of CAR-transduced T cells

25 A humanized, anti-human CD19 CAR (huCART19) lentiviral transfer vector was used to produce the genomic material packaged into VSVg pseudotyped lentiviral particles. The amino acid and nucleotide sequence of the humanized anti-human CD19 CAR (huCART19) is CAR 1, ID 104875 described in PCT publication, WO2014/153270, filed March 15, 2014, and is designated SEQ ID NOs. 85 and 31 therein.

30 Lentiviral transfer vector DNA is mixed with the three packaging components VSVg env, gag/pol and rev in combination with lipofectamine reagent to transfect Lenti-X 293T cells. Medium is changed after 24h and 30h thereafter, the virus-containing media is collected, filtered and stored at -80°C . CARTs are generated by transduction of fresh or frozen naïve T cells obtained by negative magnetic selection of healthy donor blood or leukopak. T cells are activated by incubation with anti-
35 CD3/anti-CD28 beads for 24h, after which viral supernatant or concentrated virus (MOI=2 or 10, respectively) is added to the cultures. The modified T cells are allowed to expand for about 10 days.

- 5 The percentage of cells transduced (expressing the CARs on the cell surface) and the level of CAR expression (relative fluorescence intensity, Geo Mean) are determined by flow cytometric analysis between days 7 and 9. The combination of slowing growth rate and T cell size approaching ~350 fL determines the state for T cells to be cryopreserved for later analysis.

Evaluating proliferation of CARTs

- 10 To evaluate the functionality of CARTs, the T cells are thawed and counted, and viability is assessed by Cellometer. The number of CAR-positive cells in each culture is normalized using non-transduced T cells (UTD). The impact of RAD001 on CARTs was tested in titrations with RAD001, starting at 50nM. The target cell line used in all co-culture experiments is Nalm-6, a human pre-B cell acute lymphoblastic leukemia (ALL) cell line expressing CD19 and transduced to express
15 luciferase.

For measuring the proliferation of CARTs, T cells are cultured with target cells at a ratio of 1:1. The assay is run for 4 days, when cells are stained for CD3, CD4, CD8 and CAR expression. The number of T cells is assessed by flow cytometry using counting beads as reference.

Results

- 20 The proliferative capacity of CART cells was tested in a 4 day co-culture assay. The number of CAR-positive CD3-positive T cells (dark bars) and total CD3-positive T cells (light bars) was assessed after culturing the CAR-transduced and non-transduced T cells with Nalm-6 (Fig. 43). huCART19 cells expanded when cultured in the presence of less than 0.016 nM of RAD001, and to a lesser extent at higher concentrations of the compound. Importantly, both at 0.0032 and 0.016 nM
25 RAD001 the proliferation was higher than observed without the addition of RAD001. The non-transduced T cells (UTD) did not show detectable expansion.

Example 16: Low dose RAD001 stimulates CART expansion in vivo

- This example evaluates the ability of huCAR19 cells to proliferate *in vivo* with different
30 concentrations of RAD001.

Materials and Methods:

- NALM6-luc cells:* The NALM6 human acute lymphoblastic leukemia (ALL) cell line was developed from the peripheral blood of a patient with relapsed ALL. The cells were then tagged with firefly luciferase. These suspension cells grow in RPMI supplemented with 10% heat inactivated fetal
35 bovine serum.

Mice: 6 week old NSG (NOD.Cg-Prkdc^{scid}Il2rg^{tm1Wjl}/SzJ) mice were received from the Jackson Laboratory (stock number 005557).

5 *Tumor implantation:* NALM6-luc cells were grown and expanded *in vitro* in RPMI supplemented with 10% heat inactivated fetal bovine serum. The cells were then transferred to a 15 ml conical tube and washed twice with cold sterile PBS. NALM6-luc cells were then counted and resuspended at a concentration of 10×10^6 cells per milliliter of PBS. The cells were placed on ice and immediately (within one hour) implanted in the mice. NALM6-luc cells were injected intravenously via
10 the tail vein in a 100 μ l volume, for a total of 1×10^6 cells per mouse.

CAR T cell dosing: Mice were administered 5×10^6 CAR T cells 7 days after tumor implantation. Cells were partially thawed in a 37 degree Celsius water bath and then completely thawed by the addition of 1 ml of cold sterile PBS to the tube containing the cells. The thawed cells were transferred to a 15 ml falcon tube and adjusted to a final volume of 10 mls with PBS. The cells were
15 washed twice at 1000rpm for 10 minutes each time and then counted on a hemocytometer. T cells were then resuspended at a concentration of 50×10^6 CAR T cells per ml of cold PBS and kept on ice until the mice were dosed. The mice were injected intravenously via the tail vein with 100 μ l of the CAR T cells for a dose of 5×10^6 CAR T cells per mouse. Eight mice per group were treated either with 100 μ l of PBS alone (PBS), or humanized CD19 CAR T cells.

20 *RAD001 dosing:* A concentrated micro-emulsion of 50mg equal to 1mg RAD001 was formulated and then resuspended in D5W (dextrose 5% in water) at the time of dosing. Mice were orally dosed daily (via oral gavage) with 200 μ l of the desired doses of RAD001.

PK analysis: Mice were dosed daily with RAD001 starting 7 days post tumor implantation. Dosing groups were as follows: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. Mice were bled on days 0
25 and 14 following the first and last dose of RAD001, at the following time points for PK analysis: 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours.

Results:

 The expansion and pharmacokinetics of RAD001 was tested in NSG mice with
30 NALM6-luc tumors. Daily oral dosing of RAD001 alone did not have an impact on the growth of NALM6-luc tumors (Figure 44). The pharmacokinetic analysis of RAD001 shows that it is fairly stable in the blood of tumor bearing mice (Figure 45A and 45B). Both the day 0 and day 14 PK analyses show that the RAD001 concentrations in the blood is above 10nm even 24 hours after dosing at the lowest dose tested (0.3 mg/kg).

35 Based on these doses, huCAR19 CAR T cells were dosed with and without RAD001 to determine the proliferative ability of these cells. The highest dose used was 3 mg/kg based on the levels of RAD001 in the blood 24 hours after dosing. As the concentration of RAD001 was

5 above 10nM 24 hours after the final dose of RAD001, several lower doses of RAD001 were used in the *in vivo* study with CAR T cells. The CAR T cells were dosed IV one day prior to the start of the daily oral RAD001 dosing. Mice were monitored via FACS for T cell expansion.

The lowest doses of RAD001 show an enhanced proliferation of the CAR T cells
10 (Figure 46). This enhanced proliferation is more evident and prolonged with the CD4⁺ CAR T cells than the CD8⁺ CAR T cells. However, with the CD8⁺ CAR T cells, enhanced proliferation can be seen at early time points following the CAR T cell dose.

Example 17: CD19 CAR T cells for use in treating multiple myeloma

15 Even with current regimens of chemotherapy, targeted therapies, and autologous stem cell transplant, myeloma is considered an incurable disease. The present example describes treating multiple myeloma (MM) with autologous T cells directed to CD19 with a chimeric antigen receptor (lentivirus/CD19:4-1BB:CD3zeta; also known as "CART19" or CTL019). This example demonstrates that CD19-directed CAR therapies have the potential to establish
20 deep, long-term durable remissions based on targeting the myeloma stem cell and/or tumor cells that express very low (undetectable by most methods) levels of CD19.

In treating a patient with an aggressive secondary plasma cell leukemia, we found that CART19 administered two days after a salvage autologous stem cell transplant resulted in rapid clearance of plasma cell leukemia and a very good partial response in a patient who had
25 progressed through multiple lines of chemotherapy. This patient was transfusion-dependent for months prior to the treatment; at two months after the treatment, she has recovered her blood counts (with normal-range platelet counts and white blood cell counts) and has not required transfusions since she was discharged from the hospital from her treatment.

Because myeloma cells do not naturally express CD19, the finding that CART19
30 treatment induced a rapid and significant tumor response in this tumor was surprising. Without wishing to be bound by a particular theory, it was reasoned that CART19 could be used to treat myeloma because: (1) while myeloma cells are traditionally thought to be negative for CD19 expression by flow cytometry, there are data indicating that myeloma cells may express very low levels of CD19, such that expression is detectable by RNA but not by flow cytometry or
35 immunohistochemistry; and (2) the concept of targeting the clonotypic B cell, which is thought

5 to be the cancerous stem cell that gives rise to multiple myeloma, and is particularly resistant to chemotherapy. There is a clonal relationship between B cells and myeloma tumor cells, but traditional myeloma therapy is aimed at the malignant plasma cells rather than B cells. CART19 for treating myeloma therefore targets a different cell population than most myeloma therapies.

10 In our single patient experience, the patient had circulating plasma cells, and we were able to test her tumor cells for the expression of CD19. Approximately 1-2% of her tumor cells expressed the CD19 antigen. (FIG. 47). Thus, it was reasoned that CART19 may have a direct effect on a very small population of her tumor cells; a very good partial response, though would not have been predicted based on targeting only the very small population of CD19+ tumor
15 cells.

In this case, CART19 was administered following autologous stem cell transplant rescue after high-dose melphalan. Although this is a standard therapy in myeloma, it is not curative. Furthermore, this patient had previously undergone tandem autologous stem cell transplants and relapsed early (<6 months) after transplant. Without wishing to be bound by a
20 particular theory, use of CART19 cells as described in the present example may have a non-overlapping mechanism in the treatment of myeloma when combined with a salvage autologous stem cell transplant.

A patient with refractory multiple myeloma was treated with CTL019 after myeloablative chemotherapy and ASCT. Remission was maintained despite loss of detectable
25 CTL019 and reconstitution of normal CD19-positive B cells, indicating that this response did not require sustained CTL019 activity. Moreover, this patient's response was realized even though the vast majority (99.95%) of the neoplastic plasma cells were CD19-negative by both flow cytometry and RT-PCR.

The absence of detectable CD19 expression in this patient's dominant neoplastic plasma
30 cell population suggests that the clinically relevant target of CTL019 resided outside this dominant CD19-negative population. Neoplastic plasma cells in multiple myeloma patients exhibit genetic, immunophenotypic, and functional heterogeneity. Particular subpopulations may be required for survival of the clone through anti-myeloma therapy. In the patient reported here, for example, the small CD19-expressing subset of plasma cells might have been relatively
35 melphalan-resistant but sensitive to CTL019. This finding suggests that therapeutically

5 targeting a small subset of the clone can lead to durable clinical benefit when coupled with conventional anti-myeloma therapy.

Alternatively, the clinically relevant target of CTL019 in this patient may have resided outside the neoplastic plasma cell population. For instance, the CTL019 may target a stem cell population that is relatively small but gives rise to neoplastic plasma cells. Multiple myeloma
10 may therefore be a disease of multiple late B-lineage cell types, not just terminally differentiated plasma cells, such that therapies like CTL019 that target B lymphocytes might be useful adjuncts to therapies that directly target plasma cells.

Ten additional multiple myeloma patients will be treated with CART19 in a Phase I trial, at least three patients have been treated to date.

15 Dose Rationale

With the first 3 patients, we have observed clinical activity at doses ranging from 1.4×10^7 to 1.1×10^9 CART-19 cells. This observation demonstrates, at least in the first 3 patients treated, that there is not an obvious dose response relationship. A complete response was observed in patients administered with two log fold difference in dose. Thus, unlike standard
20 drugs that are metabolized, CAR T cells can have a wide dose response range. This is most likely because the CAR T cells are able to proliferate extensively in the patients. We therefore set a dose range of $1-5 \times 10^8$ CART-19 cells for infusion. In this single-patient study offered on a compassionate use basis, the patient was offered up to 5×10^8 CART19 cells, with no lower dose limit. For the ten patient trial, patients will be offered $1-5 \times 10^7$ CART-19 cells.

25 General Design

This was single patient-study offered on a compassionate use basis; it was modeled after a Phase I study to determine if the infusion of autologous T cells transduced to express CART-19 is safe. The primary goals of the study were to determine the safety, tolerability and engraftment potential of CART -19 T cells in patients undergoing salvage ASCT after early
30 relapse following first ASCT. The protocol consists of an open label pilot study.

At entry subjects will undergo a bone marrow biopsy and routine laboratory and imaging assessment of their MM. Eligible subjects will undergo steady-state apheresis to obtain large numbers of peripheral blood mononuclear cells (PBMC) for CART-19 manufacturing. The T cells will be purified from the PBMC, transduced with TCR ζ /4-1BB lentiviral vector,
35 expanded in vitro and then frozen for future administration. The number of patients who have inadequate T cell collections, expansion or manufacturing compared to the number of patients

- 5 who have T cells successfully manufactured will be recorded; feasibility of product manufacturing is not expected to be problematic in this patient population.

Subjects will generally have had adequate peripheral blood stem cells remaining stored from the mobilization/collection performed in preparation for their first ASCT to conduct two additional ASCT. Those who do not will undergo a second mobilization/collection procedure
10 either before or after their steady-state apheresis with a regimen according to the treating physician's preference. Approximately two weeks after the initial leukapheresis, subjects will be admitted to the hospital and receive high-dose melphalan (day -2) followed by infusion of autologous stem cells two days later (day 0), and all subjects will receive infusion of CART-19 cells twelve to fourteen days later (day +12-14). Up to 10 patients will be enrolled.

- 15 All subjects will have blood tests to assess safety, and engraftment and persistence of the CART-19 cells at regular intervals through week 4 of the study. At day +42 and day +100, subjects will undergo bone marrow aspirates/biopsies to assess the bone marrow plasma cell burden and trafficking of CART-19 cells to the bone marrow. A formal response assessment will be made at day 100 according to International Myeloma Working Group (IMWG)
20 criteria¹³⁶, and TTP will be monitored according to routine clinical practice for patients with multiple myeloma. The main efficacy outcome measured in this study will be a comparison of TTP after a patient's initial ASCT to TTP after the ASCT on this study.

Treatment Regimen

Therapy for Relapsed/Progressive Multiple Myeloma

- 25 Patients may receive, prior to enrollment, therapy for relapsed/progressive multiple myeloma according to the preference of their treating physicians. Therapy may continue upon enrollment.

Patients must stop all therapy for two weeks prior to apheresis and for two weeks prior to high-dose melphalan. If more than two weeks are expected to lapse between apheresis and
30 high-dose melphalan, patients may resume therapy after apheresis at the discretion of their treating physicians.

High-dose Melphalan (day -2)

- Patients will be admitted to the hospital on day -3 or -2 and will undergo examination by the attending physician and routine laboratory tests, which will include monitoring
35 parameters for tumor lysis syndrome, prior to commencement of the treatment protocol. Blood for MM monitoring laboratory tests (SPEP, quantitative immunoglobulins, and serum free light

- 5 chain analysis), will be drawn prior to initiation of therapy if such tests had not been drawn within 7 days of admission.

High-dose therapy will consist of melphalan at a dose of 200 mg/m² administered intravenously over approximately 20 minutes on day -2. The dose of melphalan will be reduced to 140 mg/m² for patients >70 years of age or for patients of any age whom, at the discretion of the treating physician, may not tolerate a dose of 200 mg/m². All patients will receive standard anti-emetic prophylaxis, which may include dexamethasone, and standard antibiotic prophylaxis.

Stem-cell Re-infusion (day 0)

- Stem cell infusion will take place on day 0, at least 18 hours after the administration of the high-dose melphalan. Stem cells will be infused intravenously over approximately 20-60 minutes following premedication according to standard institutional practice. At least 2 x 10⁶ CD34+ progenitors/kg body weight should be infused. In addition, at least 1 x 10⁶ CD34+ progenitors/kg body weight should be available as a back-up stem-cell product to be infused in the event of delayed engraftment or late graft failure. G-CSF should be administered SQ beginning on day +5, dosed according to standard institutional practice. Other supportive care measures such as transfusion support will be done in accordance with standard institutional guidelines.

CART19 Cell Infusion (day +12-14)

- A single dose of CART-19 transduced T cells will be given consisting of up to 5 x 10⁷ CART-19 cells. The minimal acceptable dose for infusion of cells transduced with the CD19 TCR ζ 4-1BB vector is 1 x 10⁷. CART-19 cells will be given as a single dose by rapid i.v. infusion on day +12-14 after stem cell infusion. If patient fails to meet any of the inclusion criteria described herein in the 12-14 day window, the CART-19 infusion may be delayed beyond day +12-14 until the criteria is satisfied.

30 Maintenance Lenalidomide

- Subjects who received and tolerated maintenance lenalidomide after their first ASCT will re-initiate lenalidomide maintenance therapy at approximately day + 100, assuming there are no contraindications in the judgment of the treating physician. The starting dose will be 10 mg daily unless prior experience dictates an alternative starting dose for a particular patient. Maintenance therapy will continue until disease progression or intolerance.

Administration of Study Drug

5 The infusion will take place in an isolated room in Rhoads, using precautions for immunosuppressed patients. The transduced T cells will be administered by rapid intravenous infusion at a flow rate of approximately 10mL to 20 ml per minute through an 18-gauge latex free Y-type blood set with a 3-way stopcock. The duration of the infusion will be based on the total volume to be infused and the recommended infusion rate. Each infusion bag will have
10 affixed to it a label containing the following: "FOR AUTOLOGOUS USE ONLY." In addition the label will have at least two unique identifiers such as the subject's initials, birth date, and study number. Prior to the infusion, two individuals will independently verify all this information in the presence of the subject and so confirm that the information is correctly matched to the participant.

15 Packaging

Infusion will be comprised of a single dose of $1-5 \times 10^7$ CA T19-transduced cells, with a minimal acceptable dose of 1×10^7 CART-19 cells for infusion. Each bag will contain an aliquot (volume dependent upon dose) of cryomedia containing the following infusible grade reagents (% v/v): 31.25% plasmalyte-A, 31.25% dextrose (5%), 0.45% NaCl, up to 7.5%
20 DMSO, 1% dextran 40, 5% human serum albumin.

Apheresis

A large volume (12-15 liters or 4-6 blood volumes) apheresis procedure is carried out at the apheresis center. PBMC are obtained for CART-19 during this procedure. From a single leukapheresis, the intention is to harvest at least 5×10^9 white blood cells to manufacture
25 CART-19 T cells. Baseline blood leukocytes for FDA look-back requirements and for research are also obtained and cryopreserved. The cell product is expected to be ready for release approximately 2-4 weeks later. Flow cytometry lymphocyte subset quantitation, including CD19 and CD20 B cell determination. Baseline assessment is made for human anti-VSV-G and anti-murine antibody (HAMA). If a subject has previously had an adequate apheresis collection
30 banked according to current Good Manufacturing Practices at the Clinical Cell and Vaccine Production Facility these cells may be used as the source of cells for CART -19 manufacturing. Using a banked apheresis product would avert the expense, time, and risk to the subject of undergoing an additional apheresis collection.

Cytoreductive Chemotherapy

35 The lymphodepleting chemotherapy will be high-dose melphalan as described herein.

CART-19 Infusion

5 Infusion will begin on day +12-14 after stem-cell reinfusion.

 On day + 12-14 prior to the first infusion, patients will have a CBC with differential, and assessment of CD3, CD4 and CD8 counts since chemotherapy is given in part to induce lymphopenia.

 The first dose will be administered using a single dose. The cells are thawed at the
10 patient's bedside. The thawed cells will be given at as rapid an infusion rate as tolerated such that the duration of the infusion will be approximately 10-15 minutes. In order to facilitate mixing, the cells will be administered simultaneously using a Y -adapter. Subjects will be infused and premedicated as described herein. Subjects' vital signs will be assessed and pulse oxymetry done prior to dosing, at the end of the infusion, and every 15 minutes thereafter for 1
15 hour and until these are stable and satisfactory. A blood sample for determination of a baseline CART-19 level is obtained any time prior to the first infusion and 20 minutes to 4 hours after each infusion (and sent to TCSL).

Results

 Three treatment-refractory, advanced multiple myeloma patients have now been treated
20 with CTL019 in this ongoing trial. Results for two of these patients show that both have had substantial anti-tumor effects from the CTL019 therapy based on the primary efficacy assessment at the three-month time-point. The third patient has not yet reached the three-month time point. The results for the two patients are described in more detail below.

 The first myeloma patient has completed her +100 day response assessment and she had
25 a very good response to the CART19 therapy. The following tests were performed with the following results:

 -SPEP/immunofixation: negative

 -urine immunofixation: faint unmeasurable kappa light chain band on her
immunofixation (also present at day 38, so not new)

30 Otherwise, the patient met the criteria for stringent complete remission including:

 -serum free light chain ratio: normal

 -bone marrow biopsy: negative

 -IgA immunophenotyping: IgA is below the limit of detection

 Other than the faint unmeasurable kappa light chain result from urine immunofixation,
35 the patient met all criteria for "stringent complete remission". The summary of the plasma cell immunophenotyping at 3 time points (day -2, day +38, day +103) is shown in Figure 39, and

5 demonstrates that the patient's IgA is below the limit of detection. The summary shows heavy myeloma burden at day -2 and none detectable at day +38 and +103, which classifies the patient as "MRD negative" by flow analysis. At day +103, the summary shows recovery of normal, polyclonal, CD19+ plasma cells and B cells. The patient had no symptoms of disease or therapy and is functioning like a normal person.

10 The second patient treated has not yet reached the +100 day time point. However, at this time point, she is doing well but it is too early to determine the effect of the CTL019 infusion.

15 EQUIVALENTS

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific aspects, it is apparent that other aspects and variations of this invention may be devised by others skilled in the art without departing from the true
20 spirit and scope of the invention. The appended claims are intended to be construed to include all such aspects and equivalent variations.

CLAIMS

1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain, wherein said anti-BCMA binding domain comprises:

(i) a heavy chain complementary determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 394, a heavy chain complementary determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 434, a heavy chain complementary determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 474, a light chain complementary determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 514, a light chain complementary determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 554, and a light chain complementary determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 594;

(ii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 674, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 714, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 754, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 794, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 834;

(iii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 874, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 914, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 954, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 994, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1034, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1074;

(iv) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 396, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 436, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 476, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 516, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 556, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 596;

(v) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 636, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 676, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 716, a LC CDR1 comprising the amino acid sequence

of SEQ ID NO: 756, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 796, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 836; or

(vi) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 876, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 916, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 956, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 996, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1036, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1076.

2. The isolated nucleic acid molecule of claim 1, which encodes a CAR comprising: the amino acid sequence of SEQ ID NO: 94 or 96, or an amino acid sequence with 95-99% identity thereof.

3. The isolated nucleic acid molecule of claim 1 or 2, which encodes a CAR comprising: the amino acid sequence of SEQ ID NO: 79 or 81, or an amino acid sequence with 95-99% identity thereof.

4. The isolated nucleic acid molecule of any of claims 1-3, which encodes a CAR comprising:

(i) the amino acid sequence of SEQ ID NO: 94 and the amino acid sequence of SEQ ID NO: 79, or

(ii) the amino acid sequence of SEQ ID NO: 96 and the amino acid sequence of SEQ ID NO: 81.

5. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded anti-BCMA binding domain comprises:

the amino acid sequence of SEQ ID NO: 49 or 51, or an amino acid sequence with 95-99% identity thereof.

6. The isolated nucleic acid molecule of any of the preceding claims, comprising the nucleotide sequence of SEQ ID NO: 64 or 66, or a sequence with 95-99% identity thereof.

7. The isolated nucleic acid molecule of any of the preceding claims, wherein:

(i) the encoded CAR includes a transmembrane domain that comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154;

(ii) the encoded transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6, an amino acid sequence comprising at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:6, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:6; or (ii) the nucleic acid sequence encoding the transmembrane domain comprises a sequence of SEQ ID NO:17, or a sequence with 95-99% identify thereof.

8. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded anti-BCMA binding domain comprises the amino acid sequence of SEQ ID NO: 49 or 51.

9. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded anti-BCMA binding domain is connected to the transmembrane domain by a hinge region.

10. The isolated nucleic acid molecule of claim 9, wherein:

(i) the encoded hinge region comprises the amino acid sequence of SEQ ID NO:2, or a sequence with 95-99% identity thereof; or (ii) the nucleic acid sequence encoding the hinge region comprises the nucleotide sequence of SEQ ID NO: 13, or a sequence with 95-99% identify thereof.

11. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded intracellular signaling domain comprises a costimulatory intracellular signaling domain, wherein the costimulatory intracellular signaling domain is a functional signaling domain obtained from a costimulatory molecule selected from the group consisting of MHC class I molecule, TNF receptor proteins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFR, LIGHT, HVEM (LIGHTR), KIRDS2,

SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

12. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:7, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7.

13. The isolated nucleic acid molecule of any of the preceding claims, wherein the nucleic acid sequence encoding the intracellular signaling domain comprises the nucleotide sequence of SEQ ID NO:18, or a sequence with 95-99% identify thereof.

14. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta.

15. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and/or the sequence of SEQ ID NO:9 or SEQ ID NO:10; or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10.

16. The isolated nucleic acid molecule of any of the preceding claims, wherein the encoded intracellular signaling domain comprises the sequence of SEQ ID NO:7 and the sequence of SEQ ID NO:9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

17. The isolated nucleic acid molecule of any of the preceding claims, wherein the nucleic acid sequence encoding the intracellular signaling domain comprises the sequence of SEQ ID NO:18, or a sequence with 95-99% identity thereof, and/or the sequence of SEQ ID NO:20 or SEQ ID NO:21, or a sequence with 95-99% identity thereof.

18. The isolated nucleic acid molecule of any of the preceding claims, further comprising a leader sequence which encodes the amino acid sequence of SEQ ID NO: 1.

19. The isolated nucleic acid molecule of any of the preceding claims, which encodes a CAR comprising:

the amino acid sequence of SEQ ID NO: 109 or 111, or an amino acid sequence with 95-99% identity thereof,

with or without a leader sequence comprising the amino acid sequence of SEQ ID NO: 1.

20. The isolated nucleic acid molecule of any of the preceding claims, comprising the nucleotide sequence of SEQ ID NO: 124 or 126, or a nucleotide sequence with 95-99% identity thereof.

21. An isolated polypeptide molecule encoded by the nucleic acid molecule of any one of claims 1-20.

22. An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR comprises a human anti-BCMA binding domain, a transmembrane domain, and an intracellular signaling domain comprising a costimulatory domain and/or a primary signaling domain, wherein said anti-BCMA binding domain comprises:

(i) a heavy chain complementary determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 394, a heavy chain complementary determining region

2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 434, a heavy chain complementary determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 474, a light chain complementary determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 514, a light chain complementary determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 554, and a light chain complementary determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 594;

(ii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 674, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 714, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 754, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 794, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 834;

(iii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 874, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 914, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 954, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 994, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1034, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1074;

(iv) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 396, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 436, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 476, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 516, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 556, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 596;

(v) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 636, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 676, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 716, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 756, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 796, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 836; or

(vi) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 876, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 916, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 956, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 996, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1036, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1076.

23. The isolated CAR polypeptide of claim 22, comprising:
the amino acid sequence of SEQ ID NO: 94 or 96, or an amino acid sequence with 95-99% identity thereof.

24. The isolated CAR polypeptide of claim 22 or 23, comprising:
the amino acid sequence of SEQ ID NO: 79 or 81, or an amino acid sequence with 95-99% identity thereof.

25. The isolated CAR polypeptide of any of claims 22-24, comprising:
(i) the amino acid sequence of SEQ ID NO: 94 and the amino acid sequence of SEQ ID NO: 79, or
(ii) the amino acid sequence of SEQ ID NO: 96 and the amino acid sequence of SEQ ID NO: 81.

26. The isolated CAR polypeptide of any of claims 22-25, comprising:
the amino acid sequence of SEQ ID NO: 49 or 51, or an amino acid sequence with 95-99% identity thereof.

27. The isolated CAR polypeptide of any of claims 22-26, wherein the transmembrane domain comprises a transmembrane domain from a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.

28. The isolated CAR polypeptide of any of claims 22-27, wherein
(i) the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 6;
(ii) an amino acid sequence comprises at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO: 6; or
(iii) a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 6.

29. The isolated CAR polypeptide of any one of claims 22-28, wherein the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region.

30. The isolated CAR polypeptide of claim 29, wherein the hinge region comprises SEQ ID NO:2 or SEQ ID NO:36, or a sequence with 95-99% identity thereof.

31. The isolated CAR polypeptide of any of claims 22-30, wherein the costimulatory domain is a costimulatory intracellular signaling domain, wherein the costimulatory intracellular signaling domain is a functional signaling domain obtained from a costimulatory molecule selected from the group consisting of MHC class I molecule, TNF receptor proteins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

32. The isolated CAR polypeptide of any of claims 22-31, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO: 7, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 7.

33. The isolated CAR polypeptide of any of claims 22-32, wherein the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta.

34. The isolated CAR polypeptide of any of claims 22-33, wherein the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10, or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid

sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:7 and/or the amino acid sequence of SEQ ID NO:9 or SEQ ID NO:10.

35. The isolated CAR polypeptide of any of claims 22-34, wherein the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO:10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

36. The isolated CAR polypeptide of any of claims 22-35, further comprising a leader sequence which comprises the amino acid sequence of SEQ ID NO: 1.

37. The isolated CAR polypeptide of any of claims 22-36, comprising:
the amino acid sequence of SEQ ID NO: 109 or 111, or an amino acid sequence with 95-99% identity thereof,
with or without a leader sequence comprising the amino acid sequence of SEQ ID NO: 1.

38. A vector comprising a nucleic acid molecule encoding the CAR polypeptide of any of claims 22-37, wherein the vector is selected from the group consisting of a DNA vector, a RNA vector, a plasmid, a lentivirus vector, adenoviral vector, or a retrovirus vector.

39. The vector of claim 38, further comprising an EF-1 promoter comprising the sequence of SEQ ID NO: 11.

40. An immune effector cell, comprising the nucleic acid molecule of any of claims 1-20, the CAR polypeptide of any of claims 22-37, or the vector of claim 38 or 39, wherein the immune effector cell is a T cell or an NK cell.

41. A method of making an immune effector cell, comprising transducing an immune effector cell ex vivo with the vector of claim 38 or 39, wherein the immune effector cell is a T cell or an NK cell.

42. A method of generating a population of RNA-engineered immune effector cells comprising introducing an in vitro transcribed RNA or synthetic RNA into an immune effector cell ex vivo, wherein the RNA comprises a nucleic acid encoding the CAR polypeptide of any of claims 22-37, and wherein the immune effector cells are T cells or NK cells.

43. An immune effector cell, e.g., a population of immune effector cells, comprising the nucleic acid molecule of any of claims 1-20, or the CAR polypeptide of any of claims 22-37 for use in providing an anti-tumor immunity in a mammal, wherein the immune effector cell is a T cell or an NK cell.

44. The immune effector cell for use according to claim 43, wherein the cell is an autologous T cell or an allogeneic T cell.

45. An immune effector cell, e.g., a population of immune effector cells, comprising the nucleic acid molecule of any of claims 1-20, or the CAR polypeptide of any of claims 22-37 for use in treating a mammal having a cancer or malignancy, or a precancerous condition chosen from one or more of a myelodysplasia, a myelodysplastic syndrome or a preleukemia, wherein the immune effector cell is a T cell or an NK cell.

46. The immune effector cell for use according to claim 45, wherein the mammal has a hematologic cancer.

47. The immune effector cell for use according to claim 45 or 46, wherein the mammal has an acute leukemia chosen from one or more of B-cell acute lymphoid leukemia ("BALL"), T-cell acute lymphoid leukemia ("TALL"), acute lymphoid leukemia (ALL); chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia; a prostate cancer

(e.g., castrate-resistant or therapy-resistant prostate cancer, or metastatic prostate cancer), pancreatic cancer, lung cancer; or a plasma cell proliferative disorder (e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's macroglobulinemia, plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, and POEMS syndrome (also known as Crow-Fukase syndrome, Takatsuki disease, and PEP syndrome)), or a combination thereof.

48. The immune effector cell for use according to any of claims 45-47, wherein the cell, e.g., the population of immune effector cells, is to be administered in combination with one or more of:

(i) an agent that increases the efficacy of the cell comprising the CAR nucleic acid or CAR polypeptide;

(ii) an agent that ameliorates one or more side effects associated with administration of the cell comprising the CAR nucleic acid or CAR polypeptide;

(iii) an agent that treats a cancer or malignancy, or a precancerous condition chosen from one or more of a myelodysplasia, a myelodysplastic syndrome or a preleukemia .

49. The immune effector cell for use according to any of claims 45-48, wherein the cell, e.g., a population of immune effector cells, is to be administered in combination with a PD-L1 inhibitor, e.g., an anti-PD-L1 antibody.

50. The isolated nucleic acid molecule of any of claims 1-20, the isolated CAR polypeptide of any of claims 22-37, the vector of claim 38 or 39, or the immune effector cell of claim 40 for use as a medicament.

51. The isolated nucleic acid molecule of any of claims 1-20, the isolated CAR polypeptide of any of claims 22-37, the vector of claim 38 or 39, or the immune effector cell of claim 40 for use in the treatment of a disease associated with over-expression of BCMA.

52. The immune effector cell, e.g., a population of immune effector cells, of claim 40, further expressing an inhibitory molecule that comprises:

a first polypeptide that comprises an inhibitory molecule, wherein the inhibitory molecule is chosen from PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TIGIT, or a portion of the extracellular domain thereof, and

a second polypeptide that comprises an intracellular signaling domain, wherein the intracellular signaling domain comprises a costimulatory intracellular signaling domain derived from 4-1BB, CD27 or CD28, or a primary signaling domain derived from CD3 zeta, or both.

53. The immune effector cell of claim 52, wherein the inhibitory molecule comprises a first polypeptide that comprises at least a portion of the extracellular domain of PD1 and a second polypeptide comprising a costimulatory intracellular signaling domain derived from CD28 and a primary signaling domain derived from CD3 zeta.

54. The immune effector cell for use according to claim 48, wherein the agent is an mTOR inhibitor and the subject is to be administered a low, immune enhancing, dose of an mTOR inhibitor, e.g., RAD001 or rapamycin.

55. The immune effector cell for use according to claim 54, wherein the mTOR inhibitor is to be administered for an amount of time sufficient to decrease the proportion of PD-1 positive T cells, increase the proportion of PD-1 negative T cells, or increase the ratio of PD-1 negative T cells/ PD-1 positive T cells, in the peripheral blood of the subject, or in a preparation of T cells isolated from the subject.

56. The immune effector cell for use according to any of claims 45-49, wherein the cell expressing a CAR molecule is to be administered in combination with an immune effector cell comprising a CD19 CAR molecule.

57. The immune effector cell for use according to claim 56, wherein the disease associated with BCMA is multiple myeloma.

58. The immune effector cell for use according to claim 57, wherein the multiple myeloma is CD19-negative multiple myeloma.

59. The immune effector cell for use according to any of claims 45-49 and 56-58, wherein the cell expressing a CAR molecule is to be administered to the subject by dose fractionation, e.g., one, two, three, or more separate administrations of a partial dose,

optionally wherein a first percentage of the total dose is to be administered on a first day of treatment, a second percentage of the total dose is to be administered on a subsequent (e.g., second, third, fourth, fifth, sixth, or seventh or later) day of treatment, and optionally, a third percentage (e.g., the remaining percentage) of the total dose is to be administered on a yet subsequent (e.g., third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, or later) day of treatment,

optionally wherein 10% of the total dose of cells is to be administered on the first day, 30% of the total dose of cells is to be administered on the second day, and the remaining 60% of the total dose of cells is to be administered on the third day of treatment, and

optionally wherein the total cell dose comprises 1 to 5×10^7 or 1 to 5×10^8 cells.

60. An isolated anti-BCMA antigen binding domain comprising:

(i) a heavy chain complementary determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 394, a heavy chain complementary determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 434, a heavy chain complementary determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 474, a light chain complementary determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 514, a light chain complementary determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 554, and a light chain complementary determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 594;

(ii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 674, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 714, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 754, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 794, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 834;

(iii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 874, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 914, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 954, a LC CDR1 comprising the amino acid sequence

of SEQ ID NO: 994, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1034, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1074;

(iv) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 396, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 436, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 476, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 516, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 556, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 596;

(v) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 636, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 676, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 716, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 756, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 796, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 836; or

(vi) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 876, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 916, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 956, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 996, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1036, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1076.

61. The isolated anti-BCMA antigen binding domain of claim 60, comprising the amino acid sequence of SEQ ID NO: 94 or 96, or an amino acid sequence with 95-99% identity thereof.

62. The isolated anti-BCMA antigen binding domain of claim 60 or 61, comprising the amino acid sequence of SEQ ID NO: 79 or 81, or an amino acid sequence with 95-99% identity thereof.

63. The isolated anti-BCMA antigen binding domain of any one of claims 60-62, comprising (i) the amino acid sequence of SEQ ID NO: 94 and the amino acid sequence of SEQ ID NO: 79, or (ii) the amino acid sequence of SEQ ID NO: 96 and the amino acid sequence of SEQ ID NO: 81.

64. The isolated anti-BCMA antigen binding domain of any one of claims 60-63, comprising the amino acid sequence of SEQ ID NO: 49 or 51, or an amino acid sequence with 95-99% identity thereof.

65. An isolated nucleic acid molecule encoding the anti-BCMA antigen binding domain of any one of claims 60-64.

66. A vector comprising the nucleic acid molecule of claim 65.

67. A pharmaceutical composition comprising the immune effector cell of claim 40, and a pharmaceutically acceptable carrier, diluent, or excipient.